References and Bibliography for The Lupus Encyclopedia

REFERENCES

Resources, books, medical journal articles used for The Lupus Encyclopedia:

NOTE : New references used in the second edition (expected publishing date 2021) appear in bold-type font.

General

Aringer M, Burkhardt H, Burmester GR, Fischer-Betz R, Fleck M, et al. Current state of evidence on “off-label” therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland—a consensus report. Lupus. April 2012;21(4):386–401.

Petri M, Abuav R, Boumpas D, Goldblatt F, Isenberg I, Anhalt GJ, et al. Systemic lupus erythematosus. In: Stone JH, ed. A Clinician’s Pearls and Myths in Rheumatology. New York: Springer Science+Business Media; 2009:131–155.

Tsokos G. Systemic Lupus Erythematosus: Basic, applied, and clinical aspects. 2nd ed. San Diego, CA: Academic Press; 2020.

Tsokos G, Buyon JP, Koike T, Lahita RG, eds. Systemic Lupus Erythematosus. 5th ed. San Diego, Ca: Elsevier Academic Press; 201 Wallace DJ. The Lupus Book. 5th ed. New York, NY: Oxford University Press, Inc.; 2012.

Wallace DJ, Hahn, BH, eds. Dubois’ Lupus Erythematosus. 9th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2018. UpToDate, Inc. Retrieved April 21, 2019 – date of publishing, from www.uptodate.com.

READ MORE >>

Chapter 1

Aggarwal R, et al. Distinctions between diagnostic and classification criteria? Arthr Care Res. 2015;67(7):891-897.
Allison MJ, Gerszten E, Martinez AJ, Klurfeld DM. Generalized connective tissue disease in a mummy from the Huari culture (Peru). Bulletin of the New York Academy of Medicine. April 1977;53(3):292–301.
Al Sawah S, Daly RP, Foster S, Naegeli A, Benjamin K., Doll H., Bond G, Moshkovich O, Alarcón G. Understanding Delay in Diagnosis, Access to Care, and Satisfaction with Care in Lupus: Findings from a Cross-Sectional Online Survey in the United States. Presented at the European League Against Rheumatism (EULAR) 2015 Annual Conference. June 2015. Rome, Italy.
Araujo-Fernandez S, et al. Drug-induced lupus: including anti-tumour necrosis factor and interferon induced. Lupus. 2014; 23(6):545-553.
Aringer M, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthr Rheum 2019;71:1400-1412.
Arnaud L, et al. Drug-induced systemic lupus: revisiting the everchanging spectrum of the disease using the WHO pharmacovigilance database. Ann Rheum Dis. 2019;78:504-508.
Barr SG, Zonana-Nacach A, Magder LS, Petri M. Patterns of disease activity in systemic lupus erythematosus. Arthr & Rheum. 1999;42(12):2682-2688.
Bartels CM, Ramsey-Goldman R. Updates in US systemic lupus erythematosus epidemiology: tales of two cities. Arthr & Rheum. 2014;66(2):242-245.
Bateman T. A Practical Synopsis of Cutaneous Diseases, According to the Arrangements of Dr. Willan. Thomas AT, ed. 8th ed. London: Longman, Rees, Orme, Brown, Green and Longman, Paternoster-Row; 1936:298–299.
Bortoluzzi A, et al. Application of SLICC classification criteria in undifferentiated connective tissue disease and evolution in systemic lupus erythematosus: analysis of a large monocentric cohort with a long-term follow-up. Lupus. 2017;26:616-622.
Du Cange. Glossarium medie et infimelatinitatis. Carpenterii DP, Henschel GAL, Favre L, eds. Niort [France]; 1885: tomusquintus, col. 155b.
Dall’Era M, et al. The incidence and prevalence of systemic lupus erythematosus in San Francisco County, California. Arthr & Rheum. 2017;69(10):1996-2005.
Farmer S. Communities of Saint Martin: Legend and Ritual in Medieval Tours. Ithaca, NY: Cornell University Press; 1991:271–276.
Ferucci ED, et al. Prevalence and incidence of systemic lupus erythematosus in a population-based registry of American Indian and Alaska Native people. Arthr & Rheum. 2014;66(9):2494-2502.
GfK Roper. (2012). Lupus Awareness Survey for the Lupus Foundation of America [Executive Summary Report]. Washington, DC
Guigonis de Caulhiaco (Guy de Chauliac). Inventariumsive Chirurgia Magna. Vol. 2: Commentary. McVaugh M, Ogden MS, eds. Leiden, The Netherlands: Koninklyke Brill; 1997:183.
Hebernus (Pseudo-Hebernus, false attribution to the 9th Century Archbishop of Tours). Miracula B. Martini [The Miracles of St. Martin]. AD 855. In: Anastasius (the Librarian). Patrologiae Cursus Completus Sive Bibliotheca Universalis, Integra, Uniformis, Commoda, Oeconomica, Omnium SS Patrum, Doctorum Scriptorum que Ecclesiasticorum, patrologiae tomus CXXIX. Paris: J.-P. Migne; 1853: col. 1036. Translated from the Latin into English courtesy of Darrel W. Amundsen, professor emeritus of Classics, Western Washington University, Bellingham, Wa.
He Y, Sawalha AH. Drug-induced lupus erythematosus: an update on drugs and metabolisms. Current Opinion Rheum. 2018;30(5):490-496.
Hebra F, Kaposi M. On Diseases of the Skin Including the Exanthemata. London: The New
Sydenham Society; 1875:50.
Hochberg MC. Updating the American College of Rheumatology Revised Criteria for the Classification of Systemic Lupus Erythematosus. Arthr & Rheum. 1997;40(9):1725.
Ines L, et al. Classification of systemic lupus erythematosus: Systemic Lupus International Collaborating Clinics versus American College of Rheumatology criteria. A comparative study of 2,055 patients from a real-life, international systemic lupus erythematosus cohort. Arthr Care Res. 2015;67(8):1180-1185.
Izmirly PM, et al. The incidence and prevalence of systemic lupus erythematosus in New York County (Manhattan), New York. Arth & Rheum. 2017;69(10):2006-2017.
Jia L, et al. American College of Rheumatology criteria for systemic lupus erythematosus exclude half of all systemic lupus erythematosus patients. Arthr & Rheum. 2017;69(7):1502-1503.
Izmirly PM, Parton H, Wang L, McCune WJ, Lim SS, Drenkard C, Ferucci ED, Dall’Era M, Gordon C, Helmick CG, Somers EC. Prevalence of Systemic Lupus Erythematosus in the United States: Estimates From a Meta-Analysis of the Centers for Disease Control and Prevention National Lupus Registries. Arthritis Rheumatol. 2021 Jun;73(6):991-996. doi: 10.1002/art.41632. Epub 2021 Apr 23. PMID: 33474834; PMCID: PMC8169527.
Johnson SR, Brinks R, Costenbader KH, Daikh D, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger WB, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Aringer M. Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. Ann Rheum Dis. 2020 Oct;79(10):1333-1339. doi: 10.1136/annrheumdis-2020-217162. Epub 2020 Aug 14. PMID: 32816709.
Kaposi M. Lupus Vulgaris. In: Virchow RLK, ed. Handbuch der speciellenpathologie und therapie. Vol. 3, part 2: Lehrbuch der hautkrankheiten .
Stuttgart: Verlag von Ferdinand Enke; 1876:325. Translated from the German and Latin by Gary E. O’Connor.

Kernder A, Richter JG, Fischer-Betz R, Winkler-Rohlfing B, Brinks R, Aringer M, Schneider M, Chehab G. Delayed diagnosis adversely affects outcome in systemic lupus erythematosus: Cross sectional analysis of the LuLa cohort. Lupus. 2021 Mar;30(3):431-438. doi: 10.1177/0961203320983445. Epub 2021 Jan 5. PMID: 33402036; PMCID: PMC7933718.

Laday, J. More than 200,000 people in US meet criteria for systemic lupus erythematosus. Helio March 2021:40.
La vie et les miracles de Monseigneur Saint Martin [The life and miracles of Saint Martin (of Tours)]. May 7, 1496. Translated from Latin to French by Mathieu Latheron. Obtained from Paris, Bibliotèque Nationale. La Réserve (shelf mark) vélin 1159: L1 v°.
Lim SS, et al. The incidence and prevalence of systemic lupus erythematosus, 2002-2004: The Georgia Lupus Registry. Arthr & Rheum. 2014;66(2):357-368.
Low ESH, et al. Comparing the 1997 update of the 1982 American College of Rheumatology (ACR-97) and the 2012 Systemic Lupus International Collaborating Clinics (SLICC-12) criteria for systemic lupus erythematosus (SLE classification): which enables earlier classification of SLE in an urban Asian population? Lupus. 2019;28:11-18.
Makol A, Petri M. Pancreatitis in systemic lupus erythematosus: frequency and associated factors—a review of the Hopkins Lupus Cohort. Journal of Rheumatology. 2010;37:341–345.
Manzi S, Merrill J. Lupus, the chameleon: many disguises difficult to capture. Arthr & Rheum. 2017;69(10):1921-1924.
Merrill JT. The rarity of antinuclear antibody negativity in systemic lupus erythematosus: comment on the article by Merrill et al. [Reply to letter to the editor]. Arthritis & Rheumatism. March 2011;63(4):1157–1158.
Miraeus, Aubertus (Albert le Mire). Opera Diplomatica et Historica. Diplomatum Belgicorum nova collectivo sive supplementum ad Opera Diplomatica. Tomus Uno. Editio Secunda auctior et correctior. Caput XXV, pg 653. Joannes Franciscus Foppens, Brussels. 1723. [The affidavit of Eraclius, Bishop of Liege]
Morgan, C., Bland, A. R., Maker, C., Dunnage, J., & Bruce, I. N. (2018). Individuals living with lupus: findings from the LUPUS UK Members Survey 2014. Lupus, 27(4), 681–687. https://doi.org/10.1177/0961203317749746
Narain S et al. Diagnostic accuracy for lupus and other systemic autoimmune diseases in the community setting. Arch Intern Med. 2004;164:2435-2441.
Pérez-De-Lis M, Retamozo S, Flores-Chávez A, Kostov B, Perez-Alvarez R, Brito-Zerón P, Ramos-Casals M. Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry). Expert Opin Drug Safe. 2017;16(11):1255.
Petri M, Orbai A-M, Alarcon GS, Gordon C, Merrill JT et al. Derivation and Validation of Systemic Lupus International Collaborating Clinics Classification Criteria for Systemic Lupus Erythematosus. Arthr & Rheum. 2012;64(8):2677-2686.
Pickering G, et al. Treatment of systemic lupus erythematosus with steroids: report to the Medical Research Council by the Collagen Diseases and Hypersensitivity Panel. Br Med J 1961;2:915.
Pons-Estel GJ, et al. The American College of Rheumatology and the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus in two multiethnic cohorts: a commentary. Lupus. 2014;23:3-9.
Pourazizi M, et al. Lupus and lupoid misnomer: issues and challenges. Lupus. 2017;26:6-9.
Sacks JJ, Luo YH, Helmick CG. Prevalence of specific types of arthritis and other rheumatic conditions in the ambulatory health care system in the United States, 2001–2005. Arthritis Care & Research. April 2010;62(4):460–464.
Smith CD, Cyr M. The history of lupus erythematosus: from Hippocrates to Osler. Rheumatic Disease Clinics of North America. 1988;14:1–14.
Somers EC, et al. Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance Program. Arthr & Rheum. 2014;66(2):369-378.
Tedeschi SK, et al. Developing and refining new candidate criteria for SLE classification: an international collaboration. Arthr Care Res (Hoboken). 2018;70(4):571-581.
Troisi RJ et al. Menopause, postmenopausal estrogen preparations, and the risk of adult-onset asthma. A prospective cohort study. Am J Respir Crit Care Med. 1995;152(4 Pt 1):1183.
Ugarte-Gil MF, Alarcón GS. Incomplete systemic lupus erythematosus: early diagnosis or overdiagnosis? Lupus 2016;68:285-287.
Ugarte-Gil MF, González LA, Alarcón GS. Lupus: the new epidemic. Lupus 2019;28:1031-1050.
Ungprasert P, et al. Incidence of systemic lupus erythematosus in a population-based cohort using revised 1997 American College of Rheumatology and the 2012 Systemic Lupus International Collaborating Clinics classification criteria. Lupus. 2017;26:240-247.
Vedove CD, Del Giglio M, Schena D, Girolomoni G. Drug-induced lupus erythematosus. Arch Dermatol Res. 2009;301(1):99. Epub 2008 Sep 17.

Chapter 2

Aberle T, et al. Clinical and serologic features in patients with incomplete lupus classification versus systemic lupus erythematosus patients and controls. Arthr Care Res 2017;69:1780-1788.
Al Daabil M, et al. Development of SLE among “potential SLE” patients seen in consultation: long-term follow-up. Int J Clin Pract 2014;68:1508-1513.
Alharbi S, et al. Epidemiology and survival of systemic sclerosis-systemic lupus erythematosus overlap syndrome. J Rheum 2018;45:1406-1410.
Bernstein S. Can lupus be prevented? The Rheumatologist MAR 2020: 32-34.
Bitencourt N, Solow EB, Wright T, Bermas BL. Inflammatory myositis in systemic lupus erythematosus. Lupus. 2020;29(7):776-781. doi:10.1177/0961203320918021
Burgio GR, Martini A. Immunological features of diffuse connective tissue diseases. European Journal of Pediatrics. January 1990;149:224–231.
Calvo-Alen J, et al. Systemic lupus erythematosus: predictors of its occurrence among a cohort of early undifferentiated connective tissue disease. J Rheum 1996;23:469-475.
Cojocaru M, et al. Multiple autoimmune syndrome. Maedica (Buchar) 2010;5:132-134.
Connor SK. Systemic lupus erythematosus: a report on twelve cases treated with quinacrine (Atabrine) and chloroquine (Aralen). Annals of Rheumatic Diseases. 1957;16:76–81.
Costenbader KH, Schur PH. We need better classification and terminology for “people at high risk of or in the process of developing lupus.” Arthr Care Res 2015;67:593-596.

Dasdemir, S., Yildiz, M., Celebi, D., Sahin, S., Aliyeva, N., Haslak, F., Gunalp, A., Adrovic, A., Barut, K., Artim Esen, B., & Kasapcopur, O. (2022). Genetic screening of early-onset patients with systemic lupus erythematosus by a targeted next-generation sequencing gene panel. Lupus. https://doi.org/10.1177_09612033221076733
Dubois EL .The effect of the L. E. Cell test on the clinical picture of systemic lupus erythematosus. Annals of Internal Medicine. June 1953;38(6):1265–1294.
Friou GJ. Proceedings of the forty-ninth annual meeting of the American Society for Clinical Investigation held in Atlantic City, N. J., May 6, 1957: Clinical application of lupus serum nucleoprotein reaction using fluorescent antibody technique. Journal of Clinical Investigation. June 1957;36(6):890–898.
Frittoli R, et al. Impact of the birth month in the development of systemic lupus erythematosus. Lupus Sci Med 2019;6:A154.</fon t>
Hargraves MM. Discovery of the LE cell and its morphology. Mayo Clinic Proceedings. September 1969;44(9):579–599.
Hargraves MM. Presentation of two bone marrow elements: the “Tart” Cell and the “L.E.” Cell. Staff Meetings of the Mayo Clinic. January 1948;23(2):25–28.
Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, Liang MH, Kremers HM, Mayes MD, Merkel PA, Pillemer SR, Reveille JD, Stone JH; National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis & Rheum. 2008;58(1):15-25. PMID: 18163481.
Hepburn AL. Heberden historical series: the LE Cell. Rheumatology. 2001;40:826–827.
Holman H. The discovery of autoantibody to deoxyribonucleic acid. Lupus. 2011;20:441–442.
Infantino M, et al. The clinical impact of Anti-DFS70 antibodies in undifferentiated connective tissue disease: case reports and a review of the literature. Immunol Res 2017;65:293-295.
James, J., Kim-Howard, X., Bruner, B., Jonsson, M., McClain, M., Arbuckle, M., … Harley, J. (2007). Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus, 16(6), 401–409. https://doi.org/10.1177/0961203307078579

Khunsriraksakul C, et al. Construction and Applicationof Polygenic Risk Scores inAutoimmune Diseases. Fron Immun JUN 2022;13:1-10. doi: 10.3389/fimmu.2022.889296
Klemperer P, Pollack AD, Baehr G. Diffuse collagen disease: acute disseminated erythematosus and diffuse scleroderma. JAMA. May 1942;119:331–332.
Lambers WM, Westra J, Jonkman MF, Bootsma H, de Leeuw K. Incomplete Systemic Lupus Erythematosus: What Remains After Application of American College of Rheumatology and Systemic Lupus International Collaborating Clinics criteria?. Arthritis Care Res (Hoboken). 2020;72(5):607‐614. doi:10.1002/acr.23894
Lamichhane, D., & Weinstein, A. (2016). Probable systemic lupus erythematosus with cell-bound complement activation products (CB-CAPS). Lupus, 25(9), 1050–1053. https://doi.org/10.1177/0961203316635287
Li YR, et al. Genetic sharing and heritability of pediatric age-of-onset autoimmune diseases. Nat Comm 2015;2015 Oct 9;6:8442. doi: 10.1038/ncomms9442.
Liang E, Taylor M, McMahon MA. Utility of the Avise Connective Tissue Disease Test in Predicting Lupus Diagnosis and Progression of Disease [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/utility-of-the-avise-connective-tissue-disease-test-in-predicting-lupus-diagnosis-and-progression-of-disease/. Accessed December 29, 2019.
Lockshin MD, et al. Patients with overlap autoimmune disease differ from those with ‘pure’ disease. Lupus Sci Med 2015;2:e000084. doi: 10.1136/lupus-2015-000084.
Massimo Radin, Karen Schreiber, Irene Cecchi, Alessandra Bortoluzzi, Francesca Crisafulli, Cristiano M de Freitas, Beatrice Bacco, Elena Rubini, Silvia G Foddai, Melissa Padovan, Silvia Gallo Cassarino, Franco Franceschini, Danieli Andrade, Chiara Benedetto, Marcello Govoni, Tiziana Bertero, Luca Marozio, Dario Roccatello, Laura Andreoli, Savino Sciascia. A multicentre study of 244 pregnancies in undifferentiated connective tissue disease: maternal/fetal outcomes and disease evolution [published online ahead of print, 2020 Jan 14]. Rheumatology (Oxford). 2020;kez620. doi:10.1093/rheumatology/kez620
Mosca M, et al. How do patients with newly diagnosed systemic lupus erythematosus present? A multicenter cohort of early systemic lupus erythematosus to inform the development of new classification criteria. Arthr Rheum 2019;71:91-98.
Mosca M, Tani C, Talarico R, Bombardieri S. Undifferentiated connective tissue diseases (UCTD): simplified systemic autoimmune diseases. Autoimmunity Reviews. September 2010 [Epub ahead of print].

Motta F, Ramoni V, Caporali R, et al. SAT0622 ROLE OF PREGNANCY IN FLARE AND PROGRESSION INTO DEFINED RHEUMATIC DISEASE IN WOMEN WITH UNDIFFERENTIATED CONNECTIVE TISSUE DISEASE: RESULTS FROM A MONOCENTRIC OBSERVATIONAL COHORT. Annals of the Rheumatic Diseases 2019;78:1406-1408.

Munroe ME, Lu R, Zhao YD, et al. Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification. Annals of the Rheumatic Diseases 2016;75:2014-2021.
Oddis CV, Medsger Jr. TA, Weinstein A. Other Connective Tissue Diseases. Jacobi Medical Center. Educational Review Manual in Internal Medicine. volume 1: Rheumatology. Retrieved on 4/3/20 at https:///www.jacobimed.org/public/Ambulatory_files/Educational/IMRheum_07.pdf
Ramsey‐Goldman, R., Alexander, R.V., Massarotti, E.M., Wallace, D.J., Narain, S., Arriens, C., Collins, C.E., Saxena, A., Putterman, C., Kalunian, K.C., O’Malley, T., Dervieux, T. and Weinstein, A. (2020), Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology–Classified Systemic Lupus Erythematosus. Arthritis Rheumatol, 72: 78-88. doi:10.1002/art.41093Rashidi A and SI Fisher. Lupus Erythematosus Cell. Arthritis and Rheumatology 2018;70(7):1101.
Reid S, et al. A high genetic risk score is associated with early disease onset, organ damage and decreased survival in systemic lupus erythematosus. Lupus Sci Med 2019;6:A154.
Wallace DJ, ed. The Sjögren’s Book. New York: Oxford University Press; 2012.
Ugarte-Gil MF, et al. Disease features and outcomes in United States lupus patients of Hispanic origin and their Mestizo counterparts in Latin America: a commentary. Rheum (Oxford) 2016;55:436-440.
Urgate-Gil MF, González LA, AlarcónGS. Lupus: the new epidemic. Lupus 2019;28:1031-1050.
Vaz CC, et al. Undifferentiated connective tissue disease: a seven-center cross-sectional study of 184 patients. Clin Rheum 2009;28:915-921.
Young KA, et al. Screening characteristics for enrichment of individuals at higher risk for transitioning to classified SLE. Lupus 2019;28:597-606.
Yusof MYM, et al. Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status. Ann Rheum Dis 2017;77:1432-1439

Chapter 3

Abdel Galil SM, et al. Interferon alpha gene expression and serum level association of low vitamin D levels in Egyptian female patients with systemic lupus erythematosus. Lupus 2018;27:199-209.
Alarcón-Segovia D, Alarcón-Riquelme M, Cardiel MH, Caeiro F, Massardo L, et al. Familial aggregation of systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases in 1,177 lupus patients from the GLADEL cohort. Arthritis & Rheumatism. April 2005;52(4):1138–1147.
Alzate MA, et al. Coffee consumption and clinical outcomes in Colombian patients with systemic lupus erythematosus. Lupus 2017;4:doi: 10.1136/lupus-2017-000215.353
Andreoli L, Piantoni S, Fall’Ara F, et al. Vit
amin D and antiphospholipid syndrome. Lupus. June 2012;21(7):736–740.
Azzouz D, et al. Lupus nephritis is linked to disease-activity associated expansions and immunity to a gut commensal. Ann Rheum Dis 78:947-956.
Bae S-C, Lee YH. Coffee consumption and the risk of rheumatoid arthritis and systemic lupus erythematosus: a Mendelian randomization study. Clin Rheum 2018;37:2875-2879.
Bagavant H, et al. Antibodies to periodontogenic bacteria are associated with higher disease activity in lupus patients. Clin Exp Rheum 2019;37:106-111.
Bagavant H, et al. Periodontal pathogen exposure facilitates disease activity in systemic lupus erythematosus. J Immun 2018;200 (1 Suppl)45.7.
Barbhaiya M, et al. Influence of alcohol consumption on the risk of systemic lupus erythematosus among women in the Nurse’s Health Study cohorts. Arthr Care Res 2017;69:384-392.
Barbhaiya M, Costenbader KH. Ultraviolet radiation and systemic lupus erythematosus. Lupus 2014;23:588-595.
Bax CE, Chakka S, Concha JSS, Zeidi M, Werth VP. The effects of immunostimulatory herbal supplements on autoimmune skin diseases. J Am Acad Dermatol. 2021 Apr;84(4):1051-1058. doi: 10.1016/j.jaad.2020.06.037. Epub 2020 Jun 15. PMID: 32553683; PMCID: PMC7736300.
Bengtsson AA, et al. Risk factors for developing systemic lupus erythematosus: a case-control study in southern Sweden. Rheum (Oxford) 2002;41:563-571.
Benjilali, L., Tazi-Mezalek, Z., Harmouche, H., Lebbar, K., Aouni, M., Adnaoui, M., & Maaouni, A. (2007). Pernicious anemia in a young man with systemic lupus erythematosus. Lupus, 16(10), 827–829. https://doi.org/10.1177/0961203307081976
Beresford L. What is the role of Epstein-Barr virus reactivation in the development of lupus? The Rheumatologist, NOV 2020:37.
Bhatt BD. Significant symptomatic improvement of subacute cutaneous lupus after testosterone therapy in a female-to-male transgender subject. Lupus 2018;27:347-348.
Birmingham DJ, Hebert LA, Song H, Noonan WT, Rovin BH, et al. Evidence that abnormally large seasonal declines in vitamin D status may trigger SLE flare in non-African Americans. Lupus. July 2012;21(8):855–864.
Bjarnsholt T. The role of bacterial biofilms in chronic infections. Acta Path Microbio Immun Scand 2013;121:1-58.
Boeckler P, Cosnes A, Francès C, Hedelin G, Lipsker D. Association of cigarette smoking but not alcohol consumption with cutaneous lupus erythematosus. Archives of Dermatology. September 2009;145(9):1012–1016.
Bonakdar ZS, Jahanshahifar L, Jahanshahifar F, Gholamrezaei A. Vitamin D deficiency and its association with disease activity in new cases of systemic lupus erythematosus. Lupus. 2011;20:1155–1160.
Bu W, et al. Immunization with components of the viral fusion apparatus elicits antibodies that neutralize Epstein-Barr virus in B cells and epithelial cells. Immunity DOI: 10.1016/j.immuni.2019.03.010 (2019).
Burch PRJ and Rowell NR. Aetiological aspects of chronic discoid and systemic lupus erythematosus, systemic sclerosis, and Hashimoto’s thyroiditis. Lancet 1963;2:507-508.
Cervera R. “ASIA”: a new systemic autoimmune syndrome? Lupus. 2010;20:665–666.
Chiou S-H, et al. Pet dogs owned by lupus patients are at a higher risk of developing lupus. Lupus 2004;13:442-449.
Chou C-T. Alternative therapies: what role do they have in the management of lupus? Lupus. 2010;19:1425–1429.
Chung W-S, et al. Association of systemic lupus erythematosus and sleep disorders: a nationwide population-based cohort study. Lupus 2015;25:382-388.
Committee to review health effects in Vietnam Veterans of exposure to herbicides (tenth bienniel update); Board on the Health of Select Populations; Inst of Med; National Academies of Sciences, Engineering, and Medicine. Washington (DC): Nat Acad Press (US);2016 Mar 29.
Cooper GS, Dooley MA, Treadwell EL, St. Clair EW, Parks CG, et. al. Hormonal, environmental, and infectious risk factors for developing systemic lupus erythematosus. Arthritis & Rheumatism. October 1998;41(10):1714–1724.
Cooper G, Gilbert K, Greidinger E, James J, Pfau J, et al. Avanços e oportunidades atuais na pesquisa sobre lupus: influências ambientais e mecanismos da doença [Recent advances and opportunities in research on lupus: environmental influences and mechanisms of disease]. Ciência & Saúde Coletiva. November/December 2009;14(5):1865–1876.
Cooper G, Wither J, Bernatsky S, Claudio JO, Clarke A, et al. Occupational and environmental exposures and risk of systemic lupus erythematosus: silica, sunlight, solvents. Rheumatology (Oxford). November 2010;49(11):2172–2180.
Cooper GS, et al. Smoking and use of hair treatments in relation of risk of developing systemic lupus erythematosus. J Rheum 2001;28:2653-2656.
Cozier YC, et al. Relationship of cigarette smoking and alcohol consumption to incidence of systemic lupus erythematosus in a prospective cohort study of black women. Arthr Care Res 2019;71:671-677.
Criswell LA. Genome-wide association studies of SLE. The Rheumatologist. February 2011;5(2):1, 26, 27, 31–32.
Dahlgren J, et al. Cluster of systemic lupus erythematosus (SLE) associated with an oil field waste site: a cross sectional study. Environ Health Glob Access Sci Source 2007;6:8.
Danchenko N, et al. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus 2006;15:308-318.
Deapen D, Escalante A, Weinrib L, Horwitz D, Bachman B, et al. A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis & Rheumatism. March 1992;35(3):311–318.
Deng, G., Tsokos, G. Pathogenesis and targeted treatment of skin injury in SLE. Nat Rev Rheumatol 11, 663–669 (2015). https://doi.org/10.1038/nrrheum.2015.106
DeQuattro K, Trupin L, Li J, et al. Relationships Between Adverse Childhood Experiences and Health Status in Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2020;72(4):525‐533. doi:10.1002/acr.23878
Dunmire SK, Verghese PS, Balfouir HH. Primary Epstein-Barr virus infection. J Clin Virol 2018;102:84.
Ekinci Z and Ozturk K. Systemic lupus erythematosus with C1q deficiency: treatment with fresh frozen plasma. Lupus 2018;27:134-138.
Fabbri C, et al. Periodontitis treatment improves systemic lupus erythematosus response to immunosuppressive therapy. Clin Rheum 2014;33:505-509.
Feldman CH, et al. Association of childhood abuse with incident systemic lupus erythematosus in adulthood in a longitudinal cohort of women. J Rheum 2019:DOI: 10.3899/jrheum.190009
Florim GMS, et al. Fetal microchimerism in kidney biopsies of lupus nephritis patients may be associated with a beneficial effect. Arthr Res Ther 2015;17:101.
Frittoli R, Marini R, Costallat L, et al. Impact of the birth month in th
e development of systemic lupus erythematosus. Lupus Science & Med 2019;6:doi: 10.1136/lupus-2019-lsm.206
Gallo PM, et al. Amyloid-DNA composites of bacterial biofilms stimulate autoimmunity. Immun 2015;42:1171-1184.
Gaurav G, Brunner HI. Environmental triggers in systemic lupus erythematosus. Sem Arthr Rheum 2018;47:710-717.
Gergianaki I, et al. Comparison of urban versus rural environment associated systemic lupus erythematosus (SLE): risk and clinical features. Ann Rheum Dis 2017;76:300.
Gulati G, Brunner H. Environmental triggers in systemic lupus erythematosus. Sem Arthr Rheum 2018;47:710-717.

Hahn J, Cook N, Alexander E, Friedman S, Bubes V, Walter J, Kotler G, Lee I, Manson J, Costenbader K. Vitamin D and Marine n-3 Fatty Acid Supplementation and Prevention of Autoimmune Disease in the VITAL Randomized Controlled Trial [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 10). https://acrabstracts.org/abstract/vitamin-d-and-marine-n-3-fatty-acid-supplementation-and-prevention-of-autoimmune-disease-in-the-vital-randomized-controlled-trial/. Accessed December 19, 2021.

Hahn J, Leatherwood C, Malspeis S, et al. Associations between daily alcohol consumption and systemic lupus erythematosus-related cytokines and chemokines among US female nurses without SLE. Lupus. 2020;29(8):976-982. doi:10.1177/0961203320929427
Harley JB, James JA. Everyone comes from somewhere: systemic lupus erythematosus and Epstein-Barr virus induction of host interferon and humoral anti-Epstein-Barr nuclear antigen 1 immunity. Arthritis & Rheumatism. June 2010;62(6):1571–1575.
Harley JB, Chen X, Pujato M, Miller D, Maddox A, Forney C, Magnusen AF, Lynch A, Chetal K, Yukawa M, Barski A, Salomonis N, Kaufman KM, Kottyan LC, Weirauch MT. Transcription factors operate across disease loci, with EBNA2 implicated in autoimmunity. Nat Genet. 2018 May;50(5):699-707. doi: 10.1038/s41588-018-0102-3. Epub 2018 Apr 16. PMID: 29662164; PMCID: PMC6022759.
Hession MT, Au SC, Gottlieb AB. Parvovirus B 19-associated systemic lupus erythematosus: clinical mimicry or autoimmune induction? Journal of Rheum. 2010;37:2430–2432.
Hutchinson J. Harveian lectures on lupus. British Medical Journal. January 1888;1(1412):58–63.
Izmirly PM, Parton H, Wang L, McCune WJ, Lim SS, Drenkard C, Ferucci ED, Dall’Era M, Gordon C, Helmick CG, Somers EC. Prevalence of Systemic Lupus Erythematosus in the United States: Estimates From a Meta-Analysis of the Centers for Disease Control and Prevention National Lupus Registries. Arthritis Rheumatol. 2021 Jun;73(6):991-996. doi: 10.1002/art.41632. Epub 2021 Apr 23. PMID: 33474834; PMCID: PMC8169527.
Jimenez-Caliani A, Jimenez-Jorge S, Molinero P, Rubio A, Guerrero JM, Osuna C. Treatment with testosterone or estradiol in melatonin treated females and males MRL/MpJ-Faslpr mice induces negative effects in developing systemic lupus erythematosus. Journal of Pineal Research. 2008; 45(2):204–211.
Jog NR, et al. Association of Epstein-Barr virus serological reactivation with transitioning to systemic lupus erythematosus in at-risk individuals. Ann Rheum Dis 2019;78:1235-1241.
Johnson KL, McAlindon TE, Mulcahy E, Bianchi DW. Microchimerism in a female patient with systemic lupus erythematosus. Arthritis & Rheumatism.  2001;44(9):2107–2111.
Jüptner M, et al. Low copy numbers of complement C4 and homozygous deficiency of C4A may predispose to severe disease and earlier disease onset in patients with systemic lupus erythematosus. Lupus 2018;27:600-609.
Kamen DL. Vitamin D: new kid on the block? Bulletin of the NYU Hospital for Joint Diseases. 2010;68(3):218–222.
Kaufman M. Pancytopenia following use of hydralazine (“Apresoline”): report of a case. Journal of the American Medical Association. 1953;151(17):1488–1490.

Khunsriraksakul C, et al. Construction and Applicationof Polygenic Risk Scores inAutoimmune Diseases. Fron Immun JUN 2022;13:1-10. doi: 10.3389/fimmu.2022.889296

Kiyohara C, et al. Cigarette smoking, alcohol consumption, and risk of systemic lupus erythematosus: a case-control study in a Japanese population. J Rheum 2012;39:1363-1370.
Kiyohara C, et al. Modifying effect o N-acetyltransferase 2 genotype on the association between systemic lupus erythematosus and consumption of alcohol and caffeine-rich beverages. Arthr Care Res 2014;66:1148-1156.
Klein RS, et al. The risk of ultraviolet radiation exposure from indoor lamps in lupus. Autoimm Rev 2009;8:320-324.
Kremer Hovinga ICL, Koopmans M, Baelde HJ, van der Wal AM, Sijpkens YWJ, et al. Chimerism occurs twice as often in lupus nephritis as in normal kidneys. Arthritis & Rheumatism. September 2006;54(9):2944–2950.
Kuo C-F, et al. Familial risk of Sjogren’s syndrome and co-aggregation of autoimmune diseases in affected families: a nationwide population study. Arthr Rheum 2015;67:1904-1912.
Kurien BT, Scofield RH. Lipstick consumption and systemic lupus erythematosus: nothing to gloss over. Clin Rheum 2008;27:1339-1340.
Langefeld CD, et al.  Transancestral mapping and genetic load in systemic lupus erythematosus. Nat Commun 2017;8:16021. doi: 10.1038/ncomms16021. 
Lim S-Y, Ghosh SK. Autoreactive responses to an environmental factor: 1. Phthalate induces antibodies exhibiting anti-DNA specificity. Immunology. December 2003;110(4):482–492.
López P, et al. Intestinal dysbiosis in systemic lupus erythematosus: cause or consequence? Curr Opin Rheum 2016;28:515-522.
Lu-Fritts P-Y, et al. Association of systemic lupus erythematosus with uranium exposure in a community living near a uranium-processing plant. Arthr Rheum 2014;66:3105-3112.
Lupus Foundation of America, Inc. Complex genetics of lupus. Retrieved January 1, 2011, from www.lupus.org/webmodules/webarticlesnet/templates/new_aboutdiagnosis.aspx?articleid=413&zoneid=15.
Lv, J., Feng, Y., Qian, Y., & Chen, J. J. (2019). Klinefelter’s syndrome with systemic lupus erythematosus and atrial fibrillation. Lupus, 28(12), 1477–1479. https://doi.org/10.1177/0961203319877256
Maestroni GJ, Otsa K, Cutolo M. Melatonin treatment does not improve rheumatoid arthritis. British Journal of Clinical Pharmacology. 2008;65(5):797–798.
Malinow MR, Bardana EJ Jr, Goodnight SH Jr. Pancytopenia during ingestion of alfalfa seeds. Lancet. 1981 Mar 14;1(8220 Pt 1):615. doi: 10.1016/s0140-6736(81)92063-8. PMID: 6110847.
Malinow MR, Bardana EJ Jr, Pirofsky B, Craig S, McLaughlin P. Systemic lupus erythematosus-like syndrome in monkeys fed alfalfa sprouts: role of a nonprotein amino acid. Science. 1982 Apr 23;216(4544):415-7. doi: 10.1126/science.7071589. PMID: 7071589.
Manzi S, Merrill J. Lupus, the chameleon: many disguises difficult to capture. Arthr & Rheum. 2017;69(10):1921-1924.
Marques CPC, et al. Possible evidence of systemic lupus erythematosus and periodontal disease association mediation mediated by Toll-like receptors 2 and 4. Clin Exp Immun 183:187-192.
Marquez A, et al. A combined large-scale meta-analysis identifies COG6 as a novel shared risk locus for rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis 2016;76(1):286-294. doi: 10.1136/annrheumdis-2016-209436. Epub 2016 May 18.
Martinez-Ramirez R, et al. Lupus eritematoso sistemico en una lactante de 6 meses [Systemic lupus erythematosus in a 6 year old female child]. Reum Clin (article in Spanish) 2008;4:251-252.
Meroni PL, Penatti AE. Epigenetics and systemic lupus erythematosus: unmet needs. Clinic Rev Allerg Immunol 2016;50:367-376.
Michelson HE. Review and appraisal of present knowledge concerning lupus erythematosus (William Allen Pusey Memorial Lecture). Proc Inst Med Chicago 1952;19:335-351.
Miller‐Archie, S.A., Izmirly, P.M., Berman, J.R., Brite, J., Walker, D.J., Dasilva, R.C., Petrsoric, L.J. and Cone, J.E. (2020), Systemic autoimmune disease among adults exposed to the Sept
ember 11, 2001, terrorist attack. Arthritis Rheumatol. Accepted Author Manuscript. doi:10.1002/art.41175
Minkin SJ, et al. Smoking and secondhand smoke among patients with systemic lupus erythematosus and controls: associations with disease and disease damage. Arthr Res Ther 2014;16 (Suppl 1):A40
Mizus M, Li J, Goldman D, et al. Autoantibody clustering of lupus-associated pulmonary hypertension. Lupus Science & Medicine 2019;6:e000356. doi: 10.1136/lupus-2019-000356
Mofors J, Eliasson H, Ambrosi A, et al. Comorbidity and long-term outcome in patients with congenital heart block and their siblings exposed to Ro/SSA autoantibodies in utero. Ann Rheum Dis. 2019;78(5):696‐703. doi:10.1136/annrheumdis-2018-214406
Mok CC, Birmingham DJ, Ho LY, Hebert LA, Song H, Rovin BH. Vitamin D deficiency as marker for disease activity and damage in systemic lupus erythematosus: a comparison with anti-dsDNA and anti-C1q. Lupus. 2012;21:36–42.
Moolen SE, Clark E. Hemolytic anemia and in autohemagglutination; report of a case and review of the literature, with special reference to the virus of Newcastle disease. Arch Int Med (Chicago) 1952;89:270-292.
Moser KL, Kelly JA, Lessard CJ, Harley JB. Recent insights into the genetic basis of systemic lupus erythematosus. Genes & Immunity. 2009;10(5):373–379.
Moulton VR, Suarez-Fueyo A, Meidan E, Li H, Mizui M, Tsokos GC. Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective. Trends Mol Med. 2017;23(7):615-635. doi:10.1016/j.molmed.2017.05.006
Munroe ME, et al. Discerning risk of disease transition in relatives of systemic lupus erythematosus patients utilizing soluble mediators and clinical features. Arthr & Rheum 2017;69:630-642.
Murashima A, Fukazawa T, Hirashima M, Takasaki Y, Oonishi M, et al. Long term prognosis of children born to lupus patients. Annals of Rheumatic Diseases. January 2004;63(1):50–53.
Nelson P, et al. Viruses as potential pathogenic agents in systemic lupus erythematosus. Lupus 2014;23:596-605.
Nguyen MH, Bryant K, O’Neill SG. Vitamin D in SLE: a role in pathogenesis and fatigue? A review of the literature. Lupus 2018;27:2003-2011. 
Nusbaum JS, Mirza I, Shum J, et al. Sex Differences in Systemic Lupus Erythematosus: Epidemiology, Clinical Considerations, and Disease Pathogenesis. Mayo Clin Proc. 2020;95(2):384-394. doi:10.1016/j.mayocp.2019.09.012

Nüsslein-Volhard C. The Toll gene in Drosophila pattern formation. Trends Genet. 2022 Mar;38(3):231-245. doi: 10.1016/j.tig.2021.09.006. Epub 2021 Oct 11. PMID: 34649739.
O’Donovan A, et al. Elevated risk for autoimmune disorders in Iraq and Afghanistan veterans with posttraumatic stress disorder. Biol Psych 2015;77:365-374.

Orefice V, Ceccarelli F, Barbati C, et al. Caffeine intake influences disease activity and clinical phenotype in systemic lupus erythematosus patients. Lupus. 2020;29(11):1377-1384. doi:10.1177/0961203320941920

Pacenza N, Pasqualini T, Gottlieb S, Knoblovits P, Costanzo PR, Stewart Usher J, Rey RA, Martínez MP, Aszpis S. Clinical Presentation of Klinefelter’s Syndrome: Differences According to Age. Int J Endocrinol. 2012;2012:324835. doi: 10.1155/2012/324835. Epub 2012 Jan 12. PMID: 22291701; PMCID: PMC3265068.
Parks CG, De Roose AJ. Pesticides, chemical and industrial exposures in relation to systemic lupus erythematosus. Lupus 2014;23:527-536.
Pender MP. CD8+ T-cell deficiency, Epstein-Barr Virus infection, vitamin D deficiency, and steps to autoimmunity: a unifying hypothesis. Autoimm Dis 2011;2012:1-16.
Perry H, Schroeder H. Syndrome simulating collagen disease caused by hydralazine (Apresoline). J of the American Medical Association. February 1954;154(8):670–673.
Pertea M, Salzberg SL. Between a chicken and a grape: estimating the number of human genes. Genome Biology. May 2010;11:206:1–7. Retrieved January 1, 2011, from www.genomebiology.com/2010/11/5/206.
Petri M, et al. BALES: The Baltimore Lupus Environmental Study. Arthr Rheum 2001;44:S331
Petri M. Diet and systemic lupus erythematosus: from mouse and monkey to woman? Lupus. 2001;10:775–777.
Picceli, V., Skare, T., Nisihara, R., Kotze, L., Messias-Reason, I., & Utiyama, S. (2013). Spectrum of autoantibodies for gastrointestinal autoimmune diseases in systemic lupus erythematosus patients. Lupus, 22(11), 1150–1155. https://doi.org/10.1177/0961203313503911
Pontes LT, et al. New-onset lupus nephritis after male-to-female sex reassignment surgery. Lupus 2018;27:2166-2169.
Reid S, Alexsson A, Frodlund M, et al. High genetic risk score is associated with early disease onset, damage accrual and decreased survival in systemic lupus erythematosus. Annals of the Rheumatic Diseases 2020;79:363-369.
Rice GI, et al. Gain-of-function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type 1 interferon signaling. Nature Gen 2014;46:503-509.
Roberts AL, et al. Association of trauma and posttraumatic stress disorder with incident systemic lupus erythematosus in a longitudinal cohort of women. Arthr Rheum 2017;69:2162-2169.
Ruiz-Irastorza G, Gordo S, Olivares N, Egurbide M-V, Aguirre C. Changes in vitamin D levels in patients with systemic lupus erythematosus: effects on fatigue, disease activity, and damage. Arthritis Care & Research. August 2010;62(8):1160–1165.
Rutter-Locher Z, et al. Association between systemic lupus erythematosus and periodontitis: a systematic review and meta-analysis. Front Immun 2017;8:1-8.
Schnurr P, Vieilhauer M, Weather F. The brief trauma questionnaire. White River Junction (VT): National Center for PTSD;1999.
Schonfeld AR. Insecticides linked to autoimmune diseases. Rheumatology News. November 2009;8(11):12.
Scofield H, Harley JB, Harris VM. 44 47,XXX in lupus families. Lupus Science & Medicine 2019;6:doi: 10.1136/lupus-2019-lsm.44
Scofield RH, Bruner GR, Namjou B, Kimberly RP, Ramsey-Goldman R, et al. Klinefelter’s syndrome (47,XXY) in male systemic lupus erythematosus patients: support for the notion of a gene-dose effect from the X chromosome. Arthritis & Rheumatism. August 2008;58(8):2511–2517.
Shahin D, et al. Serum 25-OH vitamin D level in treatment-naive systemic lupus erythematosus patients: relation to disease activity, IL-23 and IL-17. Lupus 2017;26:917-926.
Shamekhi Z, et al. A randomized, double-blind, placebo-controlled clinical trial examining the effects of green tea extract on systemic lupus erythematosus disease activity and quality of life. Phytother Res 2017;31:1063-1071.
Sharif K, et al. Coffee and autoimmunity: more than a mere hot beverage! Autoimmun Rev 2017;16:712-721.
Sharma R, et al. Rare X chromosome abnormalities in systemic lupus erythematosus and Sjogren’s syndrome. Arthr & Rheum 2017;69:2187-2192.
Shi L-H, et al. Risk of systemic lupus erythematosus in patients with human papillomavirus infection: a population-based retrospective cohort study. Lupus 2018;27:2279-2283
Simard JF, Karlson EW, Costenbader KH, et al. Perinatal factors and adult-onset lupus. Arthritis Rheum. 2008;59(8):1155‐1161. doi:10.1002/art.23930
Sinicato NA, de Oliveira L, Lapa A, et al. Familial Aggregation of Childhood- and Adulthood-Onset Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2020;72(8):1147-1151. doi:10.1002/acr.23931
Somers EC, Richardson BC. Environmental exposures, epigenetic changes and the risk of lupus. Lupus 2014;23:568-576.
Song H, et al. Association of stress-related disorders with subsequent autoimmune disease. JAMA 2018;319:2388-2400.
Takahashi H, et al. Psychological stress in a Japanese population with systemic lupus erythematosus: Finding from KYSS study. Mod Rheum 2013;24:448-452.
Takvorian SU, Merola JF, Costenbader KH. Cigarette smoking, alcohol consumption and risk of systemic lupus erythematosus. Lupus 2014;23:537-544.
Teruel M and Alarcón-Riquelme ME. Genetics of systemic lupus erythematosus and Sjogren’s syndrome: an update. Curr Op Rheum 2016;28:506.
Tsokos GC. Mechanisms of disease: systemic lupus erythematosus. New England Journal of Medicine. December 2011;365(22):2110–2121.
Tsokos, G. C.  (2020). Autoimmunity and Organ Damage in Systemic Lupus Erythematosus. Nature Immunol. 21, 605–614.
Tsokos, G., Lo, M., Reis, P. et al. New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol 12, 716–730 (2016). https://doi.org/10.1038/nrrheum.2016.186
Urgate-Gil MF, González LA, AlarcónGS. Lupus: the new epidemic. Lupus 2019;28:1031-1050.
Vernot B and Akey JM. Resurrecting surviving Neanderthal lineages from modern human genomes. Science 2014; 343:1017-1021.
Wang B, et al. Vaccinations and risk of systemic lupus erythematosus and rheumatoid arthritis: a systematic review and meta-analysis. Autoimmun Rev 2017;16:756-765.
Wang J, et al. Is lipstick associated with the development of systemic lupus erythematosus (SLE)? Clin Rheum 2008;9:1183-1187.
Watad A, et al. Autoimmune/inflammatory syndrome induced by adjuvants (Shoenfeld’s syndrome) – an update. Lupus 2017;26:675-681.
Williams JN, et al. Pesticide exposure and risk of systemic lupus erythematosus in an urban population of predominantly African-American women. Lupus 2018;27:2129-2134.
Yang J, et al. Increased serum level of prolactin is related to autoantibody production in systemic lupus erythematosus. Lupus 2016;25:513-519.
Young KA, et al. Combined role of vitamin D status and CYP24A1 in the transition to systemic lupus erythematosus. Ann Rheum Dis 2017;76:153-158.
Young KA, et al. Less than 7 hours of sleep per night is associated with transitioning to systemic lupus erythematosus. Lupus 2018;27:1524-1531.
Young NA, et al. Estrogen modulation of endosome-associated toll-like receptor 8: an IFN alpha-independent mechanism of sex-bias in systemic lupus erythematosus. Clin Immunol 2014;151:66-77.
Zhou L-l, Wei W, Si J-F, Yuan D-P. Regulatory effect of melatonin on cytokine disturbances in the pristine-induced lupus mice. Mediators of Inflammation. Vol. 2010, article ID 951210, 7 pages, 2010. doi:10.1155/2010/951210. Retrieved July 4, 2011, from www.hindawi.com/journals/mi/2010/951210/cta/.
Zandman-Goddard G, Solomon M, Rosman Z, Peeva E, Shoenfeld Y. Environment and lupus related diseases. Lupus. 2012;21:241–250.
Zegarra-Ruiz DF, et al. A diet-sensitive commensal lactobacillus strain mediates TLR7-dependent systemic autoimmunity. Cell Host Microbe 2019;9:113-127.
Zulian F, Pluchinotta FR, Martini G, Da Dalt L, Zachello G. Severe clinical course of systemic lupus erythematosus in the first year of life. Lupus. 2008;17:780–786.

Chapter 4

Aggarwal R, Liao K, Nair R, Ringold S, Costenbader KH. Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis. Arthritis & Rheumatism. November 2009;61(11):1472–1483.
Agmon-Levin N, et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis 2014;73:17-23.
Agustinelli RA, et al. Distinctive features of positive anti-cell antibody tests (indirect immunofluorescence on HEp-2 cells) in patients with non-autoimmune diseases. Lupus 2018;28:629-634.
Akhter, E., Burlingame, R., Seaman, A., Magder, L., & Petri, M. (2011). Anti-C1q antibodies have higher correlation with flares of lupus nephritis than other serum markers. Lupus, 20(12), 1267–1274. https://doi.org/10.1177/0961203311411597
Akizuki M, et al. A soluble acidic protein of the cell nucleus which reacts with serum from patients with systemic lupus erythematosus and Sjogren’s syndrome. J Clin Invest 1977;59:264-272.
Akiyama M, Kaneko Y, Takeuchi T. Lupus aortitis: A fatal, inflammatory cardiovascular complication in systemic lupus erythematosus. Lupus. 2020;29(12):1652-1654. doi:10.1177/0961203320950017
Aldar H, Lapa AT, Bellini B, Siknicato NA, Postal M, et al. Prevalence and clinical significance of anti-ribosomal P antibody in childhood-onset systemic lupus erythematosus. Lupus. 2012;21:1225–1231. American College of Rheumatology. Position Statement: Methodology of Testing for Antinuclear Antibodies. Retrieved August 24, 2011, from www.rheumatology.org/practice/clinical/ position/ana_position_stmt.pdf
Amengual, O., Forastiero, R., Sugiura-Ogasawara, M., Otomo, K., Oku, K., Favas, C., … Atsumi, T. (2017). Evaluation of phosphatidylserine-dependent antiprothrombin antibody testing for the diagnosis of antiphospholipid syndrome: results of an international multicentre study. Lupus, 26(3), 266–276. https://doi.org/10.1177/0961203316660203
Amezcua-Guerra LM. High-sensitivity C-reactive protein is not a good indicator of infection in patients with systemic lupus erythematosus [Letter to the editor]. Lupus. 2011;20:1567–1568.
Andrade LEC, Damoiseaux J, Chan EK. Response to ‘Decision making value of nuclear dense fine speckled pattern in systemic autoimmune rheumatic disease: trick or treat?’ by Deng et al Annals of the Rheumatic Diseases 2020;79:e93.
Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20(5):1103-1112. doi:10.1681/ASN.2008101028
Araújo-Fernández S, Ahijón-Lana M, Isenberg DA. Drug-induced lupus: Including anti-tumour necrosis factor and interferon induced. Lupus. 2014;23(6):545–553. doi:10.1177/0961203314523871
Arriens C, Alexander RV, Narain S, et al. Cell-bound complement activation products associate with lupus severity in SLE. Lupus Science & Medicine 2020;7:e000377. doi: 10.1136/lupus-2019-000377
Baer AN, et al. Association of Anticentromere Antibodies With More Severe Exocrine Glandular Dysfunction in Sjögren’s Syndrome: Analysis of the Sjögren’s International
Collaborative Clinical Alliance Cohort. Arthr Care Res 2016;68:1554-1559.
Baer AN, McAdams DeMarco M, Shiboski SC for the Sjögren’s International Collaborative Clinical Alliance (SICCA) Research Groups, et al. The SSB-positive/SSA-negative antibody profile is not associated with key phenotypic features of Sjögren’s syndrome Annals of the Rheumatic Diseases 2015;74:1557-1561.

Becker Y, Loignon RC, Julien AS, et al. Anti-mitochondrial autoantibodies in systemic lupus erythematosus and their association with disease manifestations. Sci Rep. 2019 Mar;9:4530.
Bentow C, et al. Development and multi-center evaluation of a novel immunoabsorption method for anti-DFS70 antibodies. Lupus 2016;25:897-904.
Bentow, C., Lakos, G., Martis, P., et al. (2016). International multi-center evaluation of a novel chemiluminescence assay for the detection of anti-dsDNA antibodies. Lupus, 25(8), 864–872. https://doi.org/10.1177/0961203316640917
Beutler E, Waalen J. The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration? Blood 2006; 107:1747
Bhana S. (March 2019) Antinuclear antibodies (ANA). Retrieved from https:///www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Antinuclear-Antibodies-ANA (retrieved Dec 17, 2019).
Blazina Š, et al. Functional Complement Analysis Can Predict Genetic Testing Results and Long-Term Outcome in Patients With Complement Deficiencies. Front Immunol. 2018;9:500. Epub 2018 Mar 21. 
Bortoluzzi, A., Piga, M., Silvagni, E., Chessa, E., Mathieu, A., & Govoni, M. (2019). Peripheral nervous system involvement in systemic lupus erythematosus: a retrospective study on prevalence, associated factors and outcome. Lupus, 28(4), 465–474. https://doi.org/10.1177/0961203319828499
Bose N, et al. The clinical utility of anti-chromatin antibodies as measured by BioPlex 2200 in the diagnosis of systemic lupus erythematosus versus other rheumatic diseases. Int J Exp Med 2012;5:316-320.
Bossuyt X, Claessens J, De Langhe E, et al. Antinuclear antibodies by indirect immunofluorescence and solid phase assays. Ann Rheum Dis. 2020;79(6):e65. doi:10.1136/annrheumdis-2019-215443
Brewster LM, et al. Distribution of creatine kinase in the general population: implications for statin therapy. Am Heart J 2007;154:655.

Bruera S, Ventura MJ, Agarwal SK, Krause KJ, Lopez-Olivo MA. The utility of erythrocyte sedimentation rate, C-reactive protein, and procalcitonin in detecting infections in patients with systemic lupus erythematosus: A systematic review. Lupus. 2022;31(10):1163-1174. doi:10.1177/09612033221106157
Budhram A, et al. Anti-cyclic citrullinated peptide antibody as a marker of erosive arthritis in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Lupus 2014;23:1156-1163.
Buyon JP, Izmirly PM, Belmont HM, Conklin J, Kaiden N, Salmon JE, Alexander R, Dervieux T. Erythrocyte Bound C4d in the Presence of Adverse Pregnancy Outcome Events in Pregnant Women with Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/erythrocyte-bound-c4d-in-the-presence-of-adverse-pregnancy-outcome-events-in-pregnant-women-with-systemic-lupus-erythematosus/. Accessed December 29, 2019.
Buyon JP, Kim MY, Guerra MM, et al. Predictors of Pregnancy Outcomes in Patients With Lupus: A Cohort Study. Ann Intern Med. 2015;163(3):153‐163. doi:10.7326/M14-2235
Cabrera CM, et al. Serological profile and clinical features of nucleolar antinuclear pattern in patients with systemic lupus erythematosus from southwestern Spain. Lupus 2016;25:980-987.
Carpintero MF, et al. Diagnosis and risk stratification in patients with anti-RNP autoimmunity. Lupus 2015;24:1057-1066.
Carroll M, Temte J. Proteinuria in adults: a diagnostic approach. Am Fam Phys 2000;62:1333-1340.
Cervera R, Vinas O, Ramos-Casals M, Font J, Garcia-Carrasco M, Siso A, et al. Anti-chromatin antibodies in systemic lupus erythematosus: a useful marker for lupus nephropathy. Annals of Rheumatic Diseases. May 2003;62(5):431–434.
Chen TR. Re-evaluation of HeLa, HeLa S3, and HEp-2 karyotypes. Cytogen Cell Genet 1988;48:19-24.
Choi MY, et al. Antinuclear antibody-negative systemic lupus erythematosus in an international inception cohort. Arthr Care Res (Hoboken). 2019;71:893-902.
Choi MY, et al. The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients. Lupus 2017;26:1051-1059.
Christopher-Stine L, et al. Urine protein-to-creatinine ratio is a reliable measure of proteinuria in lupus nephritis. J Rheum Aug 2004, 31 (8) 1557-1559.
Clarke AE, Goss T, Piscitello A, Chandra T, O’Malley T, Dervieux T, Powell T. An Economic Evaluation on the Impact of Earlier Systemic Lupus Erythematosus (SLE) Diagnosis Using Complement C4d Activation Products in a Multivariate Assay Panel (MAP) [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/an-economic-evaluation-on-the-impact-of-earlier-systemic-lupus-erythematosus-sle-diagnosis-using-complement-c4d-activation-products-in-a-multivariate-assay-panel-map/. Accessed December 29, 2019.

Conrad K, Röber N, Andrade LEC, Mahler M. The Clinical Relevance of Anti-DFS70 Autoantibodies. Clin Rev Allergy Immunol. 2017 Apr;52(2):202-216. PubMed 27350273.
Costedoat-Chalumeau N, Amoura Z, Hulot J-S, et al. Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus. Ann Rheum Dis 2007;66:821–4.doi:10.1136/ard.2006.067835
Costedoat-Chalumeau N, et al. [Blood concentration of hydroxychloroquine in systemic lupus erythematosus care: Usefulness and limits]. Revue Médecine Interne 2017; 38:77-80.
Cross LS, et al. Antinuclear antibody-negative lupus as a distinct diagnostic entity– does it no longer exist? Q J Med 2004;97:303-308.
Daikh DI. Antinuclear antibodies and lupus: label versus meaning. Arthr Care Res 2019;71:1401-1403.
Dinse GE, Parks CG, Weinberg CR, et al. Increasing Prevalence of Antinuclear Antibodies in the United States. Arthritis Rheumatol. 2020;72(6):1026-1035. doi:10.1002/art.41214
Durcan L, et al. Hydroxychloroquine blood levels in systemic lupus erythematosus: clarifying dosing controversies and improving adherence. J Rheum 2015;42:2092-2097.
Ekinci Z and Ozturk K. Systemic lupus erythematosus with C1q deficiency: treatment with fresh frozen plasma. Lupus 2018;27:134-138.
Fattal I, et al. An antibody profile of systemic lupus erythematosus detected by antigen microarray. Immunol 2010;130:337-343.
Fedrigo A, et al. The lupus patient with positive rheumatoid factor. Lupus 2018;27:1368-1373.
Firooz N, Albert DA, Wallace DJ, Ishimori M, Berel D, Weisman MH. High-sensitivity C-reactive protein and erythrocyte sedimentation rate in systemic lupus erythematosus. Lupus.2011;20:588–597.

Fitch-Rogalsky C, Steber W, Mahler M, et al. Clinical and Serological Features of Patients Referred through a Rheumatology Triage System because of Positive Antinuclear Antibodies. PLoS One. 2014 Apr 4;9(4):e93812. PubMed 24705829
Fredi, M., Cavazzana, I., Zanola, A., Carabellese, N., Tincani, A., Mahler, M., & Franceschini, F. (2017). Anti-topoisomerase-I antibodies in systemic lupus erythematosus and potential association with the presence of anti-dsDNA antibodies. Lupus, 26(10), 1121-1122.https://doi.org/10.1177
/0961203317696592
Garcia-Vives, E., Solé, C., Moliné, T., Alvarez-Rios, A. M., Vidal, M., Agraz, I., … Cortés-Hernández, J. (2019). Antibodies to M-type phospholipase A2 receptor (PLA2R) in membranous lupus nephritis. Lupus, 28(3), 396–405. https://doi.org/10.1177/0961203319828521
Garate DG, et al. Rheumatoid factor in patients with systemic lupus erythematosus. Lupus Sci Med 2019;6:doi: 10.1136/lupus-2019-lsm.73.

Garraud O, Cognasse F. Are Platelets Cells? And if Yes, are They Immune Cells? Front Immunol. 2015 Feb 20;6:70. doi: 10.3389/fimmu.2015.00070. PMID: 25750642; PMCID: PMC4335469.
George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014;371(7):654. 
Gerli R, Caponi L, Tincani A, Scorza R, Sabbadini MG, et al. Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus: prospective evaluation in a large cohort of Italian patients. Rheumatology (Oxford). 2002;41(12):1357–1366.
Gómez-Puerta JA, Barbhaiya M, Guan H, Feldman CH, Alarcón GS, Costenbader KH. Racial/Ethnic variation in all-cause mortality among United States medicaid recipients with systemic lupus erythematosus: a Hispanic and asian paradox. Arthritis Rheumatol. 2015;67(3):752-760. doi:10.1002/art.38981
Gorphe P. A comprehensive review of HEp-2 cell line in translational research for laryngeal cancer. Am J Canc Res 2019;9:644-649.
Gussin HAE, et al. Anti–topoisomerase I (Anti–Scl‐70) antibodies in patients with systemic lupus erythematosus. Arthr Rheum 2001;44:376-383.
Hahn BH. Pregnancy in Women With Systemic Lupus Erythematosus: Messages for the Clinician. Ann Intern Med. 2015;163(3):232‐233. doi:10.7326/M15-1301
Haserick JR, Long R. Systemic lupus erythematosus preceded by false-positive serologic tests for syphilis: presentation of five cases. Annals of Internal Medicine. September 1952;37(3):559–565.
Her MY, Song JY, Kim DY. Hypocomplementemic urticarial vasculitis in systemic lupus erythematosus. J Korean Med Sci. 2009;24(1):184–186. doi:10.3346/jkms.2009.24.1.184
Howard FM Jr, et al. Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis. Ann N Y Acad Sci. 1987;505:526. 
İlgen, U., Yayla, M. E., Ateş, A., Okatan, İ., Yurteri, E. U., Torgutalp, M., … Kınıklı, G. (2018). Antiphospholipid antibodies and non-thrombotic manifestations of systemic lupus erythematosus. Lupus, 27(4), 665–669. https://doi.org/10.1177/0961203317734924
Infantino M, et al. The clinical impact of Anti-DFS70 antibodies in undifferentiated connective tissue disease: case reports and a review of the literature. Immunol Res 2017;65:293-295.
Jardel S, Fabien N, Hot A, et al. Isolated positive anti-SS-B autoantibodies are not related to clinical features of systemic autoimmune diseases: Results from a routine population survey. PLoS One. 2017;12(9):e0185104. Published 2017 Sep 20. doi:10.1371/journal.pone.0185104
Kakumanu P, Sobel ES, Narain S, Li Y, Akaogi J, Yamasaki Y, et al. Citrulline dependence of anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus as a marker of deforming/erosive arthritis. Journal of Rheumatology. November 2009;36(12):2682–2690.
Kang J-H, et al. Protective role of anti‐ribosomal P antibody in patients with lupus nephritis. Intern J Rheum Dis 2019;22: 913– 920. https://doi.org/10.1111/1756-185X.13517
Kao A, McBurney C, Sattar A, et al. Relation of platelet C4d with all-cause mortality and ischemic stroke in patients with systemic lupus erythematosus. Transl Stroke Res 2014; 5(4):510-518. 
Karassa FB, Aleltra A, Ambrozic A, Chang DM, De Keyser F, et al. Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis. Arthritis & Rheumatism. 2006;54(1):312–324.
Kavanaugh A, Tomar R, Reveille J, Solomon DH, Homburger HA. Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens. Archives of Pathology & Laboratory Medicine. January 2000;124(1):71–81.
Khogeer, H., Alfattani, A., Al Kaff, M., Al shehri, T., Khojah, O., & Owaidah, T. (2015). Antiphosphatidylserine antibodies as diagnostic indicators of antiphospholipid syndrome. Lupus, 24(2), 186–190. https://doi.org/10.1177/0961203314552462
Kim H-A, Jeon J-Y, An J-M, Koh G-R, Suh C-H. C-reactive protein is a more sensitive and specific marker for diagnosing bacterial infections in systemic lupus erythematosus compared to S100A8/A9 and procalcitonin. Journal of Rheumatology. 2012;39(4):728–734.
Kopytek, M., Natorska, J., & Undas, A. (2018). Antiphosphatidylserine/prothrombin (aPS/PT) antibodies are associated with Raynaud phenomenon and migraine in primary thrombotic antiphospholipid syndrome. Lupus, 27(5), 812–819. https://doi.org/10.1177/0961203317751644
Kumar R, et al. Anti-carbamylated protein antibodies in systemic lupus erythematosus: are they useful? [abstract] Ann Rheum dis 2019;78:1719.
Kumar V, et al. Specificity of the Crithidia luciliae method for detecting anti-DNA antibodies. Effect of absorption for lipoproteins. Immunol Invest 1985;14(3):199.
Kwon OC, Kim YG, Park JH, Park MC. Seroconversion to antinuclear antibody negativity and its association with disease flare in patients with systemic lupus erythematosus. Lupus. 2020 Jun;29(7):697-704. doi: 10.1177/0961203320917748. Epub 2020 Apr 11. PMID: 32279583.
LabCorp. Anti-dsDNA (Double-stranded) Antibodies. Retrieved on 12/7/20 at https:///www.labcorp.com/tests/096339/anti-dsdna-double-stranded-antibodies
Langkilde H, et al. Autoantibodies persist in relatives to systemic lupus erythematosus patients during 12 years follow-up. Lupus 26:723-728.
Lee AYS, et al. Utility of the HEp-2000 antinuclear antibody substrate. Ann Rheum Dis 2019. doi: 10.1136/annrheumdis-2019-215519.
Li C, et al. Differences in clinico-pathological characteristics and outcomes between proteinase 3-ANCA positivity and myeloperoxidase-ANCA positivity in lupus nephritis. Lupus 2019;28:1111-1119.
Liang E, Taylor M, McMahon M. Utility of the AVISE Connective Tissue Disease test in predicting lupus diagnosis and progression. Lupus Science & Medicine 2020;7:e000345. doi: 10.1136/lupus-2019-000345
Liang P, et al. Basophil count, a marker for disease activity in systemic lupus erythematosus. Clin Rheum 2015;34:891-896.
Liao H-T, et al. Anti-RNA polymerase III antibody in lupus patients with proteinuria. J Chin Med Assoc 2019;82:260-264.
Littlejohn E, et al. The ratio of erythrocyte sedimentation rate to C-reactive protein is useful in distinguishing infection from flare in systemic lupus erythematosus patients presenting with fever. Lupus 2018;27:1123-1129.
Mahler M, et al. Performance characteristics of different anti-double-stranded DNA antibody assays in the monitoring of systemic lupus erythematosus. J of Immun Res 2017; Volume 2017, Article ID 1720902, 5 pages https://doi.org/10.1155/2017/1720902.
Major GAC. The rarity of antinuclear antibody negativity in systemic lupus erythematosus: comment on the article by Merrill et al. Arthritis & Rheumatism 2011;63(4):1157–1158.
Marai I, Shoenfeld Y, Bizzaro N, et al. IgA and IgG tissue transglutaminase antibodies in systemic lupus erythematosus. Lupus. 2004;13(4):241‐244. doi:10.1191/0961203304lu1004oa
Martín-Nares, E., Hernandez-Molina, G., & Fragoso-Loyo, H. (2019). Aquaporin-4-IgG positive neuromyelitis optica spectrum disorder and systemic autoimmune diseases overlap syndrome: a single-center experience. Lupus, 28(11), 1302–1311. https://doi.org/10.1177/0961203319877255
Marto N, et al. Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus. Ann Rheum Dis 2005;64:444-448.
Massaro L, et al. Anti-carbamylated protein antibodies in systemic lupus erythematosus patients with articular involvement. Lupus 2018;27:105-111.
Massenburg D, Oldenbrug J, Sell A, Krause T, Wells AF. Using the SLE-key Rule-Out test in clinical practice. Lupus Open Access  2017;2:126.
McClain MT, Arbuckle MR, Heinlen LD, et al. The prevalence, onset, and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus. Arthritis Rheum. 2004;50(4):1226-1232. doi:10.1002/art.20120
Merrill JT, Petri MA, Buyon J, et al. Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE. Lupus Science & Medicine 2018;5:e000263. doi: 10.1136/lupus-2018-000263
Mesa A, et al. Differential immunoglobulin class-mediated responses to components of the U1 small nuclear ribonucleoprotein particle in systemic lupus erythematosus and mixed connective tissue disease. Lupus. 2013;22(13):1371. 
Moder K, et al. Age and an autoantibody algorithm helps distinguish patients with systemic lupus erythematosus from those with Sjogren’s syndrome. Lupus Science & Medicine 2018;5:doi: 10.1136/lupus-2018-abstract.79
Moore JE, Shulman LE, Scott JT. The natural history of systemic lupus erythematosus—an approach to its study through chronic biologic false positive reactors: interim report. Transactions of the American and Climatological Association. 1957;68:59–68.
Mosca M, et al. How do patients with newly diagnosed systemic lupus erythematosus present? A multicenter cohort of early systemic lupus erythematosus to inform the development of new classification criteria. Arthr Rheum 2019;71:91-98.

Mouritsen S, Demant E, Permin H, Wiik A. High prevalence of anti-mitochondrial antibodies among patients with some well-defined connective tissue diseases. Clin Exp Immunol. 1986 Oct;66(1):68-76. PMID: 3802575; PMCID: PMC1542653.
Munroe ME, et al. Discerning risk of disease transition in relatives of systemic lupus erythematosus patients utilizing soluble mediators and clinical features. Arthr & Rheum 2017;69:630-642.
Munroe ME, Young KA, Kamen DL, et al. Discerning Risk of Disease Transition in Relatives of Systemic Lupus Erythematosus Patients Utilizing Soluble Mediators and Clinical Features. Arthritis Rheumatol. 2017;69(3):630-642. doi:10.1002/art.40004
Murphy FT, George R, Kubota K, Fears M, Pope V, Howard RS, Dennis G. The use of westernblotting as the confirmatory test for syphilis in patients with rheumatic disease. Journal ofRheumatology. 1999;26:2448–2453.
Nakabo S. Clinical and etiological meaning of anti-carbamylated protein antibodies in rheumatoid arthritis. Immunol Med 2018;41:147-153.
Nesargikar PN, et al. The complement system: history, pathways, cascade and inhibitors. Eur J Microbiol Immunol 2012;2:103-111.
Ochs RL, et al. Autoantibodies in interstitial cystitis. J Urol 1994;151:587-592.
Ortiz-Hernandez GL, Sanchez-Hernandez ES, Casiano CA. Twenty years of research on the DFS70/LEDGF autoantibody-autoantigen system: many lessons learned but still many questions. Auto Immun Highlights. 2020;11(1):3. Published 2020 Feb 3. doi:10.1186/s13317-020-0126-4
Oxelius VA. Immunoglobulin G (IgG) subclasses and human disease. Am J Med 1984;76(3A)7.
Pan N, et al. A surge in anti-dsDNA titer predicts a severe lupus flare within six months. Lupus 2014;23:293-298.
Petri MA, et al. Hydroxychloroquine Blood Levels Predict Hydroxychloroquine Retinopathy. Arthr Rheum 2019. doi: 10.1002/art.41121. [Epub ahead of print]
Petri MA, Avci M, Magder LS. Evaluation of different ways to identify persistent positivity of lupus anticoagulant in systemic lupus erythematosus. Lupus Science & Medicine 2020;7:e000406. doi: 10.1136/lupus-2020-000406
Petri MA, Conklin J, O’Malley T, et al. Platelet-bound C4d, low C3 and lupus anticoagulant associate with thrombosis in SLE. Lupus Science & Medicine 2019;6:e000318. doi: 10.1136/lupus-2019-000318
Picceli VF et al. Spectrum of autoantibodies for gastrointestinal autoimmune diseases in systemic lupus erythematosus patients. Lupus 2013;22:1150-1155.
Pisetsky DS, et al. Assay variation in the detection of antinuclear antibodies in the sera of patients with established SLE. Ann Rheum Dis. 2018;77:911-913.
Pisetsky DS, et al. Variability in antinuclear antibody testing to assess patient eligibility for clinical trials of novel treatments for systemic lupus erythematosus. Arthr Rheum 2019;71:1534-1538.
Pradhan VD, et al. Anti-neutrophil cytoplasmic antibodies (ANCA) in systemic lupus erythematosus: prevalence, clinical associations and correlation with other autoantibodies. J Assoc Phys India 2004;52:53-537.
Putterman C, Balbir-Gurman A, Safer P et al.  The autoimmune discovery iCHIP distinguishes healthy individuals from those with SLE, rheumatoid arthritis (RA), scleroderma (SSc), Sjogren’s syndrome (SS), and the anti-phospholipid syndrome (APS). Arthritis Rheumatol  2017; 69 (suppl 10): abstract 1023.
Putterman C, Furie R, Ramsey-Goldman R, et al. Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements. Lupus Science & Medicine 2014;1:e000056. doi: 10.1136/lupus-2014-000056
Putterman C, Wu A, Reiner-Benaim A et al.  SLE-key® rule-out serologic test for excluding the diagnosis of systemic lupus erythematosus: developing the ImmunArray iCHIP. J Imm
unol Methods  2016;429:1–6.
Quismorio FP Jr, Sharma O, Koss M, et al. Immunopathologic and clinical studies in pulmonary hypertension associated with systemic lupus erythematosus. Semin Arthritis Rheum. 1984;13(4):349‐359. doi:10.1016/0049-0172(84)90015-5
Ramsey-Goldman R, Alexander R, Massarotti E, Wallace DJ, Narain S, Arriens C, Collins CE, Saxena A, Putterman C, Kalunian KC, Sace A, Lafon R, O’Malley T, Ligayon J, Ibarra C, Conklin J, Dervieux T, Weinstein A. Complement Activation Is a Feature of Diseases in the Lupus Spectrum [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/complement-activation-is-a-feature-of-diseases-in-the-lupus-spectrum/. Accessed December 29, 2019.
Ramsey-Goldman R, Li J, Dervieux T, et al. Cell-bound complement activation products in SLE. Lupus Science & Medicine 2017;4:e000236. doi: 10.1136/lupus-2017-000236.
Rensch MJ, Szyjkowski R, Shaffer RT, Fink S, Kopecky C, Grissmer L, Enzenhauer R, KadakiaS. The prevalence of celiac disease autoantibodies in patients with systemic lupus erythematosus.American Journal of Gastroenterology. 2001;96:1113–1115.
Respaldiza N, Wichmann I, Ocaña C, Garcia-Hernandez FJ, Castillo MJ, Magariño MI, et al.Anti-centromere antibodies in patients with systemic lupus erythematosus. ScandinavianJournal of Rheumatology. July 2006;35(4):290–294.
Rezaieyazdi Z, Sahebari M, Hatef MR, Abbasi B, Rafatpanah H, et al. Is there any correlationbetween high sensitive CRP and disease activity in systemic lupus erythematosus? Lupus.2011;20:1494–1500.
Robertson JM, James JA. Preclinical systemic lupus erythematosus. Rheum Dis Clin North Am. 2014;40(4):621–635. doi:10.1016/j.rdc.2014.07.004
Rubio, J., Krishfield, S., & Kyttaris, V. C. (2020). Application of the 2019 European League Against Rheumatism/American College of Rheumatology systemic lupus erythematosus classification criteria in clinical practice: a single center experience. Lupus, 29(4), 421–425. https://doi.org/10.1177/0961203320908939
Ruiz-Irastorza G, Gordo S, Olivares N, Egurbide M-V, Aguirre C. Changes in vitamin D levels in patients with systemic lupus erythematosus: effects onfatigue, disease activity, and damage. Arthritis Care & Research. August 2010;62(8):1160–1165.
Ruperto N, Hanrahan LM, Alarcón GS, Belmont HM, Brey RL, et al. International consensus for a definition of disease flare in lupus. Lupus. April 2005;20(5):453–462.
Rush S, Trupin L, Katz P, et al61 Differences in organ system involvement across racial/ethnic groups: results from the California lupus epidemiology study. Lupus Science & Medicine 2019;6:doi: 10.1136/lupus-2019-lsm.61
Rynes RI. Antimalarial Drugs. In: Textbook of Rheumatology, 5th Ed, Kelly WN, Harris ED Jr, Ruddy S, Sledge CB (Eds), WB Saunders, Philadelphia 1997.
Sarfaraz S, et al. Clinical Significance of Anti-Ribosomal P Protein Antibodies in Patients with Lupus Nephritis. Rev Rec Clin Trials 2018;13:281-286. 
Satoh, M., Vazquez-Del Mercado, M., Krzyszczak, M., Li, Y., Ceribelli, A., Burlingame, R., … Chan, E. (2012). Coexistence of anti-RNA polymerase III and anti-U1RNP antibodies in patients with systemic lupus erythematosus: two cases without features of scleroderma. Lupus, 21(1), 68–74. https://doi.org/10.1177/0961203311422712
Seo M, Yeo J, Ryu H, Choi H, Baek H. Clinical Relevance According to Staining Patterns and Titers of Antinuclear Antibody [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/clinical-relevance-according-to-staining-patterns-and-titers-of-antinuclear-antibody/. Accessed June 6, 2021.
Schur PH. Know your labs: a review of state-of-the-art testing for SLE, connective tissue disease & RA. The Rheumatologist DEC 2014: 79-88.
Shi J, Milo J, Bradey K, Bentow C, Conklin J, O’Malley T, Sace A, Lafon R, Poling D, Ibarra C, Mahler M, Dervieux T. Diagnostic Performances of Antibodies Against Carbamylated Proteins in US Based Populations with Rheumatoid Arthritis and Other Autoimmune Rheumatic Diseases [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/diagnostic-performances-of-antibodies-against-carbamylated-proteins-in-us-based-populations-with-rheumatoid-arthritis-and-other-autoimmune-rheumatic-diseases/. Accessed December 29, 2019.
Shi, Z.-R., Cao, C.-X., Tan, G.-Z., & Wang, L. (2015). The association of serum anti-ribosomal P antibody with clinical and serological disorders in systemic lupus erythematosus: a systematic review and meta-analysis. Lupus, 24(6), 588–596. https://doi.org/10.1177/0961203314560003
Siegert CE, et al. The relationship between serum titers of autoantibodies to C1q and age in the general population and in patients with systemic lupus erythematosus. Clin Immunol Immunopathol 1993;67:204-209.
Smilek DE, Lim N, Ding L, et al. Correlation of hypogammaglobulinaemia with proteinuria, and the relationship between hypogammaglobulinaemia and infection in active lupus nephritis. Lupus Science & Medicine 2017;4:e000229. doi: 10.1136/lupus-2017-000229
Sobral S, et al. Do anti-neutrophil cytoplasmic antibodies play a role in systemic lupus erythematosus (SLE) patients? Analysis of the University College Hospital SLE cohort. Lupus 2018;27:343-344.
Stegert M, et al. Clinical presentation of human C1q deficiency: how much of a lupus? Molec Immun 2015;67:3-11.
Stojan G and Petri M. Anti-C1q in systemic lupus erythematosus. Lupus 2016;25:873-877.
Stojan G, et al. Erythrocyte sedimentation rate is a predictor of renal and overall SLE disease activity. Lupus 2013;22:827-834.
Taraborelli, M., Leuenberger, L., Lazzaroni, M. G., Martinazzi, N., Zhang, W., Franceschini, F., … Erkan, D. (2016). The contribution of antiphospholipid antibodies to organ damage in systemic lupus erythematosus. Lupus, 25(12), 1365–1368. https://doi.org/10.1177/0961203316637431
Tarazi M, et al. Cutaneous lupus erythematosus patients with a negative antinuclear antibody meeting the ACR and/or SLICC criteria for systemic lupus erythematosus. Arthr Care Res 2019;71:1404-1409.
Therapeutic Research Center (2018). Biotin and labs. Retrieved 12/7/20 from https:///www.ospdocs.com/resources/uploads/files/Biotin%20and%20Labs.pdf
Thomas DE, Lyons JS, Greene BS, Petri M. Low hydroxychloroquine blood levels in patients who have had gastric bypass surgery. Lupus Science & Medicine 2019;6:e000335. doi: 10.1136/lupus-2019-000335.

Toolan HW. Growth of Human Tumors in Cortisone-treated Laboratory Animals: The Possibility of Obtaining Permanently Transplantable Human Tumors* †. Cancer Res 1 April 1953; 13 (4-5): 389–394.

Toolan HW. Transplantable Human Neoplasms Maintained in Cortisonetreated Laboratory Animals: H.S. #1; H.Ep. #1; H.Ep. #2; H.Ep. #3; and H.Emb.Rh. #1* †. Cancer Res 1 October 1954; 14 (9): 660–666.
Viana VT, et al. Ribosomal P antibody: 30 years on the road. Lupus 2017;26:453-462.
Villalta D, Bizzaro N, Tonutti E, Tozzoli R. IgG Anti-transglutaminase autoantibodies in systemic lupus erythematosus and Sjögren Syndrome [Letter to the editor]. Clinical Chemistry.20
02;48:1133.
VonMühlen CA, Tan EM. Autoantibodies in the diagnosis of systemic rheumatic diseases.Seminars in Arthritis and Rheumatism. April 1995;24(5):323–358.
Wallace DJ, Silverman SL, Conklin J, et al. Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound complement activation products. Lupus Science & Medicine 2016;3:e000127. doi: 10.1136/lupus-2015-000127
Wallace ZS, Naden RP, Chari S Members of the ACR/EULAR IgG4-RD Classification Criteria Working Group, et al. The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease. Annals of the Rheumatic Diseases 2020;79:77-87.
White, D.H.N., Chapman, P.T., O’Donnell, J.L., James, J., Frampton, C. and Stamp, L.K. (2010): Lack of association between elevated mean red cell volume and haematological toxicity in patients receiving long‐term methotrexate for rheumatoid arthritis. Internal Medicine Journal, 40: 561-565. doi:10.1111/j.1445-5994.2009.02059.x
Yap KS, et al. Association of low vitamin D with high disease activity in an Australian systemic lupus erythematosus cohort. Lupus Sci Med 2015:DOI 10.1136/lupus-2014-000064.
Zamora-Medina MDC, et al. Anti-RNP/Sm antibodies in patients with systemic lupus erythematosus and its role in thrombosis: a case-control study. Clin Rheum 2019;38:885-893.
Ziegelasch M, et al. Antibodies against carbamylated proteins and cyclic citrullinated peptides in systemic lupus erythematosus: results from two well-defined European cohorts. Arthr Res Ther 2016;18:289 (2016) doi:10.1186/s13075-016-1192-x.

Chapter 5

Apostolopoulos D, et al. Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study. Lancet Rheum 2020;2:e24-e30.
Barr SG, et al. Patterns of disease activity in systemic lupus erythematosus. Arthr Rheum 1999;42:2682-2688.
Conceição, C.T.M., Meinão, I.M., Bombana, J.A. et al. Psychoanalytic psychotherapy improves quality of life, depression, anxiety and coping in patients with systemic lupus erythematosus: a controlled randomized clinical trial. Adv Rheumatol59, 4 (2019) doi:10.1186/s42358-019-0047-y
Corneloup M, François Maurier, Denis Wahl, Geraldine Muller, Olivier Aumaitre, Pascal Seve, Gilles Blaison, Jean-Loup Pennaforte, Thierry Martin, Nadine Magy-Bertrand, Sabine Berthier, Laurent Arnaud, Abderrahmane Bourredjem, Zahir Amoura, Hervé Devilliers, the EQUAL Study Group. Disease-specific quality of life following a flare in systemic lupus erythematosus: an item response theory analysis of the French EQUAL cohort, Rheumatology, https://doi.org/10.1093/rheumatology/kez451
Corrêa, J. D., Branco, L. G. A., Calderaro, D. C., Mendonça, S. M. S., Travassos, D. V., Ferreira, G. A., … Silva, T. A. (2018). Impact of systemic lupus erythematosus on oral health-related quality of life. Lupus, 27(2), 283–289. https://doi.org/10.1177/0961203317719147
Duarte-García A, Fang H, To CH, Magder LS, Petri M. Seasonal variation in the activity of systemic lupus erythematosus. Journal of Rheumatology. 2012;39(7):1392–1398.
European Academy of Allergy and Clinical Immunology (2017). Allergen Immunotherapy Guidelines, Part 2: Recommendations. Retrieved on June 20, 2020 from https:///www.eaaci.org/documents/Part_II_-_AIT_Guidelines_-_web_edition.pdf​
Gavilán-Carrera, B, et al. Association of physical fitness components and health-related quality of life in women with systemic lupus erythematosus with mild disease activity. PLOS One 2019: (cite reviewed 18JAN20): https://doi.org/10.1371/journal.pone.0212436

Goto M, Yokogawa N, Miyoshi Y, et alSAT0208 INCIDENCES OF ADVERSE EFFECTS AND DISEASE FLARE DUE TO PNEUMOCYSTIS PNEUMONIA PROPHYLAXIS WITH TRIMETHOPRIM/SULFAMETHOXAZOLE IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTSAnnals of the Rheumatic Diseases 2020;79:1047.

Gulati G, Brunner H. Environmental triggers in systemic lupus erythematosus. Sem Arthr Rheum 2018;47:710-717.
Györi N, Giannakou I, Chatzidionysiou K, Magder L, van Vollenhoven RF, Petri M. Disease activity patterns over time in patients with SLE: analysis of the Hopkins Lupus Cohort. Lupus Sci Med. 2017;4(1):e000192. Published 2017 Feb 8. doi:10.1136/lupus-2016-000192
Hebra F, Kaposi M. Lupus Erythematosus. Tray W, ed. and trans. On Diseases of the Skin, Including Exanthemata. London: The New Sydenham Society; 1875.
Hsiao, Y.-P.; Tsai, J.-D.; Muo, C.-H.; Tsai, C.-H.; Sung, F.-C.; Liao, Y.-T.; Chang, Y.-J.; Yang, J.-H. Atopic Diseases and Systemic Lupus Erythematosus: An Epidemiological Study of the Risks and Correlations. Int. J. Environ. Res. Public Health 2014, 11, 8112-8122.
Ishiguro, M., Hashizume, H., Ikeda, T., Yamamoto, Y., & Furukawa, F. (2014). Evaluation of the quality of life of lupus erythematosus patients with cutaneous lesions in Japan. Lupus, 23(1), 93–101. https://doi.org/10.1177/0961203313509293
Jolly, M., Sequeira, W., Block, J.A., Toloza, S., Bertoli, A., Blazevic, I., Vila, L.M., Moldovan, I., Torralba, K.D., Mazzoni, D., Cicognani, E., Hasni, S., Goker, B., Haznedaroglu, S., Bourre‐Tessier, J., Navarra, S.V., Mok, C.C., Weisman, M., Clarke, A.E., Wallace, D. and Alarcón, G. (2019), Sex Differences in Quality of Life in Patients With Systemic Lupus Erythematosus. Arthritis Care Res, 71: 1647-1652. doi:10.1002/acr.23588
Kearse CL, Campbell R, Oates J, et al. Impact of diagnosis age on quality of life among patients with systemic lupus erythematosus. Lupus Science & Medicine 2019;6:doi: 10.1136/lupus-2019-lsm.154
Keramiotou K, Anagnostou C, Galanos A, et al. THE IMPACT OF EXERCISE ON HAND FUNCTION AND QUALITY OF LIFE OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A RANDOMIZED CONTROLLED TRIAL. Annals of the Rheumatic Diseases 2019;78:204.
Kolstoe, J. Systemic lupus erythematosus: adding value to our patients with the art of medicine. Value-Based Care in Rheumatology 2013;2:5.
Leung, J., Ra, J., Baker, E.A. and Kim, A.H.J. (2019), “…Not Having the Real Support That We Need”: Patients’ Experiences With Ambiguity of Systemic Lupus Erythematosus and Erosion of Social Support. ACR Open Rheumatology, 1: 135-144. doi:10.1002/acr2.1020
Lieberman P. American Academy of Allergy, Asthma, and Immunology. Abatacept and allergen skin testing and immunotherapy. retrieved on June 21, 2020 from https:///www.aaaai.org/ask-the-expert/abatacept
Mena-Vázquez N, et al. Hydroxychloroquine is associated with a lower risk of polyautoimmunity: data from the RELESSER Registry. Rheumatology, , kez562, https://doi.org/10.1093/rheumatology/kez562
Miyawaki Y, et al. Progressive reduction of serum complement levels: a risk factor for relapse in patients wit
h hypocomplementemia in systemic lupus erythematosus. Lupus 2018 Nov;27(13):2093-2100. doi: 10.1177/0961203318804892. Epub 2018 Oct 11.
Mohamed, S., Fahmy, N., Mohamed, S., & Morshedy, N. (2019). Effect of Self-Care Guideline on Quality of Life among Pregnant Women with Systemic Lupus Erythematosus. Evidence-Based Nursing Research, 1(3), 15. Retrieved from https://50.112.215.110/index.php/ebnr/article/view/68
Morgan, C., Bland, A. R., Maker, C., Dunnage, J., & Bruce, I. N. (2018). Individuals living with lupus: findings from the LUPUS UK Members Survey 2014. Lupus, 27(4), 681–687. https://doi.org/10.1177/0961203317749746
Mysliwiec V, Martin JL, Ulmer CS, et al. The Management of Chronic Insomnia Disorder and Obstructive Sleep Apnea: Synopsis of the 2019 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guidelines. Ann Intern Med. 2020;172:325–336. [Epub ahead of print 18 February 2020]. doi: https://doi.org/10.7326/M19-3575
Ogunsanya, M., Cho, S., Hudson, A. and Chong, B. (2019), Validation and reliability of a disease‐specific quality‐of‐life measure in patients with cutaneous lupus erythematosus. Br J Dermatol, 180: 1430-1437. doi:10.1111/bjd.17636
Oparina N, et al. An update on the genetics of systemic lupus erythematosus. Curr Opin Rheumatol. 2019 Nov;31(6):659-668. doi: 10.1097/BOR.0000000000000654
Otto A. ‘Type II’ SLE assessment catches what matters to patients. Rheumatology News APR 2019 (online article retrieved 1/19/20): https:///www.mdedge.com/rheumatology/article/199289/lupus-connective-tissue-diseases/type-ii-sle-assessment-catches-what
Parks, C., Biagini, R., Cooper, G., Gilkeson, G., & Dooley, M. (2010). Total serum IgE levels in systemic lupus erythematosus and associations with childhood onset allergies. Lupus, 19(14), 1614–1622. https://doi.org/10.1177/0961203310379870
Parodis I, et al. Definitions of remission in systemic lupus erythematosus: a post-hoc analysis of two randomised clinical trials. Lancet 2019;DOI: https://doi.org/10.1016/S2665-9913(19)30049-9​
Parodis, I., Lopez Benavides, A.H., Zickert, A., Pettersson, S., Möller, S., Welin Henriksson, E., Voss, A. and Gunnarsson, I. (2019), The Impact of Belimumab and Rituximab on Health‐Related Quality of Life in Patients With Systemic Lupus Erythematosus. Arthritis Care Res, 71: 811-821. doi:10.1002/acr.23718
Petri, M, Allbritton, J. Antibiotic allergy in systemic lupus erythematosus: a case-control study. J Rheumatol 1992; 19: 265–269.​
Poomsalood N, Chaiamnuay S, Narongroeknawin P, et al. PROLONGED CLINICAL REMISSION AND LOW DISEASE ACTIVITY STATUSES ARE ASSOCIATED WITH BETTER QUALITY OF LIFE IN SYSTEMIC LUPUS ERYTHEMATOSUS. Annals of the Rheumatic Diseases 2019;78:1703-1704.
Roberts G, Pfaar O, Akdis CA, et al. EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis. Allergy. 2018;73(4):765-798. doi:10.1111/all.13317
Rogers JL, Eudy AM, Criscione-Schreiber LG, et al.  novel approach to addressing fibromyalgia symptomatology in SLE. Lupus Science & Medicine 2019;6:doi: 10.1136/lupus-2019-lsm.102
Román Ivorra, J.A., Fernández-Llanio-Comella, N., San-Martín-Álvarez, A. et al. Health-related quality of life in patients with systemic lupus erythematosus: a Spanish study based on patient reports. Clin Rheumatol 38, 1857–1864 (2019) doi:10.1007/s10067-019-04485-6.
Steiman AJ, et al. Prolonged Clinical Remission in Patients with Systemic Lupus Erythematosus. J Rheum 2014;131137; DOI: 10.3899/jrheum.131137​.
Stevens B, Rodriguez M, Rakestraw A, et al. QUALITY OF LIFE IN SUBJECTS WITH PRE-PUBERTAL ONSET SYSTEMIC LUPUS ERYTHEMATOSUS. Annals of the Rheumatic Diseases 2019;78:1326-1327.
Stojan G, Kvit A, Curriero F, et al. Environmental and atmospheric factors in systemic lupus erythematosus: a regression analysis. Lupus Science & Medicine 2019;6:doi: 10.1136/lupus-2019-lsm.297
Strand, V., Berry, P., Lin, X., Asukai, Y., Punwaney, R. and Ramachandran, S. (2019), Long‐Term Impact of Belimumab on Health‐Related Quality of Life and Fatigue in Patients With Systemic Lupus Erythematosus: Six Years of Treatment. Arthritis Care Res, 71: 829-838. doi:10.1002/acr.23788
Szczęch, J., Samotij, D., Werth, V. P., & Reich, A. (2017). Trigger factors of cutaneous lupus erythematosus: a review of current literature. Lupus, 26(8), 791–807. https://doi.org/10.1177/0961203317691369​
Tani C, Vagelli R, Stagnaro C, et al. Remission and low disease activity in systemic lupus erythematosus: an achievable goal even with fewer steroids? Real-life data from a monocentric cohort. Lupus Science & Medicine 2018;5:e000234. doi: 10.1136/lupus-2017-000234.
Tselios K, Gladman DD, Urowitz MB. How can we define low disease activity in systemic lupus erythematosus? Semin Arthr Rheum 2019;48:1035-1040.
Torres-Ruiz, J & Barrera, Ana & Ortiz-Hernández, R & Alcocer-Varela, J & Ponce-de-León, A & Gomez, Diana. (2017). Microbiological and immunological profile of patients with severe lupus flares related to bloodstream infections: a retrospective cohort study. Lupus. 27. 961203317720527. 10.1177/0961203317720527.
Ugarte‐Gil, M.F., Gamboa‐Cárdenas, R.V., Reátegui‐Sokolova, C., Medina‐Chinchón, M., Zevallos, F., Elera‐Fitzcarrald, C., Pimentel‐Quiroz, V., Cucho‐Venegas, J.M., Rodríguez‐Bellido, Z., Pastor‐Asurza, C.A., Alarcón, G.S. and Perich‐Campos, R. (2020), Low Disease Activity State/Remission Predicts a Better Health‐Related Quality of Life in Systemic Lupus Erythematosus Patients. Arthritis Care Res. Accepted Author Manuscript. doi:10.1002/acr.24009

Ugarte-Gil MF, Hanly J, Urowitz M, et al. Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohortAnnals of the Rheumatic Diseases 2022;81:1541-1548.
Ugarte-Gil MF, Pons-Estel GJ, Vila LM, et al. Time in remission and low disease activity state (LDAS) are associated with a better quality of life in patients with systemic lupus erythematosus: data from a multi-ethnic, multicenter US cohort. Lupus Science & Medicine 2019;6:doi: 10.1136/lupus-2019-lsm.57
Urowitz MB, et al. Prolonged remission in systemic lupus erythematosus. J Rheum 2005;32:1467.
Van Vollenhoven R, et al. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). Ann Rheum Dis 2017;76:554–61.
Vordenbäumen S, Brinks R, Sander O, et al. [Determinants of health-related quality of life in systemic lupus erythematosus: a monocentric, retrospective long-term observational study in Germany]. Zeitschrift fur Rheumatologie. 2019 Nov;78(9)
:813-819. DOI: 10.1007/s00393-019-00691-4.
Vorobyova L, Aseeva E, Solovyev. THE EFFECT OF CUTANEOUS AND MUSCULOSKELETAL SYMPTOMS ON QUALITY OF LIFE IN PATIENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS IN RENAISSANCE COHORT. Annals of the Rheumatic Diseases 2019;78:1746.
Vorobyova L, Aseeva E, Solovyev. THE EFFECT OF DEPRESSIVE AND ANXIETY ON QUALITY OF LIFE IN PATIENT WITH SYSTEMIC LUPUS ERYTHEMATOSUSIN RENAISSANCE COHORT. Annals of the Rheumatic Diseases 2019;78:1745-1746.
Wozniacka A, Sysa-Jedrzejowska A, Robak E, Samochocki Z, Zak-Prelich M. Allergic diseases, drug adverse reactions and total immunoglobulin E levels in lupus erythematosus patients. Mediators Inflamm. 2003;12(2):95-99. doi:10.1080/0962935031000097709
Zawodniak A, Lochmatter P, Beeler A, Pichler WJ. Cross-reactivity in drug hypersensitivity reactions to sulfasalazine and sulfamethoxazole. Int Arch Allergy Immunol. 2010;153(2):152-6. doi: 10.1159/000312632. Epub 2010 Apr 22. PMID: 20413982.
Zen M, et al. Prolonged remission in Caucasian patients with SLE: prevalence and outcomes. Ann Rheum Dis 2015;74:2117-2122.
Zeña Huancas PA, Sokolova CR, Cardenas RG, et al. ASSOCIATION BETWEEN SELF-EFFICACY AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS. Annals of the Rheumatic Diseases 2019;78:1181.
Zhao, C.-N., Mei, Y.-J., Wu, G.-C., Mao, Y.-M., Wu, Q., Dan, Y.-L., & Pan, H.-F. (2019). Effect of air pollution on hospital admissions for systemic lupus erythematosus in Bengbu, China: a time series study. Lupus, 28(13), 1541–1548. https://doi.org/10.1177/0961203319882503

Chapter 6

Asim Khan, Angela Pakozdi, Ravindra Rajakariar, Andrea Cove-Smith, Myles Lewis, Dev Pyne, E090 Sleep disturbances in lupus patients, Rheumatology, Volume 58, Issue Supplement_3, April 2019, kez110.088, https://doi.org/10.1093/rheumatology/kez110.088
Avaux M, et al. Effects of two different exercise programs on chronic fatigue in lupus patients, Acta Clinica Belgica 2016;71:403-406, DOI: 10.1080/17843286.2016.1200824
Azizoddin, D. R., Gandhi, N., Weinberg, S., Sengupta, M., Nicassio, P. M., & Jolly, M. (2019). Fatigue in systemic lupus: the role of disease activity and its correlates. Lupus, 28(2), 163–173. https://doi.org/10.1177/0961203318817826
Barbacki A, Petri M, Aviña-Zubieta A, Alarcón GS, Bernatsky S. Fatigue Measurements in Systemic Lupus Erythematosus. J Rheumatol. 2019;46(11):1470-1477. doi:10.3899/jrheum.180831
Chung F, Yegneswaran B, Liao P, Chung SA, Vairavanathan S, Islam S, et al. STOP questionnaire:a tool to screen patients for obstructive sleep apnea. Anesthesiology.2008;108:812–822.
Davies RJ, Lomer MCE, Yeo SI, et al. Weight loss and improvements in fatigue in systemic lupus erythematosus: a controlled trial of a low glycaemic index diet versus a calorie restricteddiet in patients treated with corticosteroids. Lupus. May 2012;21(6):649–655.
Downie LE et al. Blue‐light filtering spectacle lenses for visual performance, sleep, and macular health in adults. The Cochrane database of Systematic Reviews 2019;1:https:///www.ncbi.nlm.nih.gov/pmc/articles/PMC6353079/
Hackett K, Davies K, Lendrem D, Hargreaves B, Ng W, Newton J. Improvement in fatigue following a multidisciplinary, biopsychosocial intervention: data from 50 primary Sjögren’s syndrome patients (abstract). Clin Exp Rheumatol. 2018;36(3):112. 
Harvard Health Publishing, Harvard Medical School (August 13, 2018). Blue light has a dark side. Retrieved 1/21/20 from https:///www.health.harvard.edu/staying-healthy/blue-light-has-a-dark-side
Hoek LJM (January 2015). The experience and impact of fatigue in patients with systemic Lupus Erythematosus, and their partners : a qualitative study (Unpublished master’s thesis). University of Twente, Enschede. 
Katz P, Pedro S, Michaud K. Sleep disturbances among women with systemic lupus erythematosus (SLE). Lupus Science & Medicine 2018;5:doi: 10.1136/lupus-2018-lsm.65
Killgore WDS, et al. A randomized, double-blind, placebo-controlled trial of blue wavelength light exposure on sleep and recovery of brain structure, function, and cognition following mild traumatic brain injury. Neurobiol of Dis 2020;134:https://doi.org/10.1016/j.nbd.2019.104679
Leuchten, N., Milke, B., Winkler-Rohlfing, B., Daikh, D., Dörner, T., Johnson, S. R., & Aringer, M. (2018). Early symptoms of systemic lupus erythematosus (SLE) recalled by 339 SLE patients. Lupus, 27(9), 1431–1436. https://doi.org/10.1177/0961203318776093
Lima, G.L., Paupitz, J., Aikawa, N.E., Takayama, L., Bonfa, E. and Pereira, R.M.R. (2016), Vitamin D Supplementation in Adolescents and Young Adults With Juvenile Systemic Lupus Erythematosus for Improvement in Disease Activity and Fatigue Scores: A Randomized, Double‐Blind, Placebo‐Controlled Trial. Arthritis Care & Research, 68: 91-98. doi:10.1002/acr.22621
Mackowiak PA, Wasserman SS, Levine MM. A critical appraisal of 98.6 degrees F, the upperlimit of the normal body temperature, and other legacies of Carl Reinhold August Wunderlich. Journal of the American Medical Association. 1992;268(12):1578–1580.
Mahieu, M. A., Ahn, G. E., Chmiel, J. S., Dunlop, D. D., Helenowski, I. B., Semanik, P., … Ramsey-Goldman, R. (2016). Fatigue, patient reported outcomes, and objective measurement of physical activity in systemic lupus erythematosus. Lupus, 25(11), 1190–1199. https://doi.org/10.1177/0961203316631632
Mahieu, M. A., Strand, V., Simon, L. S., Lipsky, P. E., & Ramsey-Goldman, R. (2016). A critical review of clinical trials in systemic lupus erythematosus. Lupus, 25(10), 1122–1140. https://doi.org/10.1177/0961203316652492
Mertz P, Schlencker A, Schneider M, et alTowards a practical management of fatigue in systemic lupus erythematosusLupus Science & Medicine 2020;7:e000441. doi: 10.1136/lupus-2020-000441
Mirbagher, L., Gholamrezaei, A., Hosseini, N. and Sayed Bonakdar, Z. (2016), Sleep quality in women with systemic lupus erythematosus: contributing factors and effects on health‐related quality of life. Int J Rheum Dis, 19: 305-311. doi:10.1111/1756-185X.12418
Miserandino, Christine (2003). “The Spoon Theory”. But You Don’t Look Sick. Retrieved 5 July 2017.
Miyamoto ST, Lendrem DW, Ng WF, Hackett KL, Valim V. Managing fatigue in patients with primary Sjögren’s syndrome: challenges and solutions. Open Access Rheumatol. 2019;11:77–88. Published 2019 Apr 24. doi:10.2147/OARRR.S167990
Morgan, C., Bland, A. R., Maker, C., Dunnage, J., & Bruce, I. N. (2018). Individuals living with lupus: findings from the LUPUS UK Members Survey 2
014. Lupus, 27(4), 681–687. https://doi.org/10.1177/0961203317749746
Mishra R, Vivino FB. Diagnosis and management of fatigue. In: Wallace, DJ, ed. The Sjögren’sBook. New York: Oxford University Press; 2012:228–234.
Nguyen, M., Bryant, K., & O’Neill, S. (2018). Vitamin D in SLE: a role in pathogenesis and fatigue? A review of the literature. Lupus, 27(13), 2003–2011. https://doi.org/10.1177/0961203318796293
O’Malley PG, Jackson JL, Santoro J, Tomkins G, Balden E, Kroenke K. Antidepressant therapyfor unexplained symptoms and symptom syndromes. Journal of Family Practice.1999;48(12):980–990.
Overman, C., Hartkamp, A., Bossema, E., Bijl, M., Godaert, G., Bijlsma, J., … Geenen, R. (2012). Fatigue in patients with systemic lupus erythematosus: the role of dehydroepiandrosterone sulphate. Lupus, 21(14), 1515–1521. https://doi.org/10.1177/0961203312459105
Palagini, L., Tani, C., Mauri, M., Carli, L., Vagnani, S., Bombardieri, S., … Mosca, M. (2014). Sleep disorders and systemic lupus erythematosus. Lupus, 23(2), 115–123. https://doi.org/10.1177/0961203313518623
Patterson SL, Schmajuk G, Jafri K, Yazdany J, Katz P. Obesity is Independently Associated With Worse Patient-Reported Outcomes in Women with Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2019;71(1):126-133. doi:10.1002/acr.23576
del Pino‐Sedeño, T., Trujillo‐Martín, M.M., Ruiz‐Irastorza, G., Cuellar‐Pompa, L., de Pascual‐Medina, A.M., Serrano‐Aguilar, P. and (2016), Effectiveness of Nonpharmacologic Interventions for Decreasing Fatigue in Adults With Systemic Lupus Erythematosus: A Systematic Review. Arthritis Care & Research, 68: 141-148. doi:10.1002/acr.22675
Rahman MM, Moniruzzan M, Sayeed JB, et al. 239 Patterns of organ involvement in SLE and their outcome: a real life experience in a lupus clinic. Lupus Science & Medicine 2019;6:doi: 10.1136/lupus-2019-lsm.239
Ratcliffe K, Ewan V, Strassheim V. Managing Your Energy by Newcastle CRESTA Fatigue Clinic 2017 (reviewed 2020); retrieved on 2/1/20 at https:///www.ncl.ac.uk/media//wwwnclacuk/facultyofmedicalsciences/files/CRESTA%20Fatigue%20Booklet%20-%20reformatted%208th%20August%202017.pdf
Ruiz-Irastorza G, et al. Changes in vitamin D levels in patients with systemic lupus erythematosus: Effects on fatigue, disease activity, and damage. Arthr Care Res 2010;62:1160-1165.
SHEARN MA, PIROFSKY B. DISSEMINATED LUPUS ERYTHEMATOSUS: Analysis of Thirty-Four Cases. AMA Arch Intern Med. 1952;90(6):790–807. doi:10.1001/archinte.1952.00240120065007
Sheon RP, Moskowitz RW. Soft Tissue Rheumatic Pain. 3rd ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 1996.
Social Security Administration (September 2008). Disability Evaluation Under Social Security (Blue Book). Retrieved on 1/21/20 from https:///www.ssa.gov/disability/professionals/bluebook/14.00-Immune-Adult.htm#14_02
Stockton KA, Kandiah DA, Paratz JD, Bennell KL. Fatigue, muscle strength and vitamin D status in women with systemic lupus erythematosus compared with healthy controls. Lupus.March 2012;21(3):271–278.
Stojan, G., Li, J., Wittmaack, A. and Petri, M. (2020), Cachexia in Systemic Lupus Erythematosus: Risk Factors and Relation to Disease Activity and Damage. Arthritis Care Res. Accepted Author Manuscript. doi:10.1002/acr.24395
Vakil M, Park S, Broder A. The complex associations between obstructive sleep apnea and auto-immune disorders: A review. Medical Hypotheses 2018;110:138-143.
Yuen HK, Holthaus, Kamen DL, Sword DO, Breland HL. Using Wii Fit to reduce fatigue among African American women with systemic lupus erythematosus: a pilot study. Lupus.2011;20:1293–1299.

Chapter 7

Abebe W. Herbal medication: potential for adverse interactions with analgesic drugs. Journal of Pharmacy and Therapeutics. December 2002;27(6):391–401.
Guillaume de Baillou. Retrieved May 7, 2011, from www.en.wikipedia.org/wiki/Guillaume_Baillou.
Ahmed S Zayat, Khaled Mahmoud, Md Yuzaiful Md Yusof, Sandeep Mukherjee, Maria-Antoinetta D’Agostino, Elizabeth M A Hensor, Richard J Wakefield, Philip G Conaghan, Christopher J Edwards, Paul Emery, Edward M Vital, Defining inflammatory musculoskeletal manifestations in systemic lupus erythematosus, Rheumatology, Volume 58, Issue 2, February 2019, Pages 304–312, https://doi.org/10.1093/rheumatology/key277
Andrews, J.S., Trupin, L., Schmajuk, G., Barton, J., Margaretten, M., Yazdany, J., Yelin, E.H. and Katz, P.P. (2015), Muscle Strength and Changes in Physical Function in Women With Systemic Lupus Erythematosus. Arthritis Care & Research, 67: 1070-1077. doi:10.1002/acr.22560
Biswas A, et al. Hansen KE, et al. Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med 2005;165(22):2671. Ann Int Med 2015;162:123.
Burlina P, Billings S, Joshi N, Albayda J. Automated diagnosis of myositis from muscle ultrasound: Exploring the use of machine learning and deep learning methods. PLoS One. 2017 Aug 30;12(8):e0184059. doi: 10.1371/journal.pone.0184059. eCollection 2017.
Chau JY, et al. Sedentary behaviour and risk of mortality from all-causes and cardiometabolic diseases in adults: evidence from the HUNT3 population cohort. Br J Sports Med 2015;49:737-742
Di Matteo, A., De Angelis, R., Cipolletta, E., Filippucci, E., & Grassi, W. (2018). Systemic lupus erythematosus arthropathy: the sonographic perspective. Lupus, 27(5), 794–801. https://doi.org/10.1177/0961203317747716
Di Matteo A, Emilio Filippucci, Edoardo Cipolletta, Iulia Satulu, Jana Hurnakova, Valentina Lato, Rossella De Angelis, Rudolf Horvath, Karel Pavelka, Fausto Salaffi, Walter Grassi, Entheseal involvement in patients with systemic lupus erythematosus: an ultrasound study, Rheumatology, Volume 57, Issue 10, October 2018, Pages 1822–1829, https://doi.org/10.1093/rheumatology/key189
Di Matteo, A., Isidori, M., Corradini, D., Cipolletta, E., McShane, A., De Angelis, R., … Grassi, W. (2019). Ultrasound in the assessment of musculoskeletal involvement in systemic lupus erythematosus: state of the art and perspectives. Lupus, 28(5), 583–590. https://doi.org/10.1177/0961203319834671
Hansen KE, et al. Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med. 2005;165(22):2671. 
Huang F, O’neill S, Fang R, et al. (THU0265) IDENTIFYING COMORBID FIBROMYALGIA IN SYSTEMIC LUPUS ERYTHEMATOSUS USING PATIENT-REPORTED OUTCOMES. Annals of the Rheumatic Diseases 2019;78:410-411.
Iagnocco T, et al. Ultrasound evaluation of hand, wrist and foot joint synovitis in systemic lupus erythematosus. Rheumatology (Oxford, England) 2014;53:465-472.
Jorge A, Wallace ZS, Zhang Y, Lu N, Costenbader KH, Choi HK. All-Cause and Ca
use-Specific Mortality Trends of End-Stage Renal Disease Due to Lupus Nephritis From 1995 to 2014. Arthritis Rheumatol. 2019;71(3):403-410. doi:10.1002/art.40729
Kaufman MB. Drug updates: information on new approvals and medication safety. The Rheumatologist. September 2011. Retrieved October 1, 2011, from www.the-rheumatologist.org/details/article/1332713/Drug_Updates.html.
Khosa, S., Khanlou, N., Khosa, G.S. and Mishra, S.K. (2018), Hydroxychloroquine‐induced autophagic vacuolar myopathy with mitochondrial abnormalities. Neuropathology, 38: 646-652. doi:10.1111/neup.12520Lawrence JS. What we know and need to know about rheumatism. New Scientist. January 1964; 219:202–205.
Leeuwenberg KE, Albayda J (2019) Muscle Ultrasound in Inflammatory Myopathies: A Critical Review. J Rheum Dis Treat 5:069. doi.org/10.23937/2469-5726/1510069
Korkus D, Gazitt T, Cohen AD, et al. Increased prevalence of Lupus Co-morbidity in Patients with Psoriatic Arthritis: A Population-Based Case-Controlled Study [published online ahead of print, 2020 May 15]. J Rheumatol. 2020;jrheum.190940. doi:10.3899/jrheum.190940
Liu, T., Li, G., Mu, R., Ye, H., Li, W., & Li, Z. (2014). Clinical and laboratory profiles of rhupus syndrome in a Chinese population: a single-centre study of 51 patients. Lupus, 23(9), 958–963. https://doi.org/10.1177/0961203314526439
Lonesky TA, et al. Hydroxychloroquine and colchicine induced myopathy. The Journal of Rheumatology November 2009, 36 (11) 2617-2618; DOI: https://doi.org/10.3899/jrheum.081315
Longstreth M. Rheumatism, Gout, and Some Allied Disorders. New York: William Wood & Co; 1882.
Mahmoud KIM (2019). Understanding and Treating Musculoskeletal Systemic Lupus Erythematosus. (Unpublished PhD thesis). University of Leeds, Leeds UK. 
Mertelsmann-Voss C, et al. Arthroplasty Rates Are Increased Among US Patients with Systemic Lupus Erythematosus: 1991–2005. J Rheum May 2014, 41 (5) 867-874; DOI: 10.3899/jrheum.130617
Mosca M, et al. The role of imaging in the evaluation of joint involvement in 102 consecutive patients with systemic lupus erythematosus. Autoimmun Rev 2015;14:10-15.
Nakhai-Pour HR, Broy P, Sheehy O, Bérard A. Use of nonaspirin nonsteroidal anti-inflammatory drugs during pregnancy and the risk of spontaneous abortion. Canadian Medical Association Journal. 2011;183:1713.
Nguyen MA, Rahnama-Moghadam S, Gilson R. An uncommon presentation of an uncommon disease: relapsing polychondritis overlap with systemic lupus erythematosus. Derm Online 2016;22:7-10.
Ogura, T., Hirata, A., Hayashi, N., Takenaka, S., Ito, H., Mizushina, K., … Kameda, H. (2017). Comparison of ultrasonographic joint and tendon findings in hands between early, treatment-naïve patients with systemic lupus erythematosus and rheumatoid arthritis. Lupus, 26(7), 707–714. https://doi.org/10.1177/0961203316676375
Patterson SL, Schmajuk G, Jafri K, Yazdany J, Katz P. Obesity is Independently Associated With Worse Patient-Reported Outcomes in Women with Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2019;71(1):126-133. doi:10.1002/acr.23576
Ribeiro, D. S., Lins, C. F., Galvão, V., Santos, W. G. D., Rosa, G., Machicado, V., … Santiago, M. B. (2018). Association of CXCL13 serum level and ultrasonographic findings of joints in patients with systemic lupus erythematosus and Jaccoud’s arthropathy. Lupus, 27(6), 939–946. https://doi.org/10.1177/0961203317753557
Ruano CA, Malheiro R, Oliveira JF, Pinheiro S, Vieira LS, Moraes-Fontes MF. Ultrasound detects subclinical joint inflammation in the hands and wrists of patients with systemic lupus erythematosus without musculoskeletal symptoms. Lupus Sci Med. 2017;4(1):e000184. Published 2017 Jan 19. doi:10.1136/lupus-2016-000184
Rubini E, Foddai SG, Radin M, et al. HOW TO DEFINE RHUPUS SYNDROME: SYSTEMATIC REVIEW OF THE CURRENT LITERATURE. Annals of the Rheumatic Diseases 2019;78:2049-2050.
Saketkoo LA, Quinet R. Revisiting Jaccoud arthropathy as an ultrasound diagnosed erosive arthropathy in systemic lupus erythematosus. Journal of Clinical Rheumatology. December 2007;13(6):322–327.
Santiago M. Jaccoud-type lupus arthropathy: practical classification criteria. Lupus Science & Medicine 2020;7:e000405. doi: 10.1136/lupus-2020-000405
Santiago MB, Galvão V, Ribeiro DS, et al. Severe Jaccoud’s arthropathy in systemic lupus erythematosus. Rheumatol Int 2015;35:1773–7.doi:10.1007/s00296-015-3351-9pmid:https:///www.ncbi.nlm.nih.gov/pubmed/26310503
Sheon RP, Moskowitz RW, Goldberg VM. Soft Tissue Rheumatic Pain: Recognition, Management, and Prevention. 3rd ed. Philadelphia, Pa: Lippincott Williams & Wilkins.
Shlotzhauer TL, McGuire JL. Living with Rheumatoid Arthritis. 2nd ed. Baltimore, Md: Johns Hopkins University Press; 2003.
Stewart, S., Dalbeth, N., Aiyer, A. and Rome, K. (2020), Objectively Assessed Foot and Ankle Characteristics in Patients With Systemic Lupus Erythematosus: A Comparison With Age‐ and Sex‐Matched Controls. Arthritis Care Res, 72: 122-130. doi:10.1002/acr.23832
Stockton, K., Kandiah, D., Paratz, J., & Bennell, K. (2012). Fatigue, muscle strength and vitamin D status in women with systemic lupus erythematosus compared with healthy controls. Lupus, 21(3), 271–278. https://doi.org/10.1177/0961203311425530
Sun F, Ye. Characteristics of myositis in Chinese patients with systemic lupus erythematosus. Lupus Science & Medicine 2019;6:doi: 10.1136/lupus-2019-lsm.246
Torrente-Segarra, V, et al. Musculoskeletal involvement and ultrasonography update in systemic lupus erythematosus: New insights and review Eur J Rheumatol. 2018 Jun; 5(2): 127–130.
Townsend RJ, Benedetti TJ, Erickson SH, Cengiz C, Gillespie WR, Gschwend J, Albert KS . Excretion of ibuprofen into breast milk. Am J Obstet Gynecol. 1984;149(2):184. 
van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Annals of the Rheumatic Diseases 2014;73:958-967.
Wright S, Filippucci E, Grassi W, Grey A, Bell A. Hand arthritis in systemic lupus erythematosus: an ultrasound pictorial essay. Lupus. August 2006;15(8):501–506.
Yan L, et al. Associated Variables of Myositis in Systemic Lupus Erythematosus: A Cross-Sectional Study. Med Sci Monit. 2017; 23: 2543–2549.
Yang BB, Xiao H, Li XJ, Zheng M. Safety and efficacy of etanercept-methotrexate combination therapy in patients with rhupus: an observational study of non-glucocorticoid treatment for rheumatic diseases. Discov Med. 2018;25(135):14‐20.
Zayat AS, Khaled Mahmoud, Md Yuzaiful Md Yusof, Sandeep Mukherjee, Maria-Antoinetta D’Agostino, Elizabeth M A Hensor, Richard J Wakefield, Philip G Conaghan, Christopher J Edwards, Paul Emery, Edward M Vital, Defining inflammatory musculoskeletal manifestations in systemic lupus erythematosus, Rheumatology, Volume 58, Issue 2, February 2019, Pages 304–312, https://doi.org/10.1093/rheumatology/key277

Chapter 8

Adelowo O, Olaosebikan H, Ajani W, Omosebi DT. Digital gangrene as the initial presentation of systemic lupus erythematosus. BMJ Case Rep. 2012;2012:bcr2012006259. Published 2012 Nov 1. doi:10.1136/bcr-2012-006259
Aguirre-Martinez, I., Vélez-Tirado, N., García-Romero, M. T., Rodríguez-Lozano, A. L., Corcuera-Delgado, C. T., Yamazaki-Nakashimada, M., & Rivas-Larrauri, F. (2019). Rowell syndrome complicated with macrophage activation syndrome in a child. Lupus, 28(14), 1716–1721. https://doi.org/10.1177/0961203319886030
Alkul, S., Behrens, E., & Stetson, C. (2019). Rowell syndrome with recurrence from photoexacerbation: A case report. SAGE Open Medical Case Reports. https://doi.org/10.1177/2050313X19847337
Arkin LM, Ansell L, Rademaker A, et al. The natural history of pediatric-onset discoid lupus erythematosus. J Am Acad Dermatol. 2015;72(4):628-633. doi:10.1016/j.jaad.2014.12.028
Arkin, L., Buhr, K., Brandling‐Bennett, H., Chiu, Y., Chong, B., Curran, M., Hunt, R., Paller, A., Werth, V., Klein‐Gitelman, M., von Scheven, E. and Ardalan, K. (2019), Practice‐based differences in paediatric discoid lupus erythematosus. Br J Dermatol, 181: 805-810. doi:10.1111/bjd.17780​
Arévalo-Bermúdez MDP, Paradela S, Balboa-Barreiro V, Fonseca E. Cutaneous lupus erythematosus: factors related to cutaneous activity and damage in a cohort of 260 patients from A Coruña, Spain [published online ahead of print, 2020 Jun 15]. Lupus. 2020;961203320930094. 
​Askling J, et al. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf. 2011;20(2):119. Epub 2010 Dec 7. 
Bahloul, E., Jallouli, M., Garbaa, S., Marzouk, S., Masmoudi, A., Turki, H., & Bahloul, Z. (2017). Hydroxychloroquine-induced hyperpigmentation in systemic diseases: prevalence, clinical features and risk factors: a cross-sectional study of 41 cases. Lupus, 26(12), 1304–1308. https://doi.org/10.1177/0961203317700486
Bauer, F. (1981). Quinacrine hydrochloride drug eruption (tropical lichenoid dermatitis). Journal of the American Academy of Dermatology, 4(2), 239–248. doi:10.1016/s0190-9622(81)70025-2
Bernstein S. Curbside Consults: Tips on diagnosing & management of … alopecia in lupus patients. The Rheumatologist January 2017:39-40.
Bhat RY, Varma C, Bhatt S, Balachandran C. Rowell syndrome. Indian Dermatol Online J. 2014;5(Suppl 1):S33–S35. doi:10.4103/2229-5178.144526
Bockle BC, Sepp NT. Smoking is highly associated with discoid lupus erythematosus and lupus erythematosus tumidus: analysis of 405 patients. Lupus 2014;24:669-674.
Bourré-Tessier J, et al. Association of smoking with cutaneous manifestations of systemic lupus erythematosus. Arthr Care Res 2013;65:1275-1280.
Callender VD, et al. Medical and surgical therapies for alopecias in black women. Dermatol Ther. 2004;17(2):164-76. 
Chanprapaph, K., Sawatwarakul, S., & Vachiramon, V. (2017). A 12-year retrospective review of bullous systemic lupus erythematosus in cutaneous and systemic lupus erythematosus patients. Lupus, 26(12), 1278–1284. https://doi.org/10.1177/0961203317699714
Chong BF, Song J, Olsen NJ. Determining risk factors for developing systemic lupus erythematosus in patients with discoid lupus erythematosus. Br J Dermatol. 2012 Jan;166(1):29-35. Epub 2011 Dec 5.
Cohen, L., Shah, V., Chen, P.-L., Messina, J., & Seminario-Vidal, L. (2020). Cutaneous squamous cell carcinoma causing a rhinophymatous mass in a patient with clinically occult hypertrophic lupus erythematosus. Lupus, 29(6), 644–648. https://doi.org/10.1177/0961203320912838
Concha JSS, Werth VP. Alopecias in lupus erythematosus. Lupus Science & Medicine 2018;5:e000291. doi: 10.1136/lupus-2018-000291
Cutillas-Marco E, et al. Vitamin D and cutaneous lupus erythematosus: effect of vitamin D replacement on disease severity. Lupus 2014;23:615-23.
de Risi-Pugliese T, et al. Clinical, histological, immunological presentations and outcomes of bullous systemic lupus erythematosus: 10 New cases and a literature review of 118 cases. Semin Arthritis Rheum. 2018;48(1):83. Epub 2017 Nov 4. 
Dall’Era M, et al. The incidence and prevalence of systemic lupus erythematosus in San Francisco County, California. Arthr & Rheum. 2017;69(10):1996-2005.
Demirci GT, Altunay IK, Sarıkaya S, Sakiz D. Lupus erythematosus and lichen planus overlap syndrome: a case report with a rapid response to topical corticosteroid therapy. Dermatol Reports. 2011;3(3):e48. Published 2011 Nov 25. doi:10.4081/dr.2011.e48
DeSouza A. 11 things a makup salesperson wishes you knew. Today March 2018; retrieved on https:///www.today.com/style/makeup-counter-etiquette-everything-you-need-know-t126003
Drenkard, C., Parker, S., Aspey, L.D., Gordon, C., Helmick, C.G., Bao, G. and Lim, S.S. (2019), Racial Disparities in the Incidence of Primary Chronic Cutaneous Lupus Erythematosus in the Southeastern US: The Georgia Lupus Registry. Arthritis Care Res, 71: 95-103. doi:10.1002/acr.23578

Drucker, A. M., Su, J., Mussani, F., Siddha, S. K., Gladman, D. D., & Urowitz, M. B. (2016). Prognostic implications of active discoid lupus erythematosus and malar rash at the time of diagnosis of systemic lupus erythematosus: Results from a prospective cohort study. Lupus, 25(4), 376–381. https://doi.org/10.1177/0961203315610645
Famenini S, et al. Demographics of women with female pattern hair loss and the effectiveness of spironolactone therapy. J Am Acad Derm 2015;73:705.
Fernandes, M. S., Girisha, B. S., Viswanathan, N., Sripathi, H., & Noronha, T. M. (2015). Discoid lupus erythematosus with squamous cell carcinoma: a case report and review of the literature in Indian patients. Lupus, 24(14), 1562–1566. https://doi.org/10.1177/0961203315599245
Fink A, et al. Lupus Anticoagulant in Patients with Chronic Venous Insufficiency. Acta Derm Ven 2003;83:287-289.
​Foering K, et al. Characterization of clinical photosensitivity in cutaneous lupus erythematosus. Am Acad Derm;69:205-213.
Fortina AB, et al. Immunosuppressive level and other risk factors for basal cell carcinoma and squamous cell carcinoma in heart transplant recipients. Arch Derm 2004;140:1079.
Francès C, Cosnes A, Duhaut P, et al. Low Blood Concentration of Hydroxychloroquine in Patients With Refractory Cutaneous Lupus Erythematosus: A French Multicenter Prospective Study. Arch Dermatol. 2012;148(4):479–484. doi:10.1001/archdermatol.2011.2558
Francès C, Piette JC. The Mystery of Sneddon Syndrome: Relationship with Antiphospholipid Syndrome and Systemic Lupus Erythematosus. Journal of Autoimmunity;15, Issue 2, September 2000, Pages 139-143

Garg S, et al. Timing and Predictors of Incident Cardiovascular Disease in Systemic Lupus Erythematosus: Risk Occurs Early and Highlights Racial Disparities. The Journal of Rheumatology Aug 2022, jrheum.220279; DOI: 10.3899/jrheum.220279 https://www.jrheum.org/content/early/2022/09/15/jrheum.220279
Grönhagen CM, Gunnarsson I, Svenungsson E, Nyberg F. Cutaneous manifestations and serological findings in 260 patients with systemic lupus erythematosus. Lupus. 2010;19:1187–1194.
Haskin A, Aguh C. All hairstyles are not created equal: What the dermatologist needs to know about black hairstyling practices and the risk of traction alopecia (TA). J Am Acad Dermatol. 2016;75(3):606. Epub 2016 Apr 22. 
He Y, Sawalha AH. Drug-induced lupus erythematosus: an update on drugs and metabolisms. Current Opinion Rheum. 2018;30(5):490-496.
Hedrich CM, et al. Chilblain lupus erythematosus — a review of the literature. Clin Rheum 2008;27:949-954.
Her MY, Song JY, Kim DY. Hypocomplementemic urticarial vasculitis in systemic lupus erythematosus. J Korean Med Sci. 2009;24(1):184–186. doi:10.3346/jkms.2009.24.1.184​
Hesselvig, J. H., Ahlehoff, O., Dreyer, L., Gislason, G., & Kofoed, K. (2017). Cutaneous lupus erythematosus and systemic lupus erythematosus are associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. Lupus, 26(1), 48–53. https://doi.org/10.1177/0961203316651739
Khudadah M, Jawad A, Pyne D. Calcinosis cutis universalis in a patient with systemic lupus erythematosus: a case report. Lupus. 2020 Oct;29(12):1630-1632. doi: 10.1177/0961203320942946. Epub 2020 Jul 21. PMID: 32693683.

Klein R, Moghadam-Kia S, Taylor L, Coley C, Okawa J, LoMonico J, Chren MM, Werth VP. Quality of life in cutaneous lupus erythematosus. J Am Acad Dermatol. 2011 May;64(5):849-58. doi: 10.1016/j.jaad.2010.02.008. Epub 2011 Mar 12. PMID: 21397983; PMCID: PMC3079065.
Izmirly P, Buyon J, Belmont HM, et al. Population-based prevalence and incidence estimates of primary discoid lupus erythematosus from the Manhattan Lupus Surveillance ProgramLupus Science & Medicine 2019;6:e000344. doi: 10.1136/lupus-2019-000344
Jallouli M, Francès C, Piette J, et al. Hydroxychloroquine-Induced Pigmentation in Patients With Systemic Lupus Erythematosus: A Case-Control Study. JAMA Dermatol. 2013;149(8):935–940. doi:10.1001/jamadermatol.2013.709
Jancin B. Cutaneous LE likely to progress to SLE early. Rheumatology News. November 2011;9(11):12.
​Jarrett, P., Thornley, S., & Scragg, R. (2016). Ethnic differences in the epidemiology of cutaneous lupus erythematosus in New Zealand. Lupus, 25(13), 1497–1502. https://doi.org/10.1177/0961203316651745​
Koch K, Tikly M. Spectrum of cutaneous lupus erythematosus in South Africans with systemic lupus erythematosus. Lupus 2019;28:1021-1026.
Kuhn A, and Rizicka T. Chapter 5 Classification of Cutaneous Lupus Erythematosus in Cutaneous Lupus Erythematosus. Springer, New York (2004):53-57.
La Placa M, Passarini B. Subacute cutaneous lupus erythematosus after a tattoo. Clinical and Experimental Dermatology. July 2009;34(5):632–633.
Lee, W. J., Kang, H. J., Shin, H. J., Won, C. H., Chang, S. E., Choi, J. H., & Lee, M. W. (2018). Neutrophilic urticarial dermatosis and Sweet-like neutrophilic dermatosis: under-recognized neutrophilic dermatoses in lupus erythematosus. Lupus, 27(4), 628–636. https://doi.org/10.1177/0961203317736145
Lipner SR. Rethinking biotin therapy for hair, nail, and skin disorders. J Am Acad Dermatol. 2018 Jun;78(6):1236-1238. doi: 10.1016/j.jaad.2018.02.018. Epub 2018 Feb 10. PMID: 29438761.​
Lospinoso, D., Fernelius, C., Edhegard, K., Finger, D., & Arora, N. (2013). Lupus erythematosus/lichen planus overlap syndrome: successful treatment with acitretin. Lupus, 22(8), 851–854. https://doi.org/10.1177/0961203313492243
Lowe GC, Henderson CL, Grau RH, Hansen CB, Sontheimer RD. A systematic review of drug-induced subacute cutaneous lupus erythematosus. Br J Dermatol. 2011 Mar;164(3):465-72. doi: 10.1111/j.1365-2133.2010.10110.x. Epub 2011 Feb 17. Erratum in: Br J Dermatol. 2014 Apr;170(4):999. Lowe, G [corrected to Lowe, G C]. PMID: 21039412.
Manger, K., von Streitberg, U., Seitz, G., Kleyer, A. and Manger, B. (2018), Hard Palate Hyperpigmentation—a Rare Side Effect of Antimalarials. Arthritis Rheumatol, 70: 152-152. doi:10.1002/art.40327
Martín-Nares, E., Hernandez-Molina, G., & Fragoso-Loyo, H. (2019). Aquaporin-4-IgG positive neuromyelitis optica spectrum disorder and systemic autoimmune diseases overlap syndrome: a single-center experience. Lupus, 28(11), 1302–1311. https://doi.org/10.1177/0961203319877255
Martín-Varillas J, Loricera J, Armesto S, et al. Apremilast therapy in refractory skin lupus lesions. Annals of the Rheumatic Diseases 2018;77:698.
Ma
rzano AV, et al. Drug-induced lupus: an update on its dermatologic aspects. Lupus 2009 Oct;18(11):935-40. doi: 10.1177/0961203309106176.
Marzano AV, et al. Drug-induced subacute cutaneous lupus: evidence for differences from its idiopathic counterpart. British Journal of Dermatology 2011;165: 335-341. doi:10.1111/j.1365-2133.2011.10397.x
Méndez-Flores S, Orozco-Topete R, Bermúdez-Bermejo P, Hernández-Molina G. Pain and pruritus in cutaneous lupus: their association with dermatologic quality of life and disease activity. Clin Exp Rheumatol. 2013;31(6):940–942.
Molomo EM, et al. Discoid lupus erythematosus-related squamous cell carcinoma of the lip in an HIV-seropositive black male. E-J Cancer Res Ther 2015;11:1036-1036.
Moraitis, E., Stathopoulos, Y., Hong, Y., Al-Obaidi, M., Mankad, K., Hacohen, Y., … Eleftheriou, D. (2019). Aquaporin-4 IgG antibody-related disorders in patients with juvenile systemic lupus erythematosus. Lupus, 28(10), 1243–1249. https://doi.org/10.1177/0961203319855125​
Navarro-Triviño, F. J., & Ortego Centeno, N. (2019). Linear lupus panniculitis of the scalp with good response to thalidomide. Lupus, 28(11), 1380–1382. https://doi.org/10.1177/0961203319873703
O’Connor DM, Jew OS, Perman MJ, Castelo-Soccio LA, Winston FK, McMahon PJ. Diagnostic accuracy of pediatric teledermatology using parent-submitted photographs: a randomized control trial [Published online November 15, 2017]. JAMA Dermatol. doi:10.1001/jamadermatol.2017.4280.
Okon LG, Werth VP. Cutaneous lupus erythematosus: diagnosis and treatment. Best Pract Res Clin Rheumatol. 2013;27(3):391-404. doi:10.1016/j.berh.2013.07.008
Olsen EA, et al. Summary of North American Hair Research Society (NAHRS)-sponsored Workshop on Cicatricial Alopecia, Duke University Medical Center, February 10 and 11, 2001. J Am Acad Dermatol. 2003 Jan;48(1):103-10. 
Patrizi A, et al. Recurrent lichenoid reaction to black tattoo ink: A case report and brief review of the literature. Acta Derm Vener 2009;89:327-328.

Patsinakidis N, Kautz O, Gibbs BF, Raap U. Lupus erythematosus tumidus: clinical perspectives. Clin Cosmet Investig Dermatol. 2019 Oct 1;12:707-719. doi: 10.2147/CCID.S166723. PMID: 31632119; PMCID: PMC6778445.
Petersen, M. P., Möller, S., Bygum, A., Voss, A., & Bliddal, M. (2018). Epidemiology of cutaneous lupus erythematosus and the associated risk of systemic lupus erythematosus: a nationwide cohort study in Denmark. Lupus, 27(9), 1424–1430. https://doi.org/10.1177/0961203318777103
Pons-Estel, G. J., Aspey, L. D., Bao, G., Pons-Estel, B. A., Wojdyla, D., Saurit, V., … Drenkard, C. (2017). Early discoid lupus erythematosus protects against renal disease in patients with systemic lupus erythematosus: longitudinal data from a large Latin American cohort. Lupus, 26(1), 73–83. https://doi.org/10.1177/0961203316651740
Pons-Estel, G. J., Quintana, R., Alarcón, G. S., Sacnún, M., Ugarte-Gil, M. F., & Pons-Estel, B. A. (2018). A 12-year retrospective review of bullous systemic lupus erythematosus in cutaneous and systemic lupus erythematosus patients. Lupus, 27(10), 1753–1754. https://doi.org/10.1177/0961203318776104
Price VH. The medical treatment of cicatricial alopecia. Semin Cutan Med Surg. 2006 Mar;25(1):56-9.
Provost T (2005). Nonspecific cutaneous manifestations of systemic lupus erythematosus [chapter] in Cutaneous lupus erythematosus (Editors Kuhn A, et al.). Springer, New York: 103.

Qi F, Liu F, Gao L. Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review. Front Immunol. 2021 Nov 18;12:790125. doi: 10.3389/fimmu.2021.790125. PMID: 34868078; PMCID: PMC8636851.
Renner R, Sticherling M. Incidental cases of subacute cutaneous lupus erythematosus in association with malignancy. Eur J Dermatol. 2008 Nov-Dec;18(6):700-4. doi: 10.1684/ejd.2008.0522. Epub 2008 Oct 27. PMID: 18955207.
Ricci, F., De Simone, C., Del Regno, L. et al. Drug-induced hair colour changes. Eur J Dermatol 26, 531–536 (2016). https://doi.org/10.1684/ejd.2016.2844
Rodriguez-Caruncho C, Bielsa I, Fernández-Figueras MT, Roca J, Carrascosa JM, Ferrándiz C. Lupus erythematosus tumidus: a clinical and histological study of 25 cases. Lupus. 2015 Jun;24(7):751-5. Epub 2014 Nov 20. 
Rowell NR, et al. Lupus Erythematosus and Erythema Multiforme-like Lesions: A Syndrome With Characteristic Immunological Abnormalities. Arch Dermatol. 1963;88(2):176–180. doi:10.1001/archderm.1963.01590200064012
Sabio, J. M., Betolaza, S. D., & Vargas-Hitos, J. A. (2019). Characteristics and safety of tattoos in patients with systemic lupus erythematosus. Lupus, 28(10), 1250–1254. https://doi.org/10.1177/0961203319867395
Sharma AN, Mesinkovska NA, Paravar T. Characterizing the adverse dermatologic effects of hydroxychloroquine: a systematic review. J Am Acad Dermatol. 2020;83(2):563-578. doi:10.1016/j.jaad.2020.04.024 
Shamriz, O., Yahia, S. H., Ramot, Y., Agmon-Levin, N., & Tal, Y. (2020). Alopecia areata in patients with systemic lupus erythematosus treated with belimumab: a plausible association. Lupus, 29(4), 426–430. https://doi.org/10.1177/0961203319899985
Shenavandeh, S., & Habibi, S. (2017). Nailfold capillaroscopic changes in patients with systemic lupus erythematosus: correlations with disease activity, skin manifestation and nephritis. Lupus, 26(9), 959–966. https://doi.org/10.1177/0961203316686702
Singh AG, Crowson CS, Singh S, et al. Risk of Cerebrovascular Accidents and Ischemic Heart Disease in Cutaneous Lupus Erythematosus: A Population-Based Cohort Study. Arthritis Care Res (Hoboken). 2016;68(11):1664-1670. doi:10.1002/acr.22892
Skowron F, et al. Functional melanonychia due to involvement of the nail matrix in systemic lupus erythematosus. Journal of the American Academy of Dermatology, Volume 47, Issue 2, S187 – S188.
Solomon DH, Glynn RJ, Karlson EW, et al. Adverse Effects of Low-Dose Methotrexate: A Randomized Trial. Ann Intern Med. 2020;172:369–380. [Epub ahead of print 18 February 2020]. doi: https://doi.org/10.7326/M19-3369
Sonkar SK, Kumar S, Atam V, et alDigital dry gangrene as a primary manifestation of systemic lupus erythematosusBMJ Case Reports CP 2019;12:e230869.
Sontheimer RD. Subacute cutaneous lupus erythematosus: 25-year evolution of a prototypic subset (subphenotype) of lupus erythematosus defined by characteristic cutaneous, pathological, immunological, and genetic findings. Autoimmun Rev. 2005 Jun;4(5):253-63. Epub 2004 Nov 12. 
Sontheimer RD, Thomas JR, Gilliam JN. Subacute Cutaneous Lupus Erythematosus: A Cutaneous Marker for a Distinct Lupus Erythematosus Subset. Arch Dermatol. 1979;115(12):1409–1415. doi:10.1001/archderm.1979.04010120007006
Stojan, G., & Petri, M. (2016). Anti-C1q in systemic lupus erythematosus. Lupus, 25(8), 873–877. https://doi.org/10.1177/0961203316645205

Stull C, Sprow G, Werth VP. Cutaneous Involvement in Systemic Lupus Erythematous: A Review for the Rheumatologist. J Rheumatol. 2022 Sep 15:jrheum.220089. doi: 10.3899/jrheum.220089. Epub ahead of print. PMID: 36109075.
Suchonwanit P, Udompanich S, Thadanipon K, Chanprapaph K. Trichoscopic signs in systemic lupus erythematosus: a comparative study with 109 patients and 305 healthy controls. J Eur Acad Dermatol Venereol. 2019 Apr;33(4):774-780. doi: 10.1111/jdv.15421. Epub 2019 Feb 18. PMID: 30633418.
Szczęch, J., Samotij, D., Werth, V. P., & Reich, A. (2017). Trigger factors of cutaneous lupus erythematosus: a review of current literature. Lupus, 26(8), 791–807. https://doi.org/10.1177/0961203317691369​
Takamasu, E., Yokogawa, N., Shimada, K., & Sugii, S. (2019). Simple dose-escalation regimen for hydroxychloroquine-induced hypersensitivity reaction in patients with systemic lupus erythematosus enabled treatment resumption. Lupus, 28(12), 1473–1476. https://doi.org/10.1177/0961203319879987
Tankunakorn J, et al. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis–Like Lupus Erythematosus. J Clin Rheum 2019;25:224-231.
Uitto J. Genetic susceptibility of alopecia. NEJM;380:873-876.
Vieira, M. L., Marques, E. R. M. C., Leda, Y. L. A., Noriega, L. F., Bet, D. L., & Pereira, G. A. A. M. (2018). Chronic cutaneous lupus erythematosus presenting as atypical acneiform and comedonal plaque: case report and literature review. Lupus, 27(5), 853–857. https://doi.org/10.1177/0961203317726377
Viguier M, et al. Clinical and histopathologic features and immunologic variables in patients with severe chilblains. A study of the relationship to lupus erythematosus. Medicine (Baltimore). 2001;80:180-188.
Vital EM, et al. Brief report: responses to rituximab suggest B cell-independent inflammation in cutaneous systemic lupus erythematosus. Arthritis Rheumatol. 2015 Jun;67(6):1586-91. 
Wallace DJ. The use of quinacrine (Atabrine) in rheumatic disease: a reexamination. Seminars in Arthritis and Rheumatism. 1989;18(4):282–297.
Wang, R. F., Maher, M., Chung, C., & Kaffenberger, J. A. (2019). Koebner phenomenon of discoid lupus erythematosus on old tattoos. Lupus, 28(2), 241–243. https://doi.org/10.1177/0961203318815578
Winkelmann RR, Kim GK, Del Rosso JQ. Treatment of Cutaneous Lupus Erythematosus: Review and Assessment of Treatment Benefits Based on Oxford Centre for Evidence-based Medicine Criteria. J Clin Aesthet Dermatol. 2013;6(1):27–38.
Wu, M., Wang, C., Ng, C., Kuo, T., Chang, Y., Yang, C., … Chen, C. (2018). Periorbital erythema and swelling as a presenting sign of lupus erythematosus in tertiary referral centers and literature review. Lupus, 27(11), 1828–1837. https://doi.org/10.1177/0961203318792358
Yan D, Borucki R, Sontheimer RD, et al. Candidate drug replacements for quinacrine in cutaneous lupus erythematosus. Lupus Science & Medicine 2020;7:e000430. doi: 10.1136/lupus-2020-000430
Yun, H., Yang, S., Chen, L., Xie, F., Winthrop, K., Baddley, J.W., Saag, K.G., Singh, J. and Curtis, J.R. (2016), Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for Vaccination. Arthritis & Rheumatology, 68: 2328-2337. doi:10.1002/art.39670
Zawodniak A, Lochmatter P, Beeler A, Pichler WJ. Cross-reactivity in drug hypersensitivity reactions to sulfasalazine and sulfamethoxazole. Int Arch Allergy Immunol. 2010;153(2):152-6. doi: 10.1159/000312632. Epub 2010 Apr 22. PMID: 20413982.
Zhang, L.L., Au, S., & Aronson, I.K. (2014). Successful long-term thalidomide therapy for discoid lupus erythematosus-lichen planus overlap syndrome. Dermatology online journal, 20 10.

Chapter 9

Abid N. Thrombocytosis in a patient with systemic lupus. J Pak Med Assoc 2013;63:1305-1306.
Abreu MM, et al. The relevance of “non-criteria” clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. Autoimmun Rev. 2015 May;14(5):401-14. Epub 2015 Jan 29. 
Akiyama M, Kaneko Y, Takeuchi T. Lupus aortitis: A fatal, inflammatory cardiovascular complication in systemic lupus erythematosus. Lupus. 2020;29(12):1652-1654. doi:10.1177/0961203320950017
Ali YM, Urowitz MB, Ibañez D, Gladman DD. Monoclonal gammopathy in systemic lupus erythematosus. Lupus. 2007;16:426–429.
Al-Samkari H, and Kuter DJ. Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia. Br J Haem 2018;183:168.
Amgen, Inc. (2017). What’s next after first-line failure in adult chronic immune thrombocytopenia? [Brochure]. [Champlain NY]. PeerDirect Publishing.
Amigo, M.-C., & Alba, P. (2020). Damage index in lupus: the role of antiphospholipid antibodies. Lupus, 29(1), 3–5. https://doi.org/10.1177/0961203319890680
Anderson, A. (2015). Systemic lupus erythematosus and extreme thrombocytosis without autosplenectomy. Rheumatology Reports, 7(1). https://doi.org/10.4081/rr.2015.6035
Andreoli, L., Piantoni, S., Dall’Ara, F., Allegri, F., Meroni, P., & Tincani, A. (2012). Vitamin D and antiphospholipid syndrome. Lupus, 21(7), 736–740. https://doi.org/10.1177/0961203312446386
Angles-Cano E, Sultan Y, Clauvel J-P. Predisposing factors to thrombosis in systemic lupus erythematosus: possible relation to endothelial cell damage. Journal of Laboratory Clinical Medicine. August 1979;94(2):312–323.
Baehr G, Klemperer P, Schifrin A. A diffuse disease of the peripheral circulation (usually associate
d with lupus erythematosus and endocarditis). American Journal of Medicine. November 1952;13(5):591–596.
Beaumont JL. [Acquired hemorrhagic syndrome caused by a circulating anticoagulant; inhibition of the thromboplastic function of the blood platelets; description of a specific test]. Sang 1954;25(1):1–15.
Bertero MT. Primary prevention in antiphospholipid antibody carriers. Lupus. 2012;21:751–754.
Bertolaccini ML, et al. 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev;Volume 13, Issue 9, September 2014, Pages 917-930.
Bowie EJW, Thompson Jr JH, Pascuzzi CA, Owen Jr CA. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. Journal of Laboratory and Clinical Medicine. September 1963;62:416–430.
Broder A and Putterman C. Hydroxychloroquine Use Is Associated with Lower Odds of Persistently Positive Antiphospholipid Antibodies and/or Lupus Anticoagulant in Systemic Lupus Erythematosus. The Journal of Rheumatology Jan 2013, 40 (1) 30-33; DOI: 10.3899/jrheum.120157
Carli L, Tani C, Vagnani S, Signorini V, Mosca M. Leukopenia, lymphopenia, and neutropenia in systemic lupus erythematosus: Prevalence and clinical impact–A systematic literature review. Seminars in Arthritis and Rheumatism. 2015 Oct;45(2):190-194. DOI: 10.1016/j.semarthrit.2015.05.009.
Castillo-Martínez D, Amezcua-Guerra LM, Bojalil R. Neutropenia and the risk of infections in ambulatory patients with systemic lupus erythematosus: a three-year prospective study cohort [Letter to the editor]. Lupus. 2011;20:998–1000.
Cervera R, Rodríguez-Pintó I, Legault K, Erkan D. 16th International Congress on Antiphospholipid Antibodies Task Force Report on Catastrophic Antiphospholipid Syndrome. Lupus. 2020 Oct;29(12):1594-1600. doi: 10.1177/0961203320951260. Epub 2020 Aug 20. PMID: 32819183.
Cohen H, Cuadrado MJ, Erkan D, Duarte-Garcia A, Isenberg DA, Knight JS, Ortel TL, Rahman A, Salmon JE, Tektonidou MG, Williams DJ, Willis R, Woller SC, Andrade D. 16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. Lupus. 2020 Oct;29(12):1571-1593. doi: 10.1177/0961203320950461. PMID: 33100166.
Cohen, E. M., D’Silva, K., Kreps, D., Son, M. B., & Costenbader, K. H. (2018). Arthritis and use of hydroxychloroquine associated with a decreased risk of macrophage activation syndrome among adult patients hospitalized with systemic lupus erythematosus. Lupus, 27(7), 1065–1071. https://doi.org/10.1177/0961203318759428
Comarmond, C., Jego, P., Veyssier-Belot, C., Marie, I., Mekinian, A., Elmaleh-Sachs, A., … Cacoub, P. (2017). Cessation of oral anticoagulants in antiphospholipid syndrome. Lupus, 26(12), 1291–1296. https://doi.org/10.1177/0961203317699285
Conley CL, Rathbun HK, et al. Circulating anticoagulant as a cause of hemorrhagic diathesis in man. Bulletin of the Johns Hopkins Hospital. October 1948;83(4):288–296.
Cooper N and Ghanima W. Immune thrombocytopenia. N Engl J Med 2019; 381:945-955; DOI: 10.1056/NEJMcp1810479
Cuneo BF, Sonesson SE, Levasseur S, et al. Home Monitoring for Fetal Heart Rhythm During Anti-Ro Pregnancies [published correction appears in J Am Coll Cardiol. 2019 Jan 8;73(1):120]. J Am Coll Cardiol. 2018;72(16):1940‐1951. doi:10.1016/j.jacc.2018.07.076
Deák, M., Bocskai, M., Burcsár, S., Dányi, O., Fekete, Z., & Kovács, L. (2014). Non-thromboembolic risk in systemic lupus erythematosus associated with antiphospholipid syndrome. Lupus, 23(9), 913–918. https://doi.org/10.1177/0961203314531839
Dentali F, Sironi AP, Ageno W, Turato S, Bonfanti C, Frattini F, Crestani S, Franchini M. Non-O blood type is the commonest genetic risk factor for VTE: results from a meta-analysis of the literature. Seminars in Thrombosis and Hemostasis 2012; 38(5): 535-548
Davies JM, et al. Review of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen: prepared on behalf of the British Committee for Standards in Haematology by a working party of the Haemato-Oncology task force. Br J Haematol. 2011 Nov;155(3):308-17. 
Erkan D, et al. Long term outcome of catastrophic antiphospholipid syndrome survivors. Ann Rheum Dis. 2003;62(6):530.
Espinosa, G., Coloma Bazán, E., & Cervera, R. (2017). Cessation of oral anticoagulants in antiphospholipid syndrome. Lupus, 26(12), 1347–1348. https://doi.org/10.1177/0961203317707829
Fanouriakis A, Bertsias G, Boumpas DT. Population-based studies in systemic lupus erythematosus: immune thrombocytopenic purpura or ‘blood-dominant’ lupus?. Ann Rheum Dis. 2020;79(6):683‐684. doi:10.1136/annrheumdis-2020-217356
Fanouriakis A, Kostopoulou M, Alunno A, et al2019 update of the EULAR recommendations for the management of systemic lupus erythematosusAnnals of the Rheumatic Diseases 2019;78:736-745.
Fayyaz A, Igoe A, Kurien BT, et al. Haematological manifestations of lupus. Lupus Science & Medicine 2015;2:e000078. doi: 10.1136/lupus-2014-000078Feinstein DI, Rapaport SI. Acquired inhibitors of blood circulation. Progress in Hemostasis and Thrombosis. 1972;1:75–95.
Fernández-Castro M, et al. Common variable immunodeficiency in systemic lupus erythematosus. Semin Arthritis Rheum. 2007;36(4):238.
Fishman S. Ventilation-perfusion lung scans. J of Nucl Med 1993;34:353.
Ganz T. Anemia of Inflammation. N Engl J Med 2019; 381:1148-1157; DOI: 10.1056/NEJMra1804281
García-Carrasco, M., Jiménez-Herrera, E. A., Gálvez-Romero, J. L., Mendoza-Pinto, C., Méndez-Martínez, S., Etchegaray-Morales, I., … Cervera, R. (2018). The anti-thrombotic effects of vitamin D and their possible relationship with antiphospholipid syndrome. Lupus, 27(14), 2181–2189. https://doi.org/10.1177/0961203318801520
Gathmann B, et al. Clinical picture and treatment of 2212 patients with common variable immunodeficiency. J Allergy Clin Immunol. 2014;134(1):116. 
Gauiran DTV, et al. Autoimmune-Associated Hemophagocytosis and Myelofibrosis in a Newly Diagnosed Lupus Patient: Case Report and Literature Review. Case Rep Hem 2019;Article ID 3879148;https://doi.org/1
0.1155/2019/3879148
Gutarra-Arana M, et al. Autoimmune Myelofibrosis. The Rheumatologist 2014;8:1,4.
Habib GS, et al. Pure red cell aplasia and lupus. Seminars in Arthritis and Rheumatism, Volume 31, Issue 4, February 2002, Pages A1-A3
Hughes GRV. Connective tissue disease and the skin [The Prosser-White Oration 1983]. Clinical and Experimental Dermatology. 1984;9:535–544.
Jovancevic, B., Lindholm, C., & Pullerits, R. (2013). Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature. Lupus, 22(7), 664–674. https://doi.org/10.1177/0961203313485489
Kanhutu K, et al. Spleen Australia guidelines for the prevention of sepsis in patients with asplenia and hyposplenism in Australia and New Zealand. Intern Med J. 2017;47(8):848.
Kaul, A., Horwood, N., & Kotecha, J. (2019). Myelofibrosis associated with systemic lupus erythematosus successfully treated with rituximab. Lupus, 28(13), 1612–1614. https://doi.org/10.1177/0961203319879993

Kernan KF, Carcillo JA. Hyperferritinemia and inflammation. Int Immunol. 2017 Nov 1;29(9):401-409. doi: 10.1093/intimm/dxx031. PMID: 28541437; PMCID: PMC5890889.
Kiboneka, A., & Ilowite, N. (1994). Reversible functional asplenia in pediatric systemic lupus erythematosus. Children’s Hospital Quarterly, 6(1), 29-31.
Kristen J. Young, Sarika Savajiyani, Vivek S. Sambhara, and Robert Raschke. Anakinra for the Treatment of Systemic Lupus Erythematosus Complicated by Macrophage Activation Syndrome. CRITICAL CARE CASE REPORTS: HEMATOLOGY, ONCOLOGY, RHEUMATOLOGY, AND IMMUNOLOGY. May 1, 2017, A5918-A5918
Legger GE, et al. Refractory Autoimmune Hemolytic Anemia in a Pediatric SLE Patient Treated with Belimumab. Ann Paed Rheum 2013;2:38-42.
Ley AB, Reader GG, Sorensen CW, Overman RS. Idiopathic hypoprothrombinemia associated with hemorrhagic diathesis, and the effect of vitamin K. Blood. 1951;6(8):740–755.
Li, Y., & Feng, X. (2018). Efficacy and safety of tacrolimus in systemic lupus erythematosus patients with refractory thrombocytopenia: a retrospective study. Lupus, 27(1), 60–65. https://doi.org/10.1177/0961203317711011
Lockshin MD, Levine AB, Erkan D. Patients with overlap autoimmune disease differ from those with ‘pure’ disease. Lupus Science & Medicine 2015;2:e000084. doi: 10.1136/lupus-2015-000084
Lorenz, G., Schul, L., Schraml, F., Riedhammer, K. M., Einwächter, H., Verbeek, M., … Moog, P. (2020). Adult macrophage activation syndrome–haemophagocytic lymphohistiocytosis: ‘of plasma exchange and immunosuppressive escalation strategies’ – a single centre reflection. Lupus, 29(3), 324–333. https://doi.org/10.1177/0961203320901594
Malec, K., Broniatowska, E., & Undas, A. (2020). Direct oral anticoagulants in patients with antiphospholipid syndrome: a cohort study. Lupus, 29(1), 37–44. https://doi.org/10.1177/0961203319889156
Matchar DB, et al. Effect of home testing of international normalized ratio on clinical events. N Engl J Med. 2010;363(17):1608.
Meroni PL, et al. Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers. Arthritis Res Ther. 2014;16(2):209. Epub 2014 4 23. 
Meyer A, Gavand P, Blaison G, et al. Neutropenia in systemic lupus: prevalence, specific features and clinical consequences. results from the large upper Rhine database. Annals of the Rheumatic Diseases 2018;77:708-709.
Meyer-Gessner M, et al. Antithyroid drug-induced agranulocytosis: clinical experience with ten patients treated at one institution and review of the literature. J Endocrinol Invest. 1994;17(1):29. 

Moulinet T, Dufrost V, Clerc-Urmès I, Wahl D, Zuily S. Risk of thrombosis, pregnancy morbidity or death in antiphospholipid antibodies positive patients with or without thrombocytopenia. Eur J Intern Med. 2021 Feb;84:101-103. doi: 10.1016/j.ejim.2020.10.011. Epub 2020 Oct 17. PMID: 33082035.
Mulliez, S. M. N., De Keyser, F., Verbist, C., Vantilborgh, A., Wijns, W., Beukinga, I., & Devreese, K. M. J. (2015). Lupus anticoagulant-hypoprothrombinemia syndrome: report of two cases and review of the literature. Lupus, 24(7), 736–745. https://doi.org/10.1177/0961203314558859
Ordi-Ros J, Sáez-Comet L, Pérez-Conesa M, et al. Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome: A Randomized Noninferiority Trial. Ann Intern Med. 2019;171:685–694. [Epub ahead of print 15 October 2019]. doi: https://doi.org/10.7326/M19-0291Oxelius VA. Immunoglobulin G (IgG) subclasses and human disease. Am J Med. 1984;76(3A):7. 
Paule R, et al. Classification of primary antiphospholipid syndrome as systemic lupus erythematosus: Analysis of a cohort of 214 patients. Autoimmun Rev 2018;17(9):866-872. doi: 10.1016/j.autrev.2018.03.011. Epub 2018 Jul 10.
Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018;132(13):1365-1371. doi:10.1182/blood-2018-04-848333
Petri MA, Avci M, Magder LS. Evaluation of different ways to identify persistent positivity of lupus anticoagulant in systemic lupus erythematosus. Lupus Science & Medicine 2020;7:e000406. doi: 10.1136/lupus-2020-000406
Petri M, Konig MF, Li J, Goldman DW. Association of Higher Hydroxychloroquine Blood Levels With Reduced Thrombosis Risk in Systemic Lupus Erythematosus. Arthritis Rheumatol. 2021 Jan 5. doi: 10.1002/art.41621. Epub ahead of print. PMID: 33403833.
Petri M, Magder L, Goldman D. Longitudinal Assessment of Anti-beta 2 Glycoprotein in SLE [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/longitudinal-assessment-of-anti-beta-2-glycoprotein-in-sle/. Accessed November 15, 2020.
Pengo V, Denas G, Banzato A, Bison E, Bracco A, et al. Secondary prevention in thrombotic antiphospholipid syndrome. Lupus. June 2012;21(7):734–735.
Plüß, M., Zeisberg, M., Müller, G. A., Vasko, R., & Korsten, P. (2018). Therapeutic response to glucocorticoids, anticoagulation and plasma exchange in a patient with primary antiphospholipid syndrome presenting with purpura fulminans. Lupus, 27(13), 2170–2173. https://doi.org/10.1177/0961203318804884
Pullen L. Advancements in Diagnosis, Treatment for Antiphospholipid Syndrome. The Rheumatologist July 2017:43.
Riancho-Zarrabeitia L, Martínez-Taboada V, Rúa-Figueroa I, Alonso F, Galindo-Izquierdo M, Ovalles J, Olivé-Marqués A, Fernández-Nebro A
, Calvo-Alén J, Menor-Almagro R, Tomero-Muriel E, Uriarte-Isacelaya E, Botenau A, Andres M, Freire-González M, Santos Soler G, Ruiz-Lucea E, Ibáñez-Barceló M, Castellví I, Galisteo C, Quevedo Vila V, Raya E, Narváez-García J, Expósito L, Hernández-Beriaín JA, Horcada L, Aurrecoechea E, Pego-Reigosa JM. Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality. Lupus. 2020 Oct;29(12):1556-1565. doi: 10.1177/0961203320950477. Epub 2020 Aug 17. PMID: 32807021.
Rodríguez-Pintó I. Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of 500 patients from the International CAPS Registry. Autoimmun Rev. 2016 Dec;15(12):1120-1124. doi: 10.1016/j.autrev.2016.09.010. Epub 2016 Sep 15.
Sciascia S, et al. Non-vitamin K antagonist oral anticoagulants and antiphospholipid syndrome. Rheumatology (Oxford). 2016;55(10):1726. Epub 2016 Feb 3. 
Song JY, et al. Clinical outcome and predictive factors of recurrence among patients with Kikuchi’s disease. Int J Infect Dis. 2009;13(3):322.
Song, L., Wang, Y., Zhang, J. et al. The risks of cancer development in systemic lupus erythematosus (SLE) patients: a systematic review and meta-analysis. Arthritis Res Ther 20, 270 (2018). https://doi.org/10.1186/s13075-018-1760-3
Stammler R, Legendre P, Cacoub P, Blanche P, Piette JC, Costedoat-Chalumeau N. Catastrophic antiphospholipid syndrome following the introduction of rivaroxaban. Lupus. 2020;29(7):787-790. doi:10.1177/0961203320914363
Tektonidou MG, Andreoli L, Limper M, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Annals of the Rheumatic Diseases 2019:annrheumdis-2019–215213.
Tomi AL, Belkhir R, Nocturne G, et al. Brief Report: Monoclonal Gammopathy and Risk of Lymphoma and Multiple Myeloma in Patients With Primary Sjögren’s Syndrome. Arthritis & Rheumatology (Hoboken, N.J.). 2016 May;68(5):1245-1250. DOI: 10.1002/art.39534.
Troldborg A, Deleuran B, Storgaard M. [Fulminant pneumococcal septicaemia in a patient with systemic lupus erythematosus and functional asplenia]. Ugeskrift for Laeger. 2014 Jun;176(27):V01140008.
Resnick ES, et al. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood. 2012;119(7):1650. Epub 2011 Dec 16. 
Santilli D, et al. Autosplenectomy and antiphospholipid antibodies in systemic lupus erythematosus: a pathogenetic relationship? Sem Arthr Rheum 2003;33:125-133.
Scheiermann C, Frenette PS, Hidalgo A. Regulation of leucocyte homeostasis in the circulation. Cardiovasc Res. 2015;107(3):340‐351. doi:10.1093/cvr/cvv099
Shusterman, M., Golub, E., Mowrey, W. B., & Broder, A. (2018). The association between ABO blood types and venous thromboembolism in individuals with a positive antiphospholipid profile is varied by sex. Lupus, 27(2), 319–326. https://doi.org/10.1177/0961203317721352
Sopeña B et al. Clinical association between Kikuchi׳s disease and systemic lupus erythematosus: A systematic literature review. Sem Arthr Rheum 2017;47:46-52.
Skoczynska, M., Crowther, M. A., Chowaniec, M., Ponikowska, M., Chaturvedi, S., & Legault, K. (2020). Thrombotic microangiopathy in the course of catastrophic antiphospholipid syndrome successfully treated with eculizumab: case report and systematic review of the literature. Lupus, 29(6), 631–639. https://doi.org/10.1177/0961203320917460
Tufano A, Coppola A, Maruotti GM, Martinelli P, Cerbone AM, Di Minno G. HELLP syndrome and its relation with the antiphospholipid syndrome. Blood Transfus. 2014;12(1):114‐118. doi:10.2450/2013.0154-13
Ungprasert, P., Chowdhary, V. R., Davis, M. D., & Makol, A. (2016). Autoimmune myelofibrosis with pancytopenia as a presenting manifestation of systemic lupus erythematosus responsive to mycophenolate mofetil. Lupus, 25(4), 427–430. https://doi.org/10.1177/0961203315615221
Üsküdar Cansu, D., Üsküdar Teke, H., Işiksoy, S. and Korkmaz, C. (2018), Bone marrow as a target organ of systemic lupus erythematosus: analysis of cases with myelofibrosis. Int J Rheum Dis, 21: 1049-1059. doi:10.1111/1756-185X.13308
Üsküdar C, et al. Is thrombocytosis always an indicator of autosplenectomy in patients with systemic lupus erythematosus? Rheumatology International . Feb 2018, Vol. 38 Issue 2, p239-247.
Vadgama, T. S., Smith, A., & Bertolaccini, M. L. (2019). Treatment in thrombotic antiphospholipid syndrome: a review. Lupus, 28(10), 1181–1188. https://doi.org/10.1177/0961203319864163
Vasiliu I, et al. Therapy with granulocyte colony-stimulating factor in systemic lupus erythematosus may be associated with severe flares. The Journal of Rheumatology Sep 2006, 33 (9) 1878-1880.
Veres K, et al. Clinical and immunoserological characteristics of the transition from primary to overlap antiphospholipid syndrome. Lupus. 2010 Nov;19(13):1520-6. Epub 2010 Aug 4. 
Watanabe, T., Oku, K., Amengual, O., Hisada, R., Ohmura, K., Nakagawa, I., … Atsumi, T. (2018). Effects of statins on thrombosis development in patients with systemic lupus erythematosus and antiphospholipid antibodies. Lupus, 27(2), 225–234. https://doi.org/10.1177/0961203317716787
Wincup C, McDonnell TCR, Rahman A. Menorrhagia: an underappreciated problem in pre-menopausal women with systemic lupus erythematosus. Lupus. 2019;28(7):916‐917. doi:10.1177/0961203319851868
Yamakami, L., Serafini, P., de Araujo, D., Bonfá, E., Leon, E., Baracat, E., & Silva, C. (2014). Ovarian reserve in women with primary antiphospholipid syndrome. Lupus, 23(9), 862–867. https://doi.org/10.1177/0961203314529468
Yelnik, C. M., Urbanski, G., Drumez, E., Caron, C., Maillard, H., Morell-Dubois, S., … Lambert, M. (2018). Anticoagulation withdrawal in antiphospholipid syndrome: a retrospective matched-control study. Lupus, 27(3), 357–364. https://doi.org/10.1177/0961203317721751
Zelie Guitton, Louis Terriou, Jean-Christophe Lega, Raphaele Nove-Josserand, Miguel Hie, Zahir Amoura, James B Bussel, Mohamed Hamidou, Eric Rosenthal, Bertrand Lioger, Dominique Chauveau, Axel C
haminade, Nadine Magy-Bertrand, Marc Michel, Sylvain Audia, Bertrand Godeau, Matthieu Mahevas, Risk of thrombosis with anti-phospholipid syndrome in systemic lupus erythematosus treated with thrombopoietin-receptor agonists, Rheumatology, Volume 57, Issue 8, August 2018, Pages 1432–1438, https://doi.org/10.1093/rheumatology/key119
Zhang Y, et al. Coagulopathy and Antiphospholipid Antibodies in Patients with COVID-19. NEJM 2020; DOI: 10.1056/NEJMc2007575
Zhu FX, Huang JY, Ye Z, Wen QQ, Wei JC. Risk of systemic lupus erythematosus in patients with idiopathic thrombocytopenic purpura: a population-based cohort study. Ann Rheum Dis. 2020;79(6):793‐799. doi:10.1136/annrheumdis-2020-217013

Chapter 10

Akiyama M, Kaneko Y, Takeuchi T. Lupus aortitis: A fatal, inflammatory cardiovascular complication in systemic lupus erythematosus. Lupus. 2020;29(12):1652-1654. doi:10.1177/0961203320950017
Alabed IB. Treatment of diffuse alveolar hemorrhage in systemic lupus erythematosus patient with local pulmonary administration of factor VIIa (rFVIIa): a case report. Medicine (Baltimore). 2014;93(14):e72. doi:10.1097/MD.0000000000000072
Al-Adhoubi, N. K., & Bystrom, J. (2020). Systemic lupus erythematosus and diffuse alveolar hemorrhage, etiology and novel treatment strategies. Lupus, 29(4), 355–363. https://doi.org/10.1177/0961203320903798
Alamoudi, O.S. and Attar, S.M. (2015), Pulmonary manifestations in SLE. Respirology, 20: 474-480. doi:10.1111/resp.12473
Anderson IJ, Davis AM. Incidental Pulmonary Nodules Detected on CT Images. JAMA. 2018;320(21):2260–2261. doi:10.1001/jama.2018.16336
Andrade C, et al. Alveolar hemorrhage in systemic lupus erythematosus: a cohort review. Lupus. 2016 Jan;25(1):75-80. Epub 2015 Sep 18. 
Asif S, Rasheed A, Mahmud TE, Asghar A. Frequency and predictors of pulmonary hypertension in patients with Systemic Lupus Erythematosus. Pak J Med Sci. 2019;35(1):86‐89. doi:10.12669/pjms.35.1.405
Badshaa H, Cheng LT, Konga KO, Liana TY, Chnga HH. Pulmonary hemorrhage in systemic lupus erythematosus. Seminars in Arthritis and Rheumatism. June 2004;33(6):414–421.
Blasco Mata LM, Acha Salazar O, González-Fernández CR, Robledo FN, Pérez-Llantada Amunárriz E. Systemic lupus erythematosus and systemic autoimmune connective tissue disorders behind recurrent diastolic heart failure. Clin Dev Immunol. 2012;2012:831434. doi:10.1155/2012/831434
Casey A, Maria Marta Perin, Juan Ignacio Enghelmayer, Cora Legarreta, Federico Zenon, Pamela Rossi, Silvana Acuña, A Betancourt, R Gomez, A Beron, D Dubinsky, Ana Maria Putruele. Shrinking lung syndrome (SLS) associated with systemic lupus erythematosus (SLE): A series of cases in a university hospital. European Respiratory Journal Sep 2019, 54 (suppl 63) OA5329; DOI: 10.1183/13993003.congress-2019.OA5329
Chen Q, Qiu F, Liu H, Li X, Li J. Altered Olfactory Function in Patients with Systemic Lupus Erythematosus. Med Sci Monit. 2019;25:5929–5933. Published 2019 Aug 9. doi:10.12659/MSM.915738
Ciaffi, Jacopo MD; Gegenava, Maka MD; Ninaber, Maarten K. MD; Huizinga, Tom W. J. MD, PhD Shrinking Lung Syndrome, JCR: Journal of Clinical Rheumatology: September 2, 2019 – Volume Publish Ahead of Print – Issue – doi: 10.1097/RHU.0000000000001132
Deeb, M., Tselios, K., Gladman, D., Su, J., & Urowitz, M. (2018). Shrinking lung syndrome in systemic lupus erythematosus: a single-centre experience. Lupus, 27(3), 365–371. https://doi.org/10.1177/0961203317722411
Fenlon HM et al. High-resolution chest CT in systemic lupus erythematosus. American Journal of Roentgenology 1996 166:2, 301-307
Flahety K, et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases N Eng J Med. Published 29 September, 2019. NEJM.org. DOI: 10.1056/NEJMoa1908681
Hodgkin JE. Benefits and the Future of Pulmonary Rehabilitation. In: Pulmonary Rehabilitation: Guidelines To Success, 4th ed, Hodgkin JE, Celli BR, Connors GL (Eds), Mosby Elsevier, St. Louis, MI 2009.
Kazzaz NM, Coit P, Lewis EE, et al. Systemic lupus erythematosus complicated by diffuse alveolar haemorrhage: risk factors, therapy and survival. Lupus Science & Medicine 2015;2:e000117. doi: 10.1136/lupus-2015-000117
Kim, J. S., Kim, D., Joo, Y. B., Won, S., Lee, J., Shin, J., & Bae, S.-C. (2018). Factors associated with development and mortality of pulmonary hypertension in systemic lupus erythematosus patients. Lupus, 27(11), 1769–1777. https://doi.org/10.1177/0961203318788163
Kishore S, Jatwani S, Malhotra B, et al. Systemic lupus erythematosus is associated with a high risk of venous thromboembolism in hospitalized patients leading to poor outcomes and a higher cost: Results from nationwide inpatient sample database 2003–2011. ACR Open Rheumatology. 2019 May 13;1(3):194–200.
Koslow, M., Kivity, S., Vishnevskia-Dai, V. et al. Unexplained cough: it is time to rule out Sjogren’s syndrome. Clin Rheumatol 37, 1215–1222 (2018). https://doi.org/10.1007/s10067-018-3987-4
Lian F, et al. Clinical features and independent predictors of interstitial lung disease in systemic lupus erythematosus. Int J Clin Exp Med 2016;9(2):4233-4242. www.ijcem.com /ISSN:1940-5901/IJCEM0015983
McCarthy B, et al. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015
Minai OA. An update in pulmonary hypertension in systemic lupus erythematosus—do we need to know about it? [Letter to the editor]. Lupus. 2009;18:92.
Mizus M, Li J, Goldman D, et al. Autoantibody clustering of lupus-associated pulmonary hypertension. Lupus Science & Medicine 2019;6:e000356. doi: 10.1136/lupus-2019-000356
MOERSCH HJ, PURNELL DC, GOOD CA. Pulmonary changes occurring in disseminated lupus erythematosus. Dis Chest. 1956 Feb;29(2):166-73. doi: 10.1378/chest.29.2.166. PMID: 13285393.
Munoz ML, et al. Into thin air: shrinking lung syndrome. Am J Med. 2014 Aug;127(8):711-3. Epub 2014 Apr 13. < /strong>
Obaidat B, Yazdani D, Wikenheiser-Brokamp KA, Gupta N. Diffuse Cystic Lung Diseases. Respir Care. 2020;65(1):111-126. doi:10.4187/respcare.07117
Perricone C, Shoenfeld N, Agmon-Levin N, de Carolis C, Perricone R, Shoenfeld Y. Smell and autoimmunity: a comprehensive review. Clin Rev Allergy Immunol. 2013;45(1):87–96. doi:10.1007/s12016-012-8343-x
Prabu, A., & Gordon, C. (2013). Pulmonary arterial hypertension in SLE: what do we know? Lupus, 22(12), 1274–1285. https://doi.org/10.1177/0961203313505010
Puhan MA, et al. Respiratory rehabilitation after acute exacerbation of COPD may reduce risk for readmission and mortality — a systematic review. Respir Res. 2005;6:54. Epub 2005 Jun 8.
Park JH, Kim DS, Park IN, et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J
Raoof S, Bondalapati P, Vydyula R, et al. Cystic Lung Diseases: Algorithmic Approach. Chest. 2016;150(4):945-965. doi:10.1016/j.chest.2016.04.026
Respir Crit Care Med. 2007;175(7):705–711. doi:10.1164/rccm.200607-912OCSantiago-Casas Y, Vila LM. Pulmonary hemorrhage in patients with systemic lupus erythematosus. Current Respiratory Medicine Reviews. February 2009;5(1):49–54.
Shoenfeld N, Agmon-Levin N, Flitman-Katzevman I, et al. The sense of smell in systemic lupus erythematosus. Arthritis Rheum. 2009;60(5):1484–1487. doi:10.1002/art.24491
Sun F, Lei Y, Wu W, et al. Two distinct clinical phenotypes of pulmonary arterial hypertension secondary to systemic lupus erythematosus. Annals of the Rheumatic Diseases 2019;78:148-150.
Sun Y, et al. Systemic lupus erythematosus-associated diffuse alveolar hemorrhage: a single-center, matched case-control study in China. Lupus. 2020;29(7):795. Epub 2020 Apr 22.
Tanni SE, et al. Influence of the oxygen delivery system on the quality of life of patients with chronic hypoxemia. J Bras Pneumol. 2007;33(2):161.
Yeatman M, et al. Lung Transplantation in patients with systemic diseases: an eleven-year experience at Papworth Hospital. J Heart Lung Transplant. 1996;15(2):144.
Velazquez ML, Highland KB. Pulmonary manifestations of systemic lupus erythematosus and Sjögren’s syndrome. Curr Opin Rheum 2018;30:449-464.
Wan, S. A., Teh, C. L., & Jobli, A. T. (2016). Lupus pneumonitis as the initial presentation of systemic lupus erythematosus: case series from a single institution. Lupus, 25(13), 1485–1490. https://doi.org/10.1177/0961203316646461
Yusuf HR, et al. Risk of venous thromboembolism among hospitalizations of adults with selected autoimmune diseases. J Thromb Thrombolysis. 2014;38(3):306. 

Chapter 11

Akiyama M, Kaneko Y, Takeuchi T. Lupus aortitis: A fatal, inflammatory cardiovascular complication in systemic lupus erythematosus. Lupus. 2020;29(12):1652-1654. doi:10.1177/0961203320950017
Al Rayes, H., Harvey, P.J., Gladman, D.D. et al. Prevalence and associated factors of resting electrocardiogram abnormalities among systemic lupus erythematosus patients without cardiovascular disease. Arthritis Res Ther 19, 31 (2017). https://doi.org/10.1186/s13075-017-1240-1
Apte M, McGwin Jr G, Vilá LM, Kaslow RA, Alarcón GS, Reveille JD, et al. Associated factors and impact of myocarditis in patients with SLE from LUMINA, a multiethnic US cohort. Rheumatology (Oxford). 2008;47(3):362–367.
Barnado, A., Carroll, R.J., Casey, C., Wheless, L., Denny, J.C. and Crofford, L.J. (2018), Phenome‐Wide Association Studies Uncover a Novel Association of Increased Atrial Fibrillation in Male Patients With Systemic Lupus Erythematosus. Arthritis Care Res, 70: 1630-1636. doi:10.1002/acr.23553
Bhusal S, et al. Clinical Implications of Persistent Sinus Tachycardia in Systemic Lupus Erythematous: A Retrospective Study. [abstract 1801];American Coll Rheum 2016. 
Bienias, P., Ciurzyński, M., Chrzanowska, A., Dudzik-Niewiadomska, I., Irzyk, K., Oleszek, K., … Pruszczyk, P. (2018). Attenuated post-exercise heart rate recovery in patients with systemic lupus erythematosus: the role of disease severity and beta-blocker treatment. Lupus, 27(2), 217–224. https://doi.org/10.1177/0961203317716318
Borenstein DG, Fye WB, Arnett FC, Stevens MB. The myocarditis of systemic lupus erythematosus: association with myositis. Annals of Internal Medicine. 1978;89:619–624.
Bourré-Tessier J, Huynh T, Clarke AE, Bernatsky S, Joseph L, et al. Features associated with cardiac abnormalities in systemic lupus erythematosus. Lupus. December 2011;20(14):1518–1525.
Brinster DR, Grizzard JD, Dash A. Lupus aortitis leading to aneurysmal dilatation in the aortic root and ascending aorta. Heart Surg Forum. 2009 Apr;12(2):E105-8. doi: 10.1532/HSF98.20081123. PMID: 19383583.
Caforio AL, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34(33):2636–2648d. doi:10.1093/eurheartj/eht210
Corominas H, Tsokos M, Quezado M, Tsokos GC. Aneurysm of the ascending aorta in systemic lupus erythematosus: Case report and review of the literature. Eur J Rheumatol. 2017;4(2):133–135. doi:10.5152/eurjrheum.2017.17066
Du Toit, R., Herbst, P. G., van Rensburg, A., du Plessis, L. M., Reuter, H., & Doubell, A. F. (2017). Clinical features and outcome of lupus myocarditis in the Western Cape, South Africa. Lupus, 26(1), 38–47. https://doi.org/10.1177/0961203316651741

Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001 May 9;285(18):2370-5. doi: 10.1001/jama.285.18.2370. PMID: 11343485.
Guindo J, et al. Recurrent pericarditis. Relief with colchicine. Circulation. 1990;82(4):1117. 
Guy, A., Tiosano, S., Comaneshter, D., Tekes-Manova, D., Shovman, O., Cohen, A. D., & Amital, H. (2016). Aortic aneurysm association with SLE – a case–control study. Lupus, 25(9), 959–963. htt
ps:/doi.org/10.1177/0961203316628999
Horneffer PJ, Miller RH, Pearson TA, Rykiel MF, Reitz BA, Gardner TJ. The effective treatment of postpericardiotomy syndrome after cardiac operations. A randomized placebo-controlled trial. J Thorac Cardiovasc Surg. 1990;100(2):292–296.
Imazio M, Gaita F, LeWinter M. Evaluation and Treatment of Pericarditis: A Systematic Review [published correction appears in JAMA. 2015 Nov 10;314(18):1978] [published correction appears in JAMA. 2016 Jan 5;315(1):90. Dosage error in article text]. JAMA. 2015;314(14):1498–1506. doi:10.1001/jama.2015.12763
Johannesdottir SA, Horváth-Puhó E, Dekkers OM, et al. Use of Glucocorticoids and Risk of Venous Thromboembolism: A Nationwide Population-Based Case-Control Study. JAMA Intern Med. 2013;173(9):743–752. doi:10.1001/jamainternmed.2013.122
Khouri C, Blaise S, Carpentier P, Villier C, Cracowski JL, Roustit M. Drug-induced Raynaud’s phenomenon: beyond β-adrenoceptor blockers. Br J Clin Pharmacol. 2016;82(1):6‐16. doi:10.1111/bcp.12912
Lourdudoss, C., & Vollenhoven, R. van. (2014). Mycophenolate mofetil in the treatment of SLE and systemic vasculitis: experience at a single university center. Lupus, 23(3), 299–304. https://doi.org/10.1177/0961203313519158
Mavrogeni S, Bratis K, Markussis V, Spargias C, Papadopoulou E, et al. The diagnostic role of cardiac magnetic resonance imaging in detecting myocardial inflammation in systemic lupus erythematosus. Differentiation from viral myocarditis. Lupus. January 2013;22(1):34–43.
Mohammed AG, Alghamdi AA, ALjahlan MA, Al-Homood IA. Echocardiographic findings in asymptomatic systemic lupus erythematosus patients. Clin Rheumatol. 2017;36(3):563–568. doi:10.1007/s10067-016-3486-4
Myung, G., Forbess, L.J., Ishimori, M.L. et al. Prevalence of resting-ECG abnormalities in systemic lupus erythematosus: a single-center experience. Clin Rheumatol 36, 1311–1316 (2017). https://doi.org/10.1007/s10067-017-3582-0
Nishimura RA, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017;70(2):252. Epub 2017 Mar 15. 
Ocampo V, Haaland D, Legault K, et al. Successful treatment of recurrent pleural and pericardial effusions with tocilizumab in a patient with systemic lupus erythematous. Case Reports 2016;2016:bcr2016215423.
Panchal L, Divate S, Vaideeswar P, Pandit SP. Cardiovascular involvement in systemic lupus erythematosus: an autopsy study of 27 patients in India. J Postgrad Med. 2006;52(1):5–10.
Quadrelli, S., Alvarez, C., Arce, S., Paz, L., Sarano, J., Sobrino, E., & Manni, J. (2009). Pulmonary involvement of systemic lupus erythematosus: analysis of 90 necropsies. Lupus, 18(12), 1053–1060. https://doi.org/10.1177/0961203309106601

Roldan CA, Sibbitt WL Jr, Qualls CR, Jung RE, Greene ER, Gasparovic CM, Hayek RA, Charlton GA, Crookston K. Libman-Sacks endocarditis and embolic cerebrovascular disease. JACC Cardiovasc Imaging. 2013 Sep;6(9):973-83. doi: 10.1016/j.jcmg.2013.04.012. PMID: 24029368; PMCID: PMC3941465.
Tselios, K., Gladman, D. D., Harvey, P., Su, J., & Urowitz, M. B. (2018). Severe brady-arrhythmias in systemic lupus erythematosus: prevalence, etiology and associated factors. Lupus, 27(9), 1415–1423. https://doi.org/10.1177/0961203318770526
Suri V, Varma S, Joshi K, Malhotra P, Kumari S, Jain S. Lupus myocarditis improvement in cardiac function after intravenous immunoglobulin therapy. Rheumatology International. 2010;30(11):1503–1505.
Vivero F, et al. Prevalence and predictors of valvular heart disease in patients with systemic lupus erythematosus. Autoimmunity Reviews
Volume 15, Issue 12, December 2016, Pages 1134-1140.
Watad A, et al. The association between systemic lupus erythematosus and valvular heart disease: an extensive data analysis. Eur J Clin Invest 2017; 47 ( 5): 366– 371.
Willett WF 3rd, Kahn MJ, Gerber MA. Lupus aortitis: a case report and review of the literature. J La State Med Soc. 1996 Feb;148(2):55-9. PMID: 8746162.
Yoo B-W, Lee S-W, Song JJ, Park Y-B, Jung SM. Clinical characteristics and long-term outcomes of Libman–Sacks endocarditis in patients with systemic lupus erythematosus. Lupus. 2020;29(9):1115-1120. doi:10.1177/0961203320930097
Your heart and blood vessels. Retrieved April 23, 2011, from www.my.clevelandclinic.org/heart/heartworks/heartfacts.aspx.
Zawadowski GM, Klarich KW, Moder KG, Edwards WD, Cooper Jr. LT. A contemporary case series of lupus myocarditis. Lupus. October 2012;21:1378–1384.

Chapter 12

ACCESS Trial Group. Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study. Arthritis Rheumatol. 2014;66(11):3096. 
Alarcon GS. The LUMINA Study: impact beyond lupus in U.S. Hispanics. The Rheumatologist. April 2011;5(4):1+.
Aragon, E., Resontoc, L. P., Chan, Y. H., Lau, Y. W., Tan, P. H., Loh, H. L., … Yap, H. K. (2016). Long-term outcomes with multi-targeted immunosuppressive protocol in children with severe proliferative lupus nephritis. Lupus, 25(4), 399–406. https://doi.org/10.1177/0961203315615220​
Aringer M, et al reply to and: Fonseca AR, Rodrigues MCF, Sztajnbok F, Land MGP, de Oliveira SKF. Does Leukopenia Influence Performance of the New European League Against Rheumatism/American College of Rheumatology Classification Criteria in an African-Descendent Population With Childhood-Onset Systemic Lupus Erythematosus? Comment on the Article by Aringer et al. Arthritis Rheumatol. 2020;72(4):694‐695. doi:10.1002/art.41178​

Arriens C, Teng YKO, Ginzler EM, Parikh SV, Askanase AD, Saxena A, Gibson K, Caster DJ, Atsumi T, Lisk L, Randhawa S, Gluck R, Solomons N, Huizinga RB. Update on the Efficacy and Safety Profile of Voclosporin: An Integrated Analysis of Clinical Trials in Lupus Nephritis. Arthritis Care Res (Hoboken). 2022 Aug 30. doi: 10.1002/acr.25007. Epub ahead of print. PMID: 36039949.
​Bertsias GK, Joint European League against rheumatism and European renal Association-European dialysis and transplant association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012;71:1771–82. doi:10.1136/annrheumdis-2012-201940.
Birmingham DJ, Shidham G, Perna A, Fine DM, Bissell M, Rodby R, Remuzzi G, Petri M, Hebert P, Rovin BH, Hebert LA. Spot PC ratio estimates of 24-hour proteinuria are more unreliable in lupus nephritis than in other forms of chronic glomerular disease. Ann Rheum Dis. 2014 Feb;73(2):475-6.
Broder A, Mowrey WB, Khan HN, et al. Tubu
lointerstitial damage predicts end stage renal disease in lupus nephritis with preserved to moderately impaired renal function: A retrospective cohort study. Semin Arthritis Rheum. 2018;47(4):545–551. doi:10.1016/j.semarthrit.2017.07.007
Castro, M., Ugolini-Lopes, M., Borba, E. F., Bonfá, E., & Seguro, L. P. C. (2018). Effectiveness of renoprotective approaches for persistent proteinuria in lupus nephritis: more than just immunosuppression. Lupus, 27(14), 2215–2219. https://doi.org/10.1177/0961203318809883
Castro-Santana LE, Colón M, Molina M, Rodríguez VE, Mayor AM, Vilá LM. Efficacy of two cyclophosphamide regimens for the treatment of lupus nephritis in Puerto Ricans: low vs standard dose. Ethnicity & Disease. Spring 2010(suppl 1);20:116–121.
Cathcart, E & Idelson, B & Scheinberg, Morton & Couser, W. (1976). Beneficial effect of methylprednisolone pulse therapy in diffuse proliferative lupus nephritis. Lancet. 1. 163-6. 10.1016/S0140-6736(76)91272-1. ​
Chacko, B., & Formby, M. (2018). A wolf in sheep’s clothing. Lupus, 27(9), 1570–1571. https://doi.org/10.1177/0961203318772020
Chen, T., Estrella, M., & Fine, D. (2012). Predictors of kidney biopsy complication among patients with systemic lupus erythematosus. Lupus, 21(8), 848–854. https://doi.org/10.1177/0961203312439334​
Chen, T. K., Gelber, A. C., Witter, F. R., Petri, M., & Fine, D. M. (2015). Renal biopsy in the management of lupus nephritis during pregnancy. Lupus, 24(2), 147–154. https://doi.org/10.1177/0961203314551812
Choi CB, Won S, Bae SC. Outcomes of multitarget therapy using mycophenolate mofetil and tacrolimus for refractory or relapsing lupus nephritis. Lupus. 2018;27(6):1007. Epub 2018 Feb 15. 
Chu, H., Wu, L., Song, D., Yu, F., & Zhao, M. (2014). Noninflammatory necrotizing vasculopathy in lupus nephritis: a single-center experience. Lupus, 23(1), 20–30. https://doi.org/10.1177/0961203313512391
Condon MB, Ashby D, Pepper RJ, et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis. 2013;72(8):1280–1286. doi:10.1136/annrheumdis-2012-202844
Cortés-Hernández J, et al. Long-term outcomes–mycophenolate mofetil treatment for lupus nephritis with addition of tacrolimus for resistant cases. Nephrol Dial Transplant. 2010;25(12):3939. Epub 2010 Jun 10. ​
Costenbader KH, et al. Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006. Arthritis Rheum. 2011;63(6):1681. 
Dall’Era M, Bruce IN, Gordon C, Manzi S, McCaffrey J, Lipsky PE. Current challenges in the development of new treatments for lupus. Ann Rheum Dis. 2019;78(6):729–735. doi:10.1136/annrheumdis-2018-214530
Dall’Era M, Cisternas MG, Smilek DE, et al. Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort. Arthritis Rheumatol. 2015;67(5):1305–1313. doi:10.1002/art.39026
Dall’Era M, et al. The incidence and prevalence of systemic lupus erythematosus in San Francisco County, California. Arthr & Rheum. 2017;69(10):1996-2005.
Davidson A, Aranow C, Mackay M. Lupus nephritis: challenges and progress. Curr Opin Rheumatol. 2019;31(6):682–688. doi:10.1097/BOR.0000000000000642
Dooley MA, Houssiau F, Aranow C, et al. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus. January 2013;22(1):63–72.
Dooley MA, Jayne D, Ginzler EM, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011;365(20):1886‐1895. doi:10.1056/NEJMoa1014460​
Dube GK, et al. Minimal change disease in systemic lupus erythematosus. Clin Nephrol. 2002;57(2):120. 

Escoda T, George J, Jarrot P-A, et al. Aortitis is an under-recognized manifestation of antiphospholipid syndrome: A case report and literature review. Lupus. 2022;31(6):744-753. doi:10.1177/09612033221091142
Fanouriakis A, 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019 Jun;78(6):736-745. doi: 10.1136/annrheumdis-2019-215089.
Fanouriakis et l 2019 Update of the Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA–EDTA) recommendations for the management of lupus nephritis Ann Rheum Dis. 2020 Mar 27. pii: annrheumdis-2020-216924. doi: 10.1136/annrheumdis-2020-216924.
Feldman CH, Broder A, Guan H, Yazdany J, Costenbader KH. Sex Differences in Health Care Utilization, End-Stage Renal Disease, and Mortality Among Medicaid Beneficiaries With Incident Lupus Nephritis. Arthritis Rheumatol. 2018;70(3):417–426. doi:10.1002/art.40392
Feldman CH, Collins J, Zhang Z, et al. Azathioprine and Mycophenolate Mofetil Adherence Patterns and Predictors Among Medicaid Beneficiaries With Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2019;71(11):1419–1424. doi:10.1002/acr.23792
Fine DM. Dialogue: Early predictors of long-term lupus nephritis outcomes: looking into the future. Lupus Sci Med. 2015 Jun 2;2(1):e000096.
Fomin A and Roberts WN. Tacrolimus for lupus nephritis. The Rheumatologist October 2016:25-26.
Freeman S. Abatacept loses ALLURE in lupus nephritis. MDedge Rheumatology News July 2018.

Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, Amoura Z, Yu X, Mok CC, Santiago MB, Saxena A, Green Y, Ji B, Kleoudis C, Burriss SW, Barnett C, Roth DA. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. N Engl J Med. 2020 Sep 17;383(12):1117-1128. doi: 10.1056/NEJMoa2001180. PMID: 32937045.
Gordon S, Denunzio T, Uy A. Success using tacrolimus in patients with proliferative and membranous lupus nephritis and refractory proteinuria. Hawaii J Med Public Health. 2013;72(9 Suppl 4):18–23.

Gracia-Tello B, David Isenberg, Kidney disease in primary anti-phospholipid antibody syndrome, Rheumatology, Volume 56, Issue 7, July 2017, Pages 1069–1080
Griffin, B., & Lightstone, L. (2013). Renoprotective strategies in lupus nephritis: beyond immunosuppression. Lupus, 22(12), 1267–1273. https://doi.org/10.1177/0961203313505927
Gupta R, et al. Collapsing glomerulopathy occurring in HIV-negative patients with systemic lupus erythematosus: report of three cases and brief review of the literature. Lupus. 2011 Jul;20(8):866-70. Epub 2011 Feb 21. 
Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care & Research. June 2012;64(6
):797–808.
Henkel G. Progress & continuing challenges in SLE. The Rheumatologist July 2014:41.
Hiramatsu, Y., Yoshida, S., Kotani, T., Nakamura, E., Kimura, Y., Fujita, D., … Arawaka, S. (2018). Changes in the blood level, efficacy, and safety of tacrolimus in pregnancy and the lactation period in patients with systemic lupus erythematosus. Lupus, 27(14), 2245–2252. https://doi.org/10.1177/0961203318809178
Houssiau FA, Isenberg D. Towards treating lupus nephritis without oral steroids: a dream-come-true?. Ann Rheum Dis. 2013;72(8):1271‐1272. doi:10.1136/annrheumdis-2013-203205
Hu, W. X., Chen, Y. H., Bao, H., Liu, Z. Z., Wang, S. F., Zhang, H. T., & Liu, Z. H. (2015). Glucocorticoid with or without additional immunosuppressant therapy for patients with lupus podocytopathy: a retrospective single-center study. Lupus, 24(10), 1067–1075. https://doi.org/10.1177/0961203315578766​
Hu W, et al. Clinical-Morphological Features and Outcomes of Lupus Podocytopathy. Clin J Am Soc Nephrol. 2016;11(4):585. Epub 2016 Mar 16. ​
Ichinose, K., Kitamura, M., Sato, S., Eguchi, M., Okamoto, M., Endo, Y., … Kawakami, A. (2019). Complete renal response at 12 months after induction therapy is associated with renal relapse-free rate in lupus nephritis: a single-center, retrospective cohort study. Lupus, 28(4), 501–509. https://doi.org/10.1177/0961203319829827
Ichinose, K., Kitamura, M., Sato, S., Fujikawa, K., Horai, Y., Matsuoka, N., … Kawakami, A. (2019). Factors predictive of long-term mortality in lupus nephritis: a multicenter retrospective study of a Japanese cohort. Lupus, 28(3), 295–303. https://doi.org/10.1177/0961203319826690
Izmirly PM, et al. The incidence and prevalence of systemic lupus erythematosus in New York County (Manhattan), New York. Arth & Rheum. 2017;69(10):2006-2017.
Jing Z, et al. Hemoglobin targets for chronic kidney disease patients with anemia: a systematic review and meta-analysis. PLoS One. 2012;7(8):e43655. Epub 2012 8 30. 
Jorge A, et al. Renal Transplantation and Survival Among Patients With Lupus Nephritis: A Cohort Study. Ann Intern Med. 2019;170(4):240. Epub 2019 Jan 22. 
Kang, J.-H., Xu, H., Choi, S.-E., Park, D.-J., Lee, J.-K., Kwok, S.-K., … Lee, S.-S. (2020). Obesity increases the incidence of new-onset lupus nephritis and organ damage during follow-up in patients with systemic lupus erythematosus. Lupus, 29(6), 578–586. https://doi.org/10.1177/0961203320913616
Kasitanon N, Fine DM, Haas M, Magder LS, Petri M. Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus. 2006;15(6):366–370. doi:10.1191/0961203306lu2313oa

Khan N, Reichel R, Khurshid A, Tso K, Broussard J, Dass A. Hydralazine-Induced Isolated Lupus Nephritis. Ochsner J. 2020 Summer;20(2):187-192. doi: 10.31486/toj.18.0128. PMID: 32612474; PMCID: PMC7310176.
Kidder D, et al. Kidney biopsy findings in primary Sjögren syndrome. Nephrol Dial Transplant. 2015 Aug;30(8):1363-9. Epub 2015 Mar 27. 
Kim, J. E., Kim, Y. C., Min, S., Lee, H., Ha, J., Chin, H. J., … Han, S. S. (2020). Transplant outcomes in kidney recipients with lupus nephritis, and systematic review. Lupus, 29(3), 248–255. https://doi.org/10.1177/0961203320902524
Koh, J. H., Lee, J., Jung, S. M., Ju, J. H., Park, S.-H., Kim, H.-Y., & Kwok, S.-K. (2015). Lupus cystitis in Korean patients with systemic lupus erythematosus: risk factors and clinical outcomes. Lupus, 24(12), 1300–1307. https://doi.org/10.1177/0961203315588575
Kraft SW, Schwartz MM, Korbet SM, Lewis EJ. Glomerular podocytopathy in patients with systemic lupus erythematosus. J Am Soc Nephrol. 2005;16(1):175–179. doi:10.1681/ASN.2004050350
Lanata, C., Mahmood, T., Fine, D., & Petri, M. (2010). Combination therapy of mycophenolate mofetil and tacrolimus in lupus nephritis. Lupus, 19(8), 935–940. https://doi.org/10.1177/0961203310365714
Levy, B., Couchoud, C., Rougier, J.-P., Jourde-Chiche, N., & Daugas, E. (2015). Outcome of patients with systemic lupus erythematosus on chronic dialysis: an observational study of incident patients of the French National Registry 2002–2012. Lupus, 24(10), 1111–1121. https://doi.org/10.1177/0961203315578763
Liberski S, Marczak D, Mazur E, Miętkiewicz K, Leis K, Gałązka P. Systemic lupus erythematosus of the urinary tract: focus on lupus cystitis. Reumatologia. 2018;56(4):255‐258. doi:10.5114/reum.2018.77978
Liu Z, Zhang H, Liu Z, et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med. 2015;162(1):18‐26. doi:10.7326/M14-1030
Liu, G., Wang, H., Le, J., Lan, L., Xu, Y., Yang, Y., … Han, F. (2019). Early-stage predictors for treatment responses in patients with active lupus nephritis. Lupus, 28(3), 283–289. https://doi.org/10.1177/0961203319826703
Londoño Jimenez A, Mowrey WB, Putterman C, Buyon J, Goilav B, Broder A. Brief Report: Tubulointerstitial Damage in Lupus Nephritis: A Comparison of the Factors Associated With Tubulointerstitial Inflammation and Renal Scarring. Arthritis Rheumatol. 2018;70(11):1801–1806. doi:10.1002/art.40575
Manou-Stathopoulou, S., & Robson, M. G. (2016). Risk of clinical deterioration in patients with lupus nephritis receiving rituximab. Lupus, 25(12), 1299–1306. https://doi.org/10.1177/0961203316641768
Medina-Rosas J, Yap KS, Anderson M, Su J, Touma Z. Utility of Urinary Protein-Creatinine Ratio and Protein Content in a 24-Hour Urine Collection in Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis. Arthritis Care Res (Hoboken). 2016;68(9):1310–1319. doi:10.1002/acr.22828
Mejía-Vilet, J. M., Córdova-Sánchez, B. M., Uribe-Uribe, N. O., Correa-Rotter, R., & Morales-Buenrostro, L. E. (2017). Prognostic significance of renal vascular pathology in lupus nephritis. Lupus, 26(10), 1042–1050. https://doi.org/10.1177/0961203317692419

Menn-Josephy, H, et al. Voclosporin Is Effective in Achieving Complete Renal Response in Severe Lupus Nephritis (abstract SA-OR31). Am Soc Nephr Kidney Week, NOV 4-7, 2021
Mills KT, et al. Sodium Excretion and the Risk of Cardiovascular Disease in Patients With Chronic Kidney Disease. JAMA. 2016 May;315(20):2200-10. 
Mok, C. C. (2005). Prognostic factors in lupus nephritis. Lupus, 14(
1), 39–44. https://doi.org/10.1191/0961203305lu2057oa
Mok CC, Ying KY, Yim CW, et al. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up. Ann Rheum Dis. 2016;75(1):30‐36. doi:10.1136/annrheumdis-2014-206456
Monroy Trujillo JM, Fine DM. Management of proliferative lupus nephritis. Panminerva Med. 2016 Dec;58(4):286-293.
Moon, S.-J., Park, H., Kwok, S.-K., Ju, J., Choi, B., Park, K.-S., … Park, S.-H. (2013). Predictors of renal relapse in Korean patients with lupus nephritis who achieved remission six months following induction therapy. Lupus, 22(5), 527–537. https://doi.org/10.1177/0961203313476357

Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022 Nov 4:S0140-6736(22)02074-8. doi: 10.1016/S0140-6736(22)02074-8. Epub ahead of print. PMID: 36351458.
Nusbaum JS, Mirza I, Shum J, et al. Sex Differences in Systemic Lupus Erythematosus: Epidemiology, Clinical Considerations, and Disease Pathogenesis. Mayo Clin Proc. 2020;95(2):384-394. doi:10.1016/j.mayocp.2019.09.012
Proença de Moraes, T., Massignan, B., Figueiredo, A. E., Barretti, P., Olandoski, M., Kirk, A., & Pecoits-Filho, R. (2015). Systemic lupus erythematous and clinical outcomes in peritoneal dialysis. Lupus, 24(3), 290–298. https://doi.org/10.1177/0961203314555353
Moroni G, Vercelloni PG, Quaglini S, et al. Changing patterns in clinical–histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis. Annals of the Rheumatic Diseases 2018;77:1318-1325.
Nishizaki Y, Tamaki H, Yukawa S, Matsui Y, Okada M. Comparison between Japanese and non-Japanese features of lupus cystitis based on case reports including novel therapy and a literature review. Intern Med. 2011;50(9):961‐968. doi:10.2169/internalmedicine.50.4708​
Norby GE, Leivestad T, Mjøen G, Hartmann A, Midtvedt K, Gran JT, et al. Premature cardiovascular disease in patients with systemic lupus erythematosus influences survival after renal transplantation. Arthritis & Rheumatism. March 2011;63(3):733–737.
Ntatsaki, E., Vassiliou, V. S., Velo-Garcia, A., Salama, A. D., & Isenberg, D. A. (2019). Renal transplantation for lupus nephritis: non-adherence and graft survival. Lupus, 28(5), 651–657. https://doi.org/10.1177/0961203319842641​
Palsson R, Short SAP, Kibbelaar ZA, et al. Bleeding Complications After Percutaneous Native Kidney Biopsy: Results From the Boston Kidney Biopsy Cohort. Kidney Int Rep. 2020;5(4):511–518. Published 2020 Mar 4. doi:10.1016/j.ekir.2020.01.012​
Park, D. J., Kang, J. H., Lee, J. W., Lee, K. E., Kim, T. J., Park, Y. W., … Lee, S. S. (2017). Risk factors to predict the development of chronic kidney disease in patients with lupus nephritis. Lupus, 26(11), 1139–1148. https://doi.org/10.1177/0961203317694257
Pattanaik D, Green J, Talwar M, Molnar M, Raza SH. Recurrence of Lupus Nephritis in Renal Transplant Recipients [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/recurrence-of-lupus-nephritis-in-renal-transplant-recipients/. Accessed May 2, 2020.
Pedrosa, T. N., Pasoto, S. G., Aikawa, N. E., Yuki, E. F., Borba, E. F., Filho, J. C. F., … Bonfa, E. (2020). Understanding the dynamics of hydroxychloroquine blood levels in lupus nephritis. Lupus, 29(6), 560–568. https://doi.org/10.1177/0961203320912832
Petri M, Bello KJ, Fang H, Magder LS. Vitamin D in systemic lupus erythematosus: modest association with disease activity and the urine protein-to-creatinine ratio. Arthritis Rheum. 2013;65(7):1865‐1871. doi:10.1002/art.37953

Rovin BH, Furie R, Teng YKO, Contreras G, Malvar A, Yu X, Ji B, Green Y, Gonzalez-Rivera T, Bass D, Gilbride J, Tang CH, Roth DA. A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. Kidney Int. 2022 Feb;101(2):403-413. doi: 10.1016/j.kint.2021.08.027. Epub 2021 Sep 22. PMID: 34560137.

Rovin BH, Solomons N, Pendergraft WF 3rd, Dooley MA, Tumlin J, Romero-Diaz J, Lysenko L, Navarra SV, Huizinga RB; AURA-LV Study Group. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int. 2019 Jan;95(1):219-231. doi: 10.1016/j.kint.2018.08.025. Epub 2018 Nov 9. PMID: 30420324.

Rovin BH, Teng YKO, Ginzler EM, Arriens C, Caster DJ, Romero-Diaz J, Gibson K, Kaplan J, Lisk L, Navarra S, Parikh SV, Randhawa S, Solomons N, Huizinga RB. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2021 May 29;397(10289):2070-2080. doi: 10.1016/S0140-6736(21)00578-X. Epub 2021 May 7. Erratum in: Lancet. 2021 May 29;397(10289):2048. PMID: 33971155.

Rubio J, Kyttaris V. Journal Club: Efficacy and Safety of Voclosporin Versus Placebo for Lupus Nephritis (AURORA 1): A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Phase 3 Trial. ACR Open Rheumatol. 2021 Dec;3(12):827-831. doi: 10.1002/acr2.11338. Epub 2021 Aug 31. PMID: 34463434; PMCID: PMC8672170.
Sakai, R., Kurasawa, T., Nishi, E., Kondo, T., Okada, Y., Shibata, A., … Amano, K. (2018). Efficacy and safety of multitarget therapy with cyclophosphamide and tacrolimus for lupus nephritis: a prospective, single-arm, single-centre, open label pilot study in Japan. Lupus, 27(2), 273–282. https://doi.org/10.1177/0961203317719148
Salvatore SP, et al. Collapsing glomerulopathy in 19 patients with systemic lupus erythematosus or lupus-like disease. Clin J Am Soc Nephrol. 2012;7(6):914. 
Sen D, Isenberg DA. Antineutrophil cytoplasmic autoantibodies in systemic lupus erythematosus. Lupus. 2003;12(9):651. ​
Sethi S, et al. ANCA-positive crescentic glomerulonephritis associated with minocycline therapy. Am J Kidney Dis. 2003;42(2):E27. 
Shea-Simonds P, et al. Lupus Podocytopathy. Rheumatology (Oxford). 2009;48(12):1616. 
Shimiau A, Tamura A, Tago O, Abe M, Nagai Y, Ishikawa O. Lupus cystitis: a case and review of the literature. Lupus. 2009;18:655–658.
Shimizu, A., Tamura, A., Tago, O., Abe, M., Nagai, Y., & Ishikawa, O. (2009). Lupus cystitis: a case report and review of the literature. Lupus, 18(7), 655–658. https://doi.org/10.1177/0961203308099634​
Short AK, Lockwood CM. Antigen specificity in hydralazine associated ANCA positive systemic vasculitis. QJM. 1995;88(11):775. 
Smith E, Al-Abadi E, Armon K, et al. Outcomes following mycophenolate mofetil versus cyclophosphamide induction treatment for proliferative juvenile-onset lupus nephritis. Lupus. 2019;28(5):613‐620. doi:10.1177/0961203319836712
Stojan, G., & Petri, M. (2016). Anti-C1q in systemic lupus erythematosus. Lupus, 25(8), 873–877. https://doi.org/10.1177/0961203316645205
Tamirou F, D’Cruz D, Sangle S, et al. Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. Ann Rheum Dis. 2016;75(3):526‐531. doi:10.1136/annrheumdis-2014-206897
Tamirou F, Lauwerys BR, Dall’Era M, et al. A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial. Lupus Sci Med. 2015;2(1):e000123. Published 2015 Nov 12. doi:10.1136/lupus-2015-000123
Tanha N, Hansen RB, Nielsen CT, Faurschou M, Jacobsen S. Clinical and Serological Associations with the Development of Incident Proteinuria in Danish Patients with Systemic Lupus Erythematosus. J Rheumatol. 2018;45(7):934–941. doi:10.3899/jrheum.170933
Tesar V, Hruskova Z. Lupus Nephritis: A Different Disease in European Patients?. Kidney Dis (Basel). 2015;1(2):110–118. doi:10.1159/000438844
Tian SY, Silverman ED, Pullenayegum E, Brown PE, Beyene J, Feldman BM. Comparative Effectiveness of Mycophenolate Mofetil for the Treatment of Juvenile-Onset Proliferative Lupus Nephritis. Arthritis Care Res (Hoboken). 2017;69(12):1887‐1894. doi:10.1002/acr.23215
Tornatore KM, Sudchada P, Dole K, DiFrancesco R, Leca N, Gundroo AC, et al. Mycophenolic acid pharmacokinetics during maintenance immunosuppression in African American and Caucasian renal transplant recipients. Journal of Clinical Pharmacology. January 2011.
Retrieved April 10, 2011, from www.jcp.sagepub.com/content/early/2011/01/05/0091270010382909.abstract.
Trujillo JM, Fine DM. Management of proliferative lupus nephritis. Panminerva Medica. 2016 Dec;58(4):286-293.​
Wang, S. F., Chen, Y. H., Chen, D. Q., Liu, Z. Z., Xu, F., Zeng, C. H., & Hu, W. X. (2018). Mesangial proliferative lupus nephritis with podocytopathy: a special entity of lupus nephritis. Lupus, 27(2), 303–311. https://doi.org/10.1177/0961203317720526
Wakasugi D, Gono T, Kawaguchi Y, Hara M, Koseki Y, et al. Frequency of class III and IV nephritis in systemic lupus erythematosus without clinical renal involvement: an analysis of predictive measures. Journal of Rheumatology. 2012;39:79–85.
Webster, P., Wardle, A., Bramham, K., Webster, L., Nelson-Piercy, C., & Lightstone, L. (2014). Tacrolimus is an effective treatment for lupus nephritis in pregnancy. Lupus, 23(11), 1192–1196. https://doi.org/10.1177/0961203314540353
Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Journal of the American Society of Nephrology. 2004;15:241–250.
Wen JY, Lo TS, Chuang YC, et al. Risks of interstitial cystitis among patients with systemic lupus erythematosus: A population-based cohort study. Int J Urol. 2019;26(9):897‐902. doi:10.1111/iju.14065​
Wofsy D, Diamond B, Houssiau FA. Crossing the Atlantic: the Euro-Lupus Nephritis regimen in North America. Arthritis Rheumatol. 2015;67(5):1144‐1146. doi:10.1002/art.39067​
Worcester S. Lupus nephritis treatment: five key components. MDedge Rheumatology September 2019:25.
Xiong, W. W., Boone, J. B., Wheless, L., Chung, C. P., Crofford, L. J., & Barnado, A. (2019). Real-world electronic health record identifies antimalarial underprescribing in patients with lupus nephritis. Lupus, 28(8), 977–985. https://doi.org/10.1177/0961203319856088
Yap DYH, Tang C, Ma MKM, et al. Longterm Data on Disease Flares in Patients with Proliferative Lupus Nephritis in Recent Years. J Rheumatol. 2017;44(9):1375–1383. doi:10.3899/jrheum.170226​
Yap, D. Y. H., Thong, K. M., Yung, S., Tang, C., Ma, B. M. Y., & Chan, T. M. (2019). Antiphospholipid antibodies in patients with lupus nephritis: clinical correlations and associations with long-term outcomes. Lupus, 28(12), 1460–1467. https://doi.org/10.1177/0961203319879990
Yu F, et al. Tubulointerstitial lesions of patients with lupus nephritis classified by the 2003 International Society of Nephrology and Renal Pathology Society system. Kidney Int. 2010;77(9):820. 
Zhang G, Li H, Huang W, Li X, Li X. Clinical features of lupus cystitis complicated with hydroureteronephrosis in a Chinese population. Journal of Rheumatology. 2011;38:667–671.
Zhang, W., Yuan, M., Hong, L., Zhou, Q., Chen, W., Yang, S., … Yu, X. (2016). Clinical outcomes of lupus nephritis patients with different proportions of crescents. Lupus, 25(14), 1532–1541. https://doi.org/10.1177/0961203316642312​
Zickuhr L, et al. Collapsing glomerulopathy, extensor tendon ruptures and autoimmune ILD. Rheumatology Connections Summer 2018:3-4.

Read More

Chapter 13

ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis & Rheumatism. April 1999;42(4):599–608.
Amick HR, et al. Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis. BMJ. 2015;351:h6019. Epub 2015 Dec 8. 
Antonchak MA, Saoudian M, Khan AR, Brunner HI, Luggen ME. Cognitive dysfunction in patients with systemic lupus erythematosus: a controlled study. Journal of Rheumatology. 2011;38:1020–1025.
Barile-Fabris L, et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis. 2005;64(4):620.
Barile L, Lavalle C. Transverse myelitis in systemic lupus erythematosus–the effect of IV pulse methylprednisolone and cyclophosphamide. J Rheumatol. 1992;19(3):370‐372.
Bertsias GK, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis. 2010;69(12):2074. 
Birnbaum J, et al. Review: Nervous System Disease in Systemic Lupus Erythematosus: Current Status and Future Directions. rthritis Rheumatol. 2019;71(1):33. Epub 2018 Nov 24. 
Birnbaum J, Petri M, Thompson R, Izbudak I, Kerr D. Distinct subtypes of myelitis in systemic lupus erythematosus. Arthritis Rheum. 2009;60(11):3378‐3387. doi:10.1002/art.24937
Blitshteyn S. Autoimmune markers and autoimmune disorders in patients with postural tachycardia syndrome (POTS). Lupus. 2015;24(13):1364‐1369. doi:10.1177/0961203315587566
Bortoluzzi, A., Piga, M., Silvagni, E., Chessa, E., Mathieu, A., & Govoni, M. (2019). Peripheral nervous system involvement in systemic lupus erythematosus: a retrospective study on prevalence, associated factors and outcome. Lupus, 28(4), 465–474. https://doi.org/10.1177/0961203319828499
Acute adverse reactions to prednisone in relation to dosage. Clin Pharmacol Ther. 1972;13(5):694‐698. doi:10.1002/c
pt1972135part1694
Bradley S and Patel NJ. Lupus Patient Develops Miller Fisher Variant of Guillain-Barré Syndrome. The Rheumatologist OCT 2018:47-48.
Buc´a A, Perkovic´ D, Martinovic´ D, Vlastelica M, Titlic´ M. Neuropsychiatric systemic lupus erythematosus: diagnostic and clinical features according to revised ACR criteria. Collegium Antropologicum. March 2009;33(1):281–288.
Callaghan BC, Gao L, Li Y, et al. Diabetes and obesity are the main metabolic drivers of peripheral neuropathy. Ann Clin Transl Neurol. 2018;5(4):397-405. Published 2018 Feb 14. doi:10.1002/acn3.531
Callaghan BC, Price RS, Feldman EL. Distal Symmetric Polyneuropathy: A Review. JAMA. 2015;314(20):2172‐2181. doi:10.1001/jama.2015.13611
Chen Q, Qiu F, Liu H, Li X, Li J. Altered Olfactory Function in Patients with Systemic Lupus Erythematosus. Med Sci Monit. 2019;25:5929‐5933. Published 2019 Aug 9. doi:10.12659/MSM.915738
Chung SW, Lee KM, Heo SH, et al. A systemic lupus erythematosus patient with thunderclap headache: reversible cerebral vasoconstriction syndrome. Lupus. 2019;28(7):898‐902. doi:10.1177/0961203319845485
Cugati S, et al. Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study. Arch Ophthalmol. 2006;124(5):726. 
Darmawan G, Hamijoyo L, Oehadian A, Bandiara R, Amalia L. Cerebral Venous Sinus Thrombosis in Systemic Lupus Erythematosus. Acta Med Indones. 2018;50(4):343‐345.
Dave S, Longmuir R, Shah VA, Wall M, Lee AG. Intracranial hypertension in systemic lupus erythematosus. Seminars in Ophthalmology. 2008;23(2):127–133.
Denburg SD, Carbotte RM, Denburg JA. Corticosteroids and neuropsychological functioning in patients with systemic lupus erythematosus. Arthritis Rheum. 1994;37(9):1311‐1320. doi:10.1002/art.1780370907
Di Stadio A, Ralli M. Systemic Lupus Erythematosus and hearing disorders: Literature review and meta-analysis of clinical and temporal bone findings. J Int Med Res. 2017;45(5):1470‐1480. doi:10.1177/0300060516688600
Drenkard, C., Parker, S., Aspey, L.D., Gordon, C., Helmick, C.G., Bao, G. and Lim, S.S. (2019), Racial Disparities in the Incidence of Primary Chronic Cutaneous Lupus Erythematosus in the Southeastern US: The Georgia Lupus Registry. Arthritis Care Res, 71: 95-103. doi:10.1002/acr.23578
Erez, D., Abarbuch, E., Natour, A., Meyer, A., Natour, A., Dovrish, Z., & Levy, Y. (2020). Audiological disturbances in patients with primary antiphospholipid syndrome. Lupus, 29(6), 533–538. https://doi.org/10.1177/0961203320904780
Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020;79(6):713‐723. doi:10.1136/annrheumdis-2020-216924
Fanouriakis A, Mastorodemos V, Pamfil C, et al. Coexistence of systemic lupus erythematosus and multiple sclerosis: prevalence, clinical characteristics, and natural history. Semin Arthritis Rheum. 2014;43(6):751‐758. doi:10.1016/j.semarthrit.2013.11.007
Ferreira, T., Reis, F., & Appenzeller, S. (2016). Posterior reversible encephalopathy syndrome and association with systemic lupus erythematosus. Lupus, 25(12), 1369–1376. https://doi.org/10.1177/0961203316643598
Ficko C, Andriamanantena D, Dumas G, Claude V, Rapp C. Maladie de Kikuchi-Fujimoto : une cause inhabituelle de méningite lymphocytaire [Kikuchi’s disease: An unusual cause of lymphocytic meningitis]. Rev Neurol (Paris). 2013;169(11):912‐913. doi:10.1016/j.neurol.2012.11.007
Fu Q, et al. Cardiac origins of the postural orthostatic tachycardia syndrome. J Am Coll Cardiol. 2010 Jun;55(25):2858-68. 
Fugate JE, Rabinstein AA. Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions [published correction appears in Lancet Neurol. 2015 Sep;14(9):874]. Lancet Neurol. 2015;14(9):914‐925. doi:10.1016/S1474-4422(15)00111-8
Galindo M, Pablos JL, Gómez-Reino JJ. Internuclear ophthalmoplegia in systemic lupus erythematosus. Semin Arthritis Rheum. 1998;28(3):179‐186. doi:10.1016/s0049-0172(98)80034-6
Garcia RJ, Francis L, Dawood M, Lai ZW, Faraone SV, Perl A. Attention deficit and hyperactivity disorder scores are elevated and respond to N-acetylcysteine treatment in patients with systemic lupus erythematosus. Arthritis Rheum. 2013;65(5):1313‐1318. doi:10.1002/art.37893
Gholizadeh, S., Azizoddin, D. R., Mills, S. D., Zamora, G., Potemra, H. M. K., Hirz, A. E., … Nicassio, P. M. (2019). Body image mediates the impact of pain on depressive symptoms in patients with systemic lupus erythematosus. Lupus, 28(9), 1148–1153. https://doi.org/10.1177/0961203319861675
Gill SS, Seitz DP. Lifestyles and Cognitive Health: What Older Individuals Can Do to Optimize Cognitive Outcomes. JAMA. 2015;314(8):774‐775. doi:10.1001/jama.2015.9526
Gomides, A. P. M., do Rosário, E. J., Borges, H. M., Gomides, H. H. M., de Pádua, P. M., & Sampaio-Barros, P. D. (2007). Sensorineural dysacusis in patients with systemic lupus erythematosus. Lupus, 16(12), 987–990. https://doi.org/10.1177/0961203307084160
Goodman BP. Immunoresponsive Autonomic Neuropathy in Sjögren Syndrome-Case Series and Literature Review. Am J Ther. 2019;26(1):e66-e71. doi:10.1097/MJT.0000000000000583
Goodman, B. P., Crepeau, A., Dhawan, P. S., Khoury, J. A., & Harris, L. A. (2017). Spectrum of Autonomic Nervous System Impairment in Sjögren Syndrome. Neurologist, 22(4), 127-130. https://doi.org/10.1097/NRL.0000000000000134
Gøransson LG, Tjensvoll AB, Herigstad A, Mellgren SI, Omdal R.   Small-diameter nerve fiber neuropathy in systemic lupus erythematosus. Arch Neurol. 2006;63(3):401. 
Graham JE, et al. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet. 1997;349
(9068):1793.
 Grysiewicz RA, et al. Epidemiology of ischemic and hemorrhagic stroke: incidence, prevalence, mortality, and risk factors. Neurol Clin. 2008 Nov;26(4):871-95, vii. 
Gupta N, Ganpati A, Mandal S, et al. Mycophenolate mofetil and deflazacort combination in neuropsychiatric lupus: a decade of experience from a tertiary care teaching hospital in southern India. Clin Rheumatol. 2017;36(10):2273‐2279. doi:10.1007/s10067-017-3775-6
Guraieb-Chahín, P., Cantú-Brito, C., Soto-Mota, A., Guerrero-Torres, L., Flores-Silva, F., Chiquete, E., … Valdés-Ferrer, S. (2020). Stroke in systemic lupus erythematosus: epidemiology, mechanism, and long-term outcome. Lupus, 29(5), 437–445. https://doi.org/10.1177/0961203320908947
Hanly JG. ACR classification criteria for systemic lupus erythematosus: limitations and revisions to neuropsychiatric variables. Lupus. 2004;13:861–864.
Hanly JG, Kozora E, Beyea SD, Birnbaum J. Review: Nervous System Disease in Systemic Lupus Erythematosus: Current Status and Future Directions. Arthritis Rheumatol. 2019;71(1):33‐42. doi:10.1002/art.40591
Hanly JG, Li Q, Su L, et al. Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis Rheumatol. 2020;72(1):67‐77. doi:10.1002/art.41070
Hanly JG, Omisade A, Su L, Farewell V, Fisk JD. Assessment of cognitive function in systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis by computerized neuropsychological tests. Arthritis Rheum. 2010;62(5):1478‐1486. doi:10.1002/art.27404
Hanly JG, Li Q, Su L, et al. Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis Rheumatol. 2019;71(2):281‐289. doi:10.1002/art.40764
Hanly JG, Urowitz MB, Su L, et al. Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. Ann Rheum Dis. 2012;71(9):1502‐1509. doi:10.1136/annrheumdis-2011-201089
Hanly JG, Urowitz MB, Gordon C, et al. Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. Annals of the Rheumatic Diseases 2020;79:356-362.
Hanly JG, Urowitz MB, O’Keeffe AG, et al. Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study [published correction appears in Arthritis Rheum. 2014 Jun;66(6):1671]. Arthritis Rheum. 2013;65(11):2887‐2897. doi:10.1002/art.38106
Hassan IM, et al. Pattern of peripheral neuropathy in systemic lupus erythematosus: clinical, electrophysiological, and laboratory properties and their association with disease activity. Egyptian Rheum & Rehab 2019;46:285-298.
Hillman CH, Pontifex MB, Raine LB, Castelli DM, Hall EE, Kramer AF. The effect of acute treadmill walking on cognitive control and academic achievement in preadolescent children. Neuroscience. 2009;159(3):1044‐1054. doi:10.1016/j.neuroscience.2009.01.057
Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2012;(7):CD002063. Published 2012 Jul 11. doi:10.1002/14651858.CD002063.pub5
Ishikura R, Morimoto N, Tanaka K, et al. Factors associated with anxiety, depression and suicide ideation in female outpatients with SLE in Japan. Clin Rheumatol. 2001;20(6):394‐400. doi:10.1007/s100670170002
Jácome Sánchez EC, García Castillo MA, González VP, Guillén López F, Correa Díaz EP. Coexistence of systemic lupus erythematosus and multiple sclerosis. A case report and literature review. Mult Scler J Exp Transl Clin. 2018;4(2):2055217318768330. Published 2018 Apr 8. doi:10.1177/2055217318768330
Jallouli M, Saadoun D, Eymard B, et al. The association of systemic lupus erythematosus and myasthenia gravis: a series of 17 cases, with a special focus on hydroxychloroquine use and a review of the literature. J Neurol. 2012;259(7):1290‐1297. doi:10.1007/s00415-011-6335-z
Jasmin, R., Sockalingam, S., Ramanaidu, L. P., & Goh, K. J. (2015). Clinical and electrophysiological characteristics of symmetric polyneuropathy in a cohort of systemic lupus erythematosus patients. Lupus, 24(3), 248–255. https://doi.org/10.1177/0961203314552115
John S, et al. Long-term outcomes after reversible cerebral vasoconstriction syndrome. Cephalalgia. 2016;36(4):387. Epub 2015 Jun 18. 
John, T. J., John, K., du Plessis, L., & Manie, M. (2019). SLE pachymeningitis and multiple cranial nerve palsies: a case report and review of the literature. Lupus, 28(9), 1154–1157. https://doi.org/10.1177/0961203319862867
Joseph FG, Lammie GA, Scolding NJ. CNS lupus: a study of 41 patients. Neurology. 2007;69(7):644‐654. doi:10.1212/01.wnl.0000267320.48939.d0
Kanapathy, A., Nik Jaafar, N. R., Shaharir, S. S., Chan, L. F., Rozita, M., & Ch’ng, S. S. (2019). Prevalence of cognitive impairment using the Montreal Cognitive Assessment questionnaire among patients with systemic lupus erythematosus: a cross-sectional study at two tertiary centres in Malaysia. Lupus, 28(7), 854–861. https://doi.org/10.1177/0961203319852153
Kang, J.-H., Xu, H., Choi, S.-E., Park, D.-J., Lee, J.-K., Kwok, S.-K., … Lee, S.-S. (2020). Obesity increases the incidence of new-onset lupus nephritis and organ damage during follow-up in patients with systemic lupus erythematosus. Lupus, 29(6), 578–586. https://doi.org/10.1177/0961203320913616
Katz P, Julian L, Tonner MC, Yazdany J, Trupin L, et al. Physical activity, obesity, and cognitive impairment among women with systemic lupus erythematosus. Arthritis Care & Research. 2012;64(4):502–510.
Keenan, TD, Agrón, E, Mares, J, et al. Adherence to a Mediterranean diet and cognitive function in the age‐related eye disease studies 1 & 2. Alzheimer’s Dement. 2020; 1– 12. https://doi.org/10.1002/alz.12077
Keiserman, B., da Silva, L.F.G., Keiserman, M.W. et al. Lupoid sclerosis. Rheumatol Int 30, 431–434 (2010). https://doi.org/10.1007/s00296-009-1175-1
< font color=”#2a2a2a”>Kello N, Anderson E, Diamond B. Cognitive Dysfunction in Systemic Lupus Erythematosus: A Case for Initiating Trials. Arthritis Rheumatol. 2019;71(9):1413‐1425. doi:10.1002/art.40933

Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Hellwig K, Pache F, Ruprecht K, Havla J, Kümpfel T, Aktas O, Hartung HP, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Stellmann JP, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Krumbholz M, Zeltner L, Ziemann U, Linker R, Schwab M, Marziniak M, Then Bergh F, Hofstadt-van Oy U, Neuhaus O, Zettl UK, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C; NEMOS (Neuromyelitis Optica Study Group). Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions. Neurol Neuroimmunol Neuroinflamm. 2018 Sep 26;5(6):e504. doi: 10.1212/NXI.0000000000000504. PMID: 30345331; PMCID: PMC6192689.
Knight AM, Trupin L, Katz P, Yelin E, Lawson EF. Depression Risk in Young Adults With Juvenile- and Adult-Onset Lupus: Twelve Years of Followup. Arthritis Care Res (Hoboken). 2018;70(3):475‐480. doi:10.1002/acr.23290
Kozora E, Hanly JG, Lapteva L, Filley CM. Cognitive dysfunction in systemic lupus erythematosus: past, present, and future. Arthritis & Rheumatism. November 2008;58(11):3286–3298.
Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. Journal of General Internal Medicine. 2001;16(9):606–613.
Levine SR, et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA. 2004;291(5):576. 
Lin, Y.‐R., Chou, L.‐C., Chen, H.‐C., Liou, T.‐H., Huang, S.‐W. and Lin, H.‐W. (2016), Increased Risk of Dementia in Patients With Systemic Lupus Erythematosus: A Nationwide Population‐Based Cohort Study. Arthritis Care & Research, 68: 1774-1779. doi:10.1002/acr.22914
Liu K, Kurien BT, Zimmerman SL, et al. X Chromosome Dose and Sex Bias in Autoimmune Diseases: Increased Prevalence of 47,XXX in Systemic Lupus Erythematosus and Sjögren’s Syndrome. Arthritis Rheumatol. 2016;68(5):1290‐1300. doi:10.1002/art.39560
Lorayne H, Lucas J. The Memory Book: The Classic Guide to Improving Your Memory at Work, at School, and at Play. New York: Ballantine Books; 1996.
Migraines are not a lupus symptom: study. Reuters. August 30, 2011. Retrieved September 11, 2011, from www.reuters.com/article/2011/08/30us-migranes-lupus-idUSTRE77T51K20110830.
Magro-Checa, C., Beaart-van de Voorde, L. J. J., Middelkoop, H. A. M., Dane, M. L., van der Wee, N. J., van Buchem, M. A., … Steup-Beekman, G. M. (2017). Outcomes of neuropsychiatric events in systemic lupus erythematosus based on clinical phenotypes; prospective data from the Leiden NP SLE cohort. Lupus, 26(5), 543–551. https://doi.org/10.1177/0961203316689145
Martín-Nares, E., Hernandez-Molina, G., & Fragoso-Loyo, H. (2019). Aquaporin-4-IgG positive neuromyelitis optica spectrum disorder and systemic autoimmune diseases overlap syndrome: a single-center experience. Lupus, 28(11), 1302–1311. https://doi.org/10.1177/0961203319877255
Mathew L, Talbot K, Love S, Puvanarajah S, Donaghy M. Treatment of vasculitic peripheral neuropathy: a retrospective analysis of outcome. QJM. 2007;100(1):41‐51. doi:10.1093/qjmed/hcl125
Mcglasson, S., Wiseman, S., Wardlaw, J., Dhaun, N. & Hunt, DPJ. Neurological Disease in Lupus: Toward a Personalized Medicine Approach. Frontiers in Immunology 2018:9.
McLaurin EY, Holliday SL, Williams P, Brey RL. Predictors of cognitive dysfunction in patients with systemic lupus erythematosus. Neurology. 2005;64(2):297‐303. doi:10.1212/01.WNL.0000149640.78684.EA
Michailidou D, Kribis M, Kataria R, Sedaliu K, Dumitrescu M. Facial and limb angioedema with parotitis and Kikuchi-like necrotizing lymphadenitis preceding neuropsychiatric systemic lupus erythematosus in a young African American male. Lupus. 2018;27(4):676‐680. doi:10.1177/0961203317726379
Moldovan I, Katsaros E, Carr FN, Cooray D, Torralba K, Shinada S, et al. The patient reported outcomes in lupus (PATROL) study: role of depression in health-related quality of life in a Southern California lupus cohort. Lupus. 2011;20:1285–1292.
Murray SG, Yazdany J, Kaiser R, Criswell LA, Trupin L, et al. Cardiovascular disease and cognitive dysfunction in systemic lupus erythematosus. Arthritis Care & Research. September 2012;64(9):1328–1333.
Nakamagoe K, Yanagiha H, Miyake Z, et al. Monocular Oculomotor Nerve Disorder Manifesting as Cranial Neuropathy in Systemic Lupus Erythematosus. Intern Med. 2018;57(23):3445‐3449. doi:10.2169/internalmedicine.1106-18
Nestor J, Yoshiyuki Arinuma, Tomás S. Huerta, Czeslawa Kowal, Elham Nasiri, Nina Kello, Yuichiro Fujieda, Alison Bialas, Tim Hammond, Uma Sriram, Beth Stevens, Patricio T. Huerta, Bruce T. Volpe, Betty Diamond; Lupus antibodies induce behavioral changes mediated by microglia and blocked by ACE inhibitors. J Exp Med 1 October 2018; 215 (10): 2554–2566. doi: https://doi.org/10.1084/jem.20180776
Ngandu T, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385(9984):2255. Epub 2015 Mar 12. 
Nikolopoulos D, Fanouriakis A, Boumpas DT. Update on the pathogenesis of central nervous system lupus. Curr Opin Rheumatol. 2019;31(6):669‐677. doi:10.1097/BOR.0000000000000655
Novak P. Autonomic Disorders. Am J Med. 2019;132(4):420‐436. doi:10.1016/j.amjmed.2018.09.027
O’Leary KC, Pontifex MB, Scudder MR, Brown ML, Hillman CH. The effects of single bouts of aerobic exercise, exergaming, and videogame play on cognitive control. Clin Neurophysiol. 2011;122(8):1518‐1525. doi:10.1016/j.clinph.2011.01.049
Oomatia A, Fang H, Petri M, Birnbaum J. Peripheral neuropathies in systemic lupus erythematosus: clinical features, disease associations, and immunologic characteristics evaluated over a twenty-five-year study period. Arthritis Rheumatol. 2014;66(4):1000‐1009. doi:10.1002/art.38302
Otto MA. Guidelines address neuropsychiatric issues in SLE. Rheumatology News. October 2010;9(10), 26.
Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. II. Psychotherapy alone or in combination with antidepressant medication. J Affect Disord. 2009;117 Suppl 1:S15. Epub 2009 Aug 13. 
Petri M, Naqibuddin M, Sampedro M, Omdal R, Carson KA. Memantine in systemic lupus erythematosus: a randomized, double-blind placebo-controlled trial. Semin Arthritis Rheum. 2011;41(2):194‐202. doi:10.1016/j.semarthrit.2011.02.005
Petri M, Naqibuddin M, Carson KA, Wallace DJ, Weisman MH, Holliday SL, et al. Depression and cognitive impairment in newly diagnosed systemic lupus erythematosus. Journal of Rheumatolog
y. 2010;37(10):2032–2038.
Pittock SJ, et al. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol. 2008;65(1):78. 
Scott TF, et al. Antiphospholipid antibody syndrome mimicking multiple sclerosis clinically and by magnetic resonance imaging. Arch Intern Med. 1994;154(8):917. 
Quintanilla-González, L., Atisha-Fregoso, Y., Llorente, L., & Fragoso-Loyo, H. (2017). Myelitis in systemic lupus erythematosus: clinical characteristics and effect in accrual damage. A single-center experience. Lupus, 26(3), 248–254. https://doi.org/10.1177/0961203316659152
Rajasekharan C, Renjith SW, Marzook A, Parvathy R. Idiopathic intracranial hypertension as the initial presentation of systemic lupus erythematosus. BMJ Case Rep. 2013;2013:bcr2012007886. Published 2013 Jan 31. doi:10.1136/bcr-2012-007886
Raphaël JC, Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2012;(7):CD001798. Published 2012 Jul 11. doi:10.1002/14651858.CD001798.pub2
Rethorst CD, Trivedi MH. Evidence-based recommendations for the prescription of exercise for major depressive disorder. J Psychiatr Pract. 2013 May;19(3):204-12. 
Ricarte, I. F., Dutra, L. A., Abrantes, F. F., Toso, F. F., Barsottini, O. G. P., Silva, G. S., … Andrade, D. (2018). Neurologic manifestations of antiphospholipid syndrome. Lupus, 27(9), 1404–1414. https://doi.org/10.1177/0961203318776110
Roberts AL, Kubzansky LD, Malspeis S, Feldman CH, Costenbader KH. Association of Depression With Risk of Incident Systemic Lupus Erythematosus in Women Assessed Across 2 Decades. JAMA Psychiatry. 2018;75(12):1225‐1233. doi:10.1001/jamapsychiatry.2018.2462
Roth C, Ferbert A. The posterior reversible encephalopathy syndrome: what’s certain, what’s new?. Pract Neurol. 2011;11(3):136‐144. doi:10.1136/practneurol-2011-000010
Saleh, Z., Menassa, J., Abbas, O., Atweh, S., & Arayssi, T. (2010). Cranial nerve VI palsy as a rare initial presentation of systemic lupus erythematosus: case report and review of the literature. Lupus, 19(2), 201–205. https://doi.org/10.1177/0961203309345722
Sarbu, N., Toledano, P., Calvo, A., Roura, E., Sarbu, M. I., Espinosa, G., … Bargalló, N. (2017). Advanced MRI techniques: biomarkers in neuropsychiatric lupus. Lupus, 26(5), 510–516. https://doi.org/10.1177/0961203316674820
Schofield, J., Blitshteyn, S., Shoenfeld, Y., & Hughes, G. (2014). Postural tachycardia syndrome (POTS) and other autonomic disorders in antiphospholipid (Hughes) syndrome (APS). Lupus, 23(7), 697–702. https://doi.org/10.1177/0961203314524468
Shaharir, S. S., Osman, S. S., Md Rani, S. A., Sakthiswary, R., & Said, M. S. M. (2018). Factors associated with increased white matter hyperintense lesion (WMHI) load in patients with systemic lupus erythematosus (SLE). Lupus, 27(1), 25–32. https://doi.org/10.1177/0961203317707062
Shoenfeld N, Agmon-Levin N, Flitman-Katzevman I, et al. The sense of smell in systemic lupus erythematosus. Arthritis Rheum. 2009;60(5):1484‐1487. doi:10.1002/art.24491
Shortall E, et al. Factors associated with mood and mood disorders in SLE. Lupus. 1995;4(4):272. 
Sibbitt Jr WL, Brooks WM, Kornfeld M, Hart BL, Bankhurst AD, Roldan CA. Magnetic resonance imaging and brain histopathology in neuropsychiatric systemic lupus erythematosus. Semin Arthritis Rheum 2010;40(1):32–52.
Sidiq M, Kirsner AB, Sheon RP. Carpal Tunnel Syndrome: First Manifestation of Systemic Lupus Erythematosus. JAMA. 1972;222(11):1416–1417. doi:10.1001/jama.1972.03210110052015
Silvagni E, Bortoluzzi A, Borrelli M, Padovan M, Furini F, Govoni M. Conventional brain magnetic resonance imaging in the longitudinal evaluation of newly diagnosed systemic lupus erythematosus patients: a retrospective analysis from a single-centre cohort. Lupus. 2020;29(5):499‐504. doi:10.1177/0961203320909955
Smith, R., Hadjivassiliou, M., Hoggard, N., Kuet, K.-P., Kilding, R., & Akil, M. (2018). An unusual case of inflammatory meningitis in a young man with systemic lupus erythematosus. Lupus, 27(11), 1864–1866. https://doi.org/10.1177/0961203318791760
Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Archives of Internal Medicine. 2006;166(10):1092–1097.
Stott R. Reconsidering, retiring the controversial ‘lupus headache.’ Helio Rheumatology November 2019:59.
Sugie Y, Okada Y, Ishitsuka T, Sadoshima S, Fujishima M. [A Case of Systemic Lupus Erythematosus Associated With Lateral Medullary Syndrome and Unilateral Internuclear Ophthalmoplegia] [Article in Japanese]. Rinsho Shinkeigaku 1989;29(1):75‐79. PMID: 2501049
Tiosano S, Nir Z, Gendelman O, et al. The association between systemic lupus erythematosus and bipolar disorder – a big data analysis. Eur Psychiatry. 2017;43:116‐119. doi:10.1016/j.eurpsy.2017.03.006
Tokunaga M, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis. 2007;66(4):470. Epub 2006 Nov 15. 
Toledano P, Orueta R, Rodríguez-Pintó I, Valls-Solé J, Cervera R, Espinosa G. Peripheral nervous system involvement in systemic lupus erythematosus: Prevalence, clinical and immunological characteristics, treatment and outcome of a large cohort from a single centre. Autoimmun Rev. 2017;16(7):750‐755. doi:10.1016/j.autrev.2017.05.011
Traynor AE, et al. Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a phase I study. Lancet. 2000;356(9231):701. 
Trebst C, Jarius S, Berthele A, et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol. 2014;261(1):1‐16. doi:10.1007/s00415-013-7169-7
Unterman A, Nolte JES, Boaz M, Abady M, Shoenfeld Y, Zandman-Goddard G. Neuropsychiatric systemic lupus erythematosus: a meta-analy
sis. Seminars in Arthritis and Rheumatism. October 2010. Retrieved on April 17, 2011, from www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6WWX-518VXJW-2&_user=10&_coverDate=10%2F20%2F2010&_rdoc=1&_fmt=high&_orig=gateway&_origin=gateway&_sort=d&_docanchor=&view=c&_
searchStrId=1729238940&_rerunOrigin=scholar.google&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5= 748aec1e383e8be1d0252af89eda56ba&searchtype=a.
Utset TO, et al. Depressive symptoms in patients with systemic lupus erythematosus: association with central nervous system lupus and Sjögren’s syndrome. J Rheumatol. 1994;21(11):2039. 
van Kijk MA, et al. Indications for requesting laboratory tests for concurrent diseases in patients with carpal tunnel syndrome: a systematic review. Clin Chem. 2003;49(9):1437. 
aran O, Kucuk H, Tufan A. Myasthenia gravis due to hydroxychloroquine. Reumatismo. 2015;67(3):849. Published 2015 Dec 30. doi:10.4081/reumatismo.2015.849
Viana, V. T., Durcan, L., Bonfa, E., & Elkon, K. B. (2017). Ribosomal P antibody: 30 years on the road. Lupus, 26(5), 453–462. https://doi.org/10.1177/0961203317690243
Wagstaff LR, et al. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy. 2003;23(7):871. 
West SG, Lupus and the nervous system: clinical aspects, psychopathology, and imaging; In Dubois’ Lupus Erythematosus and Related Syndromes, 8th ed. (2013):368-381.
Williams, J. N., Speyer, C. B., Kreps, D. J., Kimbrough, D. J., Costenbader, K., & Bhattacharyya, S. (2019). Spinal cord syndromes in patients with systemic lupus erythematosus: differentiating lupus myelitis, neuromyelitis optica, and multiple sclerosis. Lupus, 28(14), 1656–1662. https://doi.org/10.1177/0961203319886103
Wiseman, S., Bastin, M., Hamilton, I., Hunt, D., Ritchie, S. J., Amft, N., Thomson, S., Belch, J. F. F., Ralston, S. & Wardlaw, J. Fatigue and cognitive function in systemic lupus erythematosus: associations with white matter microstructural damage. A diffusion tensor MRI study and meta-analysis. Lupus 2017;26(6):588-597.
Wiseman SJ, Bastin ME, Jardine CL, et al. Cerebral small vessel disease burden is increased in systemic lupus erythematosus. Stroke 2016;47(11):2722–8.
Zhang, S., Wang, Z., Zhao, J., Wu, D. i, Li, J., Wang, Q., … Zeng, X. (2020). Clinical features of transverse myelitis associated with systemic lupus erythematosus. Lupus, 29(4), 389–397. https://doi.org/10.1177/0961203320905668
Zhao Z, Rocha NP, Salem H, Diniz BS, Teixeira AL. The association between systemic lupus erythematosus and dementia A meta-analysis. Dement Neuropsychol. 2018;12(2):143‐151. doi:10.1590/1980-57642018dn12-020006
Zheng G, et al. Aerobic exercise ameliorates cognitive function in older adults with mild cognitive impairment: a systematic review and meta-analysis of randomised controlled trials. Br J Sports Med. 2016 Apr
Zirkzee, E., Huizinga, T., Bollen, E., Buchem, M. van, Middelkoop, H., Wee, N. van der, … Steup-Beekman, G. (2014). Mortality in neuropsychiatric systemic lupus erythematosus (NPSLE). Lupus, 23(1), 31–38. https://doi.org/10.1177/0961203313512540

Chapter 14

Abusharha AA. Changes in blink rate and ocular symptoms during different reading tasks. Clin Optom (Auckl). 2017;9:133‐138. Published 2017 Nov 20. doi:10.2147/OPTO.S142718
Alani H, Henty JR, Thompson NL, Jury E, Ciurtin C. Systematic review and meta-analysis of the epidemiology of polyautoimmunity in Sjögren’s syndrome (secondary Sjögren’s syndrome) focusing on autoimmune rheumatic diseases. Scand J Rheumatol. 2018;47(2):141‐154. doi:10.1080/03009742.2017.1324909
Aoun G, Nasseh I, Berberi A. Evaluation of the oral component of Sjögren’s syndrome: An overview. J Int Soc Prev Community Dent. 2016;6(4):278‐284. doi:10.4103/2231-0762.186802
Asbell PA, Maguire MG, Pistilli M, Ying GS, Szczotka-Flynn LB, Hardten DR, Lin MC, Shtein RM, Dry Eye Assessment and Management Study Research Group. n-3 Fatty Acid Supplementation for the Treatment of Dry Eye Disease. N Engl J Med. 2018;378(18):1681. Epub 2018 Apr 13. 
Baer AN, Maynard JW, Shaikh F, Magder LS, Petri M. Secondary Sjogren’s syndrome in systemic lupus erythematosus defines a distinct disease subset. J Rheumatol. 2010;37(6):1143‐1149. doi:10.3899/jrheum.090804
Baer AN, McAdams DeMarco M, Shiboski SC, et al. The SSB-positive/SSA-negative antibody profile is not associated with key phenotypic features of Sjögren’s syndrome. Ann Rheum Dis. 2015;74(8):1557‐1561. doi:10.1136/annrheumdis-2014-206683
Baer AN, Walitt B. Update on Sjögren Syndrome and Other Causes of Sicca in Older Adults. Rheum Dis Clin North Am. 2018;44(3):419‐436. doi:10.1016/j.rdc.2018.03.002
Bologna, S. B., Nico, M. M. S., Florezi, G., Cavalcante, W. S., & Lourenço, S. V. (2018). Peculiar histopathological features in minor salivary gland in lupus erythematosus. Lupus, 27(10), 1706–1711. https://doi.org/10.1177/0961203318790672
Chang GH, Chen YC, Lin KM, et al. Real-World Database Examining the Association between Sjögren’s Syndrome and Chronic Rhinosinusitis. J Clin Med. 2019;8(2):155. Published 2019 Jan 30. doi:10.3390/jcm8020155
Cordero-Coma M, et al. Systemic immunomodulatory therapy in severe dry eye secondary to inflammation. Ocul Immunol Inflamm. 2007;15(2):99. 
Dastjerdi MH, Hamrah P, Dana R. High-frequency topical cyclosporine 0.05% in the treatment of severe dry eye refractory to twice-daily regimen. Cornea. 2009;28(10):1091‐1096. doi:10.1097/ICO.0b013e3181a16472
Drouault-Holowacz S, et al. Antioxidants intake and dry eye syndrome: a crossover, placebo-controlled, randomized trial. Eur J Ophthalmol. 2009;19(3):337.
Farag AM, Holliday C, Cimmino J, Roomian T, Papas A. Comparing the effectiveness and adverse effects of pilocarpine and cevimeline in patients with hyposalivati
on. Oral Dis. 2019;25(8):1937‐1944. doi:10.1111/odi.13192
Foulks GN, Forstot SL, Donshik PC, et al. Clinical guidelines for management of dry eye associated with Sjögren disease. Ocul Surf. 2015;13(2):118‐132. doi:10.1016/j.jtos.2014.12.001
Fox R and Fox C. ‘Practical Approach to Treatment of Sjögren’s Syndrome – Dry Mouth and Gynecologic Complaints ‘. Obtained on May 23, 2020 at https://robertfoxmd.com/SjogrensByFox/Sj%C3%B6gren’s_syndrome-Practical_Tips.pdf
Gallo PM, et al. Amyloid-DNA composites of bacterial biofilms stimulate autoimmunity. Immun 2015;42:1171-1184.
Goules A, Geetha D, Arend LJ, Baer AN. Renal involvement in primary Sjögren’s syndrome: natural history and treatment outcome. Clin Exp Rheumatol. 2019;37 Suppl 118(3):123‐132.
Grönlund MA, Stenevi U, Lundeberg T. Acupuncture treatment in patients with keratoconjunctivitis sicca: a pilot study. Acta Ophthalmol Scand. 2004;82(3 Pt 1):283. 
Hajiahmadi M, Yegdaneh A, Homayoni A, Parishani H, Moshkelgosha H, Salari-Moghaddam R. Comparative Evaluation of Efficacy of “Green Tea” and “Green Tea with Xylitol” Mouthwashes on the Salivary Streptococcus mutans and Lactobacillus Colony Count in Children: A Randomized Clinical Trial. J Contemp Dent Pract. 2019;20(10):1190-1194. Published 2019 Oct 1.
Hu, H., Merenstein, D.J., Wang, C. et al. Impact of Eating Probiotic Yogurt on Colonization by Candida Species of the Oral and Vaginal Mucosa in HIV-Infected and HIV-Uninfected Women. Mycopathologia 176, 175–181 (2013). https://doi.org/10.1007/s11046-013-9678-4
Karakus S, Baer AN, Agrawal D, Gurakar M, Massof RW, Akpek EK. Utility of Novel Autoantibodies in the Diagnosis of Sjögren’s Syndrome Among Patients With Dry Eye. Cornea. 2018;37(4):405‐411. doi:10.1097/ICO.0000000000001471
Khandelwal SS. Neurotrophic Keratopathy: The Latest Treatments. Ophthalmology Management, Volume: 24, Issue: Corneal Physician April 2020, page(s): 49-51
Kim AD, Muntz A, Lee J, Wang MTM, Craig JP. Therapeutic benefits of blinking exercises in dry eye disease [published online ahead of print, 2020 May 11]. Cont Lens Anterior Eye. 2020;S1367-0484(20)30087-4. doi:10.1016/j.clae.2020.04.014
Macsai MS. The role of omega-3 dietary supplementation in blepharitis and Meibomian gland dysfunction [AOS thesis].Transactions of the American Ophthalmological Society. December 2008;106:336–356.
Mathews PM, Hahn S, Hessen M, et al. Ocular complications of primary Sjögren syndrome in men. Am J Ophthalmol. 2015;160(3):447‐452.e1. doi:10.1016/j.ajo.2015.06.004
Meijer JM, et al. Effectiveness of rituximab treatment in primary Sjögren’s syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010;62(4):960. 
Milner MS, Beckman KA, Luchs JI, et al. Dysfunctional tear syndrome: dry eye disease and associated tear film disorders – new strategies for diagnosis and treatment. Curr Opin Ophthalmol. 2017;27 Suppl 1(Suppl 1):3‐47. doi:10.1097/01.icu.0000512373.81749.b7
Ovalles-Bonilla J, Pego Reigosa JM, Figueroa IR, et al. 121 Comparison of clinical and laboratory profiles in 3575 systemic lupus erythematosus patients with and without Sjögrens syndrome: data from the Spanish society for rheumatology lupus registry. Lupus Science & Medicine 2019;6:doi: 10.1136/lupus-2019-lsm.121
Pasoto SG, Adriano de Oliveira Martins V, Bonfa E. Sjögren’s syndrome and systemic lupus erythematosus: links and risks. Open Access Rheumatol. 2019;11:33‐45. Published 2019 Jan 29. doi:10.2147/OARRR.S167783
Pons V, Greenspan D, Debruin M. Therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, prospective multicenter study of oral fluconazole versus clotrimazole troches. The Multicenter Study Group. J Acquir Immune Defic Syndr. 1993;6(12):1311. 
Pfister RR, Burstein N. The effects of ophthalmic drugs, vehicles, and preservatives on corneal epithelium: a scanning electron microscope study. Invest Ophthalmol. 1976;15(4):246‐259.
Price EJ, Baer AN. How to treat Sjögren’s syndrome [published online ahead of print, 2019 Feb 15]. Rheumatology (Oxford). 2019;key363. doi:10.1093/rheumatology/key363
Price EJ, Saaeha Rauz, Anwar R. Tappuni, Nurhan Sutcliffe, Katie L. Hackett, Francesca Barone, Guido Granata, Wan-Fai Ng, Benjamin A. Fisher, Michele Bombardieri, Elisa Astorri, Ben Empson, Genevieve Larkin, Bridget Crampton, Simon J. Bowman, on behalf of the British Society for Rheumatology Standards, Guideline and Audit Working Group, The British Society for Rheumatology guideline for the management of adults with primary Sjögren’s Syndrome, Rheumatology, Volume 56, Issue 10, October 2017, Pages e24–e48, https://doi.org/10.1093/rheumatology/kex166
Rúa-Figueroa I, Fernández Castro M, Andreu JL, et al. Comorbidities in Patients With Primary Sjögren’s Syndrome and Systemic Lupus Erythematosus: A Comparative Registries-Based Study. Arthritis Care Res (Hoboken). 2017;69(1):38‐45. doi:10.1002/acr.23015
Rutter-Locher Z, et al. Association between systemic lupus erythematosus and periodontitis: a systematic review and meta-analysis. Front Immun 2017;8:1-8.
Sacchetti M, Lambiase A, Schmidl D, et al. Effect of recombinant human nerve growth factor eye drops in patients with dry eye: a phase IIa, open label, multiple-dose study. British Journal of Ophthalmology 2020;104:127-135.
Segal B, Bowman SJ, Fox PC, et al. Primary Sjögren’s Syndrome: health experiences and predictors of health quality among patients in the United States. Health Qual Life Outcomes. 2009;7:46. Published 2009 May 27. doi:10.1186/1477-7525-7-46
Serrano J, López-Pintor RM, Ramírez L, et al. Risk factors related to oral candidiasis in patients with primary Sjögren’s syndrome [published online ahead of print, 2020 Jul 19]. Med Oral Patol Oral Cir Bucal. 2020;23719. doi:10.4317/medoral.23719
Shiboski CH, Shiboski SC, Seror R, et al. 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren’s Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts. Arthritis Rheumatol. 2017;69(1)
:35‐45. doi:10.1002/art.39859
Sjögren’s Foundation. ‘Patient education sheet: swallowing medications with dry mouth’. Accessed May 23, 2020: https:///www.sjogrens.org/sites/default/files/inline-files/Swallowing%20Medications%20Patient%20Education%20Sheet.pdf
Sjögren H. Zur kenntnis der keratoconjunctivitis sicca (keratitis filiformis bei hypofunction der tranendrusen). Acta Ophthalmologica, Copenhagen. 1933(suppl 2):1–151.
Tseng KL, et al. A clinical study of acupuncture and SSP (silver spike point) electro-therapy for dry eye syndrome. Am J Chin Med. 2006;34(2):197.
Tsubota K, Nakamori K. Dry eyes and video display terminals. N Engl J Med. 1993;328(8):584.
van Nimwegen JF, Mossel E, Delli K, et al. Incorporation of Salivary Gland Ultrasonography Into the American College of Rheumatology/European League Against Rheumatism Criteria for Primary Sjögren’s Syndrome. Arthritis Care Res (Hoboken). 2020;72(4):583‐590. doi:10.1002/acr.24017
Yavuz S, et al. Hydroxychloroquine improves dry eye symptoms of patients with primary Sjogren’s syndrome. Rheumatol Int. 2011 Aug;31(8):1045-9. Epub 2010 Mar 23. 
Vitali C, Carotti M, Salaffi F. Is it the time to adopt salivary gland ultrasonography as an alternative diagnostic tool for the classification of patients with Sjögren’s syndrome? Comment on the article by Cornec et al. Arthritis Rheum. 2013;65(7):1950. doi:10.1002/art.37945
Vivino F et al. Sjögren’s syndrome: An update on disease pathogenesis, clinical manifestations and treatment. Clin Immunol.203: 81-121, 2019.
Wallace DJ, ed. The Sjögren’s Book. New York: Oxford University Press; 2012.
Zaieni, S. H., Derakhshan, Z., & Sariri, R. (2015). Alternations of salivary antioxidant enzymes in systemic lupus erythematosus. Lupus, 24(13), 1400–1405. https://doi.org/10.1177/0961203315593170
Zero DT, Brennan MT, Daniels TE, et al. Clinical practice guidelines for oral management of Sjögren disease: Dental caries prevention. J Am Dent Assoc. 2016;147(4):295‐305. doi:10.1016/j.adaj.2015.11.008

Chapter 15

Alves, S. C., Fasano, S., & Isenberg, D. A. (2016). Autoimmune gastrointestinal complications in patients with systemic lupus erythematosus: case series and literature review. Lupus, 25(14), 1509–1519. https://doi.org/10.1177/0961203316655210
Bessone F, Poles N, Roma MG. Challenge of liver disease in systemic lupus erythematosus: Clues for diagnosis and hints for pathogenesis. World J Hepatol. 2014;6(6):394‐409. doi:10.4254/wjh.v6.i6.394
Booy JD, Takata J, Tomlinson G, Urbach DR. The prevalence of autoimmune disease in patients with esophageal achalasia. Dis Esophagus. 2012 Apr;25(3):209-13. doi: 10.1111/j.1442-2050.2011.01249.x. Epub 2011 Sep 7. PMID: 21899655.
Breuer GS, Baer A, Dahan D, Nesher G. Lupus-associated pancreatitis. Autoimmun Rev. 2006;5(5):314‐318. doi:10.1016/j.autrev.2005.11.004
Chassaing B, Kumar M, Baker MT, Singh V, Vijay-Kumar M. Mammalian gut immunity. Biomed J. 2014;37(5):246‐258. doi:10.4103/2319-4170.130922
Chen Z, Li MT, Xu D, et al. Protein-losing enteropathy in systemic lupus erythematosus: 12 years experience from a Chinese academic center. PLoS One. 2014;9(12):e114684. Published 2014 Dec 9. doi:10.1371/journal.pone.0114684
Corrêa, J. D., Branco, L. G. A., Calderaro, D. C., Mendonça, S. M. S., Travassos, D. V., Ferreira, G. A., … Silva, T. A. (2018). Impact of systemic lupus erythematosus on oral health-related quality of life. Lupus, 27(2), 283–289. https://doi.org/10.1177/0961203317719147
Dhir V, Misra R, Agarwal V, Lawrence A, Aggarwal A. Lupus pancreatitis—early manifestation of active disease. Lupus. 2011;20:547–548.
Dwivedi, P., Kumar, R. R., Dhooria, A., Adarsh, M. B., Malhotra, S., Kakkar, N., … Dhir, V. (2019). Corticosteroid-associated lupus pancreatitis: a case series and systematic review of the literature. Lupus, 28(6), 731–739. https://doi.org/10.1177/0961203319844004
Ebert EC, Hagspiel KD. Gastrointestinal and hepatic manifestations of systemic lupus erythematosus. J Clin Gastroenterol. 2011;45(5):436. 
Enweluzo C, Aziz F. Gastroparesis: a review of current and emerging treatment options. Clin Exp Gastroenterol. 2013 Sep 5;6:161-5. doi: 10.2147/CEG.S50236. PMID: 24039443; PMCID: PMC3771488.
Fasano, Serena PhD; Coscia, Melania Alessia MD; Valentini, Gabriele MD Subclinical Pancreatitis as Onset of Systemic Lupus Erythematosus, JCR: Journal of Clinical Rheumatology: August 21, 2019 – Volume Publish Ahead of Print – Issue – doi: 10.1097/RHU.0000000000001133
Fawzy, M., Edrees, A., Okasha, H., El Ashmaui, A., & Ragab, G. (2016). Gastrointestinal manifestations in systemic lupus erythematosus. Lupus, 25(13), 1456–1462. https://doi.org/10.1177/0961203316642308
Freeman, H.J. Drug-induced sprue-like intestinal disease. Int J Celiac Dis. 2014; 2: 49–53
Freeman HJ. Adult celiac disease followed by onset of systemic lupus erythematosus. Journal of Clinical Gastroenterology. March 2008;42(3):252–255.
Fries J, Holman H. Systemic Lupus Erythematosus: A Clinical Analysis. Philadelphia: WB Saunders; 1975.
González-Regueiro JA, Cruz-Contreras M, Merayo-Chalico J, et al. Hepatic manifestations in systemic lupus erythematosus. Lupus. 2020;29(8):813-824. doi:10.1177/0961203320923398
Goodman, B. P., Crepeau, A., Dhawan, P. S., Khoury, J. A., & Harris, L. A. (2017). Spectrum of Autonomic Nervous System Impairment in Sjögren Syndrome. Neurologist, 22(4), 127-130. https://doi.org/10.1097/NRL.0000000000000134
Hasler WL. Gastroparesis–current concepts and considerations. Medscape J Med. 2008 Jan 23;10(1):16. PMID: 18324326; PMCID: PMC2258461.
Hasselbacher P, Myers AR, Passero FC. Serum amylase and macroamylase in patients with systemic lupus erythe
matosus. Br J Rheumatol. 1988;27(3):198‐201. doi:10.1093/rheumatology/27.3.198
Hoffman BI, Katz WA. The gastrointestinal manifestations of systemic lupus erythematosus: a review of the literature. Seminars in Arthritis and Rheumatism. 1980;9(4):237–247.
Huang YT, T.W. Chung, J.J. Wang, Target sign in lupus enteritis, QJM: An International Journal of Medicine, Volume 110, Issue 4, April 2017, Pages 245–246, https://doi.org/10.1093/qjmed/hcx006
Irving KS, Sen D, Tahir H, Pilkington C, Isenberg DA. A comparison of autoimmune liver disease in juvenile and adult populations with systemic lupus erythematosus—a retrospective review of cases. Rheumatology (Oxford). 2007;46(7):1171–1173.
Jansson-Knodell CL, Hujoel IA, Rubio-Tapia A, Murray JA. Not All That Flattens Villi Is Celiac Disease: A Review of Enteropathies. Mayo Clin Proc. 2018;93(4):509‐517. doi:10.1016/j.mayocp.2017.10.025​
Jia Y, Ortiz A, Mccallum R, Salameh H, Serrato P. Acute pancreatitis as the initial presentation of systematic lupus erythematosus. Case Rep Gastrointest Med. 2014;2014:571493. doi:10.1155/2014/571493​
Kamimura, T., Mimori, A., Takeda, A., Masuyama, J., Yoshio, T., Okazaki, H., … Minota, S. (1998). Acute acalculous cholecystitis in systemic lupus erythematosus: a case report and review of the literature. Lupus, 7(5), 361–363. https://doi.org/10.1191/096120398678920154
Kenar, G., Atay, K., Yüksek, G. E., Öz, B., & Koca, S. S. (2020). Gastrointestinal vasculitis due to systemic lupus erythematosus treated with rituximab: a case report. Lupus, 29(6), 640–643. https://doi.org/10.1177/0961203320910803
Koo, B. S., Hong, S., Kim, Y. J., Kim, Y.-G., Lee, C.-K., & Yoo, B. (2015). Lupus enteritis: clinical characteristics and predictive factors for recurrence. Lupus, 24(6), 628–632. https://doi.org/10.1177/0961203314558858
Law ST, Ma KM, Li KK. The clinical characteristics of lupus related protein-losing enteropathy in Hong Kong Chinese population: 10 years of experience from a regional hospital. Lupus. 2012;21(8):840. Epub 2012 Feb 17. ​
Lee, CK, Ahn, MS, Lee, EY Acute abdominal pain in systemic lupus erythematosus: Focus on lupus enteritis (gastrointestinal vasculitis). Ann Rheum Dis 2002; 61: 547–550.
Lee JH, Kwok SK, Park SH.   Lupus Mesenteric Vasculitis Limited in Stomach.   J Rheum Dis. 2012 Aug;19(4):234-235.   https://doi.org/10.4078/jrd.2012.19.4.234
Leonard MM, Sapone A, Catassi C, Fasano A. Celiac Disease and Nonceliac Gluten Sensitivity: A Review. JAMA. 2017;318(7):647‐656. doi:10.1001/jama.2017.9730
Leung, V. K., Ng, W.-L., Luk, I. S., Chau, T.-N., Chan, W.-H., Kei, S.-K., & Loke, T. K. (2007). Unique hepatic imaging features in a patient with nodular regenerative hyperplasia of the liver associating with systemic lupus erythematosus. Lupus, 16(3), 205–208. https://doi.org/10.1177/09612033707076513
Li, Z., Xu, D., Wang, Z., Wang, Y., Zhang, S., Li, M., & Zeng, X. (2017). Gastrointestinal system involvement in systemic lupus erythematosus. Lupus, 26(11), 1127–1138. https://doi.org/10.1177/0961203317707825
Loyola Rodriguez, J. P., Galvan Torres, L. J., Martinez Martinez, R. E., Abud Mendoza, C., Medina Solis, C. E., Ramos Coronel, S., … Domínguez Pérez, R. A. (2016). Frequency of dental caries in active and inactive systemic lupus erythematous patients: salivary and bacterial factors. Lupus, 25(12), 1349–1356. https://doi.org/10.1177/0961203316640909
Ludvigsson JF, Rubio-Tapia A, Chowdhary V, Murray JA, Simard JF. Increased risk of systemic lupus erythematosus in 29,000 patients with biopsy-verified celiac disease. Journal of Rheumatology. October 2012;39(10):1964–1970.
Man, B. L., & Mok, C. C. (2005). Serositis related to systemic lupus erythematosus: prevalence and outcome. Lupus, 14(10), 822–826. https://doi.org/10.1191/0961203305lu2187oa​
Marai I, Shoenfeld Y, Bizzaro N, et al. IgA and IgG tissue transglutaminase antibodies in systemic lupus erythematosus. Lupus. 2004;13(4):241‐244. doi:10.1191/0961203304lu1004oa
Maruyama, A., Nagashima, T., Iwamoto, M., & Minota, S. (2018). Clinical characteristics of lupus enteritis in Japanese patients: the large intestine-dominant type has features of intestinal pseudo-obstruction. Lupus, 27(10), 1661–1669. https://doi.org/10.1177/0961203318785770​
Medeiros MM, Fernandes GH, Pinto NSR, Silveira VA. Clinical and subclinical pancreatitis in a cohort of patients diagnosed with systemic lupus erythematosus. Clinical and Experimental Rheumatology. 2011;29(5):776–782.
Mendonça, J., Marques-Neto, J., Prando, P., & Appenzeller, S. (2009). Acute acalculous cholecystitis in juvenile systemic lupus erythematosus. Lupus, 18(6), 561–563. https://doi.org/10.1177/0961203308098587
Nassar Y, Richter S. Gastroparesis in Non-Diabetics: Associated Conditions and Possible Risk Factors. Gastroenterology Res. 2018;11(5):340-345. doi:10.14740/gr1060w
Nesher G, Breuer GS, Temprano K, Moore TL, Dahan D, Baer A, Alberton J, et al. Lupus-associated pancreatitis. Seminars in Arthritis and Rheumatism. 2006;35(4):260–267.
Nitzan O, Elias M, Saliba WR. Systemic lupus erythematosus and inflammatory bowel disease. European Journal of Internal Medicine. 2006:313–318.
Pascual-Ramos V, Duarte-Rojo A, Villa AR, et al. Systemic lupus erythematosus as a cause and prognostic factor of acute pancreatitis. Journal of Rheumatology. 2004;31(4):707–712.
Piga M, Vacca A, Porru G, Caulia A, Mathieu A. Liver involvement in systemic lupus erythematosus: incidence, clinical course and outcome of lupus hepatitis. Clinical and Experimental Rheumatology. 2010;28(4):504–510.
Piga M, Vacca A, Porru G, P Garau P, Caulia A, Mathieu A. Two different clinical subsets of lupus hepatitis exist: mimicking primary autoimmune liver diseases or part of their spectrum? Lupus. 2011;20:1450–1451.
Rajendiran A, Viswanathan S, Remalayam B, Muthu V, Alexander T. Chronic diarrhea as the presenting complaint of systemic lupus erythematosus in a man. Intern Med. 2012;51(22):3131‐3134. doi:10.2169/internalmedicine.51.8518​
Reynolds JC, et al. Acute pancreatit
is in systemic lupus erythematosus: report of twenty cases and a review of the literature. Medicine (Baltimore). 1982;61(1):25.
 Romero-Hernández F, Furuzawa-Carballeda J, Hernández-Molina G, Alejandro-Medrano E, Núñez-Álvarez CA, Hernández-Ramírez DF, Azamar-Llamas D, Olivares-Martínez E, Breña B, Palacios A, Valdovinos MA, Coss-Adame E, Ramos-Ávalos B, Torres-Landa S, Hernández-Ávila AA, Flores-Nájera A, Torres-Villalobos G. Autoimmune comorbidity in achalasia patients. J Gastroenterol Hepatol. 2018 Jan;33(1):203-208. doi: 10.1111/jgh.13839. PMID: 28568312.
Satoh Y, Kazuhisa Nakano, Yusuke Miyazaki, Shingo Nakayamada, Shunsuke Fukuyo, Satoshi Kubo, Ippei Miyagawa, Hiroko Yoshinari, Kazuyoshi Saito, Minoru Satoh & Yoshiya Tanaka (2019) The two cases of acute acalculous cholecystitis associated with systemic lupus erythematosus (SLE) presented different clinical aspects, Modern Rheumatology Case Reports, 3:2, 114-118, DOI: 10.1080/24725625.2018.1549928
Saleem F, Sharma A. Drug Induced Esophagitis. [Updated 2019 Dec 15]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: https:///www.ncbi.nlm.nih.gov/books/NBK549818/
Schouten JN, et al. Idiopathic noncirrhotic portal hypertension. Hepatology. 2011 Sep;54(3):1071-81. Epub 2011 Jul 21. 
Shor DB, Dahan S, Comaneshter D, Cohen AD, Amital H. Does inflammatory bowel disease coexist with systemic lupus erythematosus?. Autoimmun Rev. 2016;15(11):1034‐1037. doi:10.1016/j.autrev.2016.07.027

Soltani Z, Baghdadi A, Nejadhosseinian M, Faezi ST, Shahbazkhani B, Mousavi SA, Kazemi K. Celiac disease in patients with systemic lupus erythematosus. Reumatologia. 2021;59(2):85-89. doi: 10.5114/reum.2021.105416. Epub 2021 Apr 27. PMID: 33976461; PMCID: PMC8103411.
Sultan SM, Ioannou Y, Isenberg DA. A review of gastrointestinal manifestations of systemic lupus erythematosus. Rheumatology (Oxford). 1999;38(10):917–932.
Tagawa, Y., Saito, T., Takada, K., Kawahata, K., & Kohsaka, H. (2016). Successful treatment of severe refractory lupus hepatitis with mycophenolate mofetil. Lupus, 25(5), 543–546. https://doi.org/10.1177/0961203315625118​
Takahashi A, Abe K, Saito R, et al. Liver dysfunction in patients with systemic lupus erythematosus. Intern Med. 2013;52(13):1461‐1465. doi:10.2169/internalmedicine.52.9458​
Tayal V, Chiu YH, George E, Mane S. Colitis associated with active systemic lupus erythematosus successfully treated with rituximab. J Clin Rheumatol. 2011;17(2):79‐82. doi:10.1097/RHU.0b013e31820e715c
Tian XP, Zhang X. Gastrointestinal involvement in systemic lupus erythematosus: insight into pathogenesis, diagnosis and treatment. World J Gastroenterol. 2010;16(24):2971‐2977. doi:10.3748/wjg.v16.i24.2971
Wang, Z., Wu, C., Ruan, F., Li, Z., Peng, X., & Wang, P. (2020). A case of systemic lupus erythematosus with rectal necrosis. Lupus, 29(3), 334–339. https://doi.org/10.1177/0961203319897130
Wang CH, Yao TC, Huang YL, Ou LS, Yeh KW, Huang JL. Acute pancreatitis in pediatric and adult-onset systemic lupus erythematosus: a comparison and review of the literature. Lupus. 2011;20:443–452.
Yang, H., Bian, S., Xu, D., Zhang, F., & Zhang, X. (2017). Acute acalculous cholecystitis in patients with systemic lupus erythematosus: A unique form of disease flare. Lupus, 26(10), 1101–1105. https://doi.org/10.1177/0961203317699288
Yang C, Chen, S, Gaut, JP, Dehner, LP. Smooth-muscle myopathy in systemic lupus erythematosus presenting with intestinal pseudo-obstruction. Am J Gastroenterol 2016; 111: 1501–1502.
Yang QB, He YL, Peng CM, Qing YF, He Q, Zhou JG. Systemic lupus erythematosus complicated by noncirrhotic portal hypertension: A case report and review of literature. World J Clin Cases. 2018;6(13):688‐693. doi:10.12998/wjcc.v6.i13.688
Yuan S, Ye Y, Chen D, et al. Lupus mesenteric vasculitis: clinical features and associated factors for the recurrence and prognosis of disease. Semin Arthritis Rheum. 2014;43(6):759‐766. doi:10.1016/j.semarthrit.2013.11.005
Zheng RH, Wang JH, Wang SB, Chen J, Guan WM, Chen MH. Clinical and immunopathological features of patients with lupus hepatitis. Chin Med J (Engl). 2013;126(2):260‐266.
Zizic TM, Shulman LE, Stevens MB. Systemic lupus erythematosus. Medicine (Baltimore). 1975;54(5):411–426.
Zografos GN, et al. Drug-induced esophagitis. Dis Esophagus. 2009;22(8):633-7. Epub 2009 Apr 15. ​

Chapter 16

AlKharashi M, Bower KS, Stark WJ, Daoud YJ. Refractive surgery in systemic and autoimmune disease. Middle East Afr J Ophthalmol. 2014;21(1):18‐24. doi:10.4103/0974-9233.124082
Arthurs BP, M. K. Khalil, F. Chagnon, S. K. Lindley, D. P. Anderson, and M. Burnier, “Orbital infarction and melting in a patient with systemic lupus erythematosus,” Ophthalmology, vol. 106, no. 12, pp. 2387–2390, 1999.
Baglio V, M. Gharbiya, C. Balacco-Gabrieli et al., “Choroidopathy in patients with systemic lupus erythematosus with or without nephropathy,” Journal of Nephrology, vol. 24, no. 4, pp. 522–529, 2011.
Boey, M. L., Fong, P. H., Lee, J. S. C., Ng, W. Y., & Thai, A. C. (1993). Autoimmune Thyroid Disorders in SLE in Singapore. Lupus, 2(1), 51–54. https://doi.org/10.1177/096120339300200109
Burge, S.M., Frith, P.A., Juniper, R.P., and Wojnarowska, F. Mucosal involvement in systemic and chronic cutaneous lupus erythematosus. Br. J. Dermatol. 1989; 121: 727–741
Brydak-Godowska J. [Ocular changes and general condition in lupus erythematosus (SLE)– own observation.] Klinika Oczna. 2007;109(1–3):11–14.
Frigui M, Frikha F, Sellemi D, Chouayakh F, Feki J, Bahlou Z. Optic neuropathy as a presenting feature of systemic lupus erythematosus: two case reports and literature review. Lupus. 2011;20:1214–1218.
Cakici O, Karadag R, Bayramlar H, Ozkanli S, Uzuncakmak TK, Karadag AS. Periorbital discoid lupus: a rare localization in a patient with systemic lupus erythematosus. An Bras Dermatol. 2016;91(5 suppl 1):122‐124. doi:10.1590/abd1806-4841.20164708
Damato E, M. Chilov, R. Lee, A. Singh, S. Harper, and A. Dick, “Plasma exchange and rituximab in the management of acute retinal vaso-occlusive disease in systemic lupus erythematosus,” Ocular Immunology and Inflammation, vol. 19, no. 5, pp. 379–381, 2
011.
Feinfield RE, R. J. Hesse, and S. A. Rosenberg, “Orbital inflammatory disease associated with systemic lupus erythematosus,” Southern Medical Journal, vol. 84, no. 1, pp. 98–99, 1991.
Gallagher K., Viswanathan A., Okhravi N. Association of systemic lupus erythematosus with uveitis. JAMA Ophthalmol. 2015 Oct 1;133(10):1190–1193.
Ghauri AJ, Valenzuela AA, O’Donnell B, Selva D, Madge SN. Periorbital discoid lupus erythematosus. Ophthalmology. 2012;119(10):2193‐2194.e11. doi:10.1016/j.ophtha.2012.05.041
Godel V, Feiler-Ofry V, Stein R. Systemic steroids and ocular fluid dynamics. II. Systemic versus topical steroids. Acta Ophthalmol (Copenh) 1972;50(5):664–676.
Grimson BS and K. B. Simons, “Orbital inflammation, myositis, and systemic lupus erythematosus,” Archives of Ophthalmology, vol. 101, no. 5, pp. 736–738, 1983.
Hannouche D, J. F. Korobelnik, I. Cochereau et al., “Systemic lupus erythematosus with choroidopathy and serous retinal detachment,” International Ophthalmology, vol. 19, no. 2, pp. 125–127, 1995.
Izzedine, Hassane MD*; Roura, Raoul MD†; Bourry, Edward MD*; Georgin-Lavialle, Sophie MD‡; Cacoub, Patrice MD‡; Deray, Gilbert MD* The Endocrinologist: September/October 2005 – Volume 15 – Issue 5 – pp 289-291
Jordan DR, H. McDonald, B. Olberg, D. McKim, and R. McKendry, “Orbital panniculitis as the initial manifestation of systemic lupus erythematosus,” Ophthalmic Plastic and Reconstructive Surgery, vol. 9, no. 1, pp. 71–75, 1993.
T. Y. Kao, M. K. Yoon, T. J. McCulley, B. S. Ruben, and T. N. Hwang, “Acquired enophthalmos in lupus erythematosus profundus,” Journal of Neuro-Ophthalmology, vol. 30, no. 1, pp. 64–66, 2010.
Matsuo T, T. Nakayama, T. Koyama, and N. Matsuo, “Multifocal pigment epithelial damages with serous retinal detachment in systemic lupus erythematosus,” Ophthalmologica, vol. 195, no. 2, pp. 97–102, 1987.
Milner MS, Kenneth A Beckman, Jodi I Luchs, Quentin B Allen, Richard M Awdeh, John Berdahl, Thomas S Boland, Carlos Buznego, Joseph P Gira, Damien F Goldberg, David Goldman, Raj K Goyal, Mitchell A Jackson, James Katz, Terry Kim, Parag A Majmudar, Ranjan P Malhotra, Marguerite B McDonald, Rajesh K Rajpal, Tal Raviv, Sheri Rowen, Neda Shamie, Jonathan D Solomon, Karl Stonecipher, Shachar Tauber, William Trattler, Keith A Walter, George O Waring 4th, Robert J Weinstock, William F Wiley, Elizabeth Yeu. Dysfunctional tear syndrome: dry eye disease and associated tear film disorders – new strategies for diagnosis and treatment. Curr Opin Ophthalmol. 2017;27 Suppl 1(Suppl 1):3‐47. doi:10.1097/01.icu.0000512373.81749.b7
Montehermoso A, R. Cervera, J. Font et al., “Association of antiphospholipid antibodies with retinal vascular disease in systemic lupus erythematosus,” Seminars in Arthritis and Rheumatism, vol. 28, no. 5, pp. 326–332, 1999.
Nemet A.Y., Vinker S., Bahar I., Kaiserman I. The association of keratoconus with immune disorders. Cornea. 2010;29(11):1261–1264.
Nguyen Q.D., Uy H.S., Akpek E.K. Choroidopathy of systemic lupus erythematosus. Lupus. 2000;9(4):288–298.
Palejwala NV, Walia HS, Yeh S. Ocular manifestations of systemic lupus erythematosus: a review of the literature. Autoimmune Dis. 2012;2012:290898. doi:10.1155/2012/290898
Peponis V, Kyttaris VC, Tyradellis C, Vergados I, Sitaras NM. Ocular manifestations of systemic lupus erythematosus: a clinical review. Lupus. 2006;15(1):3‐12. doi:10.1191/0961203306lu2250rr
Peponis V, Kyttaris VC, Chalkiadakis SE, Bonovas S, Sitaras NM. Ocular side effects of anti-rheumatic medications: what a rheumatologist should know. Lupus. 2010;19(6):675‐682. doi:10.1177/0961203309360539
Phulke S, Kaushik S, Kaur S, Pandav SS. Steroid-induced Glaucoma: An Avoidable Irreversible Blindness. J Curr Glaucoma Pract. 2017;11(2):67‐72. doi:10.5005/jp-journals-l0028-1226
Santosa A, Vasoo S. Orbital myositis as manifestation of systemic lupus erythematosus—a case report. Postgraduate Medical Journal Online First. September 11, 2012. Retrieved January 29, 2013 from https://pmj.bmj.com/articleusage?rid=postgradmedj-2012-130974v1.
Serop S., Vianna R.N., Claeys M., De Laey J.J. Orbital myositis secondary to systemic lupus erythematosus. Acta Ophthalmol (Copenh) 1994;72(4):520–523.
Silpa-archa S., Lee J.J., Foster C.S. Ocular manifestations in systemic lupus erythematosus. Brit J Ophthalmol. 2016;100:135–141.
Shoughy SS, Tabbara KF. Ocular findings in systemic lupus erythematosus. Saudi J Ophthalmol. 2016;30(2):117‐121. doi:10.1016/j.sjopt.2016.02.001
Siebert S., Srinivasan U. Proptosis can be the presenting feature of systemic lupus erythematosus. Ann Rheum Dis. 2004;63(8):908–909. 
Sitaula R, D. N. Shah, and D. Singh, “The spectrum of ocular involvement in systemic lupus erythematosus in a tertiary eye care center in Nepal,” Ocular Immunology and Inflammation, vol. 19, no. 6, pp. 422–425, 2011.
Sivaraj R.R., Durrani O.M., Denniston A.K., Murray P.I., Gordon C. Ocular manifestations of systemic lupus erythematosus. Rheumatology. 2007;46:1757–1762.
Smith RJ, Maloney RK. Laser in situ keratomileusis in patients with autoimmune diseases. J Cataract Refract Surg. 2006;32(8):1292‐1295. doi:10.1016/j.jcrs.2006.02.059
Stafford-Brady FJ, M. B. Urowitz, D. D. Gladman, and M. Easterbrook, “Lupus retinopathy. Patterns, associations, and prognosis,” Arthritis and Rheumatism, vol. 31, no. 9, pp. 1105–1110, 1988.
Stavrou P., Murray P.I., Batta K., Gordon C. Acute ocular ischaemia and orbital inflammation associated with systemic lupus erythematosus. Brit J Ophthalmol. 2002;86(4):474–475.
Tanda ML, et al. Prevalence and natural history of Graves’ orbitopathy in a large series of patients with newly diagnosed graves’ hyperthyroidism seen at a single center. J Clin Endocrinol Metab. 2013 Apr;98(4):1443-9. Epub 2013 Feb 13. 
Tuffanelli EL and D. L. Dubois, “Cutaneous manif
estations of systemic lupus erythematosus,” Archives of Dermatology, vol. 90, pp. 377–386, 1964.
World Health Organization. Blindness and vision impairment. Retrieved on 10/25/20 from https:///www.who.int/news-room/fact-sheets/detail/blindness-and-visual-impairment
Zhanga Y, Xiaoa X, Haoa Q, Lia X, Renb J, Hu Z. The onset of systemic lupus erythematosus and thyroid dysfunction following Graves’ disease – A case report and literature review. Srp Arh Celok Lek. 2016;144(11-12):639‐644. doi:10.2298/sarh1612639z
Zink J.M., Singh-Parikshak R., Johnson C.S., Zacks D.N. Hypopyon uveitis associated with systemic lupus erythematosus and antiphospholipid antibody syndrome. Graefes Arch Clin Exp Ophthalmol. 2005;243(4):386–388. 

Chapter 17

Appenzeller S, Pallone AT, Natalin RA, Costallat LT. Prevalence of thyroid dysfunction in systemic lupus erythematosus. J Clin Rheumatol (2009) 15:117–9.10.1097/RHU.0b013e31819dbe4c
Biró E, Szekanecz Z, Czirják L, Dankó K, Kiss E, Szabó NA, Szucs G, Zeher M, Bodolay E, Szegedi G, Bakó G Clin Rheumatol. 2006 Mar; 25(2):240-5.
Ferrari SM, Elia G, Virili C, Centanni M, Antonelli A, Fallahi P. Systemic Lupus Erythematosus and Thyroid Autoimmunity. Front Endocrinol (Lausanne). 2017;8:138. Published 2017 Jun 19. doi:10.3389/fendo.2017.00138
Guldvog I, Reitsma LC, Johnsen L, et al. Thyroidectomy Versus Medical Management for Euthyroid Patients With Hashimoto Disease and Persisting Symptoms: A Randomized Trial. Ann Intern Med. 2019;170(7):453‐464. doi:10.7326/M18-0284
Hijmans W, Doniach D, Roitt IM, Holborow EJ. Serological overlap between lupus erythematosus, rheumatoid arthritis, and auto-immune thyroid disease. British Medical Journal. October 1961;2:909–914.
Kumar K, Kole AK, Karmakar PS, Ghosh A. The spectrum of thyroid disorders in systemic lupus erythematosus. Rheumatol Int (2012) 32:73–8.10.1007/s00296-010-1556-5
Litta Modignani R, Barantani E, Mazzolari M, et al., Chronic autoimmune thyroid disease, Ann Ital Med Int, 1991;6:420–26.
Luo, W., Mao, P., Zhang, L., & Yang, Z. (2018). Association between systemic lupus erythematosus and thyroid dysfunction: a meta-analysis. Lupus, 27(13), 2120–2128. https://doi.org/10.1177/0961203318805849
Mihailova D, Grigorova R, Vassileva B, Mladenova G, Ivanova N, Stephanov S, et al. Autoimmune thyroid disorders in juvenile chronic arthritis and systemic lupus erythematosus. Adv Exp Med Biol (1999) 455:55–60.10.1007/978-1-4615-4857-7_8
Mooijaart SP, Du Puy RS, Stott DJ, et al. Association Between Levothyroxine Treatment and Thyroid-Related Symptoms Among Adults Aged 80 Years and Older With Subclinical Hypothyroidism [published online ahead of print, 2019 Oct 30]. JAMA. 2019;322(20):1‐11. doi:10.1001/jama.2019.17274
Nabhan ZM, Kreher NC, Eugster EA, Hashitoxicosis in children: Clinical features and natural history, J Pediatr, 2005;146: 533–6.
Rotondi M, et al. Painful Hashimoto’s thyroiditis: myth or reality? J Endocrinol Invest. 2017;40(8):815. Epub 2017 Mar 24. J Endocrinol Invest. 2017;40(8):815. Epub 2017 Mar 24. 
Tagoe CE, Zezon A, Khattri S. Rheumatic manifestations of autoimmune thyroid disease: the other autoimmune disease. Journal of Rheumatology. 2012;39(6):1125–1129.

Chapter 18

Alijotas-Reig J. Treatment of refractory obstetric antiphospholipid syndrome: the state of the art and new trends in the therapeutic management. Lupus. 2013;22(1):6‐17. doi:10.1177/0961203312465782
Arkema EV, Askling J, Salmon JE, Simard JF. Brief Report: Sex Ratio of Offspring Born to Women With Systemic Lupus Erythematosus or Rheumatoid Arthritis. Arthritis Rheumatol. 2017;69(1):143‐147. doi:10.1002/art.39843
Arkema EV, Palmsten K, Sjöwall C, Svenungsson E, Salmon JE, Simard JF. What to Expect When Expecting With Systemic Lupus Erythematosus (SLE): A Population-Based Study of Maternal and Fetal Outcomes in SLE and Pre-SLE. Arthritis Care Res (Hoboken). 2016;68(7):988‐994. doi:10.1002/acr.22791
Askanase AD, et al. Frequency of neuro-psychiatric dysfunction in anti-SSA/SSB exposed children with and without neonatal lupus. Lupus. 2010;19(3):300. Epub 2009 Dec 14. 
Askanase AD, Miranda-Carus ME, Tang X, Katholi M, Buyon JP. The presence of IgG antibodies reactive with components of the SSA/Ro-SSB/La complex in human breast milk: implications in neonatal lupus. Arthritis Rheum. 2002;46(1):269‐271. doi:10.1002/1529-0131(200201)46:1<269::AID-ART10043>3.0.CO;2-6
Atiquzzaman M, Karim ME, Kopec J, Wong H, Anis AH. Role of Nonsteroidal Antiinflammatory Drugs in the Association Between Osteoarthritis and Cardiovascular Diseases: A Longitudinal Study. Arthritis Rheumatol. 2019;71(11):1835-1843. doi:10.1002/art.41027
Barsalou J, Costedoat-Chalumeau N, Berhanu A, et al. Effect of in utero hydroxychloroquine exposure on the development of cutaneous neonatal lupus erythematosus. Annals of the Rheumatic Diseases 2018;77:1742-1749.
Bates SM, Greer IA, Pablinger I, Sofaer S, Hirsh J. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians evidence based clinical practice guidelines (8th edition). Chest. 2008;133(6 suppl):S844.
Berglund A, et al. Changes in the cohort composition of turner syndrome and severe non-diagnosis of Klinefelter, 47,XXX and 47,XYY syndrome: a nationwide cohort study. Orphanet J Rare Dis. 2019;14(1):16. Epub 2019 Jan 14. ​
Bermas, B. L., Kim, S. C., Huybrechts, K., Mogun, H., Hernandez-Diaz, S., Bateman, B. T., & Desai, R. J. (2018). Trends in use of hydroxychloroquine during pregnancy in systemic lupus erythematosus patients from 2001 to 2015. Lupus, 27(6), 1012–1017. https://doi.org/10.1177/0961203317749046​
Boros CA et al. Hydrocephalus and macrocephaly: new manifestations of neonatal lupus erythematosus. Arthritis Rheum. 2007;57(2):261. ​
Buyon JP, Izmirly PM, Belmont HM, Conklin J, Kaiden N, Salmon JE, Alexander R, De
rvieux T. Erythrocyte Bound C4d in the Presence of Adverse Pregnancy Outcome Events in Pregnant Women with Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/erythrocyte-bound-c4d-in-the-presence-of-adverse-pregnancy-outcome-events-in-pregnant-women-with-systemic-lupus-erythematosus/. Accessed June 13, 2020.
Buyon JP, Kim MY, Guerra MM, et al. Predictors of Pregnancy Outcomes in Patients With Lupus: A Cohort Study. Ann Intern Med. 2015;163(3):153‐163. doi:10.7326/M14-2235​
Buyon JP, Mimi Y. Kim, Marta M. Guerra, Sifan Lu, Emily Reeves, Michelle Petri, Carl A. Laskin, Michael D. Lockshin, Lisa R. Sammaritano, D. Ware Branch, T. Flint Porter, Allen Sawitzke, Joan T. Merrill, Mary D. Stephenson, Elisabeth Cohn, Jane E. Salmon. Kidney Outcomes and Risk Factors for Nephritis (Flare/De Novo) in a Multiethnic Cohort of Pregnant Patients with Lupus.  CJASN Jun 2017, 12 (6) 940-946; DOI: 10.2215/CJN.11431116
Brouwer J, et al. Fertility in women with rheumatoid arthritis: influence of disease activity and medication. Ann Rheum Dis. 2015;74(10):1836. ​
Cappola AR, Casey BM. Thyroid Function Test Abnormalities During Pregnancy. JAMA. 2019;322(7):617‐619. doi:10.1001/jama.2019.10159
Chen, T. K., Gelber, A. C., Witter, F. R., Petri, M., & Fine, D. M. (2015). Renal biopsy in the management of lupus nephritis during pregnancy. Lupus, 24(2), 147–154. https://doi.org/10.1177/0961203314551812
Ciardulli A, et al. Maternal steroid therapy for fetuses with second-degree immune-mediated congenital atrioventricular block: a systematic review and meta-analysis. Acta Obstet Gynecol Scand. 2018;97(7):787. Epub 2018 Apr 18. 
Clowse ME, Behera MA, Anders CK, et al. Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis. J Womens Health (Larchmt). 2009;18(3):311‐319. doi:10.1089/jwh.2008.0857
Clowse MEB, Magder LS, Petri M. The clinical utility of measuring complement and anti-ds- DNA antibodies during pregnancy in patients with systemic lupus erythematosus. Journal of Rheumatology. 2011;38:1012–1016.
Clowse MEB, Magder LS, Petri M. Cyclophosphamide for lupus during pregnancy. Lupus. 2005;14(8):593–597.
Clowse MEB, Magder LS, Witter F, Petri M. Early risk factors for pregnancy loss in lupus. Obstetrics & Gynecology. February 2006;107(2):293–299.
Clowse MEB, Magder LS, Witter F, Petri M. Hydroxychloroquine in lupus pregnancy. Arthritis & Rheumatism. November 2006;54(11):3640–3647.
Couture J, Ben-Shoshan M, Pineau CA, et al. Risk of Allergic Conditions in Children Born to Women With Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2018;70(2):315‐319. doi:10.1002/acr.23251​
Daniel S, et al. Fetal exposure to nonsteroidal anti-inflammatory drugs and spontaneous abortions. CMAJ. 2014;186(5):E177. Epub 2014 Feb 3. 

Davis-Porada J, Kim MY, Guerra MM, Laskin CA, Petri M, Lockshin MD, Sammaritano LR, Branch DW, Sawitzke A, Merrill JT, Buyon JP, Salmon JE. Low frequency of flares during pregnancy and post-partum in stable lupus patients. Arthritis Res Ther. 2020 Mar 19;22(1):52. doi: 10.1186/s13075-020-2139-9. PMID: 32188491; PMCID: PMC7081564.
de Jesús GR, et al. Factors associated with first thrombosis in patients presenting with obstetric antiphospholipid syndrome (APS) in the APS Alliance for Clinical Trials and International Networking Clinical Database and Repository: a retrospective study. BJOG. 2019;126(5):656. Epub 2018 Oct 24. ​
de Jesús GR, Benson AE, Chighizola CB, Sciascia S, Branch DW. 16th International Congress on Antiphospholipid Antibodies Task Force Report on Obstetric Antiphospholipid Syndrome. Lupus. 2020 Oct;29(12):1601-1615. doi: 10.1177/0961203320954520. Epub 2020 Sep 3. PMID: 32883160.
Eudy AM, Siega-Riz AM, Engel SM, et alEffect of pregnancy on disease flares in patients with systemic lupus erythematosus. Annals of the Rheumatic Diseases 2018;77:855-860.
Eudy AM, Siega-Riz AM, Engel SM, et al. Preconceptional Cardiovascular Health and Pregnancy Outcomes in Women with Systemic Lupus Erythematosus. J Rheumatol. 2019;46(1):70‐77. doi:10.3899/jrheum.171066
Fairley KF, et al. Sterility and testicular atrophy related to cyclophosphamide therapy. Lancet. 1972;1(7750):568. 
Ferrini MG, Gonzalez-Cadavid NF, Rajfer J. Aging related erectile dysfunction-potential mechanism to halt or delay its onset. Transl Androl Urol. 2017;6(1):20-27. doi:10.21037/tau.2016.11.18
Geraghty LN, Pomeranz MK. Physiologic changes and dermatoses of pregnancy. Int J Dermatol. 2011 Jul;50(7):771-82. 
Götestam Skorpen C, Lydersen S, Gilboe IM, et al. Disease Activity During Pregnancy and the First Year Postpartum in Women With Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2017;69(8):1201‐1208. doi:10.1002/acr.23102
Goulabchand R, Hafidi A, Van de Perre P, et al. Mastitis in Autoimmune Diseases: Review of the Literature, Diagnostic Pathway, and Pathophysiological Key Players. J Clin Med. 2020;9(4):958. Published 2020 Mar 30. doi:10.3390/jcm9040958
Gris JC, et al. Comparative incidence of a first thrombotic event in purely obstetric antiphospholipid syndrome with pregnancy loss: the NOH-APS observational study. Blood. 2012 Mar;119(11):2624-32. Epub 2011 Dec 6. 
Hahn BH. Pregnancy in Women With Systemic Lupus Erythematosus: Messages for the Clinician. Ann Intern Med. 2015;163(3):232‐233. doi:10.7326/M15-1301
Halder, R., Malik, R., & Kashyap, R. (2017). Warm antibody hemolytic anemia—a rare presentation of neonatal lupus. Lupus, 26(6), 661–663. https://doi.org/10.1177/0961203316664594
Harris HR, Costenbader KH, Mu F, et al. Endometriosis and the risks of systemic lupus erythematosus and rheumatoid arthritis in the Nurses’ Health Study II. Annals of the Rheumatic Diseases 2016;75:1279-1284.
Harris, H. R., Simard, J. F., & Arkema, E. V. (2016). Endometriosis and systemic lupus erythematosus: a population-based case–control study. Lupus, 25(9), 1045–1049. https://doi.org/10.1177/0961203316631635
Henderson JT, Whitlock EP, O’Conner E, et al. Low-Dose Aspirin for the Prevention of Morbidity and Mortality From Preeclampsia: A Systematic Evidence
Review for the U.S. Preventive Services Task Force [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2014 Apr. (Evidence Syntheses, No. 112.) Available from: https:///www.ncbi.nlm.nih.gov/books/NBK196392/
Herrera, C. A., Heuser, C. C., & Branch, D. W. (2017). Stillbirth: the impact of antiphospholipid syndrome? Lupus, 26(3), 237–239. https://doi.org/10.1177/0961203316671815
Howard LE, et al. The impact of cyclophosphamide on menstruation and pregnancy in women with rheumatologic disease. Lupus. 2013;22(1):81. ​
Hviid A, Mølgaard-Nielsen D. Corticosteroid use during pregnancy and risk of orofacial clefts. CMAJ. 2011 Apr;183(7):796-804. Epub 2011 Apr 11. 
Izmirly PM, et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation. 2012;126(1):76. Epub 2012 May 24. ​
Izmirly PM, Halushka MK, Rosenberg AZ, et al. Clinical and pathologic implications of extending the spectrum of maternal autoantibodies reactive with ribonucleoproteins associated with cutaneous and now cardiac neonatal lupus from SSA/Ro and SSB/La to U1RNP. Autoimmun Rev. 2017;16(9):980‐983. doi:10.1016/j.autrev.2017.07.013
Izmirly P, Kim M, Friedman DM, Costedoat-Chalumeau N, Clancy R, Copel JA, Phoon CKL, Cuneo BF, Cohen RE, Robins K, Masson M, Wainwright BJ, Zahr N, Saxena A, Buyon JP. Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers. J Am Coll Cardiol. 2020 Jul 21;76(3):292-302. doi: 10.1016/j.jacc.2020.05.045. PMID: 32674792; PMCID: PMC7394202.
Izmirly PM, Kim MY, Llanos C, Le PU, Guerra MM, Askanase AD, et al. Evaluation of the risk of anti-SSA/Ro-anti-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. Annals of the Rheumatic Diseases. 2010;69:1827–1830.
Izmirly PM, Llanos C, Lee LA, Askanase A, Kim MY, Buyon JP. Cutaneous manifestations of neonatal lupus and risk of subsequent congenital heart block. Arthritis & Rheumatism. April 2010; 62(4):1153–1157.
Jancin B. Managing rheumatologic diseases in pregnancy. Rheumatology News. April 2010;9(4):28. Kubetin SK. Risk of neonatal lupus in next baby less than 20%. Rheumatology News. May  2010;9(5):2.
Kaplowitz, E.T., Ferguson, S., Guerra, M., Laskin, C.A., Buyon, J.P., Petri, M., Lockshin, M.D., Sammaritano, L.R., Branch, D.W., Merrill, J.T., Katz, P. and Salmon, J.E. (2018), Contribution of Socioeconomic Status to Racial/Ethnic Disparities in Adverse Pregnancy Outcomes Among Women With Systemic Lupus Erythematosus. Arthritis Care Res, 70: 230-235. doi:10.1002/acr.23263
Kelly EN, Sananes R, Chiu-Man C, Silverman ED, Jaeggi E. Prenatal anti-Ro antibody exposure, congenital complete atrioventricular heart block, and high-dose steroid therapy: impact on neurocognitive outcome in school-age children. Arthritis Rheumatol. 2014;66(8):2290‐2296. doi:10.1002/art.38675
Kinonen, Christopher MD; Gattuso, Paolo MD; Reddy, Vijaya B. MD Lupus Mastitis, The American Journal of Surgical Pathology: June 2010 – Volume 34 – Issue 6 – p 901-906 doi: 10.1097/PAS.0b013e3181da00fb
Kubetin SK. Use of echocardiograms in fetal heart block. Rheumatology News. May 2010;9(5):13.
Lateef A, and Petri M. Managing lupus patients during pregnancy. Best Pract Res Clin Rheum 2013;27:435-447.
Latino, J. O., Udry, S., Aranda, F. M., Perés Wingeyer, S. D. A., Fernández Romero, D. S., & de Larrañaga, G. F. (2017). Pregnancy failure in patients with obstetric antiphospholipid syndrome with conventional treatment: the influence of a triple positive antibody profile. Lupus, 26(9), 983–988. https://doi.org/10.1177/0961203317692432​
Lazzaroni MG, Fredi M, Andreoli L, et al. Triple Antiphospholipid (aPL) Antibodies Positivity Is Associated With Pregnancy Complications in aPL Carriers: A Multicenter Study on 62 Pregnancies. Front Immunol. 2019;10:1948. Published 2019 Aug 14. doi:10.3389/fimmu.2019.01948
LeFevre ML; U.S. Preventive Services Task Force. Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;161(11):819‐826. doi:10.7326/M14-1884​
Lefkou E, Mamopoulos A, Dagklis T, Vosnakis C, Rousso D, Girardi G. Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy. J Clin Invest. 2016;126(8):2933‐2940. doi:10.1172/JCI86957
Li DK, et al. Use of nonsteroidal antiinflammatory drugs during pregnancy and the risk of miscarriage. Am J Obstet Gynecol. 2018;219(3):275.e1. Epub 2018 Jun 8. ​
Limper M, Scirè CA, Talarico R, et al. Antiphospholipid syndrome: state of the art on clinical practice guidelines. RMD Open. 2018;4(Suppl 1):e000785. Published 2018 Oct 18. doi:10.1136/rmdopen-2018-000785
Liu K, Kurien BT, Zimmerman SL, et al. X Chromosome Dose and Sex Bias in Autoimmune Diseases: Increased Prevalence of 47,XXX in Systemic Lupus Erythematosus and Sjögren’s Syndrome. Arthritis Rheumatol. 2016;68(5):1290‐1300. doi:10.1002/art.39560
López-Pedrera C, Ruiz-Limón P, Aguirre MÁ, et al. Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome. Ann Rheum Dis. 2011;70(4):675‐682. doi:10.1136/ard.2010.135525
Magnus MC, et al. Role of maternal age and pregnancy history in risk of miscarriage: prospective register based study. BMJ. 2019;364:l869. Epub 2019 Mar 20. 
Marder W, Ganser MA, Romero V, et al. In utero azathioprine exposure and increased utilization of special educational services in children born to mothers with systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2013;65(5):759‐766. doi:10.1002/acr.21888
Marder W, Romero VC, Ganser MA, et al. Increased usage of special educational services by children born to mothers with systemic lupus erythematosus and antiphospholipid antibodies. Lupus Sci Med. 2014;1(1):e000034. Published 2014 Jul 15. doi:10.1136/lupus-2014-000034
Marder W. Update on pregnancy complications in systemic lupus erythematosus. Curr Opin Rheumatol. 2019;31(6):650‐658. doi:10.1097/BOR.0000000000000651
Martin V, et al. Long-term followup of children with neonatal lupus and their unaffected siblings. Arthritis Rheum. 2002;46(9):2377. 
Mayorga, J., Alpízar-Rodríguez, D., Prieto-Padilla, J., Romero-Díaz, J., & Cravioto, M. C. (2016). Prevalence of premature ovarian failure in patients with systemic lupus erythematosus. Lupus, 25(7), 675–683. https://doi.org/10.1177/0961203315622824
McDermott EM, Powell RJ. Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide. Annals of the Rheumatic Diseases 1996;55:224-229.
Mehta B, Luo Y, Xu J, et al. Trends in Maternal and Fetal Outcomes Among Pregnant Women With Systemic Lupus Erythematosus in the United States: A Cross-sectional Analysis. Ann Intern Med. 2019;171(3):164‐171. doi:10.7326/M19-0120
Meistrich ML, et al. Impact of cyclophosphamide on long-term reduction in sperm count in men treated with combination chemotherapy for Ewing and soft tissue sarcomas. Cancer. 1992;70(11):2703. 
Mofors J, Eliasson H, Ambrosi A, et al. Comorbidity and long-term outcome in patients with congenital heart block and their siblings exposed to Ro/SSA autoantibodies in utero. Ann Rheum Dis. 2019;78(5):696‐703. doi:10.1136/annrheumdis-2018-214406
Mouyis M, Flint JD, Giles IP. Safety of anti-rheumatic drugs in men trying to conceive: A systematic review and analysis of published evidence. Semin Arthritis Rheum. 2019;48(5):911‐920. doi:10.1016/j.semarthrit.2018.07.011
Nezvalová-Henriksen K, et al. Effects of ibuprofen, diclofenac, naproxen, and piroxicam on the course of pregnancy and pregnancy outcome: a prospective cohort study. BJOG. 2013 Jul;120(8):948-59. Epub 2013 Mar 14. 
Niederman R. Pregnancy gingivitis and causal inference. Evid Based Dent. 2013;14(4):107‐108. doi:10.1038/sj.ebd.6400966
Normand G, Sens F, Puthet J, et al. Not only disease activity but also chronic hypertension and overweight are determinants of pregnancy outcomes in patients with systemic lupus erythematosus. Lupus. 2019;28(4):529‐537. doi:10.1177/0961203319832097
Nothnick WB. Treating endometriosis as an autoimmune disease. Fertil Steril. 2001;76(2):223‐231. doi:10.1016/s0015-0282(01)01878-7
Nusbaum JS, Mirza I, Shum J, et al. Sex Differences in Systemic Lupus Erythematosus: Epidemiology, Clinical Considerations, and Disease Pathogenesis. Mayo Clin Proc. 2020;95(2):384-394. doi:10.1016/j.mayocp.2019.09.012
Ofori B, Oraichi D, Blais L, Rey E, Bérard A. Risk of congenital abnormalities in pregnant users of non-steroidal anti-inflammatory drugs: a nested case-control study. Birth Defects Research (Part B). August 2006; 77(4):268–279.
Otto MA. Tips for predicting high-risk pregnancies in SLE. Rheumatology News. August 2010;9(8):42.
Paduch, D.A., Fine, R.G., Bolyakov, A., & Kiper, J. (2008). New concepts in Klinefelter syndrome. Current Opinion in Urology, 18(6), 621-627.​
Pall M et al. Induction of delayed follicular rupture in the human by the selective COX-2 inhibitor rofecoxib: a randomized double-blind study. Hum Reprod. 2001;16(7):1323. 
Kristin Palmsten, Gretchen Bandoli, Gabriela Vazquez-Benitez, Min Xi, Diana L Johnson, Ronghui Xu, Christina D Chambers, Oral corticosteroid use during pregnancy and risk of preterm birth, Rheumatology, Volume 59, Issue 6, June 2020, Pages 1262–1271, https://doi.org/10.1093/rheumatology/kez405
Pasoto SG, Abrao MS, Viana VS, Bueno C, Leon EP, Bonfa E. Endometriosis and systemic lupus erythematosus: a comparative evaluation of clinical manifestations and serological autoimmune phenomena. Am J Reprod Immunol. 2005;53(2):85‐93. doi:10.1111/j.1600-0897.2005.00252.x
Pasoto SG, Mendonça BB, Bonfá E. Menstrual disturbances in patients with systemic lupus erythematosus without alkylating therapy: clinical, humoral and therapeutic associations. Lupus. March 2002; 11(3):175–180.
Petri M. The Hopkins Lupus Pregnancy Center: ten key issues in management. Rheumatic Disease Clinics of North America. May 2007; 33(2):227–235.

Pfaller B, Pupco A, Leibson T, Aletaha D, Ito S. A critical review of the reproductive safety of Leflunomide. Clin Rheumatol. 2020 Feb;39(2):607-612. doi: 10.1007/s10067-019-04819-4. Epub 2019 Nov 22. PMID: 31758422.

Pullen LC. The State-of-the-Art of Rheumatology Symposium: Lupus and Pregnancy. The Rheumatologist JUN 2012: 42-43.
Rivkees SA, Crawford JD. The relationship of gonadal activity and chemotherapy-induced gonadal damage. JAMA. 1988;259(14):2123. 
Rodrigues, B. C., Lacerda, M. I., Ramires de Jesús, G. R., Cunha dos Santos, F., Ramires de Jesús, N., Levy, R. A., & Klumb, E. M. (2019). The impact of different classes of lupus nephritis on maternal and fetal outcomes: a cohort study of 147 pregnancies. Lupus, 28(4), 492–500. https://doi.org/10.1177/0961203319829825
Rosa M, Mohammadi A. Lupus mastitis: a review. Ann Diagn Pathol. 2013;17(2):230‐233. doi:10.1016/j.anndiagpath.2012.09.003
Ruffatti A, Milanesi O, Chiandetti L, Cerutti A, Gervasi MT, et al. A combination therapy to treat second-degree anti-Ro/La-related congenital heart block. A strategy to avoid stable third-degree heart block? Lupus. 2012;21:666–671.
Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus. 2011;20(2):206‐218. doi:10.1177/0961203310395803​
Saavedra MA, et al. Primigravida is associated with flare in women with systemic lupus erythematosus. Lupus. 2015;24(2):180. Epub 2014 Sep 24. ​
Soares PM, et al. Gonad evaluation in male systemic lupus erythematosus. Arthritis Rheum. 2007;56(7):2352. 
Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis Care Res (Hoboken). 2020;72(4):461‐488. doi:10.1002/acr.24130
Sammaritano LR, Lockshin MD. Lupus science and medicine: dialogue [published correction appears in Lupus Sci Med. 2014;1(1). pii: lupus-2014-000048corr1. doi: 10.1136/lupus-2014-000048corr1]. Lupus Sci Med. 2014;1(1):e000048. Published 20
14 Jul 22. doi:10.1136/lupus-2014-000048
Saxena A, Izmirly PM, Bomar RP, et al. Factors associated with long-term cardiac dysfunction in neonatal lupus. Annals of the Rheumatic Diseases 2020;79:217-224.
Seo, M. R., Chae, J., Kim, Y. M., Cha, H. S., Choi, S. J., Oh, S., & Roh, C.-R. (2019). Hydroxychloroquine treatment during pregnancy in lupus patients is associated with lower risk of preeclampsia. Lupus, 28(6), 722–730. https://doi.org/10.1177/0961203319843343
Soh MC, Nelson-Piercy C, Dib F, Westgren M, McCowan L, Pasupathy D. Brief Report: Association Between Pregnancy Outcomes and Death From Cardiovascular Causes in Parous Women With Systemic Lupus Erythematosus: A Study Using Swedish Population Registries. Arthritis Rheumatol. 2015;67(9):2376‐2382. doi:10.1002/art.39218
Soh, M. C., Nelson-Piercy, C., Westgren, M., McCowan, L., & Pasupathy, D. (2017). Do adverse pregnancy outcomes contribute to accelerated cardiovascular events seen in young women with systemic lupus erythematosus? Lupus, 26(13), 1351–1367. https://doi.org/10.1177/0961203317719146
Spinillo A, Beneventi F, Locatelli E, et al. Early, Incomplete, or Preclinical Autoimmune Systemic Rheumatic Diseases and Pregnancy Outcome. Arthritis Rheumatol. 2016;68(10):2555‐2562. doi:10.1002/art.39737
Srivastava A, Ko J, Ogunsile J, Moliterno A, Westra WH, Semerjian A. Patient with antiphospholipid syndrome presenting with testicular torsion-like symptoms. Urol Case Rep. 2017;15:26‐27. Published 2017 Sep 6. doi:10.1016/j.eucr.2017.08.010
Stagnaro-Green A, Akhter E, Yim C, Davie TF, Magder LS, Petri M. Thyroid disease in pregnant women with systemic lupus erythematosus: increased preterm delivery. Lupus. 2011;20:690–699.
Sugawara, E., Kato, M., Fujieda, Y., Oku, K., Bohgaki, T., Yasuda, S., … Atsumi, T. (2019). Pregnancy outcomes in women with rheumatic diseases: a real-world observational study in Japan. Lupus, 28(12), 1407–1416. https://doi.org/10.1177/0961203319877258​
Tamirou F, et al. Brief report: The Euro-lupus low-dose intravenous cyclophosphamide regimen does not impact the ovarian reserve, as measured by serum levels of anti-Müllerian hormone. Arthritis Rheumatol. 2017;69(6):1267. Epub 2017 May 3. ​
Tiseo, B., Bonfá, E., Borba, E., Munhoz, G., Wood, G., Srougi, M., … Cocuzza, M. (2019). Complete urological evaluation including sperm DNA fragmentation in male systemic lupus erythematosus patients. Lupus, 28(1), 59–65. https://doi.org/10.1177/0961203318815764
Tufano A, Coppola A, Maruotti GM, Martinelli P, Cerbone AM, Di Minno G. HELLP syndrome and its relation with the antiphospholipid syndrome. Blood Transfus. 2014;12(1):114‐118. doi:10.2450/2013.0154-13
Tunks RD, Clowse ME, Miller SG, Brancazio LR, Barker PC. Maternal autoantibody levels in congenital heart block and potential prophylaxis with antiinflammatory agents. Am J Obstet Gynecol. 2013;208(1):64.e1‐64.e647. doi:10.1016/j.ajog.2012.09.020
Uhler ML, et al. The effect of nonsteroidal anti-inflammatory drugs on ovulation: a prospective, randomized clinical trial. Fertil Steril. 2001;76(5):957. 
Valdez-López M, Campos-Guzmán J, Barrera-Vargas A, Govea-Peláez S, Gómez-Martín D, Alcocer-Varela J, Aguirre-Aguilar E, Padilla-Ortíz D, Merayo-Chalico J. Sexual Function and Health-related Quality of Life in Male Patients with Systemic Lupus Erythematosus, the Untold Story [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/sexual-function-and-health-related-quality-of-life-in-male-patients-with-systemic-lupus-erythematosus-the-untold-story/. Accessed June 28, 2020.
​Vecchi, A., Borba, E., Bonfá, E., Cocuzza, M., Pieri, P., Kim, C., & Silva, C. (2011). Penile anthropometry in systemic lupus erythematosus patients. Lupus, 20(5), 512–518. https://doi.org/10.1177/0961203310384121
Vinet, É., Pineau, C., Clarke, A., Fombonne, É., Platt, R., & Bernatsky, S. (2014). Neurodevelopmental disorders in children born to mothers with systemic lupus erythematosus. Lupus, 23(11), 1099–1104. https://doi.org/10.1177/0961203314541691
Watson AR, et al. Long term effects of cyclophosphamide on testicular function. Br Med J (Clin Res Ed). 1985;291(6507):1457. ​
Williams D. Pregnancy: a stress test for life. Curr Opin Obstet Gynecol. 2003;15(6):465‐471. doi:10.1097/00001703-200312000-00002
Willis, R., Smikle, M., DeCeulaer, K., Romay-Penabad, Z., Papalardo, E., Jajoria, P., … Gonzalez, E. B. (2017). Clinical associations of proinflammatory cytokines, oxidative biomarkers and vitamin D levels in systemic lupus erythematosus. Lupus, 26(14), 1517–1527. https://doi.org/10.1177/0961203317706557
Wincup C, McDonnell TCR, Rahman A. Menorrhagia: an underappreciated problem in pre-menopausal women with systemic lupus erythematosus. Lupus. 2019;28(7):916‐917. doi:10.1177/0961203319851868
Yelnik, C. M., Lambert, M., Drumez, E., Le Guern, V., Bacri, J.-L., Guerra, M. M., … Costedoat-Chalumeau, N. (2018). Bleeding complications and antithrombotic treatment in 264 pregnancies in antiphospholipid syndrome. Lupus, 27(10), 1679–1686. https://doi.org/10.1177/0961203318787032
Yelnik CM, Laskin CA, Porter TF, et al. Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results. Lupus Science & Medicine 2016;3:e000131. doi: 10.1136/lupus-2015-000131
Zuppa AA, et al. Neonatal lupus: Follow-up in infants with anti-SSA/Ro antibodies and review of the literature. Autoimmun Rev. 2017;16(4):427. Epub 2017 Feb 14. 

Chapter 19

Abu-Shakra M, Novack V. Mortality and multiple causes of death in systemic lupus erythematosus — role of the death certificate. J Rheumatol. 2012 Mar;39(3):458-60. doi: 10.3899/jrheum.111556. PMID: 22383351.
Aceves-Avila FJ, Benites-Godínez V. Drug allergies may be more frequent in systemic lupus erythematosus than in rheumatoid arthritis. J Clin Rheumatol. 2008;14(5):261‐263. doi:10.1097/RHU.0b013e31817a241a
Aggarwal I, Li J, Trupin L, et al. Quality of Care for the Screening,
Diagnosis, and Management of Lupus Nephritis Across Multiple Health Care Settings [published online ahead of print, 2019 May 6]. Arthritis Care Res (Hoboken). 2019;10.1002/acr.23915. doi:10.1002/acr.23915
Alarcon GS. The LUMINA Study: impact beyond lupus in U.S. Hispanics. The Rheumatologist. April 2011;5(4):1+.
​Alonso MD, Martinez-Vazquez F, Diaz de Teran T, Miranda-Filloy JA, Dierssen T, et al. Late onset systemic lupus erythematosus in Northwestern Spain: differences with early onset systemic lupus erythematosus and literature review. Lupus. September 2012;21(10):1135–1148.
Agrawaal KK, S.S. Dhakal. Systemic lupus erythematosus in males: A case series Saudi J Kidney Dis Transpl, 25 (3) (2014), pp. 638-642
Chan, KL, Mok, CC. Development of systemic lupus erythematosus in a male-to-female transsexual: The role of sex hormones revisited. Lupus 2013; 22: 1399–1402.
Akhavan PS, Su J, Lou W, Gladman DD, Urowitz MB, Fortin PR. The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus. J Rheumatol. 2013;40(6):831-841. doi:10.3899/jrheum.120572
Alarcón, G. S., Ugarte-Gil, M. F., Pons-Estel, G., Vilá, L. M., Reveille, J. D., & McGwin, G. (2019). Remission and low disease activity state (LDAS) are protective of intermediate and long-term outcomes in SLE patients. Results from LUMINA (LXXVIII), a multiethnic, multicenter US cohort. Lupus, 28(3), 423–426. https://doi.org/10.1177/0961203319826693
Aljohani, R., Gladman, D. D., Su, J., & Urowitz, M. B. (2017). Disease evolution in late-onset and early-onset systemic lupus erythematosus. Lupus, 26(11), 1190–1196. https://doi.org/10.1177/0961203317696593
Alpízar-Rodríguez D, Romero-Díaz J, Sánchez-Guerrero J, Seuc AH, Cravioto Mdel C. Age at natural menopause among patients with systemic lupus erythematosus. Rheumatology (Oxford). 2014;53(11):2023-2029. doi:10.1093/rheumatology/keu222
Amaral B, Murphy G, Ioannou Y, Isenberg DA. A comparison of the outcome of adolescent and adult-onset systemic lupus erythematosus. Rheumatology (Oxford). 2014;53(6):1130-1135. doi:10.1093/rheumatology/ket488
Ambrose N, Morgan TA, Galloway J, et al. Differences in disease phenotype and severity in SLE across age groups. Lupus. 2016;25(14):1542-1550. doi:10.1177/0961203316644333
Anastasiou C, Trupin L, Glidden DV, et al. Mortality among Hospitalized Individuals with Systemic Lupus Erythematosus in the United States between 2006 and 2016 [published online ahead of print, 2020 Jun 17]. Arthritis Care Res (Hoboken). 2020;10.1002/acr.24356. doi:10.1002/acr.24356
Anstey NM, Bastian I, Dunckley H, Currie BJ. Systemic lupus erythematosus in Australian aborigines: high prevalence, morbidity and mortality. Aust N Z J Med 1993;23:646–51.
Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20(5):1103-1112. doi:10.1681/ASN.2008101028
Arbuckle MR, James JA, Dennis GJ, et al. Rapid clinical progression to diagnosis among African-American men with systemic lupus erythematosus. Lupus. 2003;12(2):99-106. doi:10.1191/0961203303lu334oa
Arora S, Nika A, Trupin L, et al. Does Systemic Lupus Erythematosus Care Provided in a Lupus Clinic Result in Higher Quality of Care Than That Provided in a General Rheumatology Clinic?. Arthritis Care Res (Hoboken). 2018;70(12):1771-1777. doi:10.1002/acr.23569
Arthritis Research Canada (May 2020). Research shows hydroxychloroquine has substantial survival benefit among patients with systemic lupus erythematosus in the general population. Retrieved on 4/17/21 at https:///www.newswire.ca/news-releases/research-shows-hydroxychloroquine-has-substantial-survival-benefit-among-patients-with-systemic-lupus-erythematosus-in-the-general-population-801493259.html
Artim-Esem B, et al. Comparison of Disease Characteristics, Organ Damage, and Survival in Patients with Juvenile-onset and Adult-onset Systemic Lupus Erythematosus in a Combined Cohort from 2 Tertiary Centers in Turkey. Journal of Rheumatology Mar 2017, jrheum.160340; DOI: 10.3899/jrheum.160340
Azizoddin DR, Jolly M, Arora S, Yelin E, Katz P. Patient-Reported Outcomes Predict Mortality in Lupus. Arthritis Care Res (Hoboken). 2019;71(8):1028-1035. doi:10.1002/acr.23734
Babaoğlu H, Li J, Goldman D, Magder LS, Petri M. Predictors of predominant Lupus Low Disease Activity State (LLDAS-50). Lupus. 2019;28(14):1648-1655. doi:10.1177/0961203319886028
Babaoğlu H, Li J, Goldman D, Magder LS, Petri M. Time to Lupus Low Disease Activity State in the Hopkins Lupus Cohort: Role of African American Ethnicity. Arthritis Care Res (Hoboken). 2020;72(2):225-232. doi:10.1002/acr.24063
Baehr, G.; Klemperer, P., and Schifrin, A. : A Diffuse Disease of the Peripheral Circulation (Usually Associated with Lupus Erythematosus and Endocarditis), Tr. A. Am. Physicians 50:139-155, 1935.
Barbhaiya, M., & Costenbader, K. (2014). Ultraviolet radiation and systemic lupus erythematosus. Lupus, 23(6), 588–595. https://doi.org/10.1177/0961203314530488
Barbhaiya M, Feldman CH, Guan H, et al. Race/Ethnicity and Cardiovascular Events Among Patients With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2017;69(9):1823-1831. doi:10.1002/art.40174
Barnado A, Carroll RJ, Casey C, Wheless L, Denny JC, Crofford LJ. Phenome-wide association study identifies marked increased in burden of comorbidities in African Americans with systemic lupus erythematosus. Arthritis Res Ther. 2018;20(1):69. Published 2018 Apr 10. doi:10.1186/s13075-018-1561-8​
Bartels CM, Ramsey-Goldman R. Editorial: Updates in US systemic lupus erythematosus epidemiology: Tales of two cities. Arthritis Rheumatol. 2014;66(2):242-245. doi:10.1002/art.38240
Bossingham D. Systemic lupus erythematosus in the far north of Queensland. Lupus 2003;12:327–31
Chae DH, Martz CD, Fuller-Rowell TE, et al. R
acial Discrimination, Disease Activity, and Organ Damage: The Black Women’s Experiences Living With Lupus (BeWELL) Study. Am J Epidemiol. 2019;188(8):1434-1443. doi:10.1093/aje/kwz105
Chehab, G., Sauer, G. M., Richter, J. G., Brinks, R., Willers, R., Fischer-Betz, R., … Schneider, M. (2018). Medical adherence in patients with systemic lupus erythematosus in Germany: predictors and reasons for non-adherence – a cross-sectional analysis of the LuLa-cohort. Lupus, 27(10), 1652–1660. https://doi.org/10.1177/0961203318785245
Christ A, Günther P, Lauterbach MAR, et al. Western Diet Triggers NLRP3-Dependent Innate Immune Reprogramming. Cell. 2018;172(1-2):162-175.e14. doi:10.1016/j.cell.2017.12.013
Clowse ME, Grotegut C. Racial and Ethnic Disparities in the Pregnancies of Women With Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2016;68(10):1567-1572. doi:10.1002/acr.22847
Contreras G, Lenz O, Pardo V, et al. Outcomes in African Americans and Hispanics with lupus nephritis. Kidney Int. 2006;69(10):1846-1851. doi:10.1038/sj.ki.5000243
Cooper GS, Dooley MA, Treadwell EL, St Clair EW, Gilkeson GS. Risk factors for development of systemic lupus erythematosus: allergies, infections, and family history. J Clin Epidemiol. 2002;55(10):982‐989. doi:10.1016/s0895-4356(02)00429-8
Couture J, Ben-Shoshan M, Pineau CA, et al. Risk of Allergic Conditions in Children Born to Women With Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2018;70(2):315‐319. doi:10.1002/acr.23251​
Dall’Era M, et al. The incidence and prevalence of systemic lupus erythematosus in San Francisco County, California. Arthr & Rheum. 2017;69(10):1996-2005.
Danchenko, N., Satia, J. A., & Anthony, M. S. (2006). Epidemiology of systemic lupus erythematosus: a comparison of worldwide                disease burden. Lupus, 15(5), 308–318. https://doi.org/10.1191/0961203306lu2305xx
Dang Do N, Umoren RA, Tarvin SE, Heilbrunn BR, Mahajerin A, Bowyer SL. Systemic lupus erythematosus in a 3-month old male presenting as thrombocytopenia. Lupus. 2011;20:527–530.
Dáran S, Apte M, Alarcón GS. Poverty, not ethnicity, accounts for the differential mortality rates among lupus patients of various ethnic groups. Journal of the National Medical Association. October 2007;99(10):1196–1198.
Demir, S., Artim-Esen, B., Şahinkaya, Y., Pehlivan, Ö., Alpay-Kanıtez, N., Omma, A., … İnanç, M. (2016). Metabolic syndrome is not only a risk factor for cardiovascular diseases in systemic lupus erythematosus but is also associated with cumulative organ damage: a cross-sectional analysis of 311 patients. Lupus, 25(2), 177–184. https://doi.org/10.1177/0961203315603140​
DeQuattro K, Trupin L, Li J, et al. Relationships Between Adverse Childhood Experiences and Health Status in Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2020;72(4):525-533. doi:10.1002/acr.23878
Drenkard C, Bao G, Lewis TT, Pobiner B, Priest J, Lim SS. Physician-patient interactions in African American patients with systemic lupus erythematosus: Demographic characteristics and relationship with disease activity and depression. Semin Arthritis Rheum. 2019;48(4):669-677. doi:10.1016/j.semarthrit.2018.05.012​
Drenkard C, Lim SS. Update on lupus epidemiology: advancing health disparities research through the study of minority populations. Curr Opin Rheumatol. 2019;31(6):689-696. doi:10.1097/BOR.0000000000000646​
Drenkard C, Parker S, Aspey LD, et al. Racial Disparities in the Incidence of Primary Chronic Cutaneous Lupus Erythematosus in the Southeastern US: The Georgia Lupus Registry. Arthritis Care Res (Hoboken). 2019;71(1):95-103. doi:10.1002/acr.23578
Dubois EL, Commons RR, Starr P, Stein CS, Morrison R. CORTICOTROPIN AND CORTISONE TREATMENT FOR SYSTEMIC LUPUS ERYTHEMATOSUS. JAMA. 1952;149(11):995–1002. doi:10.1001/jama.1952.02930280017006
Dubois E, ed. (1966). Lupus Erythematosus: A Review of the Current Status of Discoid and Systemic Lupus Erythematosus and Their Variants. New York: McGraw-Hill Book Company; 1966:396-398,403-405.
Durcan L, Clarke WA, Magder LS, Petri M. Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence. J Rheumatol. 2015;42(11):2092-2097. doi:10.3899/jrheum.150379
Falasinnu T, Chaichian Y, Li J, et al. Does SLE widen or narrow race/ethnic disparities in the risk of five co-morbid conditions? Evidence from a community-based outpatient care system. Lupus. 2019;28(14):1619-1627. doi:10.1177/0961203319884646
Falasinnu T, Chaichian Y, Simard JF. Impact of Sex on Systemic Lupus Erythematosus-Related Causes of Premature Mortality in the United States. J Womens Health (Larchmt). 2017;26(11):1214‐1221. doi:10.1089/jwh.2017.6334
Falasinnu T, Chaichian Y, Palaniappan L, Simard JF. Unraveling Race, Socioeconomic Factors, and Geographical Context in the Heterogeneity of Lupus Mortality in the United States. ACR Open Rheumatol. 2019;1(3):164‐172. Published 2019 Apr 29. doi:10.1002/acr2.1024
Falasinnu, T., Rossides, M., Chaichian, Y., & Simard, J. F. (2018). Do Death Certificates Underestimate the Burden of Rare Diseases? The Example of Systemic Lupus Erythematosus Mortality, Sweden, 2001-2013. Public Health Reports, 133(4), 481–488. https://doi.org/10.1177/0033354918777253
Feldman CH, Costenbader KH, Solomon DH, Subramanian SV, Kawachi I. Area-Level Predictors of Medication Nonadherence Among US Medicaid Beneficiaries With Lupus: A Multilevel Study. Arthritis Care Res (Hoboken). 2019;71(7):903-913. doi:10.1002/acr.23721
Feldman CH, Collins J, Zhang Z, et al. Dynamic patterns and predictors of hydroxychloroquine nonadherence among Medicaid beneficiaries with systemic lupus erythematosus. Semin Arthritis Rheum. 2018;48(2):205-213. doi:10.1016/j.semarthrit.2018.01.002
Feldman CH, Yazdany J, Guan H, Solomon DH, Costenbader KH. Medication Nonadherence Is Associated With Increased Subsequent Acute Care Utilization Among Medicaid Beneficiaries With Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2015;67(12):1712-1721. doi:10.1002/acr.22636
Fernández M, Alarcón GS, Calvo-Alén J, Andrade R, McGwin Jr G, Vilá LM, et al. A multiethnic, multicenter cohort
of patients with systemic lupus erythematosus (SLE) as a model for the study of ethnic disparities in SLE. Arthritis & Rheumatism. 2007;57(4):576. Isenberg DA. Male lupus and the Loch Ness syndrome. British Journal of Rheumatology. 1994;33(4):307–308.
Fredi M, Tomasoni F, Andreoli L, et al. DIFFERENCES BETWEEN MALE AND FEMALE PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A SINGLE CENTER EXPERIENCE OVER 20 YEARS OF FOLLOW-UP. Annals of the Rheumatic Diseases 2019;78:797-798.
Freire de Carvalho J, Patrícia do Nascimento A, Testagrossa LA, Barros RT, Bonfá E. Male gender results in more severe lupus nephritis. Rheumatology International. 2010;30(10):1311–1315.
Foraker RE, et al. Socioeconomic status, Medicaid coverage, clinical comorbidity, and rehospitalization or death after an incident heart failure hospitalization: Atherosclerosis Risk in Communities cohort (1987 to 2004). Circ Heart Fail. 2011 May;4(3):308-16. Epub 2011 Mar 23. ​
Fors Nieves CE, Izmirly PM. Mortality in Systemic Lupus Erythematosus: an Updated Review. Current rheumatology reports. 2016;18(4):21. doi:10.1007/s11926-016-0571-2.
Francès C, Cosnes A, Duhaut P, et al. Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study. Arch Dermatol. 2012;148(4):479-484. doi:10.1001/archdermatol.2011.2558
Fulp, Rachael S. MPH; McManus, Katherine D. RD, MS; Johnson, Paula A. MD, MPH Barriers to Purchasing Foods for a High-Quality, Healthy Diet in a Low-Income African American Community, Family & Community Health: July-September 2009 – Volume 32 – Issue 3 – p 206-217 doi: 10.1097/FCH.0b013e3181ab3b1d
Gandelman JS, Khan OA, Shuey MM, et al. Increased Incidence of Resistant Hypertension in Patients With Systemic Lupus Erythematosus: A Retrospective Cohort Study. Arthritis Care Res (Hoboken). 2020;72(4):534-543. doi:10.1002/acr.23880
Gergianaki I, et al. Comparison of urban versus rural environment associated systemic lupus erythematosus (SLE): risk and clinical features. Ann Rheum Dis 2017;76:300.
Gilbert S. “Blood don’t lie”: The diseased family in Flannery O’Connor’s Everything that rises must converge. Literature and Medicine. 1999,18(1):114–131.
Golder V, et al. Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study. The Lancet Rheum 2019;Published online September 6, 2019 https://dx.doi.org/10.1016/S2665-9913(19)30037-2
Gómez-Puerta JA, Barbhaiya M, Guan H, Feldman CH, Alarcón GS, Costenbader KH. Racial/Ethnic variation in all-cause mortality among United States medicaid recipients with systemic lupus erythematosus: a Hispanic and Asian paradox. Arthritis Rheumatol. 2015;67(3):752-760. doi:10.1002/art.38981
González LA, Pons-Estel GJ, Zhang J, et al. Time to neuropsychiatric damage occurrence in LUMINA (LXVI): a multi-ethnic lupus cohort. Lupus. 2009;18(9):822-830. doi:10.1177/0961203309104392
Hanly JG, Kozora E, Beyea SD, Birnbaum J. Review: Nervous System Disease in Systemic Lupus Erythematosus: Current Status and Future Directions. Arthritis Rheumatol. 2019;71(1):33‐42. doi:10.1002/art.40591​
Hardin-Fanning F.  Adherence to a Mediterranean diet in a rural Appalachian food desert. Rural and Remote Health 2013; 13: 2293. Available: www.rrh.org.au/journal/article/2293
Harvey AM, et al. Prognosis chapter in Systemic Lupus Erythematosus. Williams and Wilkins, Baltimore, MD;1955:418-426.
HARVEY, A. McGEHEE; SHULMAN, LAWRENCE E.; TUMULTY, PHILIP A.; CONLEY, C. LOCKARD; SCHOENRICH, EDYTH H. SYSTEMIC LUPUS ERYTHEMATOSUS, Medicine: December 1954 – Volume 33 – Issue 4 – p 291
Hemstreet, BA, Page, RL. Sulphonamide allergies and outcomes related to use of potentially cross-reactive drugs in hospitalized patients. Pharmacotherapy 2006; 26: 551–557.
Hernandez-Cruz B, Alonso F, Calvo Alén J, et al. Differences in clinical manifestations and increased severity of systemic lupus erythematosus between two groups of Hispanics: European Caucasians versus Latin American mestizos (data from the RELESSER registry). Lupus. 2020;29(1):27-36. doi:10.1177/0961203319889667
Hsu C-Y, Chiu W-C, Yang T-S, Chen C-J, Chen Y-C, Lai H-M, et al. Age- and gender-related longterm renal outcome in patients with lupus nephritis. Lupus. 2011;20:1135-1141.
Ingvarsson, R. F., Landgren, A. J., Bengtsson, A. A., & Jönsen, A. (2019). Good survival rates in systemic lupus erythematosus in southern Sweden, while the mortality rate remains increased compared with the population. Lupus, 28(12), 1488–1494. https://doi.org/10.1177/0961203319877947​
Izmirly PM, et al. The incidence and prevalence of systemic lupus erythematosus in New York County (Manhattan), New York. Arth & Rheum. 2017;69(10):2006-2017.
Jeffries, M., Bruner, G., Glenn, S., Sadanandan, P., Carson, C., Harley, J., & Sawalha, A. (2008). Sulpha allergy in lupus patients: a clinical perspective. Lupus, 17(3), 202–205. https://doi.org/10.1177/0961203307086640
JESSAR RA, LAMONT-HAVERS RW, RAGAN C. Natural history of lupus erythematosus disseminatus. Ann Intern Med. 1953;38(4):717-731. doi:10.7326/0003-4819-38-4-717
Jiménez-Alonso J, Jiménez-Jáimez J, Almazán MV. Pollen allergies in patients with systemic lupus erythematosus. Journal of Rheumatology. September 2004;31(9):1873.
Jorge A, McCormick N, Lu N, et al. Hydroxychloroquine and Mortality Among Patients with Systemic Lupus Erythematosus in the General Population [published online ahead of print, 2020 May 14]. Arthritis Care Res (Hoboken). 2020;10.1002/acr.24255. doi:10.1002/acr.24255​
Jorge A, Wallace ZS, Zhang Y, Lu N, Costenbader KH, Choi HK. All-Cause and Cause-Specific Mortality Trends of End-Stage Renal Disease Due to Lupus Nephritis From 1995 to 2014. Arthritis Rheumatol. 2019;71(3):403-410. doi:10.1002/art.40729
Kang KY, Kwok S-K, Ju JH, Park K-S, Cho C-S, Kim H-Y, et al. The causes of death in Korean patients with systemic lupus erythematosus over 11 years. Lupus. 2011;20:989–997.
Kang, J.-H., Xu, H.,
Choi, S.-E., Park, D.-J., Lee, J.-K., Kwok, S.-K., … Lee, S.-S. (2020). Obesity increases the incidence of new-onset lupus nephritis and organ damage during follow-up in patients with systemic lupus erythematosus. Lupus, 29(6), 578–586. https://doi.org/10.1177/0961203320913616​
Kangovi S, et al. Challenges faced by patients with low socioeconomic status during the post-hospital transition. J Gen Intern Med. 2014 Feb;29(2):283-9. Epub 2013 Aug 6. ​
Kaplowitz ET, Ferguson S, Guerra M, et al. Contribution of Socioeconomic Status to Racial/Ethnic Disparities in Adverse Pregnancy Outcomes Among Women With Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2018;70(2):230-235. doi:10.1002/acr.23263
Kheir JM, Guthridge CJ, Johnston JR, et al. Unique clinical characteristics, autoantibodies and medication use in Native American patients with systemic lupus erythematosus. Lupus Sci Med. 2018;5(1):e000247. Published 2018 Feb 27. doi:10.1136/lupus-2017-000247
Klemper P, et al. Pathology of disseminated lupus erythematosus; Arch Pathol Lab Med 32, 569-631, 1941
Koneru S. Kocharla L, Higgins GC, Ware A, Passo M, Farhey Y, et al. Adherence to medications in systemic lupus erythematosus. Journal of Clinical  Rheumatology. August 2008;14(4):195–201.
Lalani S, Pope J, deLeon F, Peschken C. Clinical features and prognosis of late-onset systemic lupus erythematosus: results from the 1000 faces of lupus study. Journal of Rheumatology. 2010;37(1):38–44.
Laustrup H, Voss A, Green A, Junker P. Occurrence of systemic lupus erythematosus in a Danish community: an 8-year prospective study. Scand J Rheumatol. 2009;38(2):128-132. doi:10.1080/03009740802419073
Legge A, Doucette S, Hanly JG. Predictors of Organ Damage Progression and Effect on Health-related Quality of Life in Systemic Lupus Erythematosus. J Rheumatol. 2016;43(6):1050-1056. doi:10.3899/jrheum.150985
Leung J, Elizabeth A Baker, Alfred H J Kim, Exploring intentional medication non-adherence in patients with systemic lupus erythematosus: the role of physician–patient interactions, Rheumatology Advances in Practice, Volume 5, Issue 1, 2021, rkaa078, https://doi.org/10.1093/rap/rkaa078
Li M, Zhang W, Leng X, et al. Chinese SLE Treatment and Research group (CSTAR) registry: I. Major clinical characteristics of Chinese patients with systemic lupus erythematosus. Lupus. 2013;22(11):1192-1199. doi:10.1177/0961203313499086
Li P, Shuker N, Hesselink DA, van Schaik RH, Zhang X, van Gelder T. Do Asian renal transplant patients need another mycophenolate mofetil dose compared with Caucasian or African American patients?. Transpl Int. 2014;27(10):994-1004. doi:10.1111/tri.12382
Lim SS, Helmick CG, Bao G, et al. Racial Disparities in Mortality Associated with Systemic Lupus Erythematosus – Fulton and DeKalb Counties, Georgia, 2002-2016. MMWR Morb Mortal Wkly Rep. 2019;68(18):419-422. Published 2019 May 10. doi:10.15585/mmwr.mm6818a4
Lopez R, Davidson JE, Beeby MD, Egger PJ, Isenberg DA. Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort. Rheumatology (Oxford). 2012;51(3):491-498. doi:10.1093/rheumatology/ker368Lu L-J, Wallace DJ, Ishimori ML, Scofield RH, Weisman MH. Male systemic lupus erythematosus: a review of sex disparities in this disease. Lupus. 2010;19:119–129.
Maningding E, Dall’Era M, Trupin L, Murphy LB, Yazdany J. Racial and Ethnic Differences in the Prevalence and Time to Onset of Manifestations of Systemic Lupus Erythematosus: The California Lupus Surveillance Project. Arthritis Care Res (Hoboken). 2020;72(5):622-629. doi:10.1002/acr.23887
Manzi S, Merrill J. Lupus, the chameleon: many disguises difficult to capture. Arthr & Rheum. 2017;69(10):1921-1924.
Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF; American Academy of Ophthalmology. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmology. 2016;123(6):1386-1394. doi:10.1016/j.ophtha.2016.01.058
Martz CD, Allen AM, Fuller-Rowell TE, et al. Vicarious Racism Stress and Disease Activity: the Black Women’s Experiences Living with Lupus (BeWELL) Study. J Racial Ethn Health Disparities. 2019;6(5):1044-1051. doi:10.1007/s40615-019-00606-8
McDougall JA, Helmick CG, Lim SS, et al. Differences in the diagnosis and management of systemic lupus erythematosus by primary care and specialist providers in the American Indian/Alaska Native population. Lupus. 2018;27(7):1169-1176. doi:10.1177/0961203318763529
Merola JF, Bermas B, Lu B, Karlson EW, Massarotti E, Schur PH, et al. Clinical manifestations and survival among adults with (SLE) according to age at diagnosis. Lupus. 2014;23(8):778–84.
Merrell M, Shulman LE. Determination of prognosis in chronic disease, illustrated by systemic lupus erythematosus. J Chronic Dis. 1955;1(1):12–32.
Miettunen, P.M., Ortiz-Alvarez, O., Petty, R.E. et al. Gender and ethnic origin have no effect on longterm outcome of childhood-onset systemic lupus erythematosus. J Rheumatol. 2004; 31: 1650–1654
Mok CC. Epidemiology and survival of systemic lupus erythematosus in Hong Kong, China. Lupus. 2011;20:767–771.
Montes RA, Mocarzel LO, Lanzieri PG, Lopes LM, Carvalho A, Almeida JR. Smoking and Its Association With Morbidity in Systemic Lupus Erythematosus Evaluated by the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index: Preliminary Data and Systematic Review. Arthritis Rheumatol. 2016;68(2):441-448. doi:10.1002/art.39427​
Morais, S. A., & Isenberg, D. A. (2017). A study of the influence of ethnicity on serology and clinical features in lupus. Lupus, 26(1), 17–26. https://doi.org/10.1177/0961203316645204
Mu, L., Hao, Y., Fan, Y., Huang, H., Yang, X., Xie, A., … Zhang, Z. (2018). Mortality and prognostic factors in Chinese patients with systemic lupus erythematosus. Lupus, 27(10), 1742–1752. https://doi.org/10.1177/0961203318789788
Mundluru SN, Larson AR. Medical dermatologic conditions in transgender women. Int J Womens Dermatol. 2018;4(4):212‐215. Published 2018 Oct 11. doi:10.1016/j.ijwd.2018.08.008​
Muñoz-Grajales, C., González, L. A., Alarcón, G. S., & Acosta-Reyes, J. (2016). Gender differences in disease activity and clinical features in newly diagnosed systemic lupus erythematosus patients. Lupus, 25(11), 1217–1223. https://doi.org/10.1177/0961203316635286
Nusbaum JS, Mirza I, Shum J, et al. Sex Differences in Systemic Lupus Erythematosus: Epidemiology, Clinical Considerations, and Disease Pathogenesis. Mayo Clin Proc. 2020;95(2):384-394. doi:10.1016/j.mayocp.2019.09.012
Ocon, A., Peredo-Wende, R., Kremer, J. M., & Bhatt, B. D. (2018). Significant symptomatic improvement of subacute cutaneous lupus after testosterone therapy in a female-to-male transgender subject. Lupus, 27(2), 347–348. https://doi.org/10.1177/0961203317734921
O’Connor, F. The Habit of Being: Letters of Flannery O’Connor. Fitzgerald S, ed. New York: Farrar, Straus and Giroux; 1988.
Osio-Salido E, Manapat-Reyes H. Epidemiology of systemic lupus erythematosus in Asia. Lupus. 2010;19(12):1365-1373. doi:10.1177/0961203310374305​
Park J, et al. Spontaneous Superior Ophthalmic Vein Thrombosis in a Transgender Man with Systemic Lupus Erythematosus. LGBT Health 2019 6:4, 202-204
Parker, B., & Bruce, I. (2013). SLE and metabolic syndrome. Lupus, 22(12), 1259–1266. https://doi.org/10.1177/0961203313502570
Parks, C., & De Roos, A. (2014). Pesticides, chemical and industrial exposures in relation to systemic lupus erythematosus. Lupus, 23(6), 527–536. https://doi.org/10.1177/0961203313511680
Patterson SL, Schmajuk G, Jafri K, Yazdany J, Katz P. Obesity is Independently Associated With Worse Patient-Reported Outcomes in Women with Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2019;71(1):126-133. doi:10.1002/acr.23576
Peschken CA, Esdaile JM. Systemic lupus erythematosus in North American Indians: a population based study. J Rheumatol. 2000 Aug;27(8):1884-91. PMID: 10955328.
Peschken CA, Katz SJ, Silverman E, Pope JE, Fortin PR, Pineau C, et al. The 1000 Canadian faces of lupus: determinants of disease outcome in a large multiethnic cohort. Journal of Rheumatology. 2009;36(6):1200–1208.
Petri M, Magder LS. Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort. Arthritis Rheumatol. 2018;70(11):1790-1795. doi:10.1002/art.40571
Pickering G, Bywaters EGL, et al. Treatment of Systemic Lupus Erythematosus with Steroids: Report to The Medical Research Council by The Collagen Diseases and Hypersensitivity Panel. Br Med J. 1961;2(5257):915-920.
Polachek A, Gladman DD, Su J, Urowitz MB. Defining Low Disease Activity in Systemic Lupus Erythematosus [published correction appears in Arthritis Care Res (Hoboken). 2019 Apr;71(4):574]. Arthritis Care Res (Hoboken). 2017;69(7):997-1003. doi:10.1002/acr.23109
Pons-Estel, G. J., Aspey, L. D., Bao, G., Pons-Estel, B. A., Wojdyla, D., Saurit, V., … Drenkard, C. (2017). Early discoid lupus erythematosus protects against renal disease in patients with systemic lupus erythematosus: longitudinal data from a large Latin American cohort. Lupus, 26(1), 73–83. https://doi.org/10.1177/0961203316651740
Pons-Estel BA, Catoggio LJ, Cardiel MH, et al. The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among “Hispanics”. Medicine (Baltimore) 2004;83:1–17.
Pontes, L. T., Camilo, D. T., De Bortoli, M. R., Santos, R. S. S., & Luchi, W. M. (2018). New-onset lupus nephritis after male-to-female sex reassignment surgery. Lupus, 27(13), 2166–2169. https://doi.org/10.1177/0961203318800571
Poomsalood, N., Narongroeknawin, P., Chaiamnuay, S., Asavatanabodee, P., & Pakchotanon, R. (2019). Prolonged clinical remission and low disease activity statuses are associated with better quality of life in systemic lupus erythematosus. Lupus, 28(10), 1189–1196. https://doi.org/10.1177/0961203319862614
Pope, J, Jerome, D, Fenlon, D, Krizova, A, Ouimet, J. Frequency of adverse drug reactions in patients with systemic lupus erythematosus. J Rheumatol 2003; 30, 480–484.
Posnick J. Systemic lupus erythematosus: the effect of corticotropin and adrenocorticoid therapy on survival rate. California Medicine. June 1963;98(6):308–312.
Prete PE. Another look at lupus in men. Lupus International. Retrieved 12/22/2013 from lupusinternational.com/About-Lupus-1-1/Men-and-Lupus/Another-Look-at-Men-and-SLE 
Qian, G., Ran, X., Zhou, C. X., Deng, D. Q., Zhang, P. L., Guo, Y., … Cai, M. (2014). Systemic lupus erythematosus patients in the low-latitude plateau of China: altitudinal influences. Lupus, 23(14), 1537–1545. https://doi.org/10.1177/0961203314544186
Renau AI, Isenberg DA. Male versus female lupus: a comparison of ethnicity, clinical features, serology and outcome over a 30 year period. Lupus. September 2012;21(10):1041–1048.
Reppe Moe, S. E., Molberg, Ø., Strøm, E. H., & Lerang, K. (2019). Assessing the relative impact of lupus nephritis on mortality in a population-based systemic lupus erythematosus cohort. Lupus, 28(7), 818–825. https://doi.org/10.1177/0961203319847275
Resende AL, Titan SM, Barros RT, Woronik V. Worse renal outcome of lupus nephritis in male patients: a case-control study. Lupus. 2011;20:561–567.
Riveros Frutos, A., Casas, I., Rúa-Figueroa, I., López-Longo, F. J., Calvo-Alén, J., Galindo, M., … Olivé Marqués, A. (2017). Systemic lupus erythematosus in Spanish males: a study of the Spanish Rheumatology Society Lupus Registry (RELESSER) cohort. Lupus, 26(7), 698–706. https://doi.org/10.1177/0961203316673728​
Ruiz, E., Ramalle-Gómara, E., Elena, Á., Quiñones, C., Alonso, V., & Posada, M. (2014). Trends in systemic lupus erythematosus mortality in Spain from 1981 to 2010. Lupus, 23(4), 431–435. https://doi.org/10.1177/0961203313517015
Santos-Ocampo, AS . New onset systemic lupus erythematosus in a transgender man: Possible role of feminizing sex hormones. J Clin Rheumatol 2007; 13: 29–30.​
Scofield RH, Bruner GR, Namjou B, Kimberly RP, Ramsey-Goldman R, et al. Kline
felter’s syndrome (47,XXY) in male systemic lupus erythematosus patients: support for the notion of a gene-dose effect from the X chromosome. Arthritis & Rheumatism. August 2008;58(8):2511–2517.
Sekigawa I, Yoshiike T, Iida N, Hashimoto H, Ogawa H. Allergic diseases in systemic lupus erythematosus: prevalence and immunological considerations. Clinical and Experimental Rheumatology. 2003;21(1):117–121.
Senecal C, Widmer RJ, Bailey K, Lerman LO, Lerman A. Usage of a Digital Health Workplace Intervention Based on Socioeconomic Environment and Race: Retrospective Secondary Cross-Sectional Study. J Med Internet Res 2018;20(4):e145
Shaharir, S. S., Kadir, W. D. A., Nordin, F., Bakar, F. A., Ting, M. W. H., Jamil, A., … Wahab, A. A. (2019). Systemic lupus erythematosus among male patients in Malaysia: how are we different from other geographical regions? Lupus, 28(1), 137–144. https://doi.org/10.1177/0961203318812676
Sharma, C., Raymond, W., Eilertsen, G. and Nossent, J. (2020), Association of Achieving Lupus Low Disease Activity State Fifty Percent of the Time With Both Reduced Damage Accrual and Mortality in Patients With Systemic Lupus Erythematosus. Arthritis Care Res, 72: 447-451. doi:10.1002/acr.23867
Singh, R. R., & Yen, E. Y. (2018). SLE mortality remains disproportionately high, despite improvements over the last decade. Lupus, 27(10), 1577–1581. https://doi.org/10.1177/0961203318786436
Sohn, I. W., Joo, Y. B., Won, S., & Bae, S. C. (2018). Late-onset systemic lupus erythematosus: Is it “mild lupus”? Lupus, 27(2), 235–242. https://doi.org/10.1177/0961203317716789
Somers EC, Richardson BC. Environmental exposures, epigenetic changes and the risk of lupus. Lupus 2014;23:568-576.
Silva CAA, Bonfá E, Borba EF, Braga AP, Moraes AJP, Saito O, Cocuzza M. Saúde reprodutiva em homens com lupus eritematoso sistemico [Reproductive health in male systemic lupus erythematosus]. Revista Brasileira de Reumatologia. May/June 2009;49(3).
Stefanidou, S., Gerodimos, C., Benos, A., Galanopoulou, V., Chatziyannis, I., Kanakoudi, F., Aslanidis, S., Boura, P., Sfetsios, T., Settas, L., Katsounaros, M., Papadopoulou, D., Giamalis, P., Dombros, N., Chatzistilianou, M., & Garyfallos, A. (2013). Clinical expression and course in patients with late onset systemic lupus erythematosus. Hippokratia, 17(2), 153–156.​
Strom BL, Schinnar R, Apter AJ, et al. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med. 2003;349(17):1628‐1635. doi:10.1056/NEJMoa022963
Styles MM, Moccia P. On Nursing: A Literary Celebration (an Anthology). Evans N, ed. New York: National League for Nursing; 1993:50–52.
Sule S, Fivush B, Neu A, Furth S. Increased risk of death in pediatric and adult patients with ESRD secondary to lupus. Pediatr Nephrol. 2011;26(1):93–8.
Suyama Y, Masato Okada, Ryo Rokutanda, Chisun Min, Belinda Sassé, Daiki Kobayashi, Osamu Takahashi, Gautam A. Deshpande, Kazuo Matsui, Yasushi Kawaguchi & Mitsumasa Kishimoto (2016) Safety and efficacy of upfront graded administration of trimethoprim–sulfamethoxazole in systemic lupus erythematosus: A retrospective cohort study, Modern Rheumatology, 26:4, 557-561, DOI: 10.3109/14397595.2015.1112467
Taddio A, Rossetto E, Rosé CD, et al. Prognostic impact of atypical presentation in pediatric systemic lupus erythematosus: results from a multicenter study. J Pediatr. 2010;156(6):972-977. doi:10.1016/j.jpeds.2009.12.022
Tan TC, Fang H, Magder LS, Petri MA. Differences between male and female systemic lupus erythematosus in a multiethnic population. Journal of Rheumatology. 2012;39(4):759–769.
Tektonidou MG, Lewandowski LB, Hu J, et al. Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016. Annals of the Rheumatic Diseases 2017;76:2009-2016.
Thompson RA. Current status of allergen immunotherapy: shortened version of a World Health Organisation-International Union of Immunological Societies Working Group report. Lancet. 1989;1(8632):259–261.
Tiffin, N., Hodkinson, B., & Okpechi, I. (2014). Lupus in Africa: can we dispel the myths and face the challenges? Lupus, 23(1), 102–111. https://doi.org/10.1177/0961203313509296​
Tselios K, Gladman DD, Sheane BJ, Su J, Urowitz M. All-cause, cause-specific and age-specific standardised mortality ratios of patients with systemic lupus erythematosus in Ontario, Canada over 43 years (1971-2013). Ann Rheum Dis. 2019;78(6):802-806. doi:10.1136/annrheumdis-2018-214802
Tselios K, Gladman DD, Touma Z, Su J, Anderson N, Urowitz MB. Clinical Remission and Low Disease Activity Outcomes Over 10 Years in Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2019;71(6):822-828. doi:10.1002/acr.23720
TUMULTY PA. The clinical course of systemic lupus erythematosus. J Am Med Assoc. 1954;156(10):947-953. doi:10.1001/jama.1954.02950100023009​
van Vollenhoven RF, Navarra SV, Levy RA, et al. Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a Phase III study extension. Rheumatology (Oxford). 2020;59(2):281-291. doi:10.1093/rheumatology/kez279
Urowitz MB, Ibañez D, Jerome D, Gladman DD. The effect of menopause on disease activity in systemic lupus erythematosus. J Rheumatol. 2006;33(11):2192-2198.
Vento S, Cainelli F. Commentary: Systemic Lupus Erythematosus in Native sub-Saharan Africans: A Systematic Review and Meta-Analysis. Front Med (Lausanne). 2020;7:202. Published 2020 May 27. doi:10.3389/fmed.2020.00202
Walsh SJ, DeChello LM. Geographical variation in mortality from systemic lupus erythematosus in the United States. Lupus. 2001;10(9):637-646. doi:10.1191/096120301682430230
Ward MM, Pyun E, Studenski S. Causes of death in systemic lupus erythematosus. Long-term followup of an inception cohort. Arthritis Rheum. 1995 Oct;38(10):1492-9. doi: 10.1002/art.1780381016. PMID: 7575699.
Wilhelm TR, Magder LS, Petri M. Remission in systemic lupus erythematosus: durable remission is rare. Ann Rheum Dis. 2017;76(3):547-553. doi:10.1136/annrheumdis-2016-209489
Yap DY, Chan TM. Lupus Nephritis in Asia: Clinical Features and Management. K
idney Dis (Basel). 2015;1(2):100-109. doi:10.1159/000430458
Yazdany J, Feldman CH, Liu J, Ward MM, Fischer MA, Costenbader KH. Quality of care for incident lupus nephritis among Medicaid beneficiaries in the United States. Arthritis Care Res (Hoboken). 2014;66(4):617-624. doi:10.1002/acr.22182
Yazdany J, Marafino BJ, Dean ML, et al. Thirty-day hospital readmissions in systemic lupus erythematosus: predictors and hospital- and state-level variation. Arthritis Rheumatol. 2014;66(10):2828-2836. doi:10.1002/art.38768
Yelin E, Trupin L, Yazdany J. A Prospective Study of the Impact of Current Poverty, History of Poverty, and Exiting Poverty on Accumulation of Disease Damage in Systemic Lupus Erythematosus. Arthritis Rheumatol. 2017;69(8):1612-1622. doi:10.1002/art.40134
Yelin E, Yazdany J, Trupin L. Relationship Between Poverty and Mortality in Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2018;70(7):1101-1106. doi:10.1002/acr.23428
Yelin E, Yazdany J, Trupin L. Relationship Between Process of Care and a Subsequent Increase in Damage in Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2017;69(6):927-932. doi:10.1002/acr.22977
Yen EY, Shaheen M, Woo JMP, et al. 46-Year Trends in Systemic Lupus Erythematosus Mortality in the United States, 1968 to 2013: A Nationwide Population-Based Study. Ann Intern Med. 2017;167(11):777-785. doi:10.7326/M17-0102]
Yen EY, Singh RR. Brief Report: Lupus-An Unrecognized Leading Cause of Death in Young Females: A Population-Based Study Using Nationwide Death Certificates, 2000-2015. Arthritis Rheumatol. 2018;70(8):1251-1255. doi:10.1002/art.40512
Yurkovich, M., Vostretsova, K., Chen, W. and Aviña‐Zubieta, J.A. (2014), Overall and Cause‐Specific Mortality in Patients With Systemic Lupus Erythematosus: A Meta‐Analysis of Observational Studies. Arthritis Care & Research, 66: 608-616. doi:10.1002/acr.22173
Zandman-Goddard, G, Solomon, M, Barzilai, A, Shoenfeld, Y. Lupus erythematosus tumidus induced by sex reassignment surgery. J Rheumatol 2007; 34: 1938–1940.
Zen M, Bassi N, Nalotto L, Canova M, Bettio S, Gatto M, et al. Disease activity patterns in a monocentric cohort of SLE patients: a seven‐year follow up study. Clin Exp Rheumatol 2012;30:856–63.
Zhang, S., Su, J., Li, X., Zhang, X., Liu, S., Wu, L., … Zeng, X. (2015). Chinese SLE Treatment and Research group (CSTAR) registry: V. gender impact on Chinese patients with systemic lupus erythematosus. Lupus, 24(12), 1267–1275. https://doi.org/10.1177/0961203315585813
Zhao, C.-N., Mei, Y.-J., Wu, G.-C., Mao, Y.-M., Wu, Q., Dan, Y.-L., & Pan, H.-F. (2019). Effect of air pollution on hospital admissions for systemic lupus erythematosus in Bengbu, China: a time series study. Lupus, 28(13), 1541–1548. https://doi.org/10.1177/0961203319882503
Zuckerman RB, et al. Readmissions, Observation, and the Hospital Readmissions Reduction Program. N Engl J Med. 2016;374(16):1543. Epub 2016 Feb 24.
Zusman, E. Z., Sayre, E. C., Aviña-Zubieta, J. A., & De Vera, M. A. (2019). Patterns of medication use before, during and after pregnancy in women with systemic lupus erythematosus: a population-based cohort study. Lupus, 28(10), 1205–1213. https://doi.org/10.1177/0961203319863111

Chapter 20

Abma JC, Martinez GM. Sexual Activity and Contraceptive Use Among Teenagers in the United States, 2011-2015. Natl Health Stat Report. 2017;(104):1-23.
Aggarwal A, Srivastava P. Childhood onset systemic lupus erythematosus: how is it different from adult SLE? Int J Rheum Dis. 2015 Feb;18(2):182-91. doi: 10.1111/1756-185X.12419. Epub 2014 Jun 26. PMID: 24965742.
Al-Abbad AJ, et al. Echocardiography and pulmonary function testing in childhood onset systemic lupus erythematosus. Lupus. 2001;10(1):32. 
Aljaberi N, Nguyen K, Strahle C, Merritt A, Mathur A, Brunner HI. The Performance of the New 2019-EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus in Children and Young Adults. Arthritis Care Res (Hoboken). 2020 Aug 25. doi: 10.1002/acr.24430. Epub ahead of print. PMID: 32841547.
Alonso MD, Martinez-Vazquez F, Diaz de Teran T, Miranda-Filloy JA, Dierssen T, et al. Late onset systemic lupus erythematosus in Northwestern Spain: differences with early onset systemic lupus erythematosus and literature review. Lupus. September 2012;21(10):1135–1148.
Amaral B, et al. A comparison of the outcome of adolescent and adult-onset systemic lupus erythematosus. Rheumatology (Oxford). 2014 Jun;53(6):1130-5. Epub 2014 Feb 6. 
Ambrose N, Morgan TA, Galloway J, et al. Differences in disease phenotype and severity in SLE across age groups. Lupus. 2016;25(14):1542-1550. doi:10.1177/0961203316644333
American College of Rheumatology. Pediatric to Adult Rheumatology Care Transition. https:///www.rheumatology.org/Practice-Quality/Pediatric-to-Adult-Rheumatology-Care-Transition. Accessed November 7,2018.
Ardoin SP, Schanberg LE, Sandborg CI, et al. Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein. Ann Rheum Dis. 2014;73(3):557-566. doi:10.1136/annrheumdis-2012-202315
Arkin LM, Buhr K, Brandling-Bennett H, et al. Practice-based differences in paediatric discoid lupus erythematosus. Br J Dermatol. 2019;181(4):805-810. doi:10.1111/bjd.17780
Arkin LM, Ansell L, Rademaker A, et al. The natural history of pediatric-onset discoid lupus erythematosus. J Am Acad Dermatol. 2015;72(4):628-633. doi:10.1016/j.jaad.2014.12.028
AlE’ed A, Vega-Fernandez P, Muscal E, et al. Challenges of Diagnosing Cognitive Dysfunction With Neuropsychiatric Systemic Lupus Erythematosus in Childhood. Arthritis Care Res (Hoboken). 2017;69(10):1449-1459. doi:10.1002/acr.23163
Azhar AS, et al. Cardiovascular complications in paediatric-onset systemic lupus erythematosus in Saudi Arabian patients. Clin Exp Rheumatol. 2017;35(3):535. Epub 2017 Feb 10. 

Benseler SM, Silverman ED. Neuropsychiatric involvement in pediatric systemic lupus erythematosus. Lupus. 2007;16(8):564-571. doi:10.1177/0961203307078971
Bergstein JM, Wiens C, Fish AJ, Vernier RL, Michael A. Avascular necrosis of bone in systemic lupus erythematosus. J Pediatr. 1974;85(1):31-35. doi:10.1016/s0022-3476(74)80281-7
Bernstein S. Teen patients, tough topics. The Rheumatologist JAN 2020:45.
Boekaerts M, Röder I. Stress, coping, and adjustment in children with a chronic disease: a review of the literature. Disabil Rehabil. 1999 Jul;21(7):311-37. doi: 10.1080/096382899297576. PMID: 10471163.
Borgia RE, Gerstein M, Levy DM, Silverman ED, Hiraki LT. Features, Treatment, and Outcomes of Macrophage Activation Syndrome in Childhood-Onset Systemic Lupus Erythematosus. Arthritis Rheumatol. 2018 Apr;70(4):616-624. doi: 10.1002/art.40417. Epub 2018 Mar 2. PMID: 29342508.
Boros CA, et al. Early determinants of atherosclerosis in paediatric systemic lupus erythematosus. Clin Exp Rheumatol. 2011;29(3):575. Epub 2011 Jun 30. 
Brunner HI, Gladman DD, Ibañez D, Urowitz MD, Silverman ED. Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum. 2008;58(2):556-562. doi:10.1002/art.23204
Bundhun PK, Kumari A, HuangF. Differences in clinical features observed between childhood-onset versus adult-onset systemic lupus erythematosus: A systematic review and meta-analysis. Medicine (Baltimore). 2017;96(37):e8086.
Chang JC, et al. Child-onset systemic lupus erythematosus is associated with a higher incidence of myopericardial manifestations compared to adult-onset disease. Lupus. 2018;27(13):2146. Epub 2018 Oct 14. 
Chang JC, Knight AM, Lawson EF. Patterns of Healthcare Use and Medication Adherence among Youth with Systemic Lupus Erythematosus during Transfer from Pediatric to Adult Care. J Rheumatol. 2020 Feb 1:jrheum.191029. doi: 10.3899/jrheum.191029. Epub ahead of print. PMID: 32007936; PMCID: PMC7394721.
Chehab, G., Sauer, G. M., Richter, J. G., Brinks, R., Willers, R., Fischer-Betz, R., … Schneider, M. (2018). Medical adherence in patients with systemic lupus erythematosus in Germany: predictors and reasons for non-adherence – a cross-sectional analysis of the LuLa-cohort. Lupus, 27(10), 1652–1660. https://doi.org/10.1177/0961203318785245
Clowse ME, Grotegut C. Racial and Ethnic Disparities in the Pregnancies of Women With Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2016;68(10):1567-1572. doi:10.1002/acr.22847
Compeyrot-Lacassagne S, et al. Prevalence and etiology of low bone mineral density in juvenile systemic lupus erythematosus. Arthritis Rheum. 2007;56(6):1966. 
Costa-Reis P, et al. Major infections in a cohort of 120 patients with juvenile-onset systemic lupus erythematosus. Clin Immunol. 2013 Dec;149(3):442-9. Epub 2013 Sep 2. 
das Chagas Medeiros, M. M., Bezerra, M. C., Braga, F. N. H. F., da Justa Feijão, M. R. M., Gois, A. C. R., Rebouças, V. C. do R., … Ribeiro, Á. M. (2016). Clinical and immunological aspects and outcome of a Brazilian cohort of 414 patients with systemic lupus erythematosus (SLE): comparison between childhood-onset, adult-onset, and late-onset SLE. Lupus, 25(4), 355–363. https://doi.org/10.1177/0961203315606983
Davis, A. M., Graham, T. B., Zhu, Y., & McPheeters, M. L. (2018). Depression and medication nonadherence in childhood-onset systemic lupus erythematosus. Lupus, 27(9), 1532–1541. https://doi.org/10.1177/0961203318779710
DeQuattro K, Evans M, Hersh AO, Yazdany J, von Scheven E, Lawson E. A quality update: improved transfer time among rheumatology patients transferring from pediatric to adult care at an academic medical center. Paper presented at: 2018 ACR/ARHP Annual Meeting; October 19-24, 2018; Chicago, IL. https://acrabstracts.org/abstract/a-quality-update-improved-transfer-time-among-rheumatology-patients-transferring-from-pediatric-to-adult-care-at-an-academic-medical-center/. Accessed October 24, 2018.
Dowshen S. Preparing your child for visits to the doctor. KidsHealth from Nemours. Retrieved 8/8/20 from https://kidshealth.org/en/parents/dr-visits.html?WT.ac=ctg
Eberhard BA. “I said no”. The Rheumatologist JAN 2020:58.
Felsenstein S, Reiff AO, Ramanathan A. Transition of Care and Health-Related Outcomes in Pediatric-Onset Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2015;67(11):1521-1528. doi:10.1002/acr.22611
Fernandes EC, Silva CA, Braga AL, Sallum AM, Campos LM, Farhat SC. Exposure to Air Pollutants and Disease Activity in Juvenile-Onset Systemic Lupus Erythematosus Patients. Arthritis Care Res (Hoboken). 2015;67(11):1609-1614. doi:10.1002/acr.22603
Ferraz MB, Goldenberg J, Hilario MO, et al. Evaluation of the 1982 ARA lupus criteria data set in pediatric patients. Committees of Pediatric Rheumatology of the Brazilian Society of Pediatrics and the Brazilian Society of Rheumatology. Clin Exp Rheumatol. 1994;12(1):83-87.
Frittoli R, Marini R, Costallat L, et al. Impact of the birth month in the development of systemic lupus erythematosus. Lupus Science & Medicine 2019;6:doi: 10.1136/lupus-2019-lsm.206
Golden NH, Abrams SA; Committee on Nutrition. Optimizing bone health in children and adolescents. Pediatrics. 2014;134(4):e1229-e1243. doi:10.1542/peds.2014-2173
Gomes RC, Silva MF, Kozu K, et al. Features of 847 Childhood-Onset Systemic Lupus Erythematosus Patients in Three Age Groups at Diagnosis: A Brazilian Multicenter Study. Arthritis Care Res (Hoboken). 2016;68(11):1736-1741. doi:10.1002/acr.22881
Gormezano NW, Silva CA, Aikawa NE, et al. Chronic arthritis in systemic lupus erythematosus: distinct features in 336 paediatric and 1830 adult patients. Clin Rheumatol. 2016;35(1):227-231. doi:10.1007/s10067-015-3127-3
Got Transition. The National Alliance to Advance Adolescent Health. www.gottransition.org
Groot N, Kardolus A, Bijl M, Dolhain R, Teng O, Zirkzee E, de Leeuw K, Fritsch-Stork R, Burdorf L, Bultink I, Kamphuis S. Effects of childhood-onset SLE on academic achievements and employment in adult life. J Rheumatol. 2020 Aug 1:jrheum.191004. doi: 10.3899/jrheum.191004. Epub ahead of print. PMID: 32739896.
Groot N, Shaikhani D, Teng YKO, et al. Long-Term Clinical Outcomes in a Cohort of Adults With Childhood-Onset Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019;71(2):290-301. doi:10.1002/art.40697
Guevara JP, et al. Point prevalence of cardiac abnormalities in children with systemic lupus erythematosus. J Rheumatol. 2001;28(4):854. 
Hagan JF Jr, Shaw JS, Duncan P, eds. Bright Futures: Guidelines for the Health Supervision of Infants, Children, and Adolescents. 3rd ed. Elk Grove Village, IL: American Academy of Pediatrics; 2008
Hagelberg S, Lee Y, Bargman J, et al. Longterm followup of childhood lupus nephritis. J Rheumatol. 2002;29(12):2635-2642.
Harry, O., Crosby, L. E., Smith, A. W., Favier, L., Aljaberi, N., Ting, T. V., … Modi, A. C. (2019). Self-management and adherence in childhood-onset systemic lupus erythematosus: what are we missing? Lupus, 28(5), 642–650. https://doi.org/10.1177/0961203319839478
Hersh AO, von Scheven E, Yazdany J, Panopalis P, Trupin L, Julian L, et al. Differences in long‐term disease activity and treatment of adult patients with childhood‐ and adult‐onset systemic lupus erythematosus. Arthritis Rheum 2009; 61: 13– 20.
Heshin-Bekenstein M, Perl L, Hersh AO, von Scheven E, Yelin E, Trupin L, Yazdany J, Lawson EF. Final adult height of patients with childhood-onset systemic lupus erythematosus: a cross sectional analysis. Pediatr Rheumatol Online J. 2018 Apr 23;16(1):30. doi: 10.1186/s12969-018-0239-8. PMID: 29688869; PMCID: PMC5913867.
Heshin-Bekenstein M, Trupin L, Yelin E, von Scheven E, Yazdany J, Lawson EF. Longitudinal disease- and steroid-related damage among adults with childhood-onset systemic lupus erythematosus. Semin Arthritis Rheum. 2019 Oct;49(2):267-272. doi: 10.1016/j.semarthrit.2019.05.010. Epub 2019 Jun 3. PMID: 31235075; PMCID: PMC7480934.
Hiraki LT, et al. Serious Infection Rates Among Children With Systemic Lupus Erythematosus Enrolled in Medicaid. Arthritis Care Res (Hoboken). 2017;69(11):1620. Epub 2017 Sep 21. 
Hiraki LT, Feldman CH, Liu J, et al. Prevalence, incidence, and demographics of systemic lupus erythematosus and lupus nephritis from 2000 to 2004 among children in the US Medicaid beneficiary population. Arthritis Rheum. 2012;64(8):2669-2676. doi:10.1002/art.34472
Hollander MC, Sage JM, Greenler AJ, et al. International consensus for provisions of quality-driven care in childhood-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2013;65(9):1416-1423. doi:10.1002/acr.21998
International Society of Clinical Densitometry. 2019 ISCD Official Positions: Pediatric. 2019
Irving KS, Sen D, Tahir H, Pilkington C, Isenberg DA. A comparison of autoimmune liver disease in juvenile and adult populations with systemic lupus erythematosus-a retrospective review of cases. Rheumatology (Oxford). 2007;46(7):1171-1173. doi:10.1093/rheumatology/kem108
Jancin B. Young lupus patients need more than medications. MDedge.com Rheumatology May 2019:23.
Johnson K. Hallucinations common in pediatric lupus. Rheumatology News. March 2010;9(3):22–23.
Joo YB, Park SY, Won S, Bae SC. Differences in Clinical Features and Mortality between Childhood-onset and Adult-onset Systemic Lupus Erythematosus: A Prospective Single-center Study. J Rheumatol. 2016;43(8):1490-1497. doi:10.3899/jrheum.151129
Jüptner M, Flachsbart F, Caliebe A, et al. Low copy numbers of complement C4 and homozygous deficiency of C4A may predispose to severe disease and earlier disease onset in patients with systemic lupus erythematosus. Lupus. 2018;27(4):600-609. doi:10.1177/0961203317735187
Kamphuis S, Silverman ED. Prevalence and burden of pediatric-onset systemic lupus erythematosus. Nat Rev Rheumatol. 2010;6(9):538-546. doi:10.1038/nrrheum.2010.121
Kann L, McManus T, Harris WA, et al. Youth Risk Behavior Surveillance – United States, 2017. MMWR Surveill Summ. 2018;67(8):1-114. Published 2018 Jun 15. doi:10.15585/mmwr.ss6708a1
King KK, Kornreich HK, Bernstein BH, Singsen BH, Hanson V. The clinical spectrum of systemic lupus erythematosus in childhood. Arthritis Rheum. 1977;20(2 Suppl):287-294.
Knight AM, Trupin L, Katz P, Yelin E, Lawson EF. Depression Risk in Young Adults With Juvenile- and Adult-Onset Lupus: Twelve Years of Followup. Arthritis Care Res (Hoboken). 2018;70(3):475-480. doi:10.1002/acr.23290
Knight A, Weiss P, Morales K, Gerdes M, Gutstein A, Vickery M, Keren R. Depression and anxiety and their association with healthcare utilization in pediatric lupus and mixed connective tissue disease patients: a cross-sectional study. Pediatr Rheumatol Online J. 2014 Sep 10;12:42. doi: 10.1186/1546-0096-12-42. PMID: 25242900; PMCID: PMC4169806.
Lawson EF, Hersh AO, Trupin L, et al. Educational and vocational outcomes of adults with childhood- and adult-onset systemic lupus erythematosus: nine years of followup. Arthritis Care Res (Hoboken). 2014;66(5):717-724. doi:10.1002/acr.22228
Lehman TJ, et al. Systemic lupus erythematosus in the first decade of life. Pediatrics. 1989;83(2):235. 
Lehman JAT, Taber SF, Nuruzzaman F. (2019). Systemic Lupus Erythematosus in Childhood and Adolescence. In D Wallace and B Hahn (Eds.), Dubois’ Lupus Erythematosus and Related Syndromes (pp.520-531). New York, New York: Elsevier.
Levy DM. Continuum of lupus care: childhood-onset SLE brings distinct challenges at each phase of life. The Rheumatologist 2014;8(1):1, 24-26.
Levy DM, Kamphuis S. Systemic lupus erythematosus in children and adolescents. Pediatr Clin North Am. 2012 Apr;59(2):345-64. doi: 10.1016/j.pcl.2012.03.007. PMID: 22560574; PMCID: PMC3348509.
Levy DM, Peschken CA, Tucker LB, et al. Influence of ethnicity on childhood-onset systemic lupus erythematosus: results from a multiethnic multicenter Canadian cohort. Arthritis Care Res (Hoboken). 2013;65(1):152-160. doi:10.1002/acr.21779
Lieberman S. “Ask The Board” in Conquering Sjogren’s, Sjogren’s Foundation MAY/JUN 2020:6-8.
Lim SH, et al. Low bone mineral density is present in newly diagnosed paediatric systemic lupus erythematosus patients. Ann Rheum Dis. 2011;70(11):1991. Epub 2011 Sep 13.

Lim SH, et al. Predicting longitudinal trajectory of bone mineral density in paediatric systemic lupus erythematosus patients. Ann Rheum Dis. 2012;71(10):1686. Epub 2012 Mar 22.
Lim LS, Lefebvre A, Benseler S, Peralta M, Silverman ED. Psychiatric illness of systemic lupus erythematosus in childhood: spectrum of clinically important manifestations. J Rheumatol. 2013;40(4):506-512. doi:10.3899/jrheum.120675
Lim, L.S.H., Pullenayegum, E., Lim, L., Gladman, D., Feldman, B. and Silverman, E. (2017), From Childhood to Adulthood: The Trajectory of Damage in Patients With Juvenile‐Onset Systemic Lupus Erythematosus. Arthritis Care Res, 69: 1627-1635. doi:10.1002/acr.23199
Livingston B, Bonner A, Pope J. Differences in clinical manifestations between childhood onset lupus and adult-onset lupus: a meta-analysis. Lupus. 2011;20:1345–1355.
Lopes SRM, et al. Outcomes of 847 childhood-onset systemic lupus erythematosus patients in three age groups. Lupus. 2017;26(9):996. Epub 2017 Jan 29. 
Luders E, Thompson PM, Kurth F. Larger hippocampal dimensions in meditation practitioners: differential effects in women and men. Front Psychol. 2015;6:186. Published 2015 Mar 6. doi:10.3389/fpsyg.2015.00186
Lupus Foundation of America. 2019 Lupus Awareness Survey. Retrieved on 7/4/20 at www.lupus.org/news/2019-lupus-awareness-survey-summary
Lupus Foundation of America. Assistance at school for children with lupus. Retrieved on 8/9/20 at www.lupus.org/resources/assistance-at-school-for-children-with-lupus
Lupus Foundation of America. Lupus at school. Retrieved on 8/9/20 at www.lupus.org/resources/lupus-at-school-a-guide-for-parents-and-kids#
Lythgoe H, Morgan T, Heaf E, Lloyd O, Al-Abadi E, Armon K, Bailey K, Davidson J, Friswell M, Gardner-Medwin J, Haslam K, Ioannou Y, Leahy A, Leone V, Pilkington C, Rangaraj S, Riley P, Tizard EJ, Wilkinson N, Beresford MW; UK JSLE Study Group. Evaluation of the ACR and SLICC classification criteria in juvenile-onset systemic lupus erythematosus: a longitudinal analysis. Lupus. 2017 Oct;26(12):1285-1290. doi: 10.1177/0961203317700484. Epub 2017 Mar 31. PMID: 28361566.
Massias, J. S., Smith, E. M. D., Al-Abadi, E., Armon, K., Bailey, K., Ciurtin, C., … Hedrich, C. M. (2020). Clinical and laboratory characteristics in juvenile-onset systemic lupus erythematosus across age groups. Lupus, 29(5), 474–481. https://doi.org/10.1177/0961203320909156

McDonald, J., Vega-Fernandez, P. & Ting, T. Findings and feasibility of major salivary gland ultrasound in childhood-onset systemic lupus erythematosus: a pilot study. Pediatr Rheumatol 19, 73 (2021). https://doi.org/10.1186/s12969-021-00561-x
McGill M. Lieberman S. “Ask The Board” in Conquering Sjogren’s, Sjogren’s Foundation MAY/JUN 2020:8.
Miller G, Merlo C, Demissie Z, Sliwa S, Park S. Trends in Beverage Consumption Among High School Students — United States, 2007–2015. MMWR Morb Mortal Wkly Rep 2017;66:112–116. DOI: https://dx.doi.org/10.15585/mmwr.mm6604a5
Mina R, Brunner HI. Pediatric lupus–are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus? Rheum Dis Clin North Am. 2010 Feb;36(1):53-80, vii-viii. doi: 10.1016/j.rdc.2009.12.012. PMID: 20202591; PMCID: PMC2837537.
Mina R, Brunner HI. Update on differences between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Res Ther. 2013 Aug 21;15(4):218. doi: 10.1186/ar4256. PMID: 23998441; PMCID: PMC3978647.
McCurdy DK, Lehman TJ, Bernstein B, et al. Lupus nephritis: prognostic factors in children. Pediatrics. 1992;89(2):240-246.
Monitoring the future: 2018 study results. National Institute on Drug Abuse, NIH. https:///www.drugabuse.gov/drug-topics/trends-statistics/infographics/monitoring-future-2018-survey-results
Moorthy, L., Peterson, M., Hassett, A., Baratelli, M., & Lehman, T. (2010). Impact of lupus on school attendance and performance. Lupus, 19(5), 620–627. https://doi.org/10.1177/0961203309355810
Morgan TA, Watson L, McCann LJ, Beresford MW. Children and adolescents with SLE: not just little adults. Lupus. 2013;22(12):1309-1319. doi:10.1177/0961203313502863
Muscal E, Brey RL. Neurologic manifestations of systemic lupus erythematosus in children and adults. Neurol Clin. 2010;28(1):61-73. doi:10.1016/j.ncl.2009.09.004
Neely J, von Scheven E. Autoimmune haemolytic anaemia and autoimmune thrombocytopenia in childhood-onset systemic lupus erythematosus: updates on pathogenesis and treatment. Curr Opin Rheumatol. 2018;30(5):498-505. doi:10.1097/BOR.0000000000000523
Novak GV, et al. Anti-RO/SSA and anti-La/SSB antibodies: Association with mild lupus manifestations in 645 childhood-onset systemic lupus erythematosus. Autoimmun Rev. 2017;16(2):132. Epub 2016 Dec 14. 
Novak GV, et al. Characteristics of 1555 childhood-onset lupus in three groups based on distinct time intervals to disease diagnosis: a Brazilian multicenter study. Lupus. 2018;27(10):1712. Epub 2018 Jul 18. 
Oni L, Wright RD, Marks S, Beresford MW, Tullus K. Kidney outcomes for children with lupus nephritis. Pediatr Nephrol. 2020 Jul 28. doi: 10.1007/s00467-020-04686-1. Epub ahead of print. PMID: 32725543.
Parodi A, Davì S, Pringe AB, Pistorio A, Ruperto N, Magni-Manzoni S, Miettunen P, Bader-Meunier B, Espada G, Sterba G, Ozen S, Wright D, Magalhães CS, Khubchandani R, Michels H, Woo P, Iglesias A, Guseinova D, Bracaglia C, Hayward K, Wouters C, Grom A, Vivarelli M, Fischer A, Breda L, Martini A, Ravelli A; Lupus Working Group of the Paediatric Rheumatology European Society. Macrophage activation syndrome in juvenile systemic lupus erythematosus: a multinational multicenter study of thirty-eight patients. Arthritis Rheum. 2009 Nov;60(11):3388-99. doi: 10.1002/art.24883. PMID: 19877067.
Pereira T, Abitbol CL, Seeherunvong W, et al. Three decades of progress in treating childhood-onset lupus nephritis. Clin J Am Soc Nephrol. 2011;6(9):2192-2199. doi:10.2215/CJN.00910111
Peschken CA, Katz SJ, Silverman E, Pope JE, Fortin PR, Pineau C, et al. The 1000 Canadian faces of lupus: determinants of disease outcome in a large multiethnic cohort. Journal of Rheumatology. 2009;36(6):1200–1208.
Peterknecht, E., Keasey, M. P., & Beresford, M. W. (2018). The effectiveness and safety of biological therapeutics in juvenile-onset systemic lupus erythematosus (JSLE): a systematic re
view. Lupus, 27(13), 2135–2145. https://doi.org/10.1177/0961203318804879
Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-2686. doi:10.1002/art.34473
Platt JL, Burke BA, Fish AJ, Kim Y, Michael AF. Systemic lupus erythematosus in the first two decades of life. American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation. 1982 Jul;2(1 Suppl 1):212-222.
Quilter MC, Hiraki LT, Korczak DJ. Depressive and anxiety symptom prevalence in childhood-onset systemic lupus erythematosus: A systematic review. Lupus. 2019 Jun;28(7):878-887. doi: 10.1177/0961203319853621. PMID: 31188723.
Reichlin M, et al. Prevalence of autoantibodies to ribosomal P proteins in juvenile-onset systemic lupus erythematosus compared with the adult disease. Arthritis Rheum. 1999;42(1):69. 
Richer O, Ulinski T, Lemelle I, et al. Abdominal manifestations in childhood-onset systemic lupus erythematosus. Ann Rheum Dis. 2007;66(2):174-178. doi:10.1136/ard.2005.050070
Rodrigues FA, et al. Comparison among ACR1997, SLICC and the new EULAR/ACR classification criteria in childhood-onset systemic lupus erythematosus. Adv Rheumatol. 2019;59(1):20. Epub 2019 May 15. 
Sabbagh S, Ronis T, White PH. Pediatric rheumatology: addressing the transition to adult-orientated health care. Open Access Rheumatol. 2018 Jul 3;10:83-95. doi: 10.2147/OARRR.S138370. PMID: 30013406; PMCID: PMC6037274.
Sadun RE, Schanberg LE. Transition and transfer of the patient with paediatric-onset lupus: a practical approach for paediatric and adult rheumatology practices. Lupus Science & Medicine 2018;5:e000282. doi: 10.1136/lupus-2018-000282
Scalzi, L.V., Hollenbeak, C.S., Mascuilli, E. et al. Improvement of medication adherence in adolescents and young adults with SLE using web-based education with and without a social media intervention, a pilot study. Pediatr Rheumatol 16, 18 (2018). https://doi.org/10.1186/s12969-018-0232-2
Schanberg LE, Sandborg C, Barnhart HX, et al. Use of atorvastatin in systemic lupus erythematosus in children and adolescents. Arthritis Rheum. 2012;64(1):285-296. doi:10.1002/art.3064
Schuetz C, Prieur AM, Quartier P. Sicca syndrome and salivary gland infiltration in children with autoimmune disorders: when can we diagnose Sjögren syndrome?. Clin Exp Rheumatol. 2010;28(3):434-439.
Sinicato NA, de Oliveira L, Lapa A, et al. Familial Aggregation of Childhood- and Adulthood-Onset Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2020;72(8):1147-1151. doi:10.1002/acr.23931
Son, M. B., Sergeyenko, Y., Guan, H., & Costenbader, K. (2016). Disease activity and transition outcomes in a childhood-onset systemic lupus erythematosus cohort. Lupus, 25(13), 1431–1439. https://doi.org/10.1177/0961203316640913
Sontichai W, Liao F, Dominguez D, Levy DM, Al Mutairi M, Ng L, Silverio F, Silverman ED, Wasserman JD, Hiraki LT. Timing of Childhood-onset Systemic Lupus Erythematosus Diagnosis Relative to Menarche Impacts Final Height. Arthritis Care Res (Hoboken). 2020 Sep 25. doi: 10.1002/acr.24461. Epub ahead of print. PMID: 32976694.
Sule S, Fivush B, Neu A, Furth S. Increased risk of death in pediatric and adult patients with ESRD secondary to lupus. Pediatr Nephrol. 2011;26(1):93–8.
Tektonidou MG, Lewandowski LB, Hu J, et al. Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016. Annals of the Rheumatic Diseases 2017;76:2009-2016.
Torreggiani S, Torcoletti M, Cuoco F, Di Landro G, Petaccia A, Corona F. Chorea, a little-known manifestation in systemic lupus erythematosus: short literature review and four case reports. Pediatr Rheumatol Online J. 2013;11(1):36. Published 2013 Oct 16. doi:10.1186/1546-0096-11-36
Trapani S, et al. Pulmonary involvement in juvenile systemic lupus erythematosus: a study on lung function in patients asymptomatic for respiratory disease. Lupus. 1998;7(8):545. 
Ugarte-Gil, M. F., González, L. A., & Alarcón, G. S. (2019). Lupus: the new epidemic. Lupus, 28(9), 1031–1050. https://doi.org/10.1177/0961203319860907
University of Michigan. Your Child Development & Behavior Resources: A guide to information & support for parents. Retrieved on 7/5/20 from https:///www.med.umich.edu/yourchild/topics/chronic.htm
Wang Z, Wang Y, Zhu R, et al. Long-term survival and death causes of systemic lupus erythematosus in China: a systemic review of observational studies. Medicine (Baltimore). 2015;94(17):e794. doi:10.1097/MD.0000000000000794
Wang LC, Yang YH, Lu MY, Chiang BL. Retrospective analysis of the renal outcome of pediatric lupus nephritis. Clin Rheumatol. 2004;23(4):318-323. doi:10.1007/s10067-004-0919-2
Wenderfer SE, Eldin KW. Lupus Nephritis. Pediatr Clin North Am. 2019 Feb;66(1):87-99. doi: 10.1016/j.pcl.2018.08.007. PMID: 30454753.
White PH, Cooley WC, Transitions Clinical Report Authoring Group, et al. Supporting the health care transition from adolescence to adulthood in the medical home [Published online October 22, 2018]. Pediatrics. https://pediatrics.aappublications.org/content/142/5/e20182587.
Yen EY, Singh RR. Brief Report: Lupus-An Unrecognized Leading Cause of Death in Young Females: A Population-Based Study Using Nationwide Death Certificates, 2000-2015. Arthritis Rheumatol. 2018;70(8):1251-1255. doi:10.1002/art.40512
Yokogawa N, Lieberman SM, Sherry DD, Vivino FB. Features of childhood Sjögren’s syndrome in comparison to adult Sjögren’s syndrome: considerations in establishing child-specific diagnostic criteria. Clin Exp Rheumatol. 2016;34(2):343-351
Zulian F, Pluchinotta FR, Martini G, Da Dalt L, Zachello G. Severe clinical course of systemic lupus erythematosus in the first year of life. Lupus. 2008;17:780–786.

Chapter 21

Abbasi J. TMAO and Heart Disease: The New Red Meat Risk?. JAMA. 2019;321(22):2149-2151. doi:10.1001/jama.2019.3910
Akdogan A, Kilic L, Akman U, et al. Aspirin resistance in systemic lupus erythematosus. A pilot study. Lupus. 2013;22(8):835-838. doi:10.1177/0961203313493487
American Diabetes Association. Standards of medical care in diabetes–2013. Diabetes Care. 2013;36 Suppl 1(Suppl 1):S11-S66. doi:10.2337/dc13-S011
Andrades C, Fuego C, Manrique-Arija S, Fernández-Nebro A. Management of cardiovascular risk in systemic lupus erythematosus: a systematic review. Lupus. 2017;26(13):1407-1419. doi:10.1177/0961203317704710
Apostolopoulos D, Vincent F, Hoi A, et alAssociations of metabolic syndrome in SLELupus Science & Medicine 2020;7:e000436. doi: 10.1136/lupus-2020-000436
Arkema EV, Svenungsson E, Von Euler M, Sjöwall C, Simard JF. Stroke in systemic lupus erythematosus: a Swedish population-based cohort study. Ann Rheum Dis. 2017;76(9):1544-1549. doi:10.1136/annrheumdis-2016-210973
Avar Aydin PO, Shan J, Brunner HI, Mitsnefes MM. Blood pressure control over time in childhood-onset systemic lupus erythematous. Lupus. 2018;27(4):657-664. doi:10.1177/0961203317751061
Aviña-Zubieta JA, To F, Vostretsova K, De Vera M, Sayre EC, Esdaile JM. Risk of Myocardial Infarction and Stroke in Newly Diagnosed Systemic Lupus Erythematosus: A General Population-Based Study. Arthritis Care Res (Hoboken). 2017;69(6):849-856. doi:10.1002/acr.23018
Barbhaiya M, Feldman CH, Chen SK, et al. Comparative Risks of Cardiovascular Disease in Systemic Lupus Erythematosus, Diabetes and General Medicaid Patients [published online ahead of print, 2020 May 31]. Arthritis Care Res (Hoboken). 2020;10.1002/acr.24328. doi:10.1002/acr.24328
Barbhaiya M, Feldman CH, Guan H, et al. Race/Ethnicity and Cardiovascular Events Among Patients With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2017;69(9):1823-1831. doi:10.1002/art.40174
Bartels CM, Buhr KA, Goldberg JW, et al. Mortality and cardiovascular burden of systemic lupus erythematosus in a US population-based cohort. J Rheumatol. 2014;41(4):680-687. doi:10.3899/jrheum.130874
Bengtsson C, Öhman M-L, Nived O, Rantapää Dahlqvist S. Cardiovascular event in systemic lupus erythematosus in northern Sweden: incidence and predictors in a 7-year follow-up study. Lupus. April 2012;21(4):452–459.
Bentley, RA, Damian J. Ruck, Hillary N. Fouts. U.S. obesity as delayed effect of excess sugar. Economics & Human Biology, 2019; 100818 DOI: 10.1016/j.ehb.2019.100818
Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, et al. Mortality in systemic lupus erythematosus. Arthritis & Rheumatism. August 2006;54(8):2550–2557.
Bili A, Tang X, Pranesh S, et al. Tumor necrosis factor α inhibitor use and decreased risk for incident coronary events in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014;66(3):355-363. doi:10.1002/acr.22166
Cairoli E, Rebella M, Danese N, Garra V, Borba EF. Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect. Lupus. October 2012;21(11):1178–1182.
Callaghan BC, Gao L, Li Y, et al. Diabetes and obesity are the main metabolic drivers of peripheral neuropathy. Ann Clin Transl Neurol. 2018;5(4):397-405. Published 2018 Feb 14. doi:10.1002/acn3.531
Centers for Disease Control and Prevention. Electronic cigarettes: What’s the bottom line? Retrieved 9/3/20 from https:///www.cdc.gov/tobacco/basic_information/e-cigarettes/pdfs/Electronic-Cigarettes-Infographic-508.pdf
Chen SK, Barbhaiya M, Solomon DH, et al. Atrial Fibrillation/flutter Hospitalizations among US Medicaid Recipients with and without Systemic Lupus Erythematosus [published online ahead of print, 2019 Nov 1]. J Rheumatol. 2019;jrheum.190502. doi:10.3899/jrheum.190502

Chen WH, Jin W, Lyu PY, Liu Y, Li R, Hu M, Xiao XJ. Carotid Atherosclerosis and Cognitive Impairment in Nonstroke Patients. Chin Med J (Engl). 2017 Oct 5;130(19):2375-2379. doi: 10.4103/0366-6999.215331. PMID: 28937045; PMCID: PMC5634090.
Cohen JB, Lotito MJ, Trivedi UK, Denker MG, Cohen DL, Townsend RR. Cardiovascular Events and Mortality in White Coat Hypertension: A Systematic Review and Meta-analysis. Ann Intern Med. 2019;170(12):853-862. doi:10.7326/M19-0223
Dalal DS. et al. A Comprehensive Review of NSAID Cardiovascular Toxicity. The Rheumatologist MAR 2019:28-29.
De Jong HJI, van Staa TP, Lalmohamed A, et al. Pattern of risks of systemic lupus erythematosus among statin users: a population-based cohort study. Ann Rheum Dis. 2017;76(10):1723-1730. doi:10.1136/annrheumdis-2016-210936
Demir S, Artim-Esen B, Şahinkaya Y, et al. Metabolic syndrome is not only a risk factor for cardiovascular diseases in systemic lupus erythematosus but is also associated with cumulative organ damage: a cross-sectional analysis of 311 patients. Lupus. 2016;25(2):177-184. doi:10.1177/0961203315603140
Durán S, Apte M, Alarcón GS. Poverty, not ethnicity, accounts for the differential mortality rates among lupus patients of various ethnic groups. Journal of the National Medical Association. October 2007;99(10):1196–1198. Endocrinology Today. DXA more accurately predicts obesity compared with BMI. Diabetes
and Metabolism. April 23, 2010. Retrieved May 22, 2011, from www.endocrinetoday.com/ view.aspx?rid=63584.
Eren E, Yilmaz N, Aydin O. High Density Lipoprotein and it’s Dysfunction. Open Biochem J. 2012;6:78-93. doi:10.2174/1874091X01206010078
Estruch R, Casas R, Ros E. Eat Even More Vegetables and Fruits to Protect Your Heart. Ann Intern Med. 2020;172(12):826-827. doi:10.7326/M20-2504
Fasano S, Pierro L, Pantano I, Iudici M, Valentini G. Longterm Hydroxychloroquine Therapy and Low-dose Aspirin May Have an Additive Effectiveness in the Primary Prevention of Cardiovascular Events in Patients with Systemic Lupus Erythematosus. J Rheumatol. 2017;44(7):1032-1038. doi:10.3899/jrheum.161351
Fasano S, Margiotta DP, Navarini L, et al. Primary prevention of cardiovascular disease in patients with systemic lupus erythematosus: case series and literature review. Lupus. 2017;26(14):1463-1472. doi:10.1177/0961203317722847
Fernandes A, McEvoy JW, Halvorsen S. “Doctor, Should I Keep Taking an Aspirin a Day?”. N Engl J Med. 2019;380(20):1967-1970. doi:10.1056/NEJMclde1903004
Fernández-Nebro A, Marenco JL, López-Longo F, et al. The effects of rituximab on the lipid profile of patients with active systemic lupus erythematosus: results from a nationwide cohort in Spain (LESIMAB). Lupus. 2014;23(10):1014-1022. doi:10.1177/0961203314534909
Fessler BJ, McGwin Jr G, Alarcón GS, Roseman JM, Bastian HM, Friedman AW, et al. Hydroxychloroquine (HCQ) usage is associated with decreased renal and cardiovascular damage in patients with systemic lupus erythematosus (S
LE). Arthritis & Rheumatism. September 2001;44(S9):S201.
Flint AC, Conell C, Ren X, et al. Effect of Systolic and Diastolic Blood Pressure on Cardiovascular Outcomes. N Engl J Med. 2019;381(3):243-251. doi:10.1056/NEJMoa1803180
Frei R. Newly diagnosed lupus patients have higher stroke risk. Pain Medicine News JUN 2014:1-2.
Frostegård J, Svenungsson E, Wu R, Gunnarsson I, Lundberg IE, Klareskog L, et al. Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations. Arthritis Rheum 2005;52:192–200.
Fulton RL, Walters MR, Morton R, et al. Acetaminophen use and risk of myocardial infarction and stroke in a hypertensive cohort. Hypertension. 2015;65(5):1008-1014. doi:10.1161/HYPERTENSIONAHA.114.04945
Gabriel IU. Obesity. Medscape. April 19, 2011. Retrieved May 22, 2011, from www.emedicine. medscape.com/article/123702–overview.
Gandelman JS, Khan OA, Shuey MM, et al. Increased Incidence of Resistant Hypertension in Patients With Systemic Lupus Erythematosus: A Retrospective Cohort Study. Arthritis Care Res (Hoboken). 2020;72(4):534-543. doi:10.1002/acr.23880
Garg S, Bartels C, Drenkard C, Bao G, Lim S. Risk of Cardiovascular Disease in SLE Is Significant Early and Highlights Racial Disparities [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/risk-of-cardiovascular-disease-in-sle-is-significant-early-and-highlights-racial-disparities/. Accessed September 3, 2020.
Gepner Y, Golan R, Harman-Boehm I, et al. Effects of Initiating Moderate Alcohol Intake on Cardiometabolic Risk in Adults With Type 2 Diabetes: A 2-Year Randomized, Controlled Trial. Ann Intern Med. 2015;163(8):569-579. doi:10.7326/M14-1650
Giles JT, Sattar N, Gabriel S, et al. Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial. Arthritis Rheumatol. 2020;72(1):31-40. doi:10.1002/art.41095
Graham L. ADA releases updated recommendations on standards of medical care in diabetes. American Family Physician. July 2010;82(2):206.
Grundy SM, Stone NJ; Guideline Writing Committee for the 2018 Cholesterol Guidelines. 2018 Cholesterol Clinical Practice Guidelines: Synopsis of the 2018 American Heart Association/American College of Cardiology/Multisociety Cholesterol Guideline. Ann Intern Med. 2019;170(11):779-783. doi:10.7326/M19-0365
Guy A, Tiosano S, Comaneshter D, et al. Aortic aneurysm association with SLE – a case-control study. Lupus. 2016;25(9):959-963. doi:10.1177/0961203316628999
Hahn BH, Grossman J, Ansell BJ, Skaggs BJ, McMahon M. Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Research & Therapy. 2008;10:213–225.
Han CY, Tang C, Guevara ME, Wei H, Wietecha T, Shao B, et al. Serum amyloid A impairs the antiinflammatory properties of HDL. J Clin Invest 2016;126:266–81.
Hansson GK, Libby P. The immune response in atherosclerosis: a double‐edged sword. Nat Rev Immunol 2006;6:508–19.
Hassan S, Milman U, Feld J, et al. Effects of anti-TNF-α treatment on lipid profile in rheumatic diseases: an analytical cohort study. Arthritis Res Ther. 2016;18(1):261. Published 2016 Nov 10. doi:10.1186/s13075-016-1148-1
Hersh AO, Trupin L, Yazdany J, Panopalis P, Julian L, Katz P, et al. Childhood-onset disease as a predictor of mortality in an adult cohort of patients with systemic lupus erythematosus.
Arthritis & Rheumatism. August 2010;62(8):1152–1159.
Hesselvig JH, Ahlehoff O, Dreyer L, Gislason G, Kofoed K. Cutaneous lupus erythematosus and systemic lupus erythematosus are associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. Lupus. 2017;26(1):48-53. doi:10.1177/0961203316651739
Ippolito A, Petri M. An update on mortality in systemic lupus erythematosus. Clinical and Experimental Rheumatology. 2008;26(suppl 51):S72–S79.
Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin converting enzyme inhibition: a patient-level meta-analysis. Annals of Internal Medicine.
2003;139(4):244–252.
Jin Y, Kang EH, Brill G, Desai RJ, Kim SC. Cardiovascular (CV) Risk after Initiation of Abatacept versus TNF Inhibitors in Rheumatoid Arthritis Patients with and without Baseline CV Disease. J Rheumatol. 2018;45(9):1240-1248. doi:10.3899/jrheum.170926
Johannesdottir SA, Horváth-Puhó E, Dekkers OM, et al. Use of Glucocorticoids and Risk of Venous Thromboembolism: A Nationwide Population-Based Case-Control Study. JAMA Intern Med. 2013;173(9):743–752. doi:10.1001/jamainternmed.2013.122
Johnson K. Clinically quiescent lupus does not progress. Rheumatology News. March 2010;9(3):20.
Jorge AM, Lu N, Keller SF, Rai SK, Zhang Y, Choi HK. The Effect of Statin Use on Mortality in Systemic Autoimmune Rheumatic Diseases. J Rheumatol. 2018;45(12):1689-1695. doi:10.3899/jrheum.171389
Jung H, Bobba R, Su J, Shariati-Sarabi Z, Gladman DD, Urowitz M, Lou W, et al. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis & Rheumatism. March 2010;62(3):863–868.
Kang EH, Jin Y, Brill G, et al. Comparative Cardiovascular Risk of Abatacept and Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis With and Without Diabetes Mellitus: A Multidatabase Cohort Study. J Am Heart Assoc. 2018;7(3):e007393. Published 2018 Jan 24. doi:10.1161/JAHA.117.007393
Karp I, Abrahamowicz M, Fortin PR, Pilote L, Neville C, et al. Longitudinal evolution of risk of coronary heart disease in systemic lupus erythematosus. Journal of Rheumatology. 2012;39(5):36–41.
Karpouzas GA, Ormseth SR, Hernandez E, Budoff MJ. Biologics May Prevent Cardiovascular Events in Rheumatoid Arthritis by Inhibiting Coronary Plaque Formation and Stabilizing High-Risk Lesions. Arthritis Rheumatol. 2020 Apr 21. doi: 10.1002/art.41293. Epub ahead of print. PMID: 32319221.
Kasitanon N, Magder LS, Petri M. Predictors of survival in systemic lupus erythematosus. Medicine. May 2006;85(3):147–156.
Katz P, Gregorich S, Yazdany J, Trupin L, Julian L, Yelin E, et al. Obesity and its measurement in a community-based sample of women with systemic lupus erythematosus. Arthritis Care & Research. February 2011;63(2):261–268.
Kaul MS, Rao SV, Shaw LK, Honeycutt E, Bardoin, St. Clair EW. Association of systemic lupus erythematosus with angiographically defined coronary artery disease: a retrospective cohort study. Arthritis Care & Research. 65(2):266–273.
Kawai VK, Avalos I, Oeser A, et al. Suboptimal inhibition of platelet cyclooxygenase 1 by aspirin in systemic lupus erythematosus: association with metabolic syndrome. Arthritis Care Res (Hoboken). 2014;66(2):285-292. doi:10.1002/acr.22169
Kiani AN, Fang H, Akhter E, et al. Apolipoprotein-containing lipoprotein subclasses and subclinical atherosclerosis in systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2015;67(3):442-446. doi:10.1002/acr.22430
Kim CH, Al-Kindi SG, Jandali B, Askari AD, Zacharias M, Oliveira GH. Incidence and risk of heart failure in systemic lupus erythematosus. Heart. 2017;103(3):227-233. doi:10.1136/heartjnl-2016-309561
Kim, S.Y., Yu, M., Morin, E.E., Kang, J., Kaplan, M.J. and Schwendeman, A. (2020), High‐Density Lipoprotein in Lupus: Disease Biomarkers and Potential Therapeutic Strategy. Arthritis Rheumatol, 72: 20-30. doi:10.1002/art.41059
Kotyla PJ. Simvastatin reduces antiphospholipid antibodies formation in patients with systemic lupus erythematosus: a preliminary study. Lupus. 2018;27(9):1572-1573. doi:10.1177/0961203318772015
Kurth T, Rist PM, Ridker PM, Kotler G, Bubes V, Buring JE. Association of Migraine With Aura and Other Risk Factors With Incident Cardiovascular Disease in Women. JAMA. 2020;323(22):2281-2289. doi:10.1001/jama.2020.7172
Laday J. Statins protective against myocardial infarction in SLE. Helio 2019:27.
Lambert RE. Clinical impact of systemic lupus erythematosus disease activity on long-term organ damage: Question and Answer. ClinTopics GlaxoSmithKline APR 2014.
Jancin B. Antiphospholipid antibodies common in first-MI patients? MDedge.com Rheumatology News NOV 2018:21.
Lazzerini PE, Capecchi PL, Laghi-Pasini F. Long QT Syndrome: An Emerging Role for Inflammation and Immunity. Front Cardiovasc Med. 2015;2:26. Published 2015 May 27. doi:10.3389/fcvm.2015.00026
Lazzerini PE, Laghi-Pasini F, Bertolozzi I, et al. Systemic inflammation as a novel QT-prolonging risk factor in patients with torsades de pointes. Heart. 2017;103(22):1821-1829. doi:10.1136/heartjnl-2016-311079
Lertratanakul A, Wu P, Dyer A, et al. 25-hydroxyvitamin D and cardiovascular disease in patients with systemic lupus erythematosus: data from a large international inception cohort. Arthritis Care Res (Hoboken). 2014;66(8):1167-1176. doi:10.1002/acr.22291
Lewandowski LB, Kaplan MJ. Update on cardiovascular disease in lupus. Curr Opin Rheumatol. 2016;28(5):468-476. doi:10.1097/BOR.0000000000000307
Liu Y, Kaplan MJ. Cardiovascular disease in systemic lupus erythematosus: an update. Curr Opin Rheumatol. 2018;30(5):441-448. doi:10.1097/BOR.0000000000000528
Liu T, Shi N, Zhang S, et al. Systemic lupus erythematosus aggravates atherosclerosis by promoting IgG deposition and inflammatory cell imbalance. Lupus. 2020;29(3):273-282. doi:10.1177/0961203320904779
Liyanage A, Lekamwasam S, Dissanayake SP, Munidasa D. Factors that determine body composition of female systemic lupus erythematosus (SLE) patients in Sri Lanka: a comparative study using dual-energy x-ray absorptiometry. Lupus. 2013;22(9):972-976. doi:10.1177/0961203313496338
McMahon M, Grossman J, FitzGerald J, Dahlin‐Lee E, Wallace DJ, Thong BY, et al. Proinflammatory high‐density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006;54:2541–9.
McMahon M, Grossman J, Skaggs B, FitzGerald J, Sahakian L, Ragavendra N, et al. Dysfunctional proinflammatory high‐density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheum 2009;60:2428–37.
Milovanovic B, et al. Cardiac autonomic dysfunction in patients with systemic lupus, rheumatoid arthritis and sudden death risk. Srp Arh Celok Lek. 2010; 138: 26-32
O’Laughlin JP, Mehta PH, Wong BC. Life Threatening Severe QTc Prolongation in Patient with Systemic Lupus Erythematosus due to Hydroxychloroquine. Case Rep Cardiol. 2016;2016:4626279. doi:10.1155/2016/4626279
Lim, L.S.H., Pullenayegum, E., Lim, L., Gladman, D., Feldman, B. and Silverman, E. (2017), From Childhood to Adulthood: The Trajectory of Damage in Patients With Juvenile‐Onset Systemic Lupus Erythematosus. Arthritis Care Res, 69: 1627-1635. doi:10.1002/acr.23199
Mavrogeni S, Sfikakis PP, Karabela G, et al. Cardiovascular magnetic resonance imaging in asymptomatic patients with connective tissue disease and recent onset left bundle branch block. Int J Cardiol. 2014;171(1):82-87. doi:10.1016/j.ijcard.2013.11.059
Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the management of arterial hypertension: the Task Force of the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESG). European Heart. 2007;28(12):1462–1536.
Medscape. What is the definition of obesity based on body fat percentage? Retrieved 8/16/20 from https:///www.medscape.com/answers/123702-11456/what-is-the-definition-of-obesity-based-on-body-fat-percentage#:~:text=In%20view%20of%20these%20limitations,31%2D33%25%20being%20borderline.

Milovanović B, Stojanović L, Milićevik N, Vasić K, Bjelaković B, Krotin M. Cardiac autonomic dysfunction in patients with systemic lupus, rheumatoid arthritis and sudden death risk. Srp Arh Celok Lek. 2010 Jan-Feb;138(1-2):26-32. doi: 10.2298/sarh1002026m. PMID: 20422909.
Mok CC, Kwok CL, Ho LY, Chan PT, Yip SF. Life expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong, China. Arthritis & Rheumatism. May 2011;63(5):1182–1189.
Mostafavi A A, Taassoarian B, Khadir V, Abbaszadeh S, Sanatkar S A, et al. Assessment of the Relationship Between Dose and Number of Effective Used Drugs on on QT Interval in Patients with Lupus, Shiraz E-Med J. 2020 ; 21(2):e83710. doi: 10.5812/semj.83710.
National Institute of Alcohol Abuse and Alcoholism. “Understanding the dangers of alcohol overdose. Retrieved on 8/16/20 from https://pubs.niaaa.nih.gov/publications/Practitioner/CliniciansGuide2005/clinicians_guide.htm (Accessed on October 10, 2011).
Nikpour M, Gladman DD, Urowitz MB. Premature coronary heart disease in systemic lupus erythematosus: what risk
factors do we understand?. Lupus. 2013;22(12):1243-1250. doi:10.1177/0961203313493031
 “Overview of Peripheral Arterial Disease – Heart and Blood Vessel Disorders”. Merck Manuals Consumer Version. Disorders of arteries that supply the brain with blood are considered separately as cerebrovascular disease. Retrieved 8/15/20 from https:///www.merckmanuals.com/en-ca/home/heart-and-blood-vessel-disorders/peripheral-arterial-disease/overview-of-peripheral-arterial-disease
Pareek A, Chandurkar N. Drug approvals in India. Lancet Diabetes Endocrinol. 2016;4(1):19-20. doi:10.1016/S2213-8587(15)00476-3
Reese T, Dickson AL, Shuey MM, et al. Increased blood pressure visit-to-visit variability in patients with systemic lupus erythematosus: association with inflammation and comorbidity burden. Lupus. 2019;28(8):954-960. doi:10.1177/0961203319856988
Restrepo JF, Del Rincon I, Molina E, Battafarano DF, Escalante A. Use of Hydroxychloroquine Is Associated With Improved Lipid Profile in Rheumatoid Arthritis Patients. J Clin Rheumatol. 2017;23(3):144-148. doi:10.1097/RHU.0000000000000502
Reynolds JA, Haque S, Williamson K, Ray DW, Alexander MY, Bruce IN. Vitamin D improves endothelial dysfunction and restores myeloid angiogenic cell function via reduced CXCL-10 expression in systemic lupus erythematosus. Sci Rep. 2016;6:22341. Published 2016 Mar 1. doi:10.1038/srep22341
Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo Jr JL, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007;115(21):2761–2788.
Rosenson RS, Brewer HB, Chapman MJ, Fazio S, Hussain MM, Kontush A, et al. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem 2011;57:392–410.
Roubille C, Richer V, Starnino T, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74(3):480-489. doi:10.1136/annrheumdis-2014-206624
Sabio JM, Vargas-Hitos JA, Martinez-Bordonado J, et al. Relationship between homocysteine levels and hypertension in systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2014;66(10):1528-1535. doi:10.1002/acr.22340
Santos MJ, Vinagre F, Canas da Silva J, Gil V, Fonseca JE. Body composition phenotypes in systemic lupus erythematosus and rheumatoid arthritis: a comparative study of Caucasian female patients. Clin Exp Rheumatol. 2011;29:470-476. 
Selak V, Jackson R, Poppe K, et al. Predicting Bleeding Risk to Guide Aspirin Use for the Primary Prevention of Cardiovascular Disease: A Cohort Study. Ann Intern Med. 2019;170(6):357-368. doi:10.7326/M18-2808
Shah NR, Braverman ER (2012) Measuring Adiposity in Patients: The Utility of Body Mass Index (BMI), Percent Body Fat, and Leptin. PLoS ONE 7(4): e33308. https://doi.org/10.1371/journal.pone.0033308
Shimbo D, Muntner P. Should Out-of-Office Monitoring Be Performed for Detecting White Coat Hypertension?. Ann Intern Med. 2019;170(12):890-892. doi:10.7326/M19-1134
Singh S, Fumery M, Singh AG, et al. Comparative Risk of Cardiovascular Events With Biologic and Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Arthritis Care Res (Hoboken). 2020;72(4):561-576. doi:10.1002/acr.23875
Smith CK, Vivekanandan‐Giri A, Tang C, Knight JS, Mathew A, Padilla RL, et al. Neutrophil extracellular trap–derived enzymes oxidize high‐density lipoprotein: an additional proatherogenic mechanism in systemic lupus erythematosus. Arthritis Rheumatol 2014;66:2532–44.
Soh MC, Nelson-Piercy C, Dib F, Westgren M, McCowan L, Pasupathy D. Brief Report: Association Between Pregnancy Outcomes and Death From Cardiovascular Causes in Parous Women With Systemic Lupus Erythematosus: A Study Using Swedish Population Registries. Arthritis Rheumatol. 2015;67(9):2376-2382. doi:10.1002/art.39218
Soh MC, Nelson-Piercy C, Westgren M, McCowan L, Pasupathy D. Do adverse pregnancy outcomes contribute to accelerated cardiovascular events seen in young women with systemic lupus erythematosus?. Lupus. 2017;26(13):1351-1367. doi:10.1177/0961203317719146
Sotos-Prieto M, et al. Changes in Diet Quality Scores and Risk of Cardiovascular Disease Among US Men and Women. Circulation. 2015 Dec;132(23):2212-9. Epub 2015 Oct 5. 
Stampfer M, Willett W. Folate supplements for stroke prevention: targeted trial trumps the rest. JAMA. 2015;313(13):1321-1322. doi:10.1001/jama.2015.1961
Steenland K, et al. Environmental tobacco smoke and coronary heart disease in the American Cancer Society CPS-II cohort. Circulation. 1996;94(4):622. 
Steiman AJ, Gladman DD, Ibañez D, Urowitz MB. Prolonged serologically active clinically quiescent systemic lupus erythematosus: frequency and outcome. Journal of Rheumatology. 2010;37:1822–1827.
Stojan G, Magder LS, Petri M. Blood Pressure Variability and Age-related Blood Pressure Patterns in Systemic Lupus Erythematosus. J Rheumatol. 2020;47(3):387-393. doi:10.3899/jrheum.181131
Taraborelli M, Sciatti E, Bonadei I, et al. Endothelial Dysfunction in Early Systemic Lupus Erythematosus Patients and Controls Without Previous Cardiovascular Events. Arthritis Care Res (Hoboken). 2018;70(9):1277-1283. doi:10.1002/acr.23495
Teh, P., Zakhary, B. & Sandhu, V.K. The impact of obesity on SLE disease activity: findings from the Southern California Lupus Registry (SCOLR). Clin Rheumatol 38, 597–600 (2019). https://doi.org/10.1007/s10067-018-4336-3
Timlin H, Petri M. Transient ischemic attack and stroke in systemic lupus erythematosus. Lupus. 2013;22(12):1251-1258. doi:10.1177/0961203313497416
Uribe AG, Alarcón GS, Sanchez ML, McGwin Jr G, Sandoval R, Fessler BJ, et al. Systemic lupus erythematosus in three ethnic groups. XVIII. Factors predictive of poor compliance with study visits. Arthritis & Rheumatism. April 2004;51(2):258–263.
Urowitz MB, Gladman DD, Anderson NM, et al. Cardiovascular events prior to or early after diagnosis of syste
mic lupus erythematosus in the systemic lupus international collaborating clinics cohort [published correction appears in Lupus Sci Med. 2016;3(1):e000143corr1]. Lupus Sci Med. 2016;3(1):e000143. Published 2016 Apr 12. doi:10.1136/lupus-2015-000143
US Department of Health and Human Services (USDHHS). The health consequences of involuntary exposure to tobacco smoke. Centers for Disease Control and Prevention, Rockville, MD, 2006.
US Department of Health and Human Services. The health consequences of smoking–50 years of progress: A report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2014.
National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health. The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General. Atlanta (GA): Centers for Disease Control and Prevention (US); 2014.Valentini G. Longterm Hydroxychloroquine Therapy and Low-dose Aspirin May Have an Additive Effectiveness in the Primary Prevention of Cardiovascular Events in Patients with Systemic Lupus Erythematosus. J Rheumatol. 2017;44(7):1032-1038. doi:10.3899/jrheum.161351
Volkmann ER, Grossman JM, Sahakian LJ, Skaggs BJ, FitzGerald J, et al. Low physical activity is associated with proinflammatory high-density lipoprotein and increased subclinical atherosclerosis in women with systemic lupus erythematosus. Arthritis Care & Research. February 2010;62(2):258–265.
Wallace DJ. Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus? [Letter]. Arthritis & Rheumatism. 1987;30:1435–1436.
Walsh SJ, Gilchrist A. Geographical clustering of mortality from systemic lupus erythematosus in the United States: contributions of poverty, Hispanic ethnicity and solar radiation. Lupus. 2006;15:662–670.
The Wall Street Journal. Too Much Fat? Try a Whole-Body Scan. 8/17/2015. Retrieved online on 8/16/2020 at https:///www.wsj.com/articles/too-much-fat-try-a-whole-body-scan-1439828879
Whelton PK, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Whitlock EP, Johnson ES. Are We There Yet? Another Milepost in the Journey to Identify Appropriate Candidates for Aspirin Primary Prevention. Ann Intern Med. 2019;170(6):411-413. doi:10.7326/M19-0416
Wilhelmsson C, Vedin JA, Elmfeldt D, Tibblin G, Wilhelmsen L. Smoking and myocardial infarction. Lancet. 1975;1(7904):415–420.
Wondafrash DZ, Desalegn TZ, Yimer EM, Tsige AG, Adamu BA, Zewdie KA. Potential Effect of Hydroxychloroquine in Diabetes Mellitus: A Systematic Review on Preclinical and Clinical Trial Studies. J Diabetes Res. 2020;2020:5214751. Published 2020 Feb 27. doi:10.1155/2020/5214751
Wood AM, et al. Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies. Lancet. 2018;391(10129):1513. 
Xie F, et al. methotrexate use and the risk for cardiovascular disease among rheumatoid patients initiating biologic disease-modifying anti-rheumatic drugs. Presented at: 2018 ACR/ARHP Annual Meeting; October 19-24, 2018; Chicago, IL. Abstract 2814.
Xie F, Yun H, Levitan EB, Muntner P, Curtis JR. Tocilizumab and the Risk of Cardiovascular Disease: Direct Comparison Among Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis Patients. Arthritis Care Res (Hoboken). 2019;71(8):1004-1018. doi:10.1002/acr.23737
Yu H, et al. Acquired long QT syndrome in hospitalized patients. Heart Rhythm. 2017;14(7):974. Epub 2017 Mar 18. 

Chapter 22

Ahmed H. Systemic Lupus Erythematosus Patients with Common Variable Immunodeficiency Disease. Congress of Clinical Rheumatology 2019. Online Symposia retrieved on 9/12/20 at https:///www.onlinesymposia.com/online-videos/51-nyrif/nyrif2019/414-systemic-lupus-erythematosus-patients-with-common-variable-immunodeficiency-disease-hamdy-ahmed-m-d
American College of Rheumatology. Herpes zoster (shingles) vaccine guidelines for immunosuppressed patients in Hotline. August 1, 2008. Retrieved May 30, 2011, from American College of Rheumatology website, www.rheumatology.org/publications/hotline/2008_08_01_shingles.asp.
Banerjee S, Biehl A, Ghaderi-Yeganeh M, Manna Z, Hasni S. Low incidence of opportunistic Infections in Lupus Patients treated with Cyclophosphamide and Steroids in a Tertiary care setting. Med Res Arch. 2017;5(3):10.18103/mra.v5i3.1084. doi:10.18103/mra.v5i3.1084
Barbhaiya, M., Feldman, C.H., Chen, S.K., Guan, H., Fischer, M.A., Everett, B.M. and Costenbader, K.H. (2020), Comparative Risks of Cardiovascular Disease in Systemic Lupus Erythematosus, Diabetes and General Medicaid Patients. Arthritis Care Res. Accepted Author Manuscript. doi:10.1002/acr.24328
Belknap R, Holland D, Feng PJ, et al. Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial. Ann Intern Med. 2017;167(10):689-697. doi:10.7326/M17-1150
Bharat A, et al. Incidence and Risk Factors for Progressive Multifocal Leukoencephalopathy among Patients with Selected Rheumatic Diseases Arthr Care Res 2012;64:612-615.
Borba EF, Saad CG, Pasoto SG, et al. Influenza A/H1N1 vaccination of patients with SLE: can antimalarial drugs restore diminished response under immunosuppressive therapy?. Rheumatology (Oxford). 2012;51(6):1061-1069. doi:10.1093/rheumatology/ker427
Borie D, Kremer JM. Considerations on the appropriateness of the John Cunningham virus antibody assay use in patients with rheumatoid arthritis. Semin Arthritis Rheum. 2015;45(2):163-166. doi:10.1016/j.semarthrit.2015.06.003
Bridges CB. Recommended adult immunization schedule: United States, 2013. Annals of Internal Medicine. February 2013;158(3):191–199.
Calabrese LH, Xie F, Yun H, et al. Herpes Zoster and the Risk of Stroke in Patients With Autoimmune Diseases. Arthritis Rheumatol. 2017;69(2):439-446. doi:10.1002/art.39855
Centers for Disease Control and Prevention (U.S.). Common Vaccine Safety Questions and Concerns. Retrieved on 9/7/20 at https:///www.cdc.gov/vaccinesafety/concerns/index.html
Chakravarty E, Michaud K, Katz R, Wolfe F. Increased incidence of herpes zoster among patients with systemic lupus erythematosus. Lupus. 2013;22(3):238-244. doi:10.1177/0961203312470186
Chen MH, Chen MH, Tsai CY, et al. Incidence and antiviral response of hepatitis C virus reactivation in lupus patients undergoing immunosuppressive therapy. Lupus. 2015;24(10):1029-1036. doi:10.1177/0961203315571465
Cheng CF, Huang YM, Lu CH, Hsieh SC, Li KJ. Prednisolone dose during treatment of tuberculosis might be a risk factor for mortality in patients with systemic lupus erythematosus: a hospital-based cohort study. Lupus. 2019;28(14):1699-1704. doi:10.1177/0961203319882759
Cho H, Kim YW, Suh C-H, et al. Concordance between the tuberculin skin test and interferon gamma release assay (IGRA) for diagnosing latent tuberculosis infection in patients with systemic lupus erythematosus and patient characteristics associated with an indeterminate IGRA. Lupus. 2016;25(12):1341-1348. doi:10.1177/0961203316639381
Collins TR. Immune deficiency: Rheumatologists should watch for warning signs. The Rheumatologist JUL 2018:74.
Colmegna I, Useche M, Rodriguez K, Hudson M, Bernatsky S, Nedjar H, Rahme E, Ward B. Efficacy of High-Dose Versus Standard-Dose Influenza Vaccine in Seropositive Rheumatoid Arthritis Patients [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/efficacy-of-high-dose-versus-standard-dose-influenza-vaccine-in-seropositive-rheumatoid-arthritis-patients/. Accessed September 12, 2020.
Costa-Reis P, et al. Major infections in a cohort of 120 patients with juvenile-onset systemic lupus erythematosus. Clin Immunol. 2013 Dec;149(3):442-9. Epub 2013 Sep 2. 
Curtis J, Bridges S, Cofield S, Bassler J, Ford T, Lindsey S, Kivitz A, Messaoudi I, Michaud K, Huffstutter J, Mikuls T, Ridley D, Shergy W, Siegel S, Winthrop K. Results from a Randomized Controlled Trial of the Safety of the Live Varicella Vaccine in TNF-Treated Patients [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/results-from-a-randomized-controlled-trial-of-the-safety-of-the-live-varicella-vaccine-in-tnf-treated-patients/. Accessed September 7, 2020.
Curtis, Jeffrey R., et al. “Risk for Herpes Zoster in Tofacitinib-Treated Rheumatoid Arthritis Patients With and Without Concomitant Methotrexate and Glucocorticoids.” Arthritis Care & Research, vol. 71, no. 9, 2019, pp. 1249-1254.
Cush J. ACIP guidelines on H. Zoster vaccination updated. RheumNow. Retrieved 9/12/20 from https://rheumnow.com/content/acip-guidelines-h-zoster-vaccination-updated
Cush J. CDC endorses new shingles vaccine over Zostavax. RheumNow. Retrieved 9/12/20 from https://rheumnow.com/content/cdc-endorses-new-shingles-vaccine-over-zostavax
Cush J. Rules for Drug Cessation with Infection. RheumNow. Retrieved 9/7/20 at https://rheumnow.com/blog/best-2017-rules-drug-cessation-infection
Danza A, Ruiz-Irastorza G. Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies. Lupus. 2013;22(12):1286-1294. doi:10.1177/0961203313493032
Dao K, Cush JJ. A vaccination primer for rheumatologists. Drug Safety Quarterly. 2012;4(1):1.
Dao KH, Herbert M, Habal N, Cush JJ. Nonserious infections: should there be cause for serious concerns?. Rheum Dis Clin North Am. 2012;38(4):707-725. doi:10.1016/j.rdc.2012.08.016
Dao KH. Top 5 things rheumatologists should know about vaccines. RheumNow. Retrieved 9/12/20 from https://rheumnow.com/blog/top-5-things-rheumatologists-should-know-about-vaccines
Das RR, Singh M. Oral zinc for the common cold [retracted in: JAMA. 2016 Dec 27;316(24):2678]. JAMA. 2014;311(14):1440-1441. doi:10.1001/jama.2014.1404
De Carolis S, Tabacco S, Rizzo F, et al. Association between false-positive TORCH and antiphospholipid antibodies in healthy pregnant women. Lupus. 2018;27(5):841-846. doi:10.1177/0961203317741564
Devlin A, Shmerling RH. Systemic lupus erythematosus and infections (2020). Systemic Lupus Erythematosus: Basic, Applied and Clinical Aspects (2nd ed.). G. C. Tsokos (Ed.). San Diego, CA: Elsevier, Inc:451-457.
DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014;371(7):635-645. doi:10.1056/NEJMoa1315727
Dooling KL, et al. Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines. MMWR Morb Mortal Wkly Rep. 2018;67(3):103. Epub 2018 Jan 26.

Douvas A, Takehana Y, Ehresmann G, Chernyovskiy T, Daar ES. Neutralization of HIV type 1 infectivity by serum antibodies from a subset of autoimmune patients with mixed connective tissue disease. AIDS Res Hum Retroviruses. 1996 Nov 1;12(16):1509-17. doi: 10.1089/aid.1996.12.1509. PMID: 8911576.
Dubois E, ed. Lupus Erythematosus: A Review of the Current Status of Discoid and Systemic Lupus Erythematosus and Their Variants. New York: McGraw-Hill Book Company; 1966.
Errante PR, et al. Primary immunodeficiency association with systemic lupus erythematosus: review of literature and lessons learned by the Rheumatology Division of a tertiary university hospital at São Paulo, Brazil. Rev Bras Reumatol Engl Ed. 2016;56(1):58. Epub 2015 Sep 1.
Fangtham M, Magder L, Petri M. Oral candidiasis in systemic lupus erythematosus. Lupus. 2014;23(7):684-690. doi:10.1177/0961203314525247
Fauci AS, Dale DC, Balow JE. Glucocorticosteroid therapy: mechanisms of action and clinical considerations. Ann Intern Med. 1976;84(3):304-315. doi:10.7326/0003-4819-84-3-304
Fayyaz A, Igoe A, Kurien BT, et al. Haematological manifestations of lupus. Lupus Sci Med. 2015;2(1):e000078. Published 2015 Mar 3. doi:10.1136/lupus-2014-000078
Feldman CH, Hiraki LT, Winkelmayer WC, et al. Serious infections among adult Medicaid beneficiaries with systemic lupus erythematosus and lupus nephritis. Arthritis Rheumatol. 2015;67(6):1577-1585. doi:10.1002/art.39070
Feldman CH, Marty FM, Winkelmayer WC, et al. Comparative Rates of Serious Infections Among Patients With Systemic Lupus Erythematosus Receiving Immunosuppressive Medications. Arthritis Rheumatol. 2017;69(2):387-397. doi:10.1002/art.39849
Firooz N, Albert DA, Wallace DJ, Ishimori M, Berel D, Weisman MH. High-sensitivity C-reactive protein and erythrocyte sedimentation rate in systemic lupus erythematosus. Lupus. 2011;20:588–597.
Freedman M, Kroger A, Hunter P, Ault KA; Advisory Committee on Immunization Practices. Recommended Adult Immunization Schedule, United States, 2020 [published correction appears in Ann Intern Med. 2020 May 5;172(9):640]. Ann Intern Med. 2020;172(5):337-347. doi:10.7326/M20-0046
Friedman MA, Winthrop K. Vaccinations for rheumatoid arthritis. Curr Opin Rheumatol. 2016;28(3):330-336. doi:10.1097/BOR.0000000000000281
Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(1):39-52. doi:10.1136/annrheumdis-2019-215882
García-Guevara G, Ríos-Corzo R, Díaz-Mora A, et al. Pneumonia in patients with systemic lupus erythematosus: Epidemiology, microbiology and outcomes. Lupus. 2018;27(12):1953-1959. doi:10.1177/0961203318799207
George MD, Baker JF, Winthrop K, Hsu JY, Wu Q, Chen L, Xie F, Yun H, Curtis JR. Risk for Serious Infection With Low-Dose Glucocorticoids in Patients With Rheumatoid Arthritis : A Cohort Study. Ann Intern Med. 2020 Sep 22. doi: 10.7326/M20-1594. Epub ahead of print. PMID: 32956604.
Ghaussy NO, Sibbitt Jr WL, Bankhurst AD, Qualls CR. Cigarette smoking and disease activity in systemic lupus erythematosus. Journal of Rheumatology. 2003;30:1215–1221.
Gilliland WR, Tsokos GC. Prophylactic use of antibiotics and immunisations in patients with SLE. Annals of the Rheumatic Diseases. 2002;61:191–192.
González-Echavarri C, Capdevila O, Espinosa G, et al. Infections in newly diagnosed Spanish patients with systemic lupus erythematosus: data from the RELES cohort. Lupus. 2018;27(14):2253-2261. doi:10.1177/0961203318811598
Grijalva CG, Zhu Y, Williams DJ, et al. Association Between Hospitalization With Community-Acquired Laboratory-Confirmed Influenza Pneumonia and Prior Receipt of Influenza Vaccination. JAMA. 2015;314(14):1488-1497. doi:10.1001/jama.2015.12160
Groot N, Heijstek MW, Wulffraat NM. Vaccinations in paediatric rheumatology: an update on current developments. Curr Rheumatol Rep. 2015;17(7):46. doi:10.1007/s11926-015-0519-y
Havens PL, Anderson JR. Updated CDC Recommendations for Universal Hepatitis C Virus Screening Among Adults and Pregnant Women: Implications for Clinical Practice. JAMA. 2020;323(22):2258-2259. doi:10.1001/jama.2020.3693
Healio Rheumatology (SEP 2012). Measles resurgence may pose unique threat to patients with inflammatory diseases:20-21.
Healio Rheumatology (MAR 2015). Study: Physicians failed to recommend vaccines to patients with SLE. Retrieved on 9/12/20 from https:///www.healio.com/news/rheumatology/20150311/study-physicians-failed-to-recommend-vaccines-to-patients-with-sle?utm_content=bufferfd253&utm_medium=social&utm_source=facebook.com&utm_campaign=buffer
Heijstek MW et al. Effects of the live attenuated measles-mumps-rubella booster vaccination on disease activity in patients with juvenile idiopathic arthritis: A randomized trial. JAMA 2013 Jun 19; 309:2449.
Henegar CE, Eudy AM, Kharat V, Hill DD, Bennett D, Haight B. Progressive multifocal leukoencephalopathy in patients with systemic lupus erythematosus: a systematic literature review. Lupus. 2016;25(6):617-626. doi:10.1177/0961203315622819
Hickman RJ. Measles: the return. The Rheumatologist AUG 2019:1,21-22.
Hiraki LT, et al. Serious Infection Rates Among Children With Systemic Lupus Erythematosus Enrolled in Medicaid. Arthritis Care Res (Hoboken). 2017;69(11):1620. Epub 2017 Sep 21. 
Hua C, Barnetche T, Combe B, Morel J. Effect of methotrexate, anti-tumor necrosis factor α, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2014;66(7):1016-1026. doi:10.1002/acr.22246
Hunter P, Fryhofer SA, Szilagyi PG. Vaccination of Adults in General Medical Practice. Mayo Clin Proc. 2020;95(1):169-183. doi:10.1016/j.mayocp.2019.02.024
Iliopoulos AG, Tsokos GC. Immunopathogenesis and spectrum of infections in systemic lupus erythematosus. Sem Arthr Rheum 1996;25(5):318-336.
Jain S, et al. Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. N Engl J Med. 2015;373(5):415. Epub 2015 Jul 14. 
Jewell ML, McCauliffe DP. Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. Journal of the American Academy of Dermatology. June 2000;42:983–987.
Kang KY, Kwok S-K, Ju JH, Park K-S, Cho C-S, Kim H-Y, et al. The causes of death in Korean patients with systemic lupus erythematosus over 11 years. Lupus. 2011;20:989–997.
Kapoor T, Mahadeshwar P, Hui-Yuen J, et al. Prevalence of progressive multifocal leukoencephalopathy (PML) in adults and children with systemic lupus erythematosus. Lupus Science & Medicine 2020;7:e000388. doi: 10.1136/lupus-2020-000388
Kartau M, et al. Progressive Multifocal Leukoencephalopathy: Current Insights. Degener Neurol Neuromuscul Dis. 2019;9:109. Epub 2019 Dec 2. 
Laprise JF, Chesson HW, Markowitz LE, et al. Effectiveness and Cost-Effectiveness of Human Papillomavirus Vaccination Through Age 45 Years in the United States. Ann Intern Med. 2020;172(1):22-29. doi:10.7326/M19-1182
Kranjčec B, Papeš D, Altarac S . D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. World J Urol. 2014 Feb;32(1):79-84. Epub 2013 Apr 30. 
Laday J. Less than 30% of patients wiht SLE receive annual flu vaccines. Helio Rheumatology:19.
Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087-2096. doi:10.1056/NEJMoa1501184
Lawson EF, Trupin L, Yelin EH, Yazdany J. Reasons for failure to receive pneumococcal and influenza vaccinations among immunosuppressed patients with systemic lupus erythematosus. Semin Arthritis Rheum. 2015;44(6):666-671. doi:10.1016/j.semarthrit.2015.01.002
Lesprit P, Pédrono G, Molina JM, et al. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. AIDS. 2007;21(18):2425-2434. doi:10.1097/QAD.0b013e3282887e91
Li TH, Lai CC, Wang WH, et al. Risk of severe herpes simplex virus infection in systemic lupus erythematosus: analysis of epidemiology and risk factors analysis in Taiwan. Ann Rheum Dis. 2019;78(7):941-946. doi:10.1136/annrheumdis-2018-214844
Liao Z, Tang H, Xu X, Liang Y, Xiong Y, Ni J. Immunogenicity and Safety of Influenza Vaccination in Systemic Lupus Erythematosus Patients Compa
red with Healthy Controls: A Meta-Analysis. PLoS One. 2016;11(2):e0147856. Published 2016 Feb 4. doi:10.1371/journal.pone.0147856
Limper AH, et al. An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med. 2011;183(1):96
Littlejohn E, et al. The ratio of erythrocyte sedimentation rate to C-reactive protein is useful in distinguishing infection from flare in systemic lupus erythematosus patients presenting with fever. Lupus 2018;27:1123-1129.
Lok ASF, et al. Reactivation of Hepatitis B During Immunosuppressive Therapy: Potentially Fatal Yet Preventable. Ann Int Med 2012;156:743.
Luijten, R. K. M. A. C., Cuppen, B. V. J., Bijlsma, J. W. J., & Derksen, R. H. W. M. (2014). Serious infections in systemic lupus erythematosus with a focus on pneumococcal infections. Lupus, 23(14), 1512–1516. https://doi.org/10.1177/0961203314543918
Mahoney D. Immunizations should precede rituximab. Rheumatology News. August 2008;8(8):28.
Macedo AC, Isaac L. Systemic Lupus Erythematosus and Deficiencies of Early Components of the Complement Classical Pathway. Front Immunol. 2016;7:55. Published 2016 Feb 24. doi:10.3389/fimmu.2016.00055 
Mahroum N, Hejly A, Tiosano S, et al. Chronic hepatitis C viral infection among SLE patients: the significance of coexistence. Immunol Res. 2017;65(2):477-481. doi:10.1007/s12026-016-8886-7
Martínez-Martínez M, Baranda-Cándido L, Abud-Mendoza C. Cutaneous papillomavirus infection in patients with rheumatoid arthritis or systemic lupus erythematosus. A case-control study. Lupus. 2013;22(9):948-952. doi:10.1177/0961203313490431
Meissner HC, Nair N, Plotkin SA. The National Vaccine Injury Compensation Program: Striking a Balance Between Individual Rights and Community Benefit. JAMA. 2019;321(4):343-344. doi:10.1001/jama.2018.20421
Mody GM, Patel N, Budhoo A, Dubula T. Concomitant systemic lupus erythematosus and HIV: case series and literature review. Semin Arthritis Rheum. 2014;44(2):186-194. doi:10.1016/j.semarthrit.2014.05.009
Mok CC. Epidemiology and survival of systemic lupus erythematosus in Hong Kong, China. Lupus. 2011;20:767–771.
Mok CC, Chan KH, Ho LY, et alSafety and immune response of a live-attenuated herpes zoster vaccine in patients with systemic lupus erythematosus: a randomised placebo-controlled trialAnnals of the Rheumatic Diseases 2019;78:1663-1668.
Mok CC, Ho LY, Fong LS, To CH. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. Ann Rheum Dis. 2013;72(5):659-664. doi:10.1136/annrheumdis-2012-201393
Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum. 2009;60(12):3761.
Nagel J, Saxne T, Geborek P, et al. Treatment with belimumab in systemic lupus erythematosus does not impair antibody response to 13-valent pneumococcal conjugate vaccine. Lupus. 2017;26(10):1072-1081. doi:10.1177/0961203317695465
Nuorti JP, Whitney CG; Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease among infants and children – use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine – recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59(RR-11):1-18.
O’Kelly B, McNally C, McConkey S, Durcan L. HIV and systemic lupus erythematosus: where immunodeficiency meets autoimmunity. Lupus. 2020;29(9):1130-1132. doi:10.1177/0961203320934851
Pachucki RJ, Corradetti C, Kohler L, Ghadiali J, Gallo PM, Nicastro L, Tursi SA, Gallucci S, Tükel Ç, Caricchio R. Persistent Bacteriuria and Antibodies Recognizing Curli/eDNA Complexes From Escherichia coli Are Linked to Flares in Systemic Lupus Erythematosus. Arthritis Rheumatol. 2020 Jun 17. doi: 10.1002/art.41400. Epub ahead of print. PMID: 32840064.
Papp KA, Haraoui B, Kumar D, et al. Vaccination Guidelines for Patients with Immune-Mediated Disorders on Immunosuppressive Therapies-Executive Summary. J Can Assoc Gastroenterol. 2019;2(4):149-152. doi:10.1093/jcag/gwy069
Park, JK, et al. Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis. 2017;76(9):1559. Epub 2017 May 3.
Pawar A, Desai RJ, Solomon DH, et al. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study. Ann Rheum Dis. 2019;78(4):456-464. doi:10.1136/annrheumdis-2018-214367
Perrillo RP, Martin P, Lok AS. Preventing hepatitis B reactivation due to immunosuppressive drug treatments. JAMA. 2015;313(16):1617-1618. doi:10.1001/jama.2015.2571
Perry LM, Winthrop KL, Curtis JR. Vaccinations for rheumatoid arthritis. Curr Rheumatol Rep. 2014;16(8):431. doi:10.1007/s11926-014-0431-x
Phillips CJ, et al. Comparison of the effectiveness of trivalent inactivated influenza vaccine and live, attenuated influenza vaccine in preventing influenza-like illness among US military service members, 2006-2009. Clin Infect Dis. 2013;56(1):11. 

Picado C, de Landazuri IO, Vlagea A, Bobolea I, Arismendi E, Amaro R, Sellarés J, Bartra J, Sanmarti R, Hernandez-Rodriguez J, Mascaró JM, Colmenero J, Vaquero EC, Pascal M. Spectrum of Disease Manifestations in Patients with Selective Immunoglobulin E Deficiency. J Clin Med. 2021 Sep 15;10(18):4160. doi: 10.3390/jcm10184160. PMID: 34575269; PMCID: PMC8466644.
Pimentel-Quiroz VR, Ugarte-Gil MF, Harvey G, et al. Factors predictive of serious infections over time in systemic lupus erythematosus patients: data from a multi-ethnic, multi-national, Latin American lupus cohort. Lupus. 2019;28(9):1101-1110. doi:10.1177/0961203319860579
Rahman P, Gladman DD, Urowitz MD. Smoking interferes with efficacy of antimalarial therapy in cutaneous lupus. Journal of Rheumatology. September 1998;25(0):1716–1719.
Rezende RPV, Ribeiro FM, Albuquerque EMN, Gayer CR, Andrade LEC, Klumb EM. Immunogenicity of pneumococcal polysaccharide vaccine in adult systemic lupus erythematosus patients undergoing immunosuppressive treatment. Lupus. 2016;25(11):1254-1259. doi:10.1177/0961203316636472
Rheumatology (The Lancet, FEB 2020). fighting flu: the importance of vaccines in rheumatic diseases:e63.
Rúa-Figueroa I, López-Longo FJ, Del Campo V, et al. Bacter
emia in Systemic Lupus Erythematosus in Patients from a Spanish Registry: Risk Factors, Clinical and Microbiological Characteristics, and Outcomes. J Rheumatol. 2020;47(2):234-240. doi:10.3899/jrheum.180882
Saslow D, et al. Human papillomavirus vaccination 2020 guideline update: American Cancer Society guideline adaptation. CA Cancer J Clin. 2020;70(4):274. Epub 2020 Jul 8.
Schaffner W, Chen WH, Hopkins RH, Neuzil K. Effective Immunization of Older Adults Against Seasonal Influenza. Am J Med. 2018;131(8):865-873. doi:10.1016/j.amjmed.2018.02.019
Science M, Johnstone J, Roth DE, Guyatt G, Loeb M. Zinc for the treatment of the common cold: a systematic review and meta-analysis of randomized controlled trials. Canadian Medical Association Journal. July 2012;184:E551–E561.
Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care & Research. May 2012;64(5):625–639.
Sollecito TP, et al. The use of prophylactic antibiotics prior to dental procedures in patients with prosthetic joints: Evidence-based clinical practice guideline for dental practitioners–a report of the American Dental Association Council on Scientific Affairs. J Am Dent Assoc. 2015 Jan;146(1):11-16.e8. Epub 2014 Dec 18.
TBFACTS. High Burden Countries. Retrieved 9/7/20 at https://tbfacts.org/high-burden-tb/
Sukumaran L, McCarthy NL, Kharbanda EO, et al. Association of Tdap Vaccination With Acute Events and Adverse Birth Outcomes Among Pregnant Women With Prior Tetanus-Containing Immunizations. JAMA. 2015;314(15):1581-1587. doi:10.1001/jama.2015.12790
Sunzini F, McInnes I, Siebert S. JAK inhibitors and infections risk: focus on herpes zoster. Ther Adv Musculoskelet Dis. 2020;12:1759720X20936059. Published 2020 Jun 29. doi:10.1177/1759720X20936059
Torres-Ruiz J, Barrera-Vargas A, Ortiz-Hernández R, Alcocer-Varela J, Ponce-de-León A, Gómez-Martín D. Microbiological and immunological profile of patients with severe lupus flares related to bloodstream infections: a retrospective cohort study. Lupus. 2018;27(2):312-318. doi:10.1177/0961203317720527
Ullman K. Vaccines & biologics. The Rheumatologist DEC 2014:52-53. 
van Vollenhoven, R.F., Hahn, B.H., Tsokos, G.C., Lipsky, P., Fei, K., Gordon, R.M., Gregan, I., Lo, K.H., Chevrier, M. and Rose, S. (2020), Maintenance of Efficacy and Safety of Ustekinumab Through One Year in a Phase II Multicenter, Prospective, Randomized, Double‐Blind, Placebo‐Controlled Crossover Trial of Patients With Active Systemic Lupus Erythematosus. Arthritis Rheumatol, 72: 761-768. doi:10.1002/art.41179
Wang S, Chen Y, Xu X, Hu W, Shen H, Chen J. Prevalence of hepatitis B virus and hepatitis C virus infection in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Oncotarget. 2017;8(60):102437-102445. Published 2017 Nov 1. doi:10.18632/oncotarget.22261
Wang C-H, Fang C-C, Chen N-C, Liu S S-H, Yu P-H, et al. Cranberry-containing products for prevention of urinary tract infections in susceptible populations: a systematic review and meta-analysis of randomized controlled trials. Archives of Internal Medicine. July
2012;172(13):988–996.
Wang S, et al. Prevalence of hepatitis B virus and hepatitis C virus infection in patients with systemic lupus erythematosus: a systematic review and meta-analysis Oncotarget 2017;8(60:102437-102445. 
Watters W 3rd, et al. Prevention of Orthopaedic Implant Infection in Patients Undergoing Dental Procedures. J Am Acad Orthop Surg. 2013;21(3):180.
Wilson W, Taubert KA, Gewitz M, Lockhart PB, Baddour LM, Levison M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2007;116(15):1736–1754.
Winthrop K. Do’s and Don’ts of Vaccination: a (very) brief guide for rheumatologists. RheumNow APR 2016 Retrieved 9/13/20 from https://rheumnow.com/blog/dos-and-donts-vaccination-very-brief-guide-rheumatologists
Winthrop K. The Immunogenicity and Safety of Zostavax® in Rheumatoid Arthritis Patients Using Abatacept (BMS-188667). Retrieved 9/7/20 from  https://clinicaltrials.gov/ct2/show/NCT03604406
Winthrop KL, Weinblatt ME, Daley CL. You can’t always get what you want, but if you try sometimes (with two tests–TST and IGRA–for tuberculosis) you get what you need. Ann Rheum Dis. 2012;71(11):1757-1760. doi:10.1136/annrheumdis-2012-201979
Winthrop KL, Wouters AG, Choy EH, et al. The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial. Arthritis Rheumatol. 2017;69(10):1969-1977. doi:10.1002/art.40187
World Health Organization. Tuberculosis. Retrieved 9/7/20 from https:///www.who.int/news-room/fact-sheets/detail/tuberculosis
Wu J, Keeley A, Mallen C, Morgan AW, Pujades-Rodriguez M. Incidence of infections associated with oral glucocorticoid dose in people diagnosed with polymyalgia rheumatica or giant cell arteritis: a cohort study in England. CMAJ. 2019 Jun 24;191(25):E680-E688. doi: 10.1503/cmaj.190178. PMID: 31235489; PMCID: PMC6592810.
Yao TC, Huang YW, Chang SM, Tsai SY, Wu AC, Tsai HJ. Association Between Oral Corticosteroid Bursts and Severe Adverse Events : A Nationwide Population-Based Cohort Study. Ann Intern Med. 2020 Sep 1;173(5):325-330. doi: 10.7326/M20-0432. Epub 2020 Jul 7. PMID: 32628532.
Yun, H., Yang, S., Chen, L., Xie, F., Winthrop, K., Baddley, J.W., Saag, K.G., Singh, J. and Curtis, J.R. (2016), Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for Vaccination. Arthritis & Rheumatology, 68: 2328-2337. doi:10.1002/art.39670

Chapter 23

Abdel-Wahab, Noha, MD, PhD, Shah, Mohsin, et al. Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease: A Systematic Review
. Ann Intern Med. 2018;168(2):121-130. doi:10.7326/M17-2073.
Andrew P, Valiani S, MacIsaac J, Mithoowani H, Verma S. Tamoxifen-associated skin reactions in breast cancer patients: from case report to literature review. Breast Cancer Res Treat. 2014;148(1):1-5. doi:10.1007/s10549-014-3150-0
Wadström H, Arkema EV, Sjöwall C, Askling J, Simard JF. Cervical neoplasia in systemic lupus erythematosus: a nationwide study. Rheumatology (Oxford). 2017;56(4):613-619. doi:10.1093/rheumatology/kew459
Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Urowitz M, et al. Race/ethnicity and cancer occurrence in systemic lupus erythematosus. Arthritis Care & Research. October 2005;53(5):781–784.
Bernatsky S, Boivin JF, Joseph L, Rajan R, Zoma A, Manzi S, et al. An international cohort study of cancer in systemic lupus erythematosus. Arthritis & Rheumatism. May 2005;52(5):1481–1490.
Bernatsky S, Easton DF, Dunning A, Michailidou K, Ramsey-Goldman R, et al. Decreased breast cancer risk in systemic lupus erythematosus: the search for a genetic basis continues. Lupus. July 2012;21(8):896–899.
Bernatsky S, Joseph L, Boivin J-F, Gordon C, Urowitz M, Gladman D, et al. The relationship between cancer and medication exposures in systemic lupus erythematosus: a case-cohort study. Annals of Rheumatic Diseases. 2008;67:74–79.
Bernatsky S, Clarke AE, Ramsey-Goldman R. Cancer in systemic lupus: what drives the risk? Cancer Causes Control. 2008;19:1413–1414.
Bernatsky S, Ramsey-Goldman R, Foulkes WD, Gordon C, Clarke AE. Breast, ovarian, and endometrial malignancies in systemic lupus erythematosus: a meta-analysis. British Journal of Cancer. 2011;104:1478–1481.
Bernatsky S, Ramsey-Goldman R, Joseph L, et al. Lymphoma risk in systemic lupus: effects of disease activity versus treatment. Ann Rheum Dis. 2014;73(1):138-142. doi:10.1136/annrheumdis-2012-202099
Bernatsky S, Ramsey-Goldman R, Joseph L, et al. Lymphoma risk in systemic lupus: effects of disease activity versus treatment. Ann Rheum Dis. 2014;73(1):138-142. doi:10.1136/annrheumdis-2012-202099
Bernatsky S, Ramsey-Goldman R, Petri M, et al. Breast cancer in systemic lupus [published correction appears in Lupus. 2017 Nov;26(13):1459]. Lupus. 2017;26(3):311-315. doi:10.1177/0961203316664595
Bernatsky, S., Ramsey‐Goldman, R., Urowitz, M.B., Hanly, J.G., Gordon, C., Petri, M.A., Ginzler, E.M., Wallace, D.J., Bae, S.‐C., Romero‐Diaz, J., Dooley, M.A., Peschken, C.A., Isenberg, D.A., Rahman, A., Manzi, S., Jacobsen, S., Lim, S.S., van Vollenhoven, R., Nived, O., Kamen, D.L., Aranow, C., Ruiz‐Irastorza, G., Sanchez‐Guerrero, J., Gladman, D.D., Fortin, P.R., Alarcón, G.S., Merrill, J.T., Kalunian, K.C., Ramos‐Casals, M., Steinsson, K., Zoma, A., Askanase, A., Khamashta, M.A., Bruce, I., Inanc, M. and Clarke, A.E. (2020), Cancer risk in a large inception SLE cohort: Effects of demographics, smoking, and medications. Arthritis Care Res. Accepted Author Manuscript. doi:10.1002/acr.24425
Bin J, Bernatsky S, Gordon C, Boivin J-F, Ginzler E, Gladman D, et al. Lung cancer in systemic lupus erythematosus. Lung Cancer. June 2007;56(3):303–306.
Dreyer L, Faurschou M, Mogensen M, Jacobsen S. High incidence of potentially virus-induced malignancies in systemic lupus erythematosus. Arthritis & Rheumatism. October 2011;63(10):3032–3037.
Buckley, L.M. and Suarez‐Almazor, M.E. (2019), Is Immune Checkpoint Inhibitor Treatment an Option for Patients With Rheumatic Diseases and Cancer?. Arthritis Rheumatol, 71: 1971-1973. doi:10.1002/art.41064
Carlesimo, M, Pigliacelli, F, D’Arino, A, et al. Isoradiotopic response of discoid lupus after radiotherapy: A case report and review of the literature. Dermatologic Therapy. 2020; 33:e13183. https://doi.org/10.1111/dth.13183
Cobo-Ibáñez T, Urruticoechea-Arana A, Rúa-Figueroa I, et al. Hormonal Dependence and Cancer in Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2020;72(2):216-224. doi:10.1002/acr.24068
Cohen L, Shah V, Chen PL, Messina J, Seminario-Vidal L. Cutaneous squamous cell carcinoma causing a rhinophymatous mass in a patient with clinically occult hypertrophic lupus erythematosus. Lupus. 2020;29(6):644-648. doi:10.1177/0961203320912838
Dhar JP, Essenmacher L, Dhar R, Magee A, Ager J, Sokol RJ. The safety and immunogenicity of Quadrivalent HPV (qHPV) vaccine in systemic lupus erythematosus. Vaccine. 2017;35(20):2642-2646. doi:10.1016/j.vaccine.2017.04.001
Dreyer L, Faurschou M, Mogensen M, Jacobsen S. High incidence of potentially virus-induced malignancies in systemic lupus erythematosus: a long-term followup study in a Danish cohort. Arthritis Rheum. 2011 Oct;63(10):3032-7. doi: 10.1002/art.30483. PMID: 21953088.
Feldman CH, Liu J, Feldman S, Solomon DH, Kim SC. Risk of high-grade cervical dysplasia and cervical cancer in women with systemic lupus erythematosus receiving immunosuppressive drugs. Lupus. 2017;26(7):682-689. doi:10.1177/0961203316672928
Fiedler B, Fiedler L, DeDonno M, et al. Underutilization of Aspirin in Patients With Advanced Colorectal Polyps. Am J Med. 2019;132(7):884-885. doi:10.1016/j.amjmed.2018.12.037
FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19):1915. 
Guo, J., Ren, Z., Li, J. et al. The relationship between cancer and medication exposure in patients with systemic lupus erythematosus: a nested case-control study. Arthritis Res Ther 22, 159 (2020). https://doi.org/10.1186/s13075-020-02228-6
Jamal S, Hudson M, Fifi-Mah A, Ye C. Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist. J Rheumatol. 2020;47(2):166-175. doi:10.3899/jrheum.190084
Jin J. JAMA PATIENT PAGE. Breast Cancer Screening Guidelines in the United States. JAMA. 2015;314(15):1658. doi:10.1001/jama.2015.11766
Kim HJ, et al. Alcohol Consumption and Breast Cancer Risk in Younger Women According to Family History of Breast Cancer and Folate Intake. Am J Epidemiol. 2017;186(5):524. 
Klein A, Polliack A, Gafter-Gvili A. Systemic lupus erythematosus and lymphoma: Incidence, pathogenesis and biology. Leuk Res. 2018;75:45-49. doi:10.1016/j.leukres.2018.11.004
Knight JS, Blayney DW, Somers EC. Patients with systemic lupus erythematosus and haematological malignancy at a tertiary care centre: timing, histopathology and therapy. Lupus Sci Med. 2014;1(1):e000051. Published 2014 Nov 14. doi:10.1136/lupus-2014-000051
Ladouceur A, Clarke AE, Ramsey-Goldman R, Bernatsky S. Malignancies in systemic lupus erythematosus: an update. Curr Opin Rheumatol. 2019;31(6):678-681. doi:10.1097/BOR.0000000000000648
Ladouceur A, Tessier-Cloutier B, Clarke AE, Ramsey-Goldman R, Gordon C, Hansen JE, Bernatsky S. Cancer and Systemic Lupus Erythematosus. Rheum Dis Clin North Am. 2020 Aug;46(3):533-550. doi: 10.1016/j.rdc.2020.05.005. Epub 2020 Jun 10. PMID: 32631602.
Lau E, Ong K, Kurtz S, Schmier J, Edidin A. Mortality following the diagnosis of a vertebral compression fracture in the Medicare population. J Bone Joint Surg Am. 2008 Jul;90(7):1479-86. doi: 10.2106/JBJS.G.00675. PMID: 18594096.
Lei J, et al. HPV Vaccination and the risk of invasive cervical cancer. NEJM 2020;383;14:1340.
Lin A, Abu-Isa E, Griffith KA, Ben-Josef E. Toxicity of radiotherapy in patients with collagen vascular disease. Cancer. 2008;113(3)648–653.
Lin D, Lehrer EJ, Rosenberg J, Trifiletti DM, Zaorsky NG. Toxicity after radiotherapy in patients with historically accepted contraindications to treatment (CONTRAD): An international systematic review and meta-analysis. Radiother Oncol. 2019;135:147-152. doi:10.1016/j.radonc.2019.03.006
Lo JC, Hui RL, Grimsrud CD, et al. The association of race/ethnicity and risk of atypical femur fracture among older women receiving oral bisphosphonate therapy. Bone. 2016;85:142-147. doi:10.1016/j.bone.2016.01.002
Löfström B, Backlin C, Sundström C, Ekbom A, Lundberg IE. A closer look at non-Hodgkin’s lymphoma cases in a national Swedish systemic lupus erythematosus cohort: a nested case-control study. Annals of Rheumatic Diseases. 2007;66:1627–1632.
Lyles KW, Colón-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357(18):1799-1809. doi:10.1056/NEJMoa074941
Mamtani R, Clark AS, Scott FI, et al. Association Between Breast Cancer Recurrence and Immunosuppression in Rheumatoid Arthritis and Inflammatory Bowel Disease: A Cohort Study. Arthritis Rheumatol. 2016;68(10):2403-2411. doi:10.1002/art.39738
Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF; American Academy of Ophthalmology. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmology. 2016;123(6):1386-1394. doi:10.1016/j.ophtha.2016.01.058
McDonald JA, Goyal A, Terry MB. Alcohol Intake and Breast Cancer Risk: Weighing the Overall Evidence. Curr Breast Cancer Rep. 2013;5(3):10.1007/s12609-013-0114-z. doi:10.1007/s12609-013-0114-z
Mercer LK, Galloway JB, Lunt M, et al. Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis. 2017;76(3):497-503. doi:10.1136/annrheumdis-2016-209389
Moyer VA; U.S. Preventive Services Task Force. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;160(5):330-338. doi:10.7326/M13-2771
Nath R, Mant C, Luxton J, et al. High risk of human papillomavirus type 16 infections and of development of cervical squamous intraepithelial lesions in systemic lupus erythematosus patients. Arthritis Rheum. 2007;57(4):619-625. doi:10.1002/art.22667
Ni J, Qiu L-J, Hu L-F, et al. Lung, liver, prostate, bladder malignancies risk in systemic lupus erythematosus: evidence from a meta-analysis. Lupus. 2014;23(3):284-292. doi:10.1177/0961203313520060
Oeffinger KC, Fontham ET, Etzioni R, et al. Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society [published correction appears in JAMA. 2016 Apr 5;315(13):1406]. JAMA. 2015;314(15):1599-1614. doi:10.1001/jama.2015.12783
Ornstein MC, Calabrese C, Wood LS, et al. Myalgia and Arthralgia Immune-related Adverse Events (irAEs) in Patients With Genitourinary Malignancies Treated With Immune Checkpoint Inhibitors. Clin Genitourin Cancer. 2019;17(3):177-182. doi:10.1016/j.clgc.2019.01.021
Palter JT. Lupus in action The Lupus Foundation of America. Lupus Living Magazine Spring 2014:26
Parikh-Patel A, White RH, Allen M, Cress R. Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California. Cancer Causes Control. 2008;19:887–894.
Pinn ME, Gold DG, Petersen IA, Osborn TG, Brown PD, Miller RC. Systemic lupus erythematosus, radiotherapy, and the risk of acute and chronic toxicity: the Mayo Clinic experience. International Journal of Radiation Oncology • Biology • Physics. June 2008;71(2):498–506.
Raaschou P, Simard JF, Holmqvist M, Askling J; ARTIS Study Group. Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden. BMJ. 2013;346:f1939. Published 2013 Apr 8. doi:10.1136/bmj.f1939
Ragnarsson O, Gröndal G, Steinsson K. Risk of malignancy in an unselected cohort of Icelandic patients with systemic lupus erythematosus. Lupus. 2003;12(9):687–691.
Raschi E, Antonazzo IC, Poluzzi E, et al. Drug-induced systemic lupus erythematosus: should immune checkpoint inhibitors be added to the evolving list? Annals of the Rheumatic Diseases Published Online First: 12 June 2019. doi: 10.1136/annrheumdis-2019-215819
Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol. 2019;14(2):89-103. doi:10.5114/pg.2018.81072
Rees F, Doherty M, Grainge M, Lanyon P, Davenport G, Zhang W. Burden of Comorbidity in Systemic Lupus Erythematosus in the UK, 1999-2012. Arthritis Care Res (Hoboken). 2016;68(6):819-827. doi:10.1002/acr.22751
Richter MD, Crowson C, Kottschade LA, Finnes HD, Markovic SN, Thanarajasingam U. Rheumatic Syndromes Associated With Immune Checkpoint Inhibitors: A Single-Center Cohort of Sixty-One
Patients. Arthritis Rheumatol. 2019;71(3):468-475. doi:10.1002/art.40745
Richter MD, Pinkston O, Kottschade LA, Finnes HD, Markovic SN, Thanarajasingam U. Brief Report: Cancer Immunotherapy in Patients With Preexisting Rheumatic Disease: The Mayo Clinic Experience. Arthritis Rheumatol. 2018;70(3):356-360. doi:10.1002/art.40397
Song, L., Wang, Y., Zhang, J. et al. The risks of cancer development in systemic lupus erythematosus (SLE) patients: a systematic review and meta-analysis. Arthritis Res Ther 20, 270 (2018). https://doi.org/10.1186/s13075-018-1760-3
Szczęch J, Samotij D, Werth VP, Reich A. Trigger factors of cutaneous lupus erythematosus: a review of current literature. Lupus. 2017;26(8):791-807. doi:10.1177/0961203317691369
Tam S-S, Chan PKS, Ho SC, Yu M-Y, Yim S-F, Cheung T-H, et al. Risk factors for squamous intraepithelial lesions in systemic lupus erythematosus: a prospective cohort study. Arthritis Care & Research. February 2011;63(2):269–276.
The Johns Hopkins Lupus Center. Lupus and cancer. Retrieved June 4, 2011, from the Johns Hopkins Lupus Center website, www.hopkinslupus.org/lupus-info/lifestyle-additional-information/lupus-cancer/
Tison, A., Quéré, G., Misery, L., Funck‐Brentano, E., Danlos, F.‐X., Routier, E., Robert, C., Loriot, Y., Lambotte, O., Bonniaud, B., Scalbert, C., Maanaoui, S., Lesimple, T., Martinez, S., Marcq, M., Chouaid, C., Dubos, C., Brunet‐Possenti, F., Stavris, C., Chiche, L., Beneton, N., Mansard, S., Guisier, F., Doubre, H., Skowron, F., Aubin, F., Zehou, O., Roge, C., Lambert, M., Pham‐Ledard, A., Beylot‐Barry, M., Veillon, R., Kramkimel, N., Giacchero, D., De Quatrebarbes, J., Michel, C., Auliac, J.‐B., Gonzales, G., Decroisette, C., Le Garff, G., Carpiuc, I., Vallerand, H., Nowak, E., Cornec, D., Kostine, M. and (2019), Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study. Arthritis Rheumatol, 71: 2100-2111. doi:10.1002/art.41068
Watson SL, Weeks BK, Weis LJ, Harding AT, Horan SA, Beck BR. High-Intensity Resistance and Impact Training Improves Bone Mineral Density and Physical Function in Postmenopausal Women With Osteopenia and Osteoporosis: The LIFTMOR Randomized Controlled Trial. J Bone Miner Res. 2018 Feb;33(2):211-220. doi: 10.1002/jbmr.3284. Epub 2017 Oct 4. Erratum in: J Bone Miner Res. 2019 Mar;34(3):572. PMID: 28975661.
White AJ, et al. Lifetime Alcohol Intake, Binge Drinking Behaviors, and Breast Cancer Risk. Am J Epidemiol. 2017;186(5):541. 
Wilt TJ, et al. Screening for cancer: advice for high-value care from the American College of Physicians. Ann Intern Med. 2015;162(10):718. 

Chapter 24

Abbasi J. Amid Osteoporosis Treatment Crisis, Experts Suggest Addressing Patients’ Bisphosphonate Concerns. JAMA. 2018 Jun 26;319(24):2464-2466. doi: 10.1001/jama.2018.7097. PMID: 29874373.
Abrahmsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. Journal of Bone and Mineral Research. 2009;24(6):1095–1102.
Adami G, Saag KG. Glucocorticoid-induced osteoporosis update. Curr Opin Rheumatol. 2019 Jul;31(4):388-393. doi: 10.1097/BOR.0000000000000608. PMID: 31045947.
Adler RA, et al. Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016;31(1):16.
Anagnostis P, et al. Calcium and vitamin D supplements and fractures in community-dwelling adults. JAMA 2018;319:2041.
Andersen BN, Johansen PB, Abrahamsen B. Proton pump inhibitors and osteoporosis. Curr Opin Rheumatol. 2016 Jul;28(4):420-5. doi: 10.1097/BOR.0000000000000291. PMID: 27224743.
Bhambri R. et al. Changes in bone mineral density following treatment of osteomalacia. J Clin Densitom. 2006;9(1):120. Epub 2006 Mar 27. 
Binding C, Bjerring Olesen J, Abrahamsen B, Staerk L, Gislason G, Nissen Bonde A. Osteoporotic Fractures in Patients With Atrial Fibrillation Treated With Conventional Versus Direct Anticoagulants. J Am Coll Cardiol. 2019 Oct 29;74(17):2150-2158. doi: 10.1016/j.jacc.2019.08.1025. PMID: 31648707.
Bischoff-Ferrari HA, Willett WC, Orav EJ, Lips P, Meunier PJ, Lyons RA, Flicker L, Wark J, Jackson RD, Cauley JA, Meyer HE, Pfeifer M, Sanders KM, Stähelin HB, Theiler R, Dawson-Hughes B. A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med. 2012 Jul 5;367(1):40-9. doi: 10.1056/NEJMoa1109617. Erratum in: N Engl J Med. 2012 Aug 2;367(5):481. Oray, Endel J [corrected to Orav, Endel J]. PMID: 22762317.
Black DM, Geiger EJ, Eastell R, Vittinghoff E, Li BH, Ryan DS, Dell RM, Adams AL. Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates. N Engl J Med. 2020 Aug 20;383(8):743-753. doi: 10.1056/NEJMoa1916525. PMID: 32813950.
Black, DM, et al. Atypical femur fractures: review and epidemiology, relationship to bisphosphonates, prevention and clinical management. Endocr Rev 2019;40(2):333-368.
Black DM, Rosen CJ. Clinical Practice. Postmenopausal Osteoporosis. N Engl J Med. 2016 Jan 21;374(3):254-62. doi: 10.1056/NEJMcp1513724. Erratum in: N Engl J Med. ;374(18):1797. PMID: 26789873.
Bliuc, D., Tran, T., van Geel, T., Adachi, J.D., Berger, C., van den Bergh, J., Eisman, J.A., Geusens, P., Goltzman, D., Hanley, D.A., Josse, R., Kaiser, S., Kovacs, C.S., Langsetmo, L., Prior, J.C., Nguyen, T.V., Center, J.R. and (2019), Reduced Bone Loss Is Associated With Reduced Mortality Risk in Subjects Exposed to Nitrogen Bisphosphonates: A Mediation Analysis. J Bone Miner Res, 34: 2001-2011. doi:10.1002/jbmr.3816
Bonakdar ZS, Jahanshahifar L, Jahanshahifar F, Gholamrezaei A. Vitamin D deficiency and its association with disease activity in new cases of systemic lupus erythematosus. Lupus. 2011;20:1155–1160.
Brunk D. Anabolic agents for osteoporosis have limited role so far. Rheumatology News AUG 2017:32.
Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, Humphrey MB, Lane NE, Magrey M, Miller M, Morrison L, Rao M, Robinson AB, Saha S, Wolver S, Bannuru RR, Vaysbrot E, Osani M, Turgunbaev M, Miller AS, McAlindon T. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol. 2017
Aug;69(8):1521-1537. doi: 10.1002/art.40137. Epub 2017 Jun 6. Erratum in: Arthritis Rheumatol. 2017 Nov;69(11):2246. PMID: 28585373.
Bultink IE, Lems WF. Lupus and fractures. Curr Opin Rheumatol. 2016 Jul;28(4):426-32. doi: 10.1097/BOR.0000000000000290. PMID: 26978130.
Bultink IE. Osteoporosis and fractures in systemic lupus erythematosus. Arthritis Care & Research. 2012;64(1):2–8. Drug Safety Quarterly. The American College of Rheumatology. October 2011;3(2).
Burns RB, Rosen H, Berry S, Smetana GW. How Would You Manage This Patient With Osteoporosis?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center. Ann Intern Med. 2018 Jun 5;168(11):801-808. doi: 10.7326/M18-0950. PMID: 29868815.
Caplan L, Hansen KE, Saag KG. Response to the American College of Physicians Osteoporosis Guideline, 2017 Update. Arthritis Rheumatol. 2017 Nov;69(11):2097-2101. doi: 10.1002/art.40305. Epub 2017 Oct 17. PMID: 28881479.
Carli L, Tani C, Spera V, et al. Risk factors for osteoporosis and fragility fractures in patients with systemic lupus erythematosus. Lupus Science & Medicine 2016;3:e000098. doi: 10.1136/lupus-2015-000098
Cohen SB, et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum. 2008;58(5):1299. 
Cramarossa G, Urowitz MB, Su J, Gladman D, Touma Z. Prevalence and associated factors of low bone mass in adults with systemic lupus erythematosus. Lupus. 2017 Apr;26(4):365-372. doi: 10.1177/0961203316664597. Epub 2016 Aug 20. PMID: 27522094.
Craven J. Romosozumab benefits osteoporosis patients regardless of renal insufficiency. Rheumatology News NOV 2019:36.
Curtis JR, et al. The impact of the duration of bisphosphonate drug holidays on hip fracture rates [abstract]. Arthr Rheum 2017;26(suppl 10).
Curtis JR, Xie F, Yun H, Saag KG, Chen L, Delzell E. Risk of hospitalized infection among rheumatoid arthritis patients concurrently treated with a biologic agent and denosumab. Arthritis Rheumatol. 2015 Jun;67(6):1456-64. doi: 10.1002/art.39075. PMID: 25708920.
Eastell R, Clifford J Rosen, Dennis M Black, Angela M Cheung, M Hassan Murad, Dolores Shoback, Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline, The Journal of Clinical Endocrinology & Metabolism, Volume 104, Issue 5, May 2019, Pages 1595–1622, https://doi.org/10.1210/jc.2019-00221
Ensrud KE, Crandall CJ. Bisphosphonates for Postmenopausal Osteoporosis. JAMA. 2019 Oct 17. doi: 10.1001/jama.2019.15781. Epub ahead of print. PMID: 31621799.
European Medicines Agency recommends limiting long-term use of calcitonin medicines https:///www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/public_health_alerts/2012/07/human_pha_detail_000065.jsp&mid=WC0b01ac058001d126 (Accessed on October 17, 2012). no abstract available.
FDA. Background Document for Meeting of Advisory Committee for Reproductive Health Drugs and Drug Safety and Risk Management Advisory Committee. https:///www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/ UCM341779.pdf (Accessed on March 06, 2013). no abstract available.
FDA. https:///www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisory Committee/UCM270958.pdf (Accessed on June 13, 2012). No abstract available
Cosman F, et al. Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial. Mayo Clin Proc. 2017;92(2):200. 
European Medicines Agency recommends limiting long-term use of calcitonin medicines https:///www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/public_health_alerts/2012/07/human_pha_detail_000065.jsp&mid=WC0b01ac058001d126 (Accessed on October 17, 2012). 
no abstract available
Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid- induced osteoporosis. Arthritis Care & Research. 2010;62:1515–1526.
Hansdóttir H. Raloxifene for older women: a review of the literature. Clin Interv Aging. 2008;3(1):45-50. doi:10.2147/cia.s224
Health Information. Office of Dietary Supplements, National Institutes of Health. Dietary supplemental fact sheet: Vitamin D: Health Professional. February 25, 2011. Retrieved June 5, 2011, from www.ods.od.nih.gov/factsheets/vitamind/.
Hetény S, Ohlsson C, Carlsten H, Forsblad-d’Elia H. Prevalence and risk factors of vertebral compression fractures in female SLE patients. Arthritis Research & Therapy. August 2010;12(4):R153.
Hoff, M., Skovlund, E., Skurtveit, S. et al. Proton pump inhibitors and fracture risk. The HUNT study, Norway. Osteoporos Int 31, 109–118 (2020). https://doi.org/10.1007/s00198-019-05206-0
Holliman K. Glucocorticoids: a fracture risk at any dose. The Rheumatologist. March 2011; 43–54. Kamen DL. Vitamin D: new kid on the block? Bulletin of the NYU Hospital for Joint Diseases. 2010;68(3):218–222.
Institute of Medicine. Report at a Glance, Report Brief: Dietary reference intakes for calcium and vitamin D, released 11/30/2010. https:///www.iom.edu/Reports/2010/Dietary-Reference-Intakes-for-Calcium-and-Vitamin-D/Report-Brief.aspx (Accessed on December 01, 2010).
International Society of Clinical Densitometry. ISCD Official Positions. Retrieved 9/30/20 from https:///www.iscd.org/official-positions/2019-iscd-official-positions-adult/
Ishani A, et al. The effect of raloxifene treatment in postmenopausal women with CKD. J Am Soc Nephrol. 2008 Jul;19(7):1430-8. Epub 2008 Apr 9.
Jamal SA, et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res. 2011;26(8):1829. 
Jamal SA, et al. Fracture risk assessment in patients with chronic kidney disease. Osteoporos Int. 2012 Apr;23(4):1191-8. Epub 2011 Sep 8. 
Johnell O, et al. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis
. J Clin Endocrinol Metab. 2002;87(3):985. 
Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L, Moe SM, Shroff R, Tonelli MA, Toussaint ND, Vervloet MG, Leonard MB. Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder: Synopsis of the Kidney Disease: Improving Global Outcomes 2017 Clinical Practice Guideline Update. Ann Intern Med. 2018 Mar 20;168(6):422-430. doi: 10.7326/M17-2640. Epub 2018 Feb 20. PMID: 29459980.
Khan AA, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015;30(1):3. 
Khan AA, Rios LP, Sándor GKB, Khan N, Peters E, Rahman MO, et al. Bisphosphonate-associated osteonecrosis of the jaw in Ontario: a survey of oral and maxillofacial surgeons. Journal of Rheumatology. 2011;38(7):1396–1402.
Lai E-L, Huang W-N, Chen H-H, et al. Ten-year fracture risk by FRAX and osteoporotic fractures in patients with systemic autoimmune diseases. Lupus. 2019;28(8):945-953. doi:10.1177/0961203319855122
Laroche M, Cantogrel S, Jamard B, et al. Comparison of the analgesic efficacy of pamidronate and synthetic human calcitonin in osteoporotic vertebral fractures: a double-blind controlled study. Clin Rheumatol. 2006;25:683-686
Lau WCY, Cheung CL, Man KKC, Chan EW, Sing CW, Lip GYH, Siu CW, Lam JKY, Lee ACH, Wong ICK. Association Between Treatment With Apixaban, Dabigatran, Rivaroxaban, or Warfarin and Risk for Osteoporotic Fractures Among Patients With Atrial Fibrillation: A Population-Based Cohort Study. Ann Intern Med. 2020 Jul 7;173(1):1-9. doi: 10.7326/M19-3671. Epub 2020 May 19. PMID: 32423351.
Leutner M, Matzhold C, Bellach L, et al. Diagnosis of osteoporosis in statin-treated patients is dose-dependent. Annals of the Rheumatic Diseases 2019;78:1706-1711.
Levis S, Strickman-Stein N, Ganjei-Azar P, Xu P, Doerge DR, Krischer J. Soy isoflavones in the prevention of menopausal bone loss and menopausal symptoms: a randomized, doubleblind trial. Archives of Internal Medicine. August 2011;171(15):1363–1369.
Lewiecki EM, Bilezikian JP, Khosla S, Marcus R, McClung MR, Miller PD, et al. Osteoporosis update from the 2010 Santa Fe Bone Symposium. Journal of Clinical Densitometry: Assessment of Skeletal Health. 2011;14(1):1–21.
Liao MT, Chien WC, Wang JC, Chung CH, Chu SJ, Tsai SH. Increased risk of bisphosphonate-related osteonecrosis of the jaw in patients with Sjögren’s syndrome: nationwide population-based cohort study. BMJ Open. 2019 Feb 13;9(2):e024655. doi: 10.1136/bmjopen-2018-024655. PMID: 30765404; PMCID: PMC6398708.
Lyu H, Yoshida K, Zhao SS, Wei J, Zeng C, Tedeschi SK, Leder BZ, Lei G, Tang P, Solomon DH. Delayed Denosumab Injections and Fracture Risk Among Patients With Osteoporosis : A Population-Based Cohort Study. Ann Intern Med. 2020 Oct 6;173(7):516-526. doi: 10.7326/M20-0882. Epub 2020 Jul 28. PMID: 32716706.
Meier RPH, Perneger TV, Stern R, Rizzoli R, Pete RE. Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. Archives of Internal Medicine. 2012;172:930–936.
Morrison RS, et al. The medical consultant’s role in caring for patients with hip fracture. Ann Intern Med. 1998;128(12 Pt 1):1010.  National Osteoporosis Foundation. 25 calcium-rich foods. Retrieved June 5, 2011, from www.bones.nof.org/site/PageServerpagename=NOF_25th_Anniversary_CalciumRich_Foods.
Nevitt MC, et al. Reduced risk of back pain following teriparatide treatment: a meta-analysis. Osteoporos Int. 2006;17(2):273. Epub 2005 Sep 2. 
Ofluoglu D, Akyuz G, Unay O, Kayhan O. The effect of calcitonin on beta-endorphin levels in postmenopausal osteoporotic patients with back pain. Clin Rheumatol. 2007;26:44-49.
Østensen M, Khamashta M, Lockshin M, Parke A, Brucato A, Carp H, et al. Anti-inflammatory and immunosuppressive drugs and reproduction [Review]. Arthritis Research & Therapy. May 2006;8:209–227.
Panula, J, et al. Mortality and cause of death in hip fracture patients aged 65 or older: a population-based study. BMC Musculoskelet Disord. 2011;12:105. Epub 2011 May 20.
Pullen L. Bone health tips. The Rheumatologist MAR 2019:88.
Qaseem A, Forciea MA, McLean RM, Denberg TD; Clinical Guidelines Committee of the American College of Physicians. Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians. Ann Intern Med. 2017 Jun 6;166(11):818-839. doi: 10.7326/M15-1361. Epub 2017 May 9. Erratum in: Ann Intern Med. 2017 Sep 19;167(6):448. PMID: 28492856.
Rees F, Doherty M, Grainge M, Lanyon P, Davenport G, Zhang W. Burden of Comorbidity in Systemic Lupus Erythematosus in the UK, 1999-2012. Arthritis Care Res (Hoboken). 2016 Jun;68(6):819-27. doi: 10.1002/acr.22751. PMID: 26473719.
Rosen CJ, Gallagher JC. The 2011 IOM report on vitamin D and calcium requirements for North America: clinical implications for providers treating patients with low bone mineral density. Journal of Clinical Densitometry: Assessment of Skeletal Health. 2011;14(2):79–84.
Roux C, Briot K. The crisis of inadequate treatment in osteoporosis. February 2020 The Lancet Rheumatology 2(2):e110-e119
Ruiz-Irastorza G, Gordo S, Olivares N, Egurbide M-V, Aguirre C. Changes in vitamin D levels in patients with systemic lupus erythematosus: effects on fatigue, disease activity, and damage. Arthritis Care & Research. August 2010; 62(8):1160–1165.
Saag KG, et al. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. N Engl J Med. 2017;377(15):1417. Epub 2017 Sep 11. 
Santoro N, Johnson J. Diagnosing the Onset of Menopause. JAMA. 2019 Jul 22. doi: 10.1001/jama.2019.6250. Epub ahead of print. PMID: 31329213.
Santos MJ, Vinagre F, Canas da Silva J, Gil V, Fonseca JE. Body composition phenotypes in systemic lupus erythematosus and rheumatoid arthritis: a comparative study of Caucasian female patients. Clin Exp Rheumatol. 2011;29:470-476. 
Sapkota S, Baig S, Hess T, O’Connell AM, Menk J, Shyne M, Fazeli P, Ensrud K, Shmagel A. Vitamin D and bisphosphonate therapy in systemic lupus erythematosus patients who receive glucocorticoids: are we offering the
best care? Lupus. 2020 Mar;29(3):263-272. doi: 10.1177/0961203320903086. Epub 2020 Jan 29. PMID: 31996109.
Schilcher J, Koeppen V, Aspenberg P, Michaëlsson K. Risk of atypical femoral fracture during and after bisphosphonate use. Acta Orthop. 2015 Feb;86(1):100-7. doi: 10.3109/17453674.2015.1004149. Epub 2015 Jan 13. PMID: 25582459; PMCID: PMC4366670.
Sosa M, Gómez de Tejada MJ. Glucocorticoid-Induced Osteoporosis. N Engl J Med. 2019 Apr 4;380(14):1378-1379. doi: 10.1056/NEJMc1901239. PMID: 30943350.
Sumit R. Majumdar, Suzanne N. Morin, Lisa M. Lix, et al. Change in Bone Mineral Density Is an Indicator of Treatment-Related Antifracture Effect in Routine Clinical Practice: A Registry-Based Cohort Study. Annals of Internal Medicine 2016;165:465-472. [Epub ahead of print 19 July 2016]. doi:https://doi.org/10.7326/M15-2937
Swayambunathan J, Dasgupta A, Rosenberg PS, Hannan MT, Kiel DP, Bhattacharyya T. Incidence of hip fracture over 4 decades in the Framingham Heart Study. JAMA Intern Med. 2020 Jul 27. doi: 10.1001/jamainternmed.2020.2975. Online ahead of print.
Tedeschi SK, Kim SC, Guan H, Grossman JM, Costenbader KH. Comparative Fracture Risks Among United States Medicaid Enrollees With and Those Without Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019 Jul;71(7):1141-1146. doi: 10.1002/art.40818. Epub 2019 Jun 5. PMID: 30714690; PMCID: PMC6594862.
Trovas G. Letter to the Editor: Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Nine Clinical Cases Report. J Clin Endocrinol Metab. 2017 Mar 1;102(3):1086. doi: 10.1210/jc.2016-3781. PMID: 28359104.
Wotton CJ, Green J, Brown A, Armstrong MEG, Floud S, Beral V, Reeves GK; Million Women Study collaborators. Use of oral bisphosphonates and risk of hospital admission with osteonecrosis of the jaw: Large prospective cohort study in UK women. Bone. 2019 Jul;124:69-74. doi: 10.1016/j.bone.2019.04.003. Epub 2019 Apr 5. PMID: 30959190.

Chapter 25

Agarwala S, Shah S, Joshi VR. The use of alendronate in the treatment of avascular necrosis of the femoral head: follow-up to eight years. Journal of Bone and Joint Surgery (British Volume). 2009;91(8):1013–1018.
Ajmal M, Matas AJ, Kuskowski M, Cheng EY. Does statin usage reduce the risk of corticosteroid-related osteonecrosis in renal transplant population? Orthop Clin North Am. 2009;40(2):235. 
Bosco G, Vezzani G, Mrakic Sposta S, Rizzato A, Enten G, Abou-Samra A, Malacrida S, Quartesan S, Vezzoli A, Camporesi E. Hyperbaric oxygen therapy ameliorates osteonecrosis in patients by modulating inflammation and oxidative stress. J Enzyme Inhib Med Chem. 2018;33(1):1501. 
Claßen T, Becker A, Landgraeber S, Haversath M, Li X, Zilkens C, Krauspe R, Jäger M. Long-term Clinical Results after Iloprost Treatment for Bone Marrow Edema and Avascular Necrosis. Orthop Rev (Pavia). 2016;8(1):6150. Epub 2016 Mar 31. 
Dubois EL, ed. Dubois’ Lupus Erythematosus. New York: McGraw Hill; 1966:229–239.
Dubois EL, Cozen L. Avascular (aseptic) necrosis associated with systemic lupus erythematosus. Journal of the American Medical Association. 1960;174(8):966–971.
Glueck CJ, Freiberg RA, Wang P. Koo KH, Mont M, Jones L. Treatment of osteonecrosis of the hip and knee with enoxaparin. Osteonecrosis. Berlin, Germany: Springer-Verlag; 2014. 241–7.​
Guo, Peipei MMa; Gao, Fuqiang MDb; Wang, Yanhua MDc; Zhang, Zhenkun MMd; Sun, Wei MDb,*; Jiang, Baoguo MDc; Wang, Bailiang MDb; Li, Zirong MDb The use of anticoagulants for prevention and treatment of osteonecrosis of the femoral head, Medicine: April 2017 – Volume 96 – Issue 16 – p e6646 doi: 10.1097/MD.0000000000006646
Karim AR, et al. Osteonecrosis of the knee: review. Ann Transl Med. 2015;3(1):6. 
Hussein S, Manon Suitner, Sarah Béland-Bonenfant, Alexandra Baril-Dionne, Ben Vandermeer, Nancy Santesso, Stephanie Keeling, Janet E. Pope, Aurore Fifi-Mah and Josiane Bourré-Tessier. Monitoring of Osteonecrosis in Systemic Lupus Erythematosus: A Systematic Review and Metaanalysis. The Journal of Rheumatology October 2018, 45 (10) 1462-1476; DOI: https://doi.org/10.3899/jrheum.170837
Li D, et al. Efficacy of bisphosphonates in the treatment of femoral head osteonecrosis: A PRISMA-compliant meta-analysis of animal studies and clinical trials. Sci Rep. 2018;8(1):1450. Epub 2018 Jan 23. 
Massari L, Fini M, Cadossi R, Setti S, Traina GC. Biophysical stimulation with pulsed electromagnetic fields in osteonecrosis of the femoral head. J Bone Joint Surg Am. 2006 Nov;88 Suppl 3:56-60. 
Mont MA, Carbone JJ, Fairbank AC. Core decompression versus nonoperative management for osteonecrosis of the hip. Clinical Orthopaedics and Related Research. 1996;324:169–178.
Nagasawa K, Tada Y, Koarada S, Tsukamoto H, Horiuchi T, Yoshizawa S, et al. Prevention of steroid-induced osteonecrosis of femoral head in systemic lupus erythematosus by anticoagulant. Lupus. 2006;15(6):354–357.
Nagasawa K, Tsukamoto H, Tada Y, Mayumi T, Satoh H, Onitsuka H, et al. Imaging study  on the mode of development and changes in avascular necrosis of the femoral head in systemic lupus erythematosus: long-term observations. British Journal of Rheumatology. 1994;33(4):343–347.
Prasad R, Ibanez D, Gladman D, Urowitz M. The role of non-corticosteroid related factors in osteonecrosis (ON) in systemic lupus erythematosus: a nested case-control study of inception patients. Lupus. 2007;16:157–162.
Tse SM, Mok CC. Time trend and risk factors of avascular bone necrosis in patients with systemic lupus erythematosus. Lupus. 2017;26(7):715-722. doi:10.1177/0961203316676384​
Wen Z, et al. Influence of cigarette smoking on osteonecrosis of the femoral head (ONFH): a systematic review and meta-analysis. Hip Int. 2017;27(5):425. Epub 2017 May 29. 
Zhang Q, Liu L, Sun W, Gao F, Cheng L, Li Z. Extracorporeal shockwave therapy in osteonecrosis of femoral head: A systematic review of now available clinical evidences. Medicine (Baltimore). 2017;96(4):e5897. 
Zhang, K., Zheng, Y., Jia, J. et al. Systemic lupus erythematosus patients with high disease activity are associated with accelerated incidence of osteonecrosis: a systematic review and meta-analysis. Clin Rheumatol 37, 5–11 (2018). https://doi.org/10.1007/s10067-017-3820-5
Zizic TM. Avascular necrosis of bone. Current Opinion in Rheumatology. 1990;2:26–37.

Chapter 26

Aziz A. Alkatib, Mihaela Cosma, Mohamed B. Elamin, Dana Erickson, Brian A. Swiglo, Patricia J. Erwin, Victor M. Montori, A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials of DHEA Treatment Effects on Quality of Life in Women with Adrenal Insufficiency, The Journal of Clinical Endocrinology & Metabolism, Volume 94, Issue 10, 1 October 2009, Pages 3676–3681, https://doi.org/10.1210/jc.2009-0672
Faure L, Kolenc M. [Comatous form of acute adrenal insufficiency caused by sudden interruption of cortisone therapy of long duration in persistent asthma; cure by an extracted adrenal cortex hormone]. Journal de Medecine de Bordeaux et du Sud-Ouest. October 1954;131(10):1196–1199.
Hussain S, et al. Fasting with adrenal insufficiency: Practical guidance for healthcare professionals managing patients on steroids during Ramadan. Clin Endocrinol (Oxf). 2020;93(2):87. Epub 2020 Jun 15. 
Lewis L, Robinson RF, Yee J, Hacker LA, Eisen G. Fatal adrenal cortical insufficiency precipitated by surgery during prolonged continuous cortisone treatment. Annals of Internal Medicine. July 1953;39(1):116–126.
Salem M, Tainsh Jr RE, Bromberg J, Loriaux DL, Chernow B. Perioperative glucocorticoid coverage: a reassessment 42 years after emergence of a problem. Annals of Surgery. 1994;219(4):416–425.
Siddiqi SS, Singh SK, Khan SA, et al. Guidelines regarding management of adrenal insufficiency in the Holy month of Ramadan. Indian J Endocrinol Metab. 2012;16(4):519-521. doi:10.4103/2230-8210.97999​

Chapter 27

Aaron LA, et al. Overlapping conditions among patients with chronic fatigue syndrome, fibromyalgia, and temporomandibular disorder. Arch Intern Med. 2000;160(2):221. 
Abebe W. Herbal medication: potential for adverse interactions with analgesic drugs. Journal of Clinical Pharmacy and Therapeutics. December 2002;27(6):391–401.
Altan L, Korkmaz N, Bingol U, Gunay B. Effect of pilates training on people with fibromyalgia syndrome: a pilot study. Arch Phys Med Rehabil. 2009 Dec;90(12):1983-8. doi: 10.1016/j.apmr.2009.06.021. PMID: 19969158.​
Alves CR, Santiago BM, Lima FR, et al. Creatine supplementation in fibromyalgia: a randomized, double-blind, placebo-controlled trial. Arthritis Care Res (Hoboken) 2013; 65:1449.​
Arnold LM, et al. Family study of fibromyalgia. Arthritis Rheum. 2004;50(3):944. 
Ben-Ami Shor D, Weitzman D, Dahan S, Gendelman O, Bar-On Y, Amital D, Shalev V, Chodick G, Amital H. Adherence and Persistence with Drug Therapy among Fibromyalgia Patients: Data from a Large Health Maintenance Organization. J Rheumatol. 2017 Oct;44(10):1499-1506. doi: 10.3899/jrheum.170098. Epub 2017 Aug 1. Erratum in: J Rheumatol. 2017 Nov;44(11):1762. PMID: 28765248.
Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. Mil Med. 2015 Jul; 180(7):721-3.
Brosseau L, Wells GA, Tugwell P, Egan M, Wilson KG, Dubouloz CJ, Casimiro L, Robinson VA, McGowan J, Busch A, Poitras S, Moldofsky H, Harth M, Finestone HM, Nielson W, Haines-Wangda A, Russell-Doreleyers M, Lambert K, Marshall AD, Veilleux L; Ottawa Panel Members. Ottawa Panel evidence-based clinical practice guidelines for aerobic fitness exercises in the management of fibromyalgia: part 1 and 2. Phys Ther. 2008 Jul;88(7):857-86. doi: 10.2522/ptj.20070200. Epub 2008 May 22. PMID: 18497301.
Busch AJ, Webber SC, Brachaniec M, Bidonde J, Bello-Haas VD, Danyliw AD, Overend TJ, Richards RS, Sawant A, Schachter CL. Exercise therapy for fibromyalgia. Curr Pain Headache Rep. 2011 Oct;15(5):358-67. doi: 10.1007/s11916-011-0214-2. PMID: 21725900; PMCID: PMC3165132.
Carson JW, Carson KM, Jones KD, Bennett RM, Wright CL, Mist SD. A pilot randomized controlled trial of the Yoga of Awareness program in the management of fibromyalgia. Pain. 2010;151(2):530–539.
Clayton EW. Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: An IOM Report on Redefining an Illness. JAMA. 2015;313(11):1101–1102. doi:10.1001/jama.2015.1346
Cuatrecasas G, Alegre C, Fernandez-Solà J, et al. Growth hormone treatment for sustained pain reduction and improvement in quality of life in severe fibromyalgia. Pain 2012; 153:1382.
Curtis AF, Miller MB, Rathinakumar H, et al. Opioid use, pain intensity, age, and sleep architecture in patients with fibromyalgia and insomnia. Pain 2019; 160:2086.​
Cush J. The Obfuscation of fibromyalgia. RheumNow JUN 2015; retrieved 10/24/20 from https://rheumnow.com/blog/obfuscation-fibromyalgia
Davis KD, Nima Aghaeepour, Andrew H. Ahn, Martin S. Angst, David Borsook, Ashley Brenton, Michael E. Burczynski, Christopher Crean, Robert Edwards, Brice Gaudilliere, Georgene W. Hergenroeder, Michael J. Iadarola, Smriti Iyengar, Yunyun Jiang, Jiang-Ti Kong, Sean Mackey, Carl Y. Saab, Christine N. Sang, Joachim Scholz, Marta Segerdahl, Irene Tracey, Christin Veasley, Jing Wang, Tor D. Wager, Ajay D. Wasan, Mary Ann Pelleymounter. Discovery and validation of biomarkers to aid the development of safe and effective pain therapeutics: challenges and opportunities. Nat Rev Neurol. 2020; 16(7): 381–400. Published online 2020 Jun 15. doi: 10.1038/s41582-020-0362-2
de Medeiros SA, de Almeida Silva HJ, do Nascimento RM, da Silva Maia JB, de Almeida Lins CA, de Souza MC. Mat Pilates is as effective as aquatic aerobic exercise in treating women with fibromyalgia: a clinical, randomized and blind trial. Adv Rheumatol. 2020 Apr 6;60(1):21. doi: 10.1186/s42358-020-0124-2. PMID: 32252822.
Estévez-López F, Camiletti-Moirón D, Aparicio VA, Segura-Jiménez V,Álvarez-Gallardo IC, Soriano-Maldonado A, Borges-Cosic M, Acosta-Manzano P, Geenen R, Delgado-Fernández M, Martínez-González LJ, Ruiz JR,Álvarez-Cubero MJ. Identification of candidate genes associated with fibromyalgia susceptibility in southern Spanish women: the al-Ándalus project. J Transl Med. 2018;16(1):43. Epub 2018 Feb 27. 
Ellis SD, Kelly ST, Shurlock JH, Hepburn ALN. The role of vitamin D testing and replacement in fibromyalgia: a systematic literature review. BMC Rheumatol 2018; 2:28.
Ernberg M, Christidis N, Ghafouri B, et al. Plasma Cytokine Levels in Fibromyalgia and Their Response to 15 Weeks of Progressive Resistance Exercise or Relaxation The
rapy. Mediators Inflamm. 2018;2018:3985154. Published 2018 Apr 18. doi:10.1155/2018/3985154
Evdokimov D, Frank J, Klitsch A, Unterecker S, Warrings B, Serra J, Papagianni A, Saffer N, Meyer Zu Altenschildesche C, Kampik D, Malik RA, Sommer C, Üçeyler N. Reduction of skin innervation is associated with a severe fibromyalgia phenotype. Ann Neurol. 2019 Oct;86(4):504-516. doi: 10.1002/ana.25565. Epub 2019 Aug 21. PMID: 31376174.
Fitzcharles MA, Ste-Marie PA, Goldenberg DL, Pereira JX, Abbey S, Choinière M, Ko G, Moulin DE, Panopalis P, Proulx J, Shir Y; National Fibromyalgia Guideline Advisory Panel. 2012 Canadian Guidelines for the diagnosis and management of fibromyalgia syndrome: executive summary. Pain Res Manag. 2013 May-Jun;18(3):119-26. doi: 10.1155/2013/918216. PMID: 23748251; PMCID: PMC3673928.
Gaskell H, Moore RA, Derry S, Stannard C. Oxycodone for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2014
Gavilán-Carrera B, Segura-Jiménez V, Mekary RA, Borges-Cosic M, Acosta-Manzano P, Estévez-López F, Álvarez-Gallardo IC, Geenen R, Delgado-Fernández M. Substituting Sedentary Time With Physical Activity in Fibromyalgia and the Association With Quality of Life and Impact of the Disease: The al-Ándalus Project. Arthritis Care Res (Hoboken). 2019 Feb;71(2):281-289. doi: 10.1002/acr.23717. Epub 2019 Jan 7. PMID: 30055083.
Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. Journal of the American Medical Association. 2004;292(19):2388–2395.
Goldenberg DL, Clauw DJ, Palmer RE, Clair AG. Opioid Use in Fibromyalgia: A Cautionary Tale. Mayo Clin Proc 2016; 91:640.
Goldenberg DL, et al. High frequency of fibromyalgia in patients with chronic fatigue seen in a primary care practice. Arthritis Rheum. 1990;33(3):381. 
Goldenberg DL, et al. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum. 1996;39(11):1852. 
Gupta A, Silman AJ. Psychological stress and fibromyalgia: a review of the evidence suggesting a neuroendocrine link. Arthritis Research & Therapy. April 2004;6(3):98–106.
Hajak G, Rodenbeck A, Voderholzer U, Riemann D, Cohrs S, Hohagen F, Berger M, Rüther E. Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study. J Clin Psychiatry. 2001 Jun;62(6):453-63. doi: 10.4088/jcp.v62n0609. PMID: 11465523.
Häuser W, Petzke F, Sommer C. Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome. Journal of Pain. 2010;11(6):505–521.
Häuser W, Petzke F, Uçeyler N, Sommer C. Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis. Rheumatology (Oxford). 2010;50(3):532–543.
Hwang JM, Lee BJ, Oh TH, et al. Association between initial opioid use and response to a brief interdisciplinary treatment program in fibromyalgia. Medicine (Baltimore) 2019; 98:e13913.
Jason LA, Sunnquist M, Brown A, McManimen S, Furst J. Reflections on the Institute of Medicine’s systemic exertion intolerance disease. Pol Arch Med Wewn. 2015;125(7-8):576-581. doi:10.20452/pamw.2973
Kales A, Bixler EO, Soldatos CR, Jacoby JA, Kales JD. Lorazepam: effects on sleep and withdrawal phenomena. Pharmacology. 1986;32(3):121-30. doi: 10.1159/000138160. PMID: 3960963.
Lee C, Liptan G, Kantorovich S, Sharma M, Brenton A. Association of Catechol-O-methyltransferase single nucleotide polymorphisms, ethnicity, and sex in a large cohort of fibromyalgia patients. BMC Rheumatol. 2018;2:38. Epub 2018 Dec 12. 
Krystal AD, Durrence HH, Scharf M, Jochelson P, Rogowski R, Ludington E, Roth T. Efficacy and Safety of Doxepin 1 mg and 3 mg in a 12-week Sleep Laboratory and Outpatient Trial of Elderly Subjects with Chronic Primary Insomnia. Sleep. 2010 Nov;33(11):1553-61. doi: 10.1093/sleep/33.11.1553. PMID: 21102997; PMCID: PMC2954705.
Macfarlane GJ, Kronisch C, Dean LE, Atzeni F, Häuser W, FlußE, Choy E, Kosek E, Amris K, Branco J, Dincer F, Leino-Arjas P, Longley K, McCarthy GM, Makri S, Perrot S, Sarzi-Puttini P, Taylor A, Jones GT. EULAR revised recommendations for the management of fibromyalgia.Ann Rheum Dis 2017;76(2):318.Epub 2016 Jul 4. 
Mascarenhas RO, Souza MB, Oliveira MX, Lacerda AC, Mendonça VA, Henschke N, Oliveira VC. Association of Therapies With Reduced Pain and Improved Quality of Life in Patients With Fibromyalgia: A Systematic Review and Meta-analysis. JAMA Intern Med. 2020 Oct. PubMed #33104162
Mayhew E, Ernst E. Acupuncture for fibromyalgia—a systematic review of randomized clinical trials. Rheumatology (Oxford). 2007;46(5):801–804.
Morgan PT, Malison RT. Pilot study of lorazepam and tiagabine effects on sleep, motor learning, and impulsivity in cocaine abstinence. Am J Drug Alcohol Abuse. 2008;34(6):692-702. doi: 10.1080/00952990802308221. PMID: 18850496.
Nishikai M, Akiya K. Fluvoxamine therapy for fibromyalgia. Journal of Rheumatology. 2010;30(5):1124–1125.
O’Malley PG, Balden E, Tomkins G, Santoro J, Kroenke K, Jackson JL. Treatment of fibromyalgia with antidepressants: a meta-analysis. J Gen Intern Med. 2000;15(9):659. 
Park DJ, Kim SH, Nah SS, Lee JH, Kim SK, Lee YA, Hong SJ, Kim HS, Lee HS, Kim HA, Joung CI, Kim SH, Lee SS. Association between brain-derived neurotrophic factor gene polymorphisms and fibromyalgia in a Korean population: a multicenter study. Arthritis Res Ther. 2018;20(1):220. Epub 2018 Oct 3. 
Ramírez M, Martínez-Martínez LA, Hernández-Quintela E, Velazco-Casapía J, Vargas A, Martínez-Lavín M. Small fiber neuropathy in women with fibromyalgia. An in vivo assessment using corneal confocal bio-microscopy. Semin Arthritis Rheum. 2015 Oct;45(2):214-9. doi: 10.1016/j.semarthrit.2015.03.003. Epub 2015 Mar 19. PMID: 26094164.
Rothschild B. Restoration of Sleep Physiology vs. Sedation for Sleep Disorders, Fibromyalgia. The Rheumatologist JUN 2015:67-68.
Russell IJ, Perkins AT, Michalek JE, Oxybate SXB-26 Fibromyalgia Syndrome Study Group. Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: a randomized, double-blind, placebo-controlled, multicenter clinical trial. Arthritis Rheum 2009; 60:
299.
Segura-Jiménez V, Romero-Zurita A, Carbonell-Baeza A, Aparicio VA, Ruiz JR, Delgado-Fernández M. Effectiveness of Tai-Chi for decreasing acute pain in fibromyalgia patients. Int J Sports Med. 2014 May;35(5):418-23. doi: 10.1055/s-0033-1353214. Epub 2013 Nov 7. PMID: 24203799.
Sewitch MJ, Dobkin PL, Bernatsky S, Baron M, Starr M, Cohen M, Fitzcharles MA. Medication non-adherence in women with fibromyalgia. Rheumatology (Oxford). 2004;43(5):648–654.
Spaeth M, Bennett RM, Benson BA, et al. Sodium oxybate therapy provides multidimensional improvement in fibromyalgia: results of an international phase 3 trial. Ann Rheum Dis 2012; 71:935.​
Uçeyler N, Häuser W, Sommer C. Systematic review with meta-analysis: cytokines in fibromyalgia syndrome. BMC Musculoskelet Disord. 2011;12:245. Epub 2011 Oct 28. 
Uguz F. Poor feeding and severe sedation in a newborn nursed by a mother on a low dose of amitriptyline. Breastfeed Med. 2017;12:67-68. [PubMed 27870551]
van de Donk T, Niesters M, Kowal MA, et al. An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia. Pain 2019; 160:860.
Walitt B, Klose P, Fitzcharles MA, et al. Cannabinoids for fibromyalgia. Cochrane Database Syst Rev 2016; 7:CD011694.
Wallace DJ, Gavin IM, Karpenko O, Barkhordar F, Gillis BS. Cytokine and chemokine profiles in fibromyalgia, rheumatoid arthritis and systemic lupus erythematosus: a potentially useful tool in differential diagnosis. Rheumatol Int. 2015;35(6):991-996. doi:10.1007/s00296-014-3172-2
Wallace DJ. Does my daughter have lupus? Lupus. 2016;25(9):957-958. doi:10.1177/0961203316639382
Wang YF, Chen YT, Tsai CW, Yen YC, Chen YC, Shia BC, Wang SJ. Persistence of pregabalin treatment in Taiwan: a nation-wide population-based study. J Headache Pain. 2020 May 19;21(1):54. doi: 10.1186/s10194-020-01123-4. PMID: 32429883; PMCID: PMC7236209.
Wang C, Schmid CH, Rones R, Kalish R, Yinh J, Goldenberg DL, et al. A randomized trial of tai chi for fibromyalgia. New England Journal of Medicine. 2010;363(8):743–754.
Ware MA, Fitzcharles MA, Joseph L, Shir Y. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesth Analg 2010; 110:604.​
Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, Russell AS, Russell IJ, Winfield JB, Yunus MB. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken). 2010 May;62(5):600-10. doi: 10.1002/acr.20140. PMID: 20461783.
Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis & Rheumatism. 1990;33(2):160–172.
Wolfe F, Walitt B. Culture, science and the changing nature of fibromyalgia. Nat Rev Rheumatol. 2013 Dec;9(12):751-5. doi: 10.1038/nrrheum.2013.96. Epub 2013 Jul 2. PMID: 23820862.​
Yilmaz R, Salli A, Cingoz HT, et al. Efficacy of vitamin D replacement therapy on patients with chronic nonspecific widespread musculoskeletal pain with vitamin D deficiency. Int J Rheum Dis 2016; 19:1255.​
Younger J, Noor N, McCue R, Mackey S. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum 2013; 65:529.
Zhang XC, Chen H, Xu WT, Song YY, Gu YH, Ni GX. Acupuncture therapy for fibromyalgia: a systematic review and meta-analysis of randomized controlled trials. J Pain Res. 2019;12:527. Epub 2019 Jan 30. 

Chapter 28

Aldoori WH, et al. Prospective study of diet and the risk of duodenal ulcer in men. Am J Epidemiol. 1997;145(1):42. 
Andersen BN, Johansen PB, Abrahamsen B. Proton pump inhibitors and osteoporosis. Curr Opin Rheumatol. 2016 Jul;28(4):420-5. doi: 10.1097/BOR.0000000000000291. PMID: 27224743.
Bhaat DL, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2008;52(18):1502. 
Graham DY, Agrawal NM, Campbell DR, Haber MM, Collis C, Lukasik NL, et al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Archives of Internal Medicine. 2002;162(2):169–175.
Hooi JKY, et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology. 2017;153(2):420. Epub 2017 Apr 27. 
Kang JY, et al. Acid perfusion of duodenal ulcer craters and ulcer pain: a controlled double blind study. Gut. 1986;27(8):942. 
Kidd M, Modlin IM. A century of helicobacter pylori: paradigms lost—paradigms regained. Digestion. 1998;59(1):1–15.
Lanza FL, Chan FK, Quigley EM, Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. American Journal of Gastroenterology. 2009;104(3):728–738.
Lu CL, et al. Silent peptic ulcer disease: frequency, factors leading to “silence,” and implications regarding the pathogenesis of visceral symptoms. Gastrointest Endosc. 2004;60(1):34. 
Lynch RG. Helicobacter pylori and ulcers. ASIP Bulletin. February 2005;8(1):15–16.
Marshall B. Helicobacter Pioneers: Firsthand Accounts from the Scientists Who Discovered Helicobacters, 1892–1982. Oxford: Blackwell; 2002.
Rissling O, Glander P, Hambach P, et al. No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study. Br J Clin Pharmacol. 2015; Apr 24 (Epub ahead of print): doi: 10.1111/bcp.12664. [PubMed 25913040]
Shimamoto T, et al. No
association of coffee consumption with gastric ulcer, duodenal ulcer, reflux esophagitis, and non-erosive reflux disease: a cross-sectional study of 8,013 healthy subjects in Japan. PLoS One. 2013;8(6):e65996. Epub 2013 Jun 12. 
Wu M-C, Huang J-Y, Chen H-H, Wei JC-C. Effect of early eradication therapy on systemic lupus erythematosus risk in patients with Helicobacter pylori infection: a nationwide population-based cohort study. Lupus. 2020;29(7):751-760. doi:10.1177/0961203320923393

Chapter 29

Barr SG, Zonana-Nacach A, Magder LS, Petri M. Patterns of disease activity in systemic lupus erythematosus. Arthritis Rheum. 1999 Dec;42(12):2682-8. doi: 10.1002/1529-0131(199912)42:12<2682::AID-ANR26>3.0.CO;2-6. PMID: 10616018.
Callaway JL, Stokes JH. Relapse in lupus erythematosus after treatment with sodium gold thiosulfate. Archives of Dermatology and Syphilology. 1938;37(4):627–630.
Danowski A, Magder L, Petri M. Flares in lupus: Outcome Assessment Trial (FLOAT), a comparison between oral methylprednisolone and intramuscular triamcinolone. J Rheumatol. 2006 Jan;33(1):57-60. PMID: 16395750.
Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Annals of the Rheumatic Diseases 2019;78:736-745.
Farmer S. Communities of Saint Martin: Legend and Ritual in Medieval Tours. Ithaca, NY: Cornell University Press; 1991:272–276.
Federal Drug Administration. How to dispose of unused medicines. Retrieved August 7, 2011, from www.fda.gov/downloads/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/UnderstandingOver-the-CounterMedicines/ucm107163.pdf.
Feng X, Zou Y, Pan W, Wang W, Wu M, Zhang M, et al. Prognostic indicators of hospitalized patients with systemic lupus erythematosus: a large retrospective multicenter study in China. Journal of Rheumatology. 2011;38:1289–1295.
Floris A, Piga M, Cappellazzo G, et alFRI0341 Lupus low disease activity state (LLDAS) versus clinical remission as treatment targets in the first 18 months of systemic lupus erythematosus managementAnnals of the Rheumatic Diseases 2018;77:706-707.
Fox T. Tuberculae, or degenerations. In: Skin Diseases; Their Description, Pathology, Diagnosis, and Treatment. With a Copious Formulary. London: Robert Hardwicke; 1864:200–205.
Gordon C, Maame-Boatemaa Amissah-Arthur, Mary Gayed, Sue Brown, Ian N. Bruce, David D’Cruz, Benjamin Empson, Bridget Griffiths, David Jayne, Munther Khamashta, Liz Lightstone, Peter Norton, Yvonne Norton, Karen Schreiber, David Isenberg, for the British Society for Rheumatology Standards, Audit and Guidelines Working Group, The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults, Rheumatology, Volume 57, Issue 1, January 2018, Pages e1–e45, https://doi.org/10.1093/rheumatology/kex286
Gordon C, Amissah-Arthur MB, Gayed M, Brown S, Bruce IN, D’Cruz D, Empson B, Griffiths B, Jayne D, Khamashta M, Lightstone L, Norton P, Norton Y, Schreiber K, Isenberg D; British Society for Rheumatology Standards, Audit and Guidelines Working Group. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology (Oxford). 2018 Jan 1;57(1):e1-e45. doi: 10.1093/rheumatology/kex286. PMID: 29029350.
Goswami RP, Sit H, Ghosh P, Sircar G, Ghosh A. Steroid-free remission in lupus: myth or reality; an observational study from a tertiary referral centre. Clin Rheumatol. 2019 Apr;38(4):1089-1097. doi: 10.1007/s10067-018-4377-7. Epub 2018 Dec 6. PMID: 30523554.
Green, J. Lupus. In: A Practical Compendium of the Diseases of the Skin with Cases including Consideration of the More Frequent and Intractable Forms of These Affections. London: Whittaker and Co; 1835:241–254.
Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012;64(6):797-808. doi:10.1002/acr.21664
Hebernus (Pseudo-Hebernus, false attribution to the 9th Century Archbishop of Tours). Miracula B. Martini [The Miracles of St. Martin]. AD 855. In: Anastasius (the Librarian). Patrologiae Cursus Completus Sive Bibliotheca Universalis, Integra, Uniformis, Commoda, Oeconomica, Omnium SS Patrum, Doctorum Scriptorum que Ecclesiasticorum, patrologiae tomus CXXIX. Paris: J.-P. Migne; 1853: col. 1036.Hunt T. Lupus. In: A Guide to the Treatment of Diseases of the Skin: With Suggestions for Their Prevention. 8th ed. London: T. Richards; 1865:159–172.
Hunt T. On the arrangement and treatment of cutaneous diseases. The Provincial Medical and Surgical Journal (now British Medical Journal). March 1846;145–146.
Jancin B. Hydroxychloroquine may help SLE patients to discontinue immunosuppressant medications. Rheumatology News May 2019:4.
Kernder A, Richter JG, Fischer-Betz R, et al. Quality of care predicts outcome in systemic lupus erythematosus: a cross-sectional analysis of a German long-term study (LuLa cohort). Lupus. 2020;29(2):136-143. doi:10.1177/0961203319896626
Kini V, Ho PM. Interventions to Improve Medication Adherence: A Review. JAMA. 2018 Dec 18;320(23):2461-2473. doi: 10.1001/jama.2018.19271. PMID: 30561486.
Koneru S, Kocharla L, Higgins G, Ware A, Passo M, Farhey Y, et al. Adherence to medications in systemic lupus erythematosus. Journal of Clinical Rheumatology. August 2008;14(4):195–201.
Miller HE. Gold and sodium thiosulphate in the treatment of lupus erythematosus. California and Western Medicine. October 1928;29(4):243–246.
Neugut AI, Ghatak AT, Miller RL. Anaphylaxis in the United States: an investigation into its epidemiology. Archives of Internal Medicine. January 2001;161(1):15–21.
New York Times Study Links Heavy Use of a Pain Reliever to Kidney Failure. Retrieved 11/29/20 from https:///www.nytimes.com/1994/12/22/us/study-links-heavy-use-of-a-pain-reliever-to-kidney-failure.html
Norton S. A brief history of potable gold. Molecular Interventions. June 2008;8(3):120–123.
Park WY. Controversies in acetaminophen nephrotoxicity. Kidney Res Clin Pract. 2020;39(1):4-6. doi:10.23876/j.krcp.20.027
Pedrosa TN, Pasoto SG, Aikawa NE, et al. Understanding the dynamics of hydroxychloroquine blood levels in lupus nephritis. Lupus. 2020;29(6):560-568. doi:10.1177/0961203320912832</ font>
Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. N Engl J Med. 1994 Dec 22;331(25):1675-9. doi: 10.1056/NEJM199412223312502. PMID: 7969358.
Petri M, Magder LS. Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort. Arthritis Rheumatol. 2018 Nov;70(11):1790-1795. doi: 10.1002/art.40571. PMID: 29806142; PMCID: PMC6203602.
Pfizer, Inc. Celebrex highlights of prescribing information. Retrieved on August 7, 2011, from www.pfizer.com/files/products/uspi_celebrex.pdf.
Rowell NR. Some historical aspects of skin disease in lupus erythematosus. Lupus. 1997;6:76–83.
Safe disposal of used needles and other “sharps.” Drug Safety Quarterly. 2012;4(1):3.
Sheane BJ, Gladman DD, Su J, Urowitz MB. Disease Outcomes in Glucocorticosteroid-Naive Patients With Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2017 Feb;69(2):252-256. doi: 10.1002/acr.22938. PMID: 27214378.
Squire B. On the treatment of lupus by linear scarification. British Medical Journal. May 1880;1(1009):654.
Tselios K, Gladman DD, Touma Z, Su J, Anderson N, Urowitz MB. Disease course patterns in systemic lupus erythematosus. Lupus. 2019;28(1):114-122. doi:10.1177/0961203318817132​
Ugarte-Gil MF, Acevedo-Vásquez E, Alarcón GS, Pastor-Asurza CA, Alfaro-Lozano JL, Cucho-Venegas JM, Segami MI, Wojdyla D, Soriano ER, Drenkard C, Brenol JC, de Oliveira e Silva Montandon AC, Costallat LT, Massardo L, Molina-Restrepo JF, Guibert-Toledano M, Silveira LH, Amigo MC, Barile-Fabris LA, Chacón-Díaz R, Esteva-Spinetti MH, Pons-Estel GJ, McGwin G Jr, Pons-Estel BA; GLADEL. The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus: data from a multiethnic Latin American cohort. Ann Rheum Dis. 2015 Jun;74(6):1019-23. doi: 10.1136/annrheumdis-2013-204620. Epub 2014 Feb 13. PMID: 24525909.
United Rheumatology. Clinical Practice Guidelines: systemic lupus erythematosus. version 1/1/2019 retrieved 11/29/20 at https://unitedrheumatology.com/wp-content/uploads/2019/04/UnitedRheum_Clinical-Treatment_Guideline_SLE_2019.pdf​
van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Annals of the Rheumatic Diseases 2014;73:958-967.​
Yao TC, Huang YW, Chang SM, Tsai SY, Wu AC, Tsai HJ. Association Between Oral Corticosteroid Bursts and Severe Adverse Events : A Nationwide Population-Based Cohort Study. Ann Intern Med. 2020 Sep 1;173(5):325-330. doi: 10.7326/M20-0432. Epub 2020 Jul 7. PMID: 32628532.

Chapter 30

Abeer IH, et al. Comparative study between visual evoked potential and visual acuity, field of vision, and fundus examination as screening tool for early diagnosis of hydroxychloroquine and chloroquine retinal toxicity in rheumatic patients. J Med Scient Res 2020;3(3):161-167.
Aduriz-Lorenzo PM, Aduriz-Llaneza P, Araiz-Iribarren J, Khamashta MA. Current opinion on hydroxychloroquine-related retinal toxicity screening: where do we stand now? Lupus. 2020;29(7):671-675. doi:10.1177/0961203320919499
Al-Rawi H, Meggitt SJ, Williams FM, Wahie S. Steady-state pharmacokinetics of hydroxychloroquine in patients with cutaneous lupus erythematosus. Lupus. 2018;27(5):847-852. doi:10.1177/0961203317727601
Apostolopoulos D, et al. Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study. Lancet Rheum NOV 2019;DOI: 10.1016/S2665-9913(19)30105-5
Babaoglu H, Li J, Goldman D, Magder LS, Petri M. Predictors of predominant Lupus Low Disease Activity State (LLDAS-50). Lupus. 2019;28(14):1648-1655. doi:10.1177/0961203319886028
Bahloul E, Jallouli M, Garbaa S, Marzouk S, Masmoudi A, Turki H, Bahloul Z. Hydroxychloroquine-induced hyperpigmentation in systemic diseases: prevalence, clinical features and risk factors: a cross-sectional study of 41 cases. Lupus. 2017;26(12):1304. Epub 2017 Mar 29. 
Basko v. Sterling Drug, Inc., 416 F.2d 417 (2d Cir. 1969) (n.d.). Retrieved August 24, 2011, from Basko vs Sterling drug.
Bauer F. Quinacrine hydrochloride drug eruption (tropical lichenoid dermatitis): its early and late sequelae and its malignant potential: a review. Journal of the American Academy of Dermatology. 1981;4:239–248.
Bernstein S. Can lupus be prevented? The Rheumatologist MAR 2020:32.
Broder A, Putterman C. Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and/or lupus anticoagulant in systemic lupus erythematosus. Journal of Rheumatology. 2013;40(1):30–33.
Kevin Broderick, MD, Harrison Ngo, BS, Reshma Katira, MD [abstract]. Evaluation of SD-OCT Results in Screening Patients in Early and Later Stages of HCQ Maculopathy. American Academy of Ophth. AAO 2020 Vision Virtual Meeting, NOV 13-15.
Browning DJ. Bull’s-eye maculopathy associated with quinacrine therapy for malaria. American Journal of Ophthalmology. March 2004;137(3):577–579.
Browning, DJ, Lee, C. Relative sensitivity and specificity of 10-2 visual fields, multifocal electroretinography, and spectral domain optical coherence tomography in detecting hydroxychloroquine and chloroquine retinopathy. Clin Ophthalmol 2014; 8: 1389–1399.
Browning DJ, Lee C. Scotoma analysis of 10-2 visual field testing with a red target in screening for hydroxychloroquine retinopathy. Clin Ophthalmol. 2015;9:1499-1509. Published 2015 Aug 20. doi:10.2147/OPTH.S87850
Cairoli E, Rebella M, Danese N, Garra V, Borba E. Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect. Lupus. 2012;21(11):1178-1182. doi:10.1177/0961203312450084
Carr RE, Henkind P, Rothfield N, Siegel IM. Ocular toxicity of antimalarial drugs: long-term follow-up. American Journal of Ophthalmology. October 1
968;66(4):738–744.
Chacón-Dulcey V, López-Labady J, Villarroel-Dorrego M, et al. Oral manifestations associated with antimalarial therapy in patients with systemic lupus erythematosus. Lupus. 2020;29(7):761-766. doi:10.1177/0961203320922620
Chloroquine[package insert] . (revision 2009). Westward Pharmceutical.
Costedoat-Chalumeau N, Amoura Z, Hulot J-S, et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum. 2006 Oct;54(10):3284–3290.
Costedoat-Chalumeau N, Galicier L, Aumaître O, et al. Hydroxychloroquine in systemic lupus erythematosus: Results of a French multicentre controlled trial (PLUS Study). Ann Rheum Dis. 2013 Nov;72(11):1786–1792.
Costedoat-Chalumeau N, Tamirou F, Le Guern V, et al. [Blood concentration of hydroxychloroquine in systemic lupus erythematosus care: Usefulness and limits]. Rev Med Interne. 2017 Feb;38(2):77–80.
Cremers FPM, Lee W, Collin RWJ, Allikmets R. Clinical spectrum, genetic complexity and therapeutic approaches for retinal disease caused by ABCA4 mutations. Prog Retin Eye Res. 2020 Nov;79:100861. doi: 10.1016/j.preteyeres.2020.100861. Epub 2020 Apr 9. PMID: 32278709; PMCID: PMC7544654.
Devine BJ. Gentamycin therapy. Drug Intelligence and Clinical Pharmacology. 1974;8:650–655.
Durcan L, Clarke WA, Magder LS, Petri M. Hydroxychloroquine blood levels in systemic lupus erythematosus: Clarifying dosing controversies and improving adherence. J Rheumatol. 2015 Nov;42(11):2092–2097.
Eftekhar SP, Kazemi S, Barary M, Javanian M, Ebrahimpour S, Ziaei N. Effect of Hydroxychloroquine and Azithromycin on QT Interval Prolongation and Other Cardiac Arrhythmias in COVID-19 Confirmed Patients. Cardiovasc Ther. 2021 Feb 27;2021:6683098. doi: 10.1155/2021/6683098. PMID: 33688374; PMCID: PMC7924072.
Evans J. Antimalarials remain essential for lupus. Rheumatology News. November 2009; 8(11):1, 31.
Fasano S, Margiotta DP, Navarini L, et al. Primary prevention of cardiovascular disease in patients with systemic lupus erythematosus: case series and literature review. Lupus. 2017;26(14):1463-1472. doi:10.1177/0961203317722847
Fine SD. Winthrop Laboratories: combination drug containing quinacrine hydrochloride, chloroquine phosphate, and hydroxychloroquine sulfate; notice of opportunity for hearing on proposal to withdraw approval of new drug application [Notices]. Federal Register. November 1972;37(221):24209–24210.
Gaffar R, Pineau CA, Bernatsky S, Scott S, Vinet É. Risk of Ocular Anomalies in Children Exposed In Utero to Antimalarials: A Systematic Literature Review. Arthritis Care Res (Hoboken). 2019 Dec;71(12):1606-1610. doi: 10.1002/acr.23808. PMID: 30418703.
Geraldino-Pardilla L, Perel-Winkler A, Miceli J, et al. Association between hydroxychloroquine levels and disease activity in a predominantly Hispanic systemic lupus erythematosus cohort. Lupus. 2019;28(7):862-867. doi:10.1177/0961203319851558
González-Sixto B, García-Doval I, Oliveira R, Posada C, García-Cruz MA, Cruces M. Aspectos prácticos de la quinacrina como tratamiento del lupus eritematoso cutáneo: serie de casos [Quinacrine in the treatment of cutaneous lupus erythematosus: practical aspects and a case series]. Actas Dermosifiliogr. 2010 Jan-Feb;101(1):54-8. Spanish. PMID: 20109393.
Götestam Skorpen C, Hoeltzenbein M, Tincani A, et alThe EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactationAnnals of the Rheumatic Diseases 2016;75:795-810.
Gupta A, Joshi A, Chester-Wasko M, Sharma TS. Association of Hydroxychloroquine Use and Incident Atrial Fibrillation in Systemic Lupus Erythematosus: A Retrospective Study [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/association-of-hydroxychloroquine-use-and-incident-atrial-fibrillation-in-systemic-lupus-erythematosus-a-retrospective-study/. Accessed January 6, 2021.

Haj-Ali M, Belmont H. Whole Blood Hydroxychloroquine Levels Do Not Correlate with QTc Intervals in a Cohort of 84 SLE Patients: Evidence That Antimalarials Are Not Associated with Cardiac Conduction System Toxicity [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 10). https://acrabstracts.org/abstract/whole-blood-hydroxychloroquine-levels-do-not-correlate-with-qtc-intervals-in-a-cohort-of-84-sle-patients-evidence-that-antimalarials-are-not-associated-with-cardiac-conduction-system-toxicity/. Accessed January 30, 2022.

Harvey AM, Shulman LE, Tumulty PA, Conley CL, Schoenrich EH. Systemic Lupus Erythematosus: Review of the Literature and Clinical Analysis of 138 Cases. Baltimore, Md: Williams & Wilkins Company; 1955.
Hassan F, Naffaa  ME, Paz Z. (2020). Value of Antimalarial Drugs in the Treatment of Lupus. In G.C. Tsokos (Ed.). Systemic Lupus Erythematosus: Basic, Applied and Clinical Aspects, Ed 2 (pp. 591-596). Cambridge, Massachusetts: Academic Press. 
Hayami T, Tanaka T, Fujimoto N. Successful short desensitization for the eruption of hydroxychloroquine. Lupus. 2019;28(7):918-919. doi:10.1177/0961203319851564
Hobbs HE, Sorsby A, Freedman A. Retinopathy following chloroquine therapy. Lancet. 1950; 2(7101):478–480.
Hoque, M.R., Aviña‐Zubieta, J.A., De Vera, M.A., Qian, Y., Esdaile, J.M. and Xie, H. (2021), Impact of Antimalarial Adherence on Mortality among Patients with Newly Diagnosed Systemic Lupus Erythematosus: A Population‐based Cohort Study. Arthritis Care & Research. Accepted Author Manuscript. https://doi.org/10.1002/acr.24550
Hurtado PR, Hurtado-Pérez E, Luo C, Bednarz J, Hissaria P, A Peh C. Unexpectedly, low hydroxychloroquine concentration enhances DNA-induced immune stimulation in vitro: potential implication in non-compliant patients with SLE. Lupus. 2020;29(2):216-218. doi:10.1177/0961203319897810
Izmirly P, Kim M, Friedman DM, Costedoat-Chalumeau N, Clancy R, Copel JA, Phoon CKL, Cuneo BF, Cohen RE, Robins K, Masson M, Wainwright BJ, Zahr N, Saxena A, Buyon JP. Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers. J Am Coll Cardiol. 2020 Jul 21;76(3):292-302. doi: 10.1016/j.jacc.2020.05.045. PMID: 32674792; PMCID: PMC7394202.
Jung H, Bobba R, Su J, Shariati-Sarabi Z, Bladman DD, Urowitz M, et al. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis & Rheumatism. March 2010;62(3):863–868.
Katitanon N, et al. Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus. 2006;15(6):366–370.Keeble TW. A cure for the ague: the contribution of Robert Talbor (1642–81). Journal of the Royal Society of Medicine. May 1997;90:285–290.
Kersley GD, Glyn J. A Concise International History of Rheumatology and Rehabilitation: Friends and Foes. London. Royal Society of Medicine Services Limited; 1991:88–89.
Leden I. Antimalarial drugs—350 years. Scandinavian Journal of Rheumatology. 1981;10:307–312.
Liu LH, Fevrier HB, Goldfien R, Hemmerling A, Herrinton LJ. Understanding Nonadherence with Hydroxychloroquine Therapy in Systemic Lupus Erythematosus. J Rheumatol. 2019 Oct;46(10):1309-1315. doi: 10.3899/jrheum.180946. Epub 2019 Feb 1. PMID: 30709949.
Luzzatto L, Nannelli C, Notaro R. Glucose-6-Phosphate Dehydrogenase Deficiency. Hematol Oncol Clin North Am. 2016;30(2):373-93. doi:10.1016/j.hoc.2015.11.006. Review. [PubMed 27040960]
Lyons, Jonathan S.. “Impact of the Revised American Academy of Ophthalmology Guidelines Regarding Hydroxychloroquine Screening On Actual Practice.” American Journal of Ophthalmology, vol. 156, no. 2, 2013, p. 410.
Lyons JS, Severns ML. Detection of early hydroxychloroquine retinal toxicity enhanced by ring ratio analysis of multifocal electroretinography. Am J Ophthalmol. 2007 May;143(5):801-809. doi: 10.1016/j.ajo.2006.12.042. Epub 2007 Mar 6. PMID: 17336914.
Marder W. Update on pregnancy complications in systemic lupus erythematosus. Curr Opin Rheumatol. 2019 Nov;31(6):650-658. doi: 10.1097/BOR.0000000000000651. PMID: 31464707.
Marmor MF. Hydroxychloroquine retinopathy still alive and well: how rheumatologists are affected by new guidelines from ophthalmology. The Rheumatologist. May 2011;1, 51, 56.
Marmor MF, et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology. 2016 Jun;123(6):1386–1394.
Marmor MF, Kellner U, Lai TYY, Lyons JS, Mieler WF. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. February 2011;118(2):415–422.
Marmor MF, Melles RB. Disparity between visual fields and optical coherence tomography in hydroxychloroquine retinopathy. Ophthalmology. 2014 Jun;121(6):1257-62. doi: 10.1016/j.ophtha.2013.12.002. Epub 2014 Jan 16. PMID: 24439759.
Marshall E, Robertson M, Kam S, Penwarden A, Riga P, Davies N. Prevalence of hydroxychloroquine retinopathy using 2018 Royal College of Ophthalmologists diagnostic criteria. Eye (Lond). 2021 Jan;35(1):343-348. doi: 10.1038/s41433-020-1038-2. Epub 2020 Jun 25. Erratum in: Eye (Lond). 2020 Jul 20;: PMID: 32587388; PMCID: PMC7316164.
Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014 Dec;132(12):1453-60. doi: 10.1001/jamaophthalmol.2014.3459. Erratum in: JAMA Ophthalmol. 2014 Dec;132(12):1493. PMID: 25275721.
Michaud, M. and Gaches, F. (2016), Hydroxychloroquine in Systemic Lupus Erythematosus: Comment on the Article by Muangchan et al. Arthritis Care & Research, 68: 1052-1053. https://doi.org/10.1002/acr.22780
Moez J, Francès C, Piette J-C, et al. Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus: A case-control study. JAMA Dermatol. 2013 Aug;149(8):935–940.
Mohammad S, Clowse MEB, Eudy AM, Criscione-Schreiber LG. Hydroxychloroquine is Not Associated with Hemolytic Anemia in Glucose-6-Phosphate Dehydrogenase (G6PD) Deficient Patients. Arthritis Care Res (Hoboken). Published online May 26, 2017. doi:10.1002/acr.23296
Moschos MM, Nitoda E, Chatziralli IP, et al. Assessment of hydroxychloroquine maculopathy after cessation of treatment: an optical coherence tomography and multifocal electroretinography study. Drug Des Devel Ther2015;9:2993–9.doi:10.2147/DDDT.S81303
Müller-Calleja N, Lackner KJ. Response to: ‘Protective effects of antimalarials in Chinese patients with systemic lupus erythematosus’ by Wang et al. Ann Rheum Dis. 2019 Aug;78(8):e81. doi: 10.1136/annrheumdis-2018-213853. Epub 2018 Jun 26. PMID: 29945922.
Munster T, Gibbs JP, Shen D, Baethge BA, Botstein GR, Caldwell J, Dietz F, Ettlinger R, Golden HE, Lindsley H, McLaughlin GE, Moreland LW, Roberts WN, Rooney TW, Rothschild B, Sack M, Sebba AI, Weisman M, Welch KE, Yocum D, Furst DE. Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum. 2002 Jun;46(6):1460-9. doi: 10.1002/art.10307. PMID: 12115175.
Murray, P., Denniston, A. (2014). Oxford Handbook of Ophthalmology. United Kingdom: OUP Oxford.
O’Connell TF, Bradley CJ, Abbas AE, Williamson BD, Rusia A, Tawney AM, Gaines R, Schott J, Dmitrienko A, Haines DE. Hydroxychloroquine/Azithromycin Therapy and QT Prolongation in Hospitalized Patients With COVID-19. JACC Clin Electrophysiol. 2021 Jan;7(1):16-25. doi: 10.1016/j.jacep.2020.07.016. Epub 2020 Aug 5. PMID: 33478708; PMCID: PMC7406234.
Østensen M, Khamashta M, Lockshin M, Parke A, Brucato A, Carp H, et al. Anti-inflammatory and immunosuppressive drugs and reproduction [Review]. Arthritis Research & Therapy. May 2006;8:209–227.
Page F. Treatment of lupus erythematosus with Mepacrine. The Lancet. October 1951;2(6687):755–758.

Park E, Giles J, Perez-Recio T, Pina P, Depender C, Bathon J, Geraldino-Pardilla L. Hydroxychloroquine Use Was Not Associated with QTc Length in a Large Cohort of SLE and RA Patients [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/hydroxychloroquine-use-was-not-associated-with-qtc-length-in-a-large-cohort-of-sle-and-ra-patients/. Accessed January 30, 2022.

Pareek A, Ravi Tejraj Mehta, Shruti Dharmadhikari, Kumar Naidu, Comment on: Incidence of blindness in a population of rheumatic patients treated with hydroxychloroquine, Rheumatology Advances in Practice, Volume 3, Issue 2, 2019, rkz041, https://doi.org/10.1093/rap/rkz041
Parodis I, Lopez Benavides AH, Zickert A, Pettersson S, Möller S, Welin Henriksson E, Voss A, Gunnarsson I. The Impact of Belimumab and Rituximab on Health-Related Quality of Life in Patients With Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2019 Jun;71(6):811-821. doi: 10.1002/acr.23718. PMID: 30055091.
Payne JF. A post-graduate lecture on lupus erythematosus. The Clinical Journal. August 1894;4:223–229.
Peponis V, Kyttaris VC, Chalkiadakis SE, Bonovas S, Sitaras NM. Ocular side effects of anti-rheumatic medications: what a rheumatologist should know [Review]. Lupus. 2010;19:675–682.
Petri M, Elkhalifa M, Goldman D, et al. Hydroxychloroquine blood levels show significant trend test for risk for retinopathy [abstract 2897]. Arthritis Rheum. 2018;70(suppl 10).
Petri M, Konig MF, Li J, Goldman DW. Association of Higher Hydroxychloroquine Blood Levels With Reduced Thrombosis Risk in Systemic Lupus Erythematosus. Arthritis Rheumatol. 2021 Jan 5. doi: 10.1002/art.41621. Epub ahead of print. PMID: 33403833.
Petri M, Rosenbaum JT. Guidelines for SLE: HCQ dose should not be more than 5 mg/kg in all patients. Chicago, IL: “The Great Debate”: American College of Rheumatology Annual Meeting, 2018.
Pham BH, Marmor MF. Sequential changes in hydroxychloroquine retinopathy up to 20 years after stopping the drug: implications for mild versus severe toxicity. Retina2018. [Epub ahead of print].
Plaquenil [package insert] . (revision 01/2017). Bridgewater, NJ: Sanofi-Aventis
Pullen LC. Rheumatologists Debate Hydroxychloroquine Dosing Guidelines for Lupus. The Rheumatologist FEB 2019. Retrieved 1/4/21 at https:///www.the-rheumatologist.org/article/rheumatologists-debate-hydroxychloroquine-dosing-guidelines-for-lupus/
Rosenbaum JT, Costenbader KH, Desmarais J, Ginzler EM, Fett N, Goodman SM, O’Dell JR, Schmajuk G, Werth VP, Melles RB, Marmor MF. ACR, AAD, RDS, and AAO 2020 Joint Statement on Hydroxychloroquine Use with Respect to Retinal Toxicity. Arthritis Rheumatol. 2021 Feb 9. doi: 10.1002/art.41683. Epub ahead of print. PMID: 33559327.
Rynes RI. Antimalarial Drugs. In: Textbook of Rheumatology, 5th Ed, Kelly WN, Harris ED Jr, Ruddy S, Sledge CB (Eds), WB Saunders, Philadelphia 1997.
Ruiz-Irastorza G, Khamashta MA. Hydroxychloroquine: the cornerstone of lupus therapy [Editorial]. Lupus. 2008;17:271–273.

Sahyoun JY, Sabeti S, Robert MC. Drug-induced corneal deposits: an up-to-date review. BMJ Open Ophthalmol. 2022 Mar 25;7(1):e000943. doi: 10.1136/bmjophth-2021-000943. PMID: 35415268; PMCID: PMC8961126.

Saleh M, Gabriels J, Chang D, Soo Kim B, Mansoor A, Mahmood E, Makker P, Ismail H, Goldner B, Willner J, Beldner S, Mitra R, John R, Chinitz J, Skipitaris N, Mountantonakis S, Epstein LM. Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection. Circ Arrhythm Electrophysiol. 2020 Jun;13(6):e008662. doi: 10.1161/CIRCEP.120.008662. Epub 2020 Apr 29. PMID: 32347743; PMCID: PMC7299095
Seo MR, Chae J, Kim YM, et al. Hydroxychloroquine treatment during pregnancy in lupus patients is associated with lower risk of preeclampsia. Lupus. 2019;28(6):722-730. doi:10.1177/0961203319843343
Shah S, Shah K, Turagam MK, Lakkireddy D, Garg J. Effects of Hydroxychloroquine With or Without Azithromycin on QT Interval in COVID-19: A Systematic Review. Electrophysiology Collaborative Consortium for Meta-analysis-Electram Investigators. Am J Ther. 2020 Dec 29;Publish Ahead of Print. doi: 10.1097/MJT.0000000000001238. Epub ahead of print. PMID: 33416244.
Shee JC. Lupus erythematosus treated with chloroquine. Lancet. July 1953;265(6778):201–202.
Shinjo SK, Bonfá E, Wojdyla D, Borba EF, Ramirez LA, Scherbarth HR, et al. Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis & Rheumatism. March 2010;62(3):855–862.
Shroyer NF, Lewis RA, Lupski JR. Analysis of the ABCR (ABCA4) gene in 4-aminoquinoline retinopathy: is retinal toxicity by chloroquine and hydroxychloroquine related to Stargardt disease? Am J Ophthalmol. 2001 Jun;131(6):761-6. doi: 10.1016/s0002-9394(01)00838-8. PMID: 11384574.
Takamasu E, Yokogawa N, Shimada K, Sugii S. Simple dose-escalation regimen for hydroxychloroquine-induced hypersensitivity reaction in patients with systemic lupus erythematosus enabled treatment resumption. Lupus. 2019;28(12):1473-1476. doi:10.1177/0961203319879987
Tal Y, Maoz Segal R, Langevitz P, Kivity S, Darnizki Z, Agmon-Levin N. Hydroxychloroquine desensitization, an effective method to overcome hypersensitivity—a multicenter experience. Lupus. 2018;27(5):703-707. doi:10.1177/0961203317735185
Thomas DE, et al. Low hydroxychloroquine blood levels in patients who have had gastric bypass surgery. Lupus Sci Med. 2019 Jun;6(1):e000335.
Thomas DE, et al. Should Hydroxychloroquine Level Testing Be Standard Care in Lupus? The Rheumatologist FEB 2020. Retrieved on 1/4/21 at https:///www.the-rheumatologist.org/article/should-hydroxychloroquine-level-testing-be-standard-care-in-lupus/?singlepage=1
Thomas WE. Hahnemann’s allergy to quinine. March 4, 2002. Retrieved August 24, 2011, from www.angelfire.com/mb2/quinine/allergy.html.
Torigoe M, Sakata K, Ishii A, Iwata S, Nakayamada S, Tanaka Y. Hydroxychloroquine efficiently suppresses inflammatory responses of human class-switched memory B cells via Toll-like receptor 9 inhibition. Clin Immunol. 2018 Oct;195:1-7. doi: 10.1016/j.clim.2018.07.003. Epub 2018 Jul 4. PMID: 29981383.
Tselios K, Deeb M, Gladman DD, Harvey P, Urowitz MB. Antimalarial-induced cardiomyopathy: a systematic review of the literature. Lupus. 2018;27(4):591-599. doi:10.1177/0961203317734922
Ugarte A, Porta S, Ríos R, et al. Combined mepacrine–hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity. Lupus. 2018;27(10):1718-1722. doi:10.1177/0961203318768877
Wallace DJ. The history of antimalarials. Lupus. 1996;5(suppl 1):S2–S3.
Van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: Recommendations from an international task force. Ann Rheum Dis. 2014 Jun;73(6):958–967.
Vaz CC, Couto M, Medeiros D, Miranda L, Costa J, Nero P, Barros R, Santos MJ, Sousa E, Barcelos A, Inês L. Undifferentiated connective tissue disease: a seven-center cross-sectional study of 184 patients. Clin Rheumatol. 2009 Aug;28(8):915-21. doi: 10.1007/s10067-009-1175-2. Epub 2009 Apr 24. PMID: 19390908.
Wallace DJ. Is there a role for quinacrine (Atabrine) in the new millennium? [Editorial]. Lupus. 2000;9:81–82.
Wallace DJ. The use of quinacrine (Atabrine) in rheumatic disease: a reexamination. Seminars in Arthritis and Rheumatism. 1989;18(4):282–297.
Wallace DJ. Thromb
ovascular events in systemic lupus erythematosus: comment on the article by Jung et al. [Letter to the editor]. Arthritis & Rheumatism. September 2010;62(9):2824–2825.
Wang F, Muller S. Manipulating autophagic processes in autoimmune diseases: a special focus on modulating chaperone-mediated autophagy, an emerging therapeutic target. Front Immunol. 2015;6:252. Published 2015 May 19. doi:10.3389/fimmu.2015.00252
Wu J, Keeley A, Mallen C, Morgan AW, Pujades-Rodriguez M. Incidence of infections associated with oral glucocorticoid dose in people diagnosed with polymyalgia rheumatica or giant cell arteritis: a cohort study in England. CMAJ. 2019 Jun 24;191(25):E680-E688. doi: 10.1503/cmaj.190178. PMID: 31235489; PMCID: PMC6592810.
Yao TC, Huang YW, Chang SM, Tsai SY, Wu AC, Tsai HJ. Association Between Oral Corticosteroid Bursts and Severe Adverse Events : A Nationwide Population-Based Cohort Study. Ann Intern Med. 2020 Sep 1;173(5):325-330. doi: 10.7326/M20-0432. Epub 2020 Jul 7. PMID: 32628532
Yusuf IH, Sharma S, Luqmani R, et al. Hydroxychloroquine retinopathy. Eye 2017;31:828–45.doi:10.1038/eye.2016.298

Chapter 31

Baehr G, Soffer LJ. Treatment of disseminated lupus erythematosus with cortisoneand adrenocorticotropin. The Bulletin of the New York Academy of Medicine. April
1950;26(4):229–234.
Danowski A, Magder L, Petri M. Flares in lupus: outcome assessment trial (FLOAT), a comparison between oral methylprednisolone and intramuscular triamcinolone. Journal of Rheumatology. 2006;33(1):57–60.
Danza A, Borgia I, Narváez JI, et al. Intravenous pulses of methylprednisolone to treat flares of immune-mediated diseases: how much, how long? Lupus. 2018;27(7):1177-1184. doi:10.1177/0961203318768888​
Duarte-García A, Matteson EL, Shah ND. Older Drugs With Limited Trial Evidence: Are They Worth the Expense? The Case of Repository Corticotropin Marketed as H.P. Acthar Gel. Ann Intern Med. 2019 Jun 4;170(11):791-792. doi: 10.7326/M18-3513. Epub 2019 May 28. PMID: 31060052.
Dubois EL, Commons RR, Starr P, Stein Jr CS, Morrison R. Corticotropin and cortisone treatment for systemic lupus erythematosus. Journal of the American Medical Association. July 1952;149(11):995–1002.
Duru N, van der Goes MC, Jacobs JW, Andrews T, Boers M, Buttgereit F, Caeyers N, Cutolo M, Halliday S, Da Silva JA, Kirwan JR, Ray D, Rovensky J, Severijns G, Westhovens R, Bijlsma JW. EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2013 Dec;72(12):1905-13. doi: 10.1136/annrheumdis-2013-203249. Epub 2013 Jul 19. PMID: 23873876.​
Fiechtner JJ, Montroy T. Treatment of moderately to severely active systemic lupus erythematosus with adrenocorticotropic hormone: a single-site, open-label trial. Lupus. 2014 Aug;23(9):905-12. doi: 10.1177/0961203314532562. Epub 2014 May 2. PMID: 24795067; PMCID: PMC4232266.
George MD, Baker JF, Winthrop K, Hsu JY, Wu Q, Chen L, Xie F, Yun H, Curtis JR. Risk for Serious Infection With Low-Dose Glucocorticoids in Patients With Rheumatoid Arthritis : A Cohort Study. Ann Intern Med. 2020 Sep 22. doi: 10.7326/M20-1594. Epub ahead of print. PMID: 32956604.
Gray RG, Tenenbaum J, Gottlieb NL. Local corticosteroid injection treatment in rheumatic disorders. Seminars in Arthritis and Rheumatism. May 1981;10(4):231–254.
Hench PS, Kendall EC, Slocumb CH, Polley HF. The effect of the adrenal cortex (17-hydroxy- 11-dehydrocorticosterone: compound E) and of pituitary adrenocorticotrophic hormone on rheumatoid arthritis: preliminary report. Annals of the Rheumatic Diseases.
1949;8:97–104.
Hillier SG. Diamonds are forever: the cortisone legacy [Review]. Journal of Endocrinology. 2007;195:1–6.
Kendall EC. The development of cortisone as a therapeutic agent [Nobel lecture]. Les Prix Nobel. December 1951.
Moghadam-Kia S, Werth V. Prevention and treatment of systemic glucocorticoid side effects [Review]. International Journal of Dermatology. 2010;49:239–248.
Orr H. Acute disseminated lupus erythematosus. Canadian Medical Association Journal. May 1950;62:432–437.
Østensen M, Khamashta M, Lockshin M, Parke A, Brucato A, Carp H, et al. Anti-inflammatory and immunosuppressive drugs and reproduction [Review]. Arthritis Research & Therapy. May 2006;8:209–227.
Roberts WN, Babcock EA, Breitbach SA, Owen DS, Irby WR. Corticosteroid injection in rheumatoid arthritis does not increase rate of total joint arthroplasty. Journal of Rheumatology. 1996;23(6):1001–1004.
Werth B. The Billion Dollar Molecule: One Company’s Quest for the Perfect Drug. 1st Touchstone Edition. New York: Simon & Schuster, 1995:129.
Yao TC, Huang YW, Chang SM, Tsai SY, Wu AC, Tsai HJ. Association Between Oral Corticosteroid Bursts and Severe Adverse Events : A Nationwide Population-Based Cohort Study. Ann Intern Med. 2020 Sep 1;173(5):325-330. doi: 10.7326/M20-0432. Epub 2020 Jul 7. PMID: 32628532.

Chapter 32

ACR, COVID-19 Vaccine Clinical Guidance Summary for Patients with Rheumatic and Musculoskeletal Diseases. Developed by the ACR COVID-19 Vaccine Clinical Guidance Task Force. 2/8/21. Retrieved on 2/13/21 at https:///www.rheumatology.org/Portals/0/Files/COVID-19-Vaccine-Clinical-Guidance-Rheumatic-Diseases-Summary.pdf
Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysler E, Sánchez-Guerrero J, Solomons N, Wofsy D; Aspreva Lupus Management Study Group. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009 May;20(5):1103-12. doi: 10.1681/ASN.2008101028. Epub 2009 Apr 15. PMID: 19369404; PMCID: PMC2678035.
Askanase AD, Wallace DJ, Weisman MH, Tseng CE, Bernstein L, Belmont HM, Seidman E, Ishimori M, Izmirly PM, Buyon JP. Use of pharmacogenetics, enzymatic phenotyping, and metabolite monitoring to guide treatment with azathioprine in patients with systemic lupus erythematosus. J Rheumatol. 2009;36(1):89. 
Barthel HR. Leflunomide for the treatment of systemic lupus erythematosus: comment on the article by McMurray [Letter to the editor]. Arthritis Care & Research. 2001;45:472.
Bartlett RR, Popovic S, Raiss RX. Development of autoimm
unity in MRL/lpr mice and the effects of drugs on this murine disease. Scandinavian Journal of Rheumatology Supplement. 1988;75:290–299.
Bedoui Y, Guillot X, Sélambarom J, et al. Methotrexate an Old Drug with New Tricks. Int J Mol Sci. 2019;20(20):5023. Published 2019 Oct 10. doi:10.3390/ijms20205023
Benito-Garcia E, Heller JE, Chibnik LB, Maher NE, Matthews HM, Bilics JA, Weinblatt ME, Shadick NA. Dietary caffeine intake does not affect methotrexate efficacy in patients with rheumatoid arthritis. J Rheumatol. 2006 Jul;33(7):1275-81. PMID: 16821266.
Bérard A, Zhao JP, Shui I, Colilla S. Leflunomide use during pregnancy and the risk of adverse pregnancy outcomes. Ann Rheum Dis. 2018 Apr;77(4):500-509. doi: 10.1136/annrheumdis-2017-212078. Epub 2017 Dec 8. PMID: 29222350.
Braun J, Kästner P, Flaxenberg P, Währisch J, Hanke P, Demary W, von Hinüber U, Rockwitz K, Heitz W, Pichlmeier U, Guimbal-Schmolck C, Brandt A; MC-MTX.6/RH Study Group. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum. 2008 Jan;58(1):73-81. doi: 10.1002/art.23144. PMID: 18163521.
Bykerk VP. A Call to Systematically Monitor for Adverse Events in Users of Low-Dose Methotrexate Therapy. Ann Intern Med. 2020 Mar 17;172(6):425-426. doi: 10.7326/M20-0435. Epub 2020 Feb 18. PMID: 32066142.
Chen W, Liu Q, Chen W, Tang X, Fu P, Liu F, et al. Outcomes of maintenance therapy with tacrolimus versus azathioprine for active lupus nephritis: a multicenter randomized clinical trial. Lupus 2012;21:944-52
Colombel JF, Ferrari N, Debuysere H, Marteau P, Gendre JP, Bonaz B, SouléJC, Modigliani R, Touze Y, Catala P, Libersa C, Broly F. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn’s disease and severe myelosuppression during azathioprine therapy. Gastroenterology. 2000;118(6):1025. 
Conway R, Low C, Coughlan RJ, O’Donnell MJ, Carey JJ. Risk of liver injury among methotrexate users: A meta-analysis of randomised controlled trials. Semin Arthritis Rheum. 2015 Oct;45(2):156-62. doi: 10.1016/j.semarthrit.2015.05.003. Epub 2015 May 19. PMID: 26088004.
Corley CC, Lessner HE, Larsen WE. Azathioprine therapy of “autoimmune” diseases. American Journal of Medicine. September 1966;41(3):404–412.
Curtis JR, Xie F, Yang S, Bernatsky S, Chen L, Yun H, Winthrop K. Risk for Herpes Zoster in Tofacitinib-Treated Rheumatoid Arthritis Patients With and Without Concomitant Methotrexate and Glucocorticoids. Arthritis Care Res (Hoboken). 2019 Sep;71(9):1249-1254. doi: 10.1002/acr.23769. Epub 2019 Jul 29. PMID: 30295428.
Dalrymple JM, Stamp LK, O’Donnell JL, Chapman PT, Zhang M, Barclay ML. Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 2008 Nov;58(11):3299-308. doi: 10.1002/art.24034. PMID: 18975321.
de Rotte MC, den Boer E, de Jong PH, Pluijm SM, Ćalasan MB, Weel AE, Huisman AM, Gerards AH, van Schaeybroeck B, Wulffraat NM, Lindemans J, Hazes JM, de Jonge R. Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in patients with rheumatoid arthritis. Ann Rheum Dis. 2015 Feb;74(2):408-14. doi: 10.1136/annrheumdis-2013-203725. Epub 2013 Dec 2. PMID: 24297383.
Dervieux T, et al. Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum. 2006 Oct;54(10):3095-103. 
Desai RJ, Pawar A, Weinblatt ME, Kim SC. Comparative Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Receiving Tofacitinib Versus Those Receiving Tumor Necrosis Factor Inhibitors: An Observational Cohort Study. Arthritis Rheumatol. 2019 Jun;71(6):892-900. doi: 10.1002/art.40798. Epub 2019 Apr 29. PMID: 30552833.
Drachtman RA, Cole PD, Golden CB, James SJ, Melnyk S, Aisner J, Kamen BA. Dextromethorphan is effective in the treatment of subacute methotrexate neurotoxicity. Pediatr Hematol Oncol. 2002 Jul-Aug;19(5):319-27. doi: 10.1080/08880010290057336. PMID: 12078863.
Dubois EL. Nitrogen mustard in treatment of systemic lupus erythematosus. Archives of Internal Medicine. May 1954;93(5):667–672.
Erickson AR, Reddy V, Vogelgesang SA, West SG. Usefulness of the American College of Rheumatology recommendations for liver biopsy in methotrexate-treated rheumatoid arthritis patients. Arthritis & Rheumatism. August 1995;38(8):1115–1119.
Fanouriakis A, Tziolos N, Bertsias G, et alUpdate οn the diagnosis and management of systemic lupus erythematosusAnnals of the Rheumatic Diseases 2021;80:14-25.
Fanouriakis A, Bertsias G. Changing paradigms in the treatment of systemic lupus erythematosus. Lupus Science & Medicine 2019;6:e000310. doi: 10.1136/lupus-2018-000310
Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, Cervera R, Doria A, Gordon C, Govoni M, Houssiau F, Jayne D, Kouloumas M, Kuhn A, Larsen JL, Lerstrøm K, Moroni G, Mosca M, Schneider M, Smolen JS, Svenungsson E, Tesar V, Tincani A, Troldborg A, van Vollenhoven R, Wenzel J, Bertsias G, Boumpas DT. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019 Jun;78(6):736-745. doi: 10.1136/annrheumdis-2019-215089. Epub 2019 Mar 29. Can methotrexate be given safely to men with RA and planning to have children? Medscape. June 5, 2006. Retrieved September 5, 2011, from www.medscape.com/ viewarticle/533259.
Fragoulis GE, Conway R, Nikiphorou E. Methotrexate and interstitial lung disease: controversies and questions. A narrative review of the literature. Rheumatology (Oxford). 2019 Nov 1;58(11):1900-1906. doi: 10.1093/rheumatology/kez337. PMID: 31504978.
Fuerst M, et al. Leflunomide increases the risk of early healing complications in patients with rheumatoid arthritis undergoing elective orthopedic surgery. Rheumatol Int. 2006;26(12):1138. Epub 2006 May 31. 
Gheith O, Al-Otaibi T, Mansour H. Next-generation calcineurin inhibitors in development for the prevention of organ rejection. Transplant Research and Risk Management. 2014;6:23-30; https://doi.org/10.2147/TRRM.S35875
Gillibrand PN. Systemic lupus erythematosus in pregnancy treated with azathioprin
e. Proceedings of the Royal Society of Medicine. September 1966;59(9):834.
Goodman LS, Gilman A. The Pharmacological Basis of Therapeutics. 2nd ed. New York: The MacMillan Co; 2009:1414–1425.
Gordon S, Denunzio T, Uy A. Success using tacrolimus in patients with proliferative and membranous lupus nephritis and refractory proteinuria. Hawaii J Med Public Health. 2013;72(9 Suppl 4):18-23.
Sarfaraz Hasni, Sarthak Gupta , Michael Davis , Elaine Poncio , Yenealem Temesgen-Oyelakin , Phillip Carlucci, Xinghao Wang, Mohammad Naqi, Martin Playford, Rishi Goel, Xiaobai Li, Ann Biehl, Isabel Ochoa-Navas, Zerai Manna, Yinghui Shi, Don Thomas, Jinguo Chen, Angélique Biancotto, Richard Apps, Foo Cheung, Yuri Kotliarov, Ashley Babyak, Katie Stagliano, John Tsang, Wanxia Tsai, Laura Vian, Nathalia Gazaniga, Valentina Giudice, Stephen Brooks, Meggan Mackay, Peter Gregersen, Betty Diamond, Nehal Mehta, Alan Remaley, John O’Shea, Massimo Gadina and Mariana Kaplan. A phase 1B/2A trial of tofacitinib, an oral janus kinase inhibitor, in systemic lupus erythematosus. Lupus Science & Medicine 2019;6:doi: 10.1136/lupus-2019-lsm.183
Henstell HH, Tober JN, Newman BA. The influence of nitrogen mustard on mycosis fungoides: observations relating its effect to the reticuloendothelial system. Blood. 1947;2(6):564–577.
Hill RD, Scott GW. Cytotoxic drugs for systemic lupus. British Medical Journal. February 1964;1(5379):370.
Hiramatsu Y, Yoshida S, Kotani T, Nakamura E, Kimura Y, Fujita D, Nagayasu Y, Shabana K, Makino S, Takeuchi T, Arawaka S. Changes in the blood level, efficacy, and safety of tacrolimus in pregnancy and the lactation period in patients with systemic lupus erythematosus. Lupus. 2018 Dec;27(14):2245-2252. doi: 10.1177/0961203318809178. Epub 2018 Nov 4. PMID: 30394835.
Humphreys JH, Warner A, Costello R, Lunt M, Verstappen SMM, Dixon WG. Quantifying the hepatotoxic risk of alcohol consumption in patients with rheumatoid arthritis taking methotrexate. Ann Rheum Dis. 2017 Sep;76(9):1509-1514. doi: 10.1136/annrheumdis-2016-210629. Epub 2017 Mar 23. PMID: 28341765; PMCID: PMC5561375.
Juge PA, Lee JS, Lau J, Kawano-Dourado L, Rojas Serrano J, Sebastiani M, Koduri G, Matteson E, Bonfiglioli K, Sawamura M, Kairalla R, Cavagna L, Bozzalla Cassione E, Manfredi A, Mejia M, Rodríguez-Henriquez P, González-Pérez MI, Falfán-Valencia R, Buendia-Roldán I, Pérez-Rubio G, Ebstein E, Gazal S, Borie R, Ottaviani S, Kannengiesser C, Wallaert B, Uzunhan Y, Nunes H, Valeyre D, Saidenberg-Kermanac’h N, Boissier MC, Wemeau-Stervinou L, Flipo RM, Marchand-Adam S, Richette P, Allanore Y, Dromer C, Truchetet ME, Richez C, Schaeverbeke T, Lioté H, Thabut G, Deane KD, Solomon JJ, Doyle T, Ryu JH, Rosas I, Holers VM, Boileau C, Debray MP, Porcher R, Schwartz DA, Vassallo R, Crestani B, Dieudé P. Methotrexate and rheumatoid arthritis associated interstitial lung disease. Eur Respir J. 2021 Feb 11;57(2):2000337. doi: 10.1183/13993003.00337-2020. PMID: 32646919.
Khanna D, Park GS, Paulus HE, Simpson KM, Elashoff D, Cohen SB, Emery P, Dorrier C, Furst DE. Reduction of the efficacy of methotrexate by the use of folic acid: post hoc analysis from two randomized controlled studies. Arthritis Rheum. 2005 Oct;52(10):3030-8. doi: 10.1002/art.21295. PMID: 16200612.
Kostopoulou, M., Adamichou, C. & Bertsias, G. An Update on the Diagnosis and Management of Lupus Nephritis. Curr Rheumatol Rep 22, 30 (2020). https://doi.org/10.1007/s11926-020-00906-7
Kremer JM, Alarcón GS, Lightfoot RW Jr, Willkens RF, Furst DE, Williams HJ, Dent PB, Weinblatt ME. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum. 1994 Mar;37(3):316-28. doi: 10.1002/art.1780370304. PMID: 8129787.
Li P, Shuker N, Hesselink DA, van Schaik RH, Zhang X, van Gelder T. Do Asian renal transplant patients need another mycophenolate mofetil dose compared with Caucasian or African American patients? Transpl Int. 2014 Oct;27(10):994-1004. doi: 10.1111/tri.12382. Epub 2014 Aug 22. PMID: 24963914.
Liu Z, Zhang H, Liu Z, Xing C, Fu P, Ni Z, Chen J, Lin H, Liu F, He Y, He Y, Miao L, Chen N, Li Y, Gu Y, Shi W, Hu W, Liu Z, Bao H, Zeng C, Zhou M. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med. 2015 Jan 6;162(1):18-26. doi: 10.7326/M14-1030. PMID: 25383558.
Lorico S, Colton B. Medication management and pharmacokinetic changes after bariatric surgery. Can Fam Physician. 2020;66(6):409-416.

Marshall A, McGrath C, Torigian D, Papanicolaou N, Lal P, Kaplan Tweed C. Low-dose cyclophosphamide associated with hemorrhagic cystitis in a breast cancer patient. Breast J. 2012 May-Jun;18(3):272-5. doi: 10.1111/j.1524-4741.2011.01161.x. Epub 2011 Oct 5. PMID: 21972971.
Martin K, Bentaberry F, Dumoulin C, Miremont-Salamé G, Haramburu F, Dehais J, Schaeverbeke T. Peripheral neuropathy associated with leflunomide: is there a risk patient profile? Pharmacoepidemiol Drug Saf. 2007 Jan;16(1):74-8. doi: 10.1002/pds.1282. PMID: 16845649.
Medical discoveries. Cyclosporine. Retrieved September 3, 2011, from www.discoveriesinmedicine.com/Com-En/Cyclosporine.html.
Nash P, Kerschbaumer A, Dörner T, et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Annals of the Rheumatic Diseases 2021;80:71-87.
Novikova DS, Udachkina HV, Markelova EI, Kirillova IG, Misiyuk AS, Demidova NV, Popkova TV. Dynamics of body mass index and visceral adiposity index in patients with rheumatoid arthritis treated with tofacitinib. Rheumatol Int. 2019 Jul;39(7):1181-1189. doi: 10.1007/s00296-019-04303-x. Epub 2019 May 3. PMID: 31053871.
Ordi-Ros J, Sáez-Comet L, Pérez-Conesa M, Vidal X, Mitjavila F, Castro Salomó A, Cuquet Pedragosa J, Ortiz-Santamaria V, Mauri Plana M, Cortés-Hernández J. Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial. Ann Rheum Dis. 2017 Sep;76(9):1575-1582. doi: 10.1136/annrheumdis-2016-210882. Epub 2017 Apr 27. PMID: 28450313.
Osborne ED, Jordon JW, Hoak FC, Pschierer FJ. Nitrogen mustard therapy in cutaneous blastomatous disease. Journal of the American Medical Association. 1947;135(17):1123–1128.
Østensen M, Khamashta M, Lockshin M, Parke A, Brucato A, Carp H, et al. Anti-inflammatory and immunosuppressive drugs and reproduction [Review]. Arthritis Research & Therapy. May 2006;8:209–227.
Pego-Reigosa JM, Cobo-Ibáñez T, Calvo-Alén J, Loza-Santamaría E, Rahman A, Muñoz-Fernández S, Rúa-Figueroa Í. Efficacy and safety of nonbiologic immunosuppressants in the treatment of nonre
nal systemic lupus erythematosus: a systematic review. Arthritis Care Res (Hoboken). 2013 Nov;65(11):1775-85. doi: 10.1002/acr.22035. PMID: 23609987.

Pfaller B, Pupco A, Leibson T, Aletaha D, Ito S. A critical review of the reproductive safety of Leflunomide. Clin Rheumatol. 2020 Feb;39(2):607-612. doi: 10.1007/s10067-019-04819-4. Epub 2019 Nov 22. PMID: 31758422.
Pfizer. PFIZER SHARES CO-PRIMARY ENDPOINT RESULTS FROM POST-MARKETING REQUIRED SAFETY STUDY OF XELJANZ® (TOFACITINIB) IN SUBJECTS WITH RHEUMATOID ARTHRITIS (RA). Retrieved on 2/2/21 at https:///www.pfizer.com/news/press-release/press-release-detail/pfizer-shares-co-primary-endpoint-results-post-marketing
Pisoni CN, Sanchez FJ, Karim Y, Cuadrado MJ, D’Cruz DP, Abbs IC, et al. Mycophenolate mofetil in systemic lupus erythematosus: efficacy and tolerability in 86 patients. Journal of Rheumatology. 2005;32:1047–1052.
Rahier J-F, Moutschen M, Gompet AV, Ranst MV, Louis E, Segaert S, et al. Vaccinations in patients with immune-mediated inflammatory diseases [Review]. Rheumatology. 2010;49:1815–1827.
Rissling O, Glander P, Hambach P, et al. No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study. Br J Clin Pharmacol. 2015; Apr 24 (Epub ahead of print): doi: 10.1111/bcp.12664. 
Rohn RJ, Bond WH. Some effects of nitrogen mustard and triethylene melamine in acute disseminated lupus erythematosus. American Journal of the Medical Sciences. August 1953;226(2):179–190.
Rothenberg RJ, Graziano FM, Grandone JT, Goldberg JW, Bjarnason DF, Finesilver AG. The use of methotrexate in steroid-resistant systemic lupus erythematosus. Arthritis & Rheumatism. May 1988;31(5):612–615.
Ruiz-Irastorza G, George Bertsias, Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs, Rheumatology, Volume 59, Issue Supplement_5, December 2020, Pages v69–v81, https://doi.org/10.1093/rheumatology/keaa403
Seah CS, Wong KH, Chew AGK, Jayaratnam FJ. Cyclophosphamide in the treatment of systemic lupus erythematosus [Research article]. British Medical Journal. February 1966;1:333–335.
Solomon, D.H. et al. (2020, February 18). Adverse Effects of Low-Dose Methotrexate: A Randomized Trial. Retrieved from https://pubmed.ncbi.nlm.nih.gov/32066146/
Sparks JA, Dellaripa PF, Glynn RJ, et al. Pulmonary Adverse Events in Patients Receiving Low-Dose Methotrexate in the Randomized, Double-Blind, Placebo-Controlled Cardiovascular Inflammation Reduction Trial. Arthritis Rheumatol. 2020;72(12):2065-2071. doi:10.1002/art.41452
Sugawara E, Kato M, Fujieda Y, Oku K, Bohgaki T, Yasuda S, Umazume T, Morikawa M, Watari H, Atsumi T. Pregnancy outcomes in women with rheumatic diseases: a real-world observational study in Japan. Lupus. 2019 Oct;28(12):1407-1416. doi: 10.1177/0961203319877258. Epub 2019 Sep 24. PMID: 31551035.
Takeuchi T, Wakasugi N, Uno S, Makino H. Long-term Safety and Effectiveness of Tacrolimus in Patients With Lupus Nephritis: 5-year Interim Postmarketing Surveillance Study in Japan (TRUST). J Rheumatol. 2021 Jan 1;48(1):74-81. doi: 10.3899/jrheum.191008. Epub 2020 Apr 1. PMID: 32238515.
Tam L-S, Li EK, Wong C-K, Lam CWK, Szeto C-C. Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus [Concise report]. Lupus. 2004;13:601–604.
Tanaka N, et al. Examination of the risk of continuous leflunomide treatment on the incidence of infectious complications after joint arthroplasty in patients with rheumatoid arthritis. J Clin Rheumatol. 2003;9(2):115. 
Tanaka Y, et al. Jak and Syk: Emerging their relevance to the treatment of inflammatory diseases. Inflamm and Regener 2011;31(3):237-244. Retrieved on 1/15/21 from doi:https://doi.org/10.2492/inflammregen.31.237
Tani C, Elefante E, Martin-Cascón M, et al. Tacrolimus in non-Asian patients with SLE: a real-life experience from three European centres. Lupus Science & Medicine 2018;5:e000274. doi: 10.1136/lupus-2018-000274
Thomas DE, et al. Low hydroxychloroquine blood levels in patients who have had gastric bypass surgery. Lupus Sci Med. 2019 Jun;6(1):e000335.
van der Heijden EH, Hartgring SA, Kruize AA, Radstake TR, van Roon JA. Additive immunosuppressive effect of leflunomide and hydroxychloroquine supports rationale for combination therapy for Sjögren’s syndrome. Expert Rev Clin Immunol. 2019 Jul;15(7):801-808. doi: 10.1080/1744666X.2019.1624527. Epub 2019 Jun 13. PMID: 31192747.
Udomkarnjananun S, Townamchai N, Virojanawat M, Avihingsanon Y, Praditpornsilpa K. An Unusual Manifestation of Calcineurin Inhibitor-Induced Pain Syndrome in Kidney Transplantation: A Case Report and Literature Review. Am J Case Rep. 2018;19:442-446. Published 2018 Apr 14. doi:10.12659/ajcr.908886

Uppugunduri CRS, Storelli F, Mlakar V, Huezo-Diaz Curtis P, Rezgui A, Théorêt Y, Marino D, Doffey-Lazeyras F, Chalandon Y, Bader P, Daali Y, Bittencourt H, Krajinovic M, Ansari M. The Association of Combined GSTM1 and CYP2C9 Genotype Status with the Occurrence of Hemorrhagic Cystitis in Pediatric Patients Receiving Myeloablative Conditioning Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation. Front Pharmacol. 2017 Jul 11;8:451. doi: 10.3389/fphar.2017.00451. PMID: 28744217; PMCID: PMC5504863.
van Roon EN, van de Laar MA. Methotrexate bioavailability. Clin Exp Rheumatol. 2010 Sep-Oct;28(5 Suppl 61):S27-32. Epub 2010 Oct 28. PMID: 21044430.
Wallace DJ, Furie RA, Tanaka Y, Kalunian KC, Mosca M, Petri MA, Dörner T, Cardiel MH, Bruce IN, Gomez E, Carmack T, DeLozier AM, Janes JM, Linnik MD, de Bono S, Silk ME, Hoffman RW. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2018 Jul 21;392(10143):222-231. doi: 10.1016/S0140-6736(18)31363-1. Erratum in: Lancet. 2018 Aug 11;392(10146):476. PMID: 30043749.
Wang HY, Cui TG, Hou FF, Ni ZH, Chen XM, Lu FM, et al. Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study [Paper]. Lupus. 2008;17:638–644.
Webster P, Wardle A, Bramham K, Webster L, Nelson-Piercy C, Lightstone L. Tacrolimus is an effective treatment for lupus nephritis in pregnancy. Lupus. 2014;23(11):1192-1196. doi:10.1177/0961203314540353
White DH, Chapman PT, O’Donnell JL, James J, Frampton C, Stamp LK. Lack of association between elevated mean red cell volume and haematological toxicity in patients receiving long-term methotrexate for rheumatoid arthritis. Intern Med J. 2010 Aug;40(8):561-5. doi: 10.1111/j.1445-5994.2009.02059.x. Epub 2009 Oct 7. PMID: 19811562.
Wilhelmus S, Ingeborg M. Bajema, George K.
Bertsias, Dimitrios T. Boumpas, Caroline Gordon, Liz Lightstone, Vladimir Tesar, David R. Jayne, Lupus nephritis management guidelines compared, Nephrology Dialysis Transplantation, Volume 31, Issue 6, June 2016, Pages 904–913, https://doi.org/10.1093/ndt/gfv102
Wollenhaupt J, Silverfield J, Lee EB, et al. Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, long term extension studies. J Rheumatol. 2014;41(5):837-852. doi: 10.3899/jrheum.130683.
Yates M, Mootoo A, Adas M, Bechman K, Rampes S, Patel V, Qureshi S, Cope AP, Norton S, Galloway JB. Venous Thromboembolism Risk With JAK Inhibitors: A Meta-Analysis. Arthritis Rheumatol. 2021 May;73(5):779-788. doi: 10.1002/art.41580. Epub 2021 Mar 25. PMID: 33174384.
You H, Zhang G, Wang Q, et alSuccessful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centreAnnals of the Rheumatic Diseases 2019;78:1441-1443.
Yu MB, Firek A, Langridge WHR. Predicting methotrexate resistance in rheumatoid arthritis patients. Inflammopharmacology. 2018 Jun;26(3):699-708. doi: 10.1007/s10787-018-0459-z. Epub 2018 Mar 12. PMID: 29532212.
Zhang FS, Nie YK, Jin XM, Yu HM, Li YN, Sun Y. The efficacy and safety of leflunomide therapy in lupus nephritis by repeat kidney biopsy. Rheumatology International. 2009;29(11):1331–1335.
Zhou T, Lin S, Yang S, Lin W. Efficacy and safety of tacrolimus in induction therapy of patients with lupus nephritis. Drug Des Devel Ther. 2019;13:857-869. Published 2019 Mar 12. doi:10.2147/DDDT.S189156
Zink I. Does gastric bypass result in reduced absorption of MTX? The Rheumatologist MAR 2015:50.

Chapter 33

ACR, COVID-19 Vaccine Clinical Guidance Summary for Patients with Rheumatic and Musculoskeletal Diseases. Developed by the ACR COVID-19 Vaccine Clinical Guidance Task Force. 2/8/21. Retrieved on 2/13/21 at https:///www.rheumatology.org/Portals/0/Files/COVID-19-Vaccine-Clinical-Guidance-Rheumatic-Diseases-Summary.pdf​
Aringer M, Houssiau F, Gordon C, Graninger WB, Voll RE, et al. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: longterm follow-up of 13 patients. Rheumatology (Oxford). November 2009;48(11):1451–1454.
Arriens C, Polyakova S, Adzerikho I, et al [abstract]. OP0277 AURORA PHASE 3 STUDY DEMONSTRATES VOCLOSPORIN STATISTICAL SUPERIORITY OVER STANDARD OF CARE IN LUPUS NEPHRITIS (LN). Annals of the Rheumatic Diseases 2020;79:172-173.
Bharat A, Xie F, Baddley JW, Beukelman T, Chen L, et al. Incidence and risk factors for progressive multifocal leukoencephalopathy among patients with selected rheumatic diseases. Arthritis & Care Research. 2012;64(4):612–615.
Cassia MA, Alberici F, Jones RB, Smith RM, Casazza G, Urban ML, Emmi G, Moroni G, Sinico RA, Messa P, Hall F, Vaglio A, Gallieni M, Jayne DR. Rituximab as Maintenance Treatment for Systemic Lupus Erythematosus: A Multicenter Observational Study of 147 Patients. Arthritis Rheumatol. 2019 Oct;71(10):1670-1680. doi: 10.1002/art.40932. Epub 2019 Aug 30. PMID: 31102498.
Chambers CD. Biologics in pregnancy: an update on everything you are too afraid your patients are going to ask. American College of Rheumatology 2009 Annual Scientific Meeting, Philadelphia, Pa.
Clifford DB, Ances B, Costello C, Rosen-Schmidt S, Andersson M, Parks D, et al. Rituximab associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Archives of Neurology. May 2011. Retrieved September 4, 2011.
Coico R, Sunshine G. Immunology: A Short Course. Hoboken, NJ: Wiley-Blackwell; 2009. Drug Safety Quarterly. The American College of Rheumatology. October 2011;3(2).
Cortés-Hernández J, Egri N, Vilardell-Tarrés M, Ordi-Ros J. Etanercept in refractory lupus arthritis: An observational study. Semin Arthritis Rheum. 2015 Jun;44(6):672-9. doi: 10.1016/j.semarthrit.2015.01.006. Epub 2015 Jan 23. PMID: 25712812.
Curtis J, Bridges S, Cofield S, Bassler J, Ford T, Lindsey S, Kivitz A, Messaoudi I, Michaud K, Huffstutter J, Mikuls T, Ridley D, Shergy W, Siegel S, Winthrop K. Results from a Randomized Controlled Trial of the Safety of the Live Varicella Vaccine in TNF-Treated Patients [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/results-from-a-randomized-controlled-trial-of-the-safety-of-the-live-varicella-vaccine-in-tnf-treated-patients/. Accessed February 18, 2021.
Cush J. Problems with biologic drug storage. RheumNow JAN 2018. Retrieved 2/16/21 from https://rheumnow.com/content/problems-biologic-drug-storage
Cush J. TB management questions. Retrieved 2/17/21 from https://rheumnow.com/content/tb-management-questions
Erkan D, Vega J, Ramón G, Kozora E, Lockshin M. A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome. Arthritis & Rheumatism. February 2013;65(3):464–471.
FDA. Biosimilar and Interchangeable Biologics: More Treatment Choices. Retrieved 2/17/21 from https:///www.fda.gov/consumers/consumer-updates/
biosimilar-and-interchangeable-biologics-more-treatment-choices#:~:text=A%20biosimilar%20is%20a%20biologic,original%20biologic%20or%20reference%20product).
FDA (JAN 2017). Nonproprietary naming of biological products: guidance for industry. Retrieved on 2/15/21 at https:///www.fda.gov/media/93218/download
Fernández-Nebro A, Marenco de la Fuente LJ, Carreño L, Galindo Izquierdo M, Tomero E, et al. Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study. Lupus. September 2012;21(10):1063–1076.
Haynes K, Beukelman T, Curtis JR, Newcomb C, Herrinton LJ, et al. Tumor necrosis factor inhibitor therapy and cancer risk in chronic immune-mediated diseases. Arthritis & Rheumatism. January 2013;65(1):48–58. Interferon. Retrieved September 4, 2011, from www.wikipedia.org/wiki/Interferon.
Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proceedings of the Royal Society B: Biological Sciences. September 1957;147(927):258–267.
Kapoor T, Mahadeshwar P, Hui-Yuen J, et al. Prevalence of progressive multifocal leukoencephalopathy (PML) in adults and children with systemic lupus erythematosus. Lupus Science & Medicine 2020;7:e000388. doi: 10.1136/lupus-2020-000388
Katz R. Polyarthritis in systemic lupus erythematosus treated with infliximab. Rush University Medical Center. Retrieved September 4, 2011.
Kendall EC. The development of cortisone as a therapeutic agent [Nobel lecture]. Les Prix Nobel. December 1951.
Mariette X, Matucci-Cerinic M, Pavelka K, Taylor P, van Vollenhoven R, Heatley R, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Annals of Rheumatic Diseases. September 2011. Retrieved September 24, 2011
Md Yusof MY, Vital EM, McElvenny DM, Hensor EMA, Das S, Dass S, Rawstron AC, Buch MH, Emery P, Savic S. Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases. Arthritis Rheumatol. 2019 Nov;71(11):1812-1823. doi: 10.1002/art.40937. Epub 2019 Sep 26. PMID: 31131994.
Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatoid diseases. Arthritis & Rheumatism. December 2009;60(12):3761–3765.
Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy in patients with rheumatic disease: are patients with systemic lupus erythematosus at particular risk? Autoimmunity Review December 2008;8(2):144–146.
Newswire Canada. Celltrion Healthcare receives Health Canada marketing authorization for world’s first subcutaneous formulation of infliximab, Remsima™ SC, for the treatment of people with rheumatoid arthritis. Retrieved 2/16/21 from https:///www.newswire.ca/news-releases/celltrion-healthcare-receives-health-canada-marketing-authorization-for-world-s-first-subcutaneous-formulation-of-infliximab-remsima-tm-sc-for-the-treatment-of-people-with-rheumatoid-arthritis-831511546.html
Østensen M, Förger F. Management of RA medications in pregnant patients. Nature Reviews Rheumatology. July 2009;5:382–390.
Pinto LF, Velásquez CJ, Prieto C, Mestra L, Forero E, Márquez JD. Rituximab induces a rapid and sustained remission in Colombian patients with severe and refractory systemic lupus erythematosus. Lupus. 2011;20:1219–1226.
Pongtarakulpanit N, Pisitkun P, Ngamjanyaporn P. Efficacy and safety of rituximab biosimilar in refractory lupus. Lupus Science & Medicine 2020;7:e000442. doi: 10.1136/lupus-2020-000442
Raaschou P, Simard JF, Neovius M, Askling J. Does cancer that occurs during or after antitumor necrosis factor therapy have a worse prognosis? Arthritis & Rheumatism. July 2011;63(7):1812–1822.
Ramos-Casals M, Soto MJ, Cuadrado MJ, Khamashta MA. Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus. 2009;18:767–776.
Sawsen JH, Uppal SS, Narayanan Nampoory MR, Johny KV, Gupta R, Al-Oun M. Safety and efficacy of infliximab in a patient with active WHO class IV lupus nephritis [Case report]. Clinical Rheumatology. 2007;26(6):973–975.
Shannon E, Daffy J, Jones H, Paulson A, Vicik SM. Etanercept (Enbrel®) alternative storage at ambient temperature. Clin Pharmacol. 2017 Jul 21;9:87-99. doi: 10.2147/CPAA.S131832. PMID: 28790869; PMCID: PMC5531722.
Smolen JS. Slide presentation and abstract. Blocking proinflammatory cytokines in lupus. Poster session at the 7th International Congress on SLE and Related Conditions, May 9–13, 2004, New York, NY.
Solomon DH, Mercer E, Kavanaugh A. Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: a review of their methodologies and results. Arthritis & Rheumatism. 2012;64(1):21–32.
Thompson AE, Rieder SW, Pope JE. Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis & Rheumatism. June 2011;63(6):1479–1485. Tumor necrosis factor-alpha.
Wang X, Yan J, Wang L, Pan D, Xu Y, Wang F, Sheng J, Li X, Yang M. Oral delivery of anti-TNF antibody shielded by natural polyphenol-mediated supramolecular assembly for inflammatory bowel disease therapy. Theranostics. 2020 Aug 29;10(23):10808-10822. doi: 10.7150/thno.47601. PMID: 32929381; PMCID: PMC7482796.​
Ward MM, Dasgupta A. Pre-operative withholding of infliximab and the risk of infections after major surgery in patients with rheumatoid arthritis. Rheumatology (Oxford). 2020 Dec 1;59(12):3917-3926. doi: 10.1093/rheumatology/keaa291. PMID: 32710102; PMCID: PMC7733718.
< span style=”color:rgb(129, 129, 129)”>Weckerle CE, Mangale D, Franek BS, Kelly JA, Kumabe M, et al. Large-scale analysis of tumor necrosis factor α levels in systemic lupus erythematosus. Arthritis & Rheumatism. September 2012;64(9):2947–2952.
Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis & Rheumatism.
2007;56(9):2886–2895.
Yang BB, Xiao H, Li XJ, Zheng M. Safety and efficacy of etanercept-methotrexate combination therapy in patients with rhupus: an observational study of non-glucocorticoid treatment for rheumatic diseases. Discov Med. 2018 Jan;25(135):14-20. PMID: 29466690.
Zhu L-J, Yang X, Yu X-Q. Anti-TNF-α therapies in systemic lupus erythematosus [Review article]. Journal of Biomedicine and Biotechnology. Vol. 2010, Article ID 465898, 8 pages, 2010. doi:10.1155/2010/465898. Retrieved September 4, 2011, from www.hindawi.com/journals/jbb/2010/465898/cta/.Aringer M, Houssiau F, Gordon C, Graninger WB, Voll RE, et al. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: longterm follow-up of 13 patients. Rheumatology (Oxford). November 2009;48(11):1451–1454.
Arriens C, Polyakova S, Adzerikho I, et al [abstract]. OP0277 AURORA PHASE 3 STUDY DEMONSTRATES VOCLOSPORIN STATISTICAL SUPERIORITY OVER STANDARD OF CARE IN LUPUS NEPHRITIS (LN). Annals of the Rheumatic Diseases 2020;79:172-173.
Bharat A, Xie F, Baddley JW, Beukelman T, Chen L, et al. Incidence and risk factors for progressive multifocal leukoencephalopathy among patients with selected rheumatic diseases. Arthritis & Care Research. 2012;64(4):612–615.
Cassia MA, Alberici F, Jones RB, Smith RM, Casazza G, Urban ML, Emmi G, Moroni G, Sinico RA, Messa P, Hall F, Vaglio A, Gallieni M, Jayne DR. Rituximab as Maintenance Treatment for Systemic Lupus Erythematosus: A Multicenter Observational Study of 147 Patients. Arthritis Rheumatol. 2019 Oct;71(10):1670-1680. doi: 10.1002/art.40932. Epub 2019 Aug 30. PMID: 31102498.
Chambers CD. Biologics in pregnancy: an update on everything you are too afraid your patients are going to ask. American College of Rheumatology 2009 Annual Scientific Meeting, Philadelphia, Pa.
Clifford DB, Ances B, Costello C, Rosen-Schmidt S, Andersson M, Parks D, et al. Rituximab associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Archives of Neurology. May 2011. Retrieved September 4, 2011.
Coico R, Sunshine G. Immunology: A Short Course. Hoboken, NJ: Wiley-Blackwell; 2009. Drug Safety Quarterly. The American College of Rheumatology. October 2011;3(2).
Cortés-Hernández J, Egri N, Vilardell-Tarrés M, Ordi-Ros J. Etanercept in refractory lupus arthritis: An observational study. Semin Arthritis Rheum. 2015 Jun;44(6):672-9. doi: 10.1016/j.semarthrit.2015.01.006. Epub 2015 Jan 23. PMID: 25712812.
Curtis J, Bridges S, Cofield S, Bassler J, Ford T, Lindsey S, Kivitz A, Messaoudi I, Michaud K, Huffstutter J, Mikuls T, Ridley D, Shergy W, Siegel S, Winthrop K. Results from a Randomized Controlled Trial of the Safety of the Live Varicella Vaccine in TNF-Treated Patients [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/results-from-a-randomized-controlled-trial-of-the-safety-of-the-live-varicella-vaccine-in-tnf-treated-patients/. Accessed February 18, 2021.
Cush J. Problems with biologic drug storage. RheumNow JAN 2018. Retrieved 2/16/21 from https://rheumnow.com/content/problems-biologic-drug-storage
Cush J. TB management questions. Retrieved 2/17/21 from https://rheumnow.com/content/tb-management-questions
Erkan D, Vega J, Ramón G, Kozora E, Lockshin M. A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome. Arthritis & Rheumatism. February 2013;65(3):464–471.
FDA. Biosimilar and Interchangeable Biologics: More Treatment Choices. Retrieved 2/17/21 from https:///www.fda.gov/consumers/consumer-updates/
biosimilar-and-interchangeable-biologics-more-treatment-choices#:~:text=A%20biosimilar%20is%20a%20biologic,original%20biologic%20or%20reference%20product).
FDA (JAN 2017). Nonproprietary naming of biological products: guidance for industry. Retrieved on 2/15/21 at https:///www.fda.gov/media/93218/download
Fernández-Nebro A, Marenco de la Fuente LJ, Carreño L, Galindo Izquierdo M, Tomero E, et al. Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study. Lupus. September 2012;21(10):1063–1076.
Haynes K, Beukelman T, Curtis JR, Newcomb C, Herrinton LJ, et al. Tumor necrosis factor inhibitor therapy and cancer risk in chronic immune-mediated diseases. Arthritis & Rheumatism. January 2013;65(1):48–58. Interferon. Retrieved September 4, 2011, from www.wikipedia.org/wiki/Interferon.
Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proceedings of the Royal Society B: Biological Sciences. September 1957;147(927):258–267.
Kapoor T, Mahadeshwar P, Hui-Yuen J, et al. Prevalence of progressive multifocal leukoencephalopathy (PML) in adults and children with systemic lupus erythematosus. Lupus Science & Medicine 2020;7:e000388. doi: 10.1136/lupus-2020-000388
Katz R. Polyarthritis in systemic lupus erythematosus treated with infliximab. Rush University Medical Center. Retrieved September 4, 2011.
Kendall EC. The development of cortisone as a therapeutic agent [Nobel lecture]. Les Prix Nobel. December 1951.
Mariette X, Matucci-Cerinic M, Pavelka K, Taylor P, van Vollenhoven R, Heatley R, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Annals of Rheumatic Diseases. September 2011. Retrieved September 24, 2011
Md Yusof MY, Vital EM, McElvenny DM, Hensor EMA, Das S, Dass S, Rawstron AC, Buch MH, Emery P, Savic S. Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases. Arthritis Rheumatol. 2019 Nov;71(11):1812-1823. doi: 10.1002/art.40937. Epub 2019 Sep 26. PMID: 31131994.
Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatoid diseases. Arthritis & Rheumatism. December 2009;60(12):3761–3765.
Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy in patients with rheumatic disease: are patients with systemic lupus erythematosus at particular risk? Autoimmunity Review December 2008;8(2):144–146.
Newswire Canada. Celltrion Healthcare receives Health Canada marketing authorization for world’s first subcutaneous formulation of infliximab, Remsima™ SC, for the treatment of people with rheumatoid arthritis. Retrieved 2/16/21 from https:///www.newswire.ca/news-releases/celltrion-healthcare-receives-health-canada-marketing-authorization-for-world-s-first-subcutaneous-formulation-of-infliximab-remsima-tm-sc-for-the-treatment-of-people-with-rheumatoid-arthritis-831511546.html
Østensen M, Förger F. Management of RA medications in pregnant patients. Nature Reviews Rheumatology. July 2009;5:382–390.
Pinto LF, Velásquez CJ, Prieto C, Mestra L, Forero E, Márquez JD. Rituximab induces a rapid and sustained remission in Colombian patients with severe and refractory systemic lupus erythematosus. Lupus. 2011;20:1219–1226.
Pongtarakulpanit N, Pisitkun P, Ngamjanyaporn P. Efficacy and safety of rituximab biosimilar in refractory lupus. Lupus Science & Medicine 2020;7:e000442. doi: 10.1136/lupus-2020-000442
Raaschou P, Simard JF, Neovius M, Askling J. Does cancer that occurs during or after antitumor necrosis factor therapy have a worse prognosis? Arthritis & Rheumatism. July 2011;63(7):1812–1822.
Ramos-Casals M, Soto MJ, Cuadrado MJ, Khamashta MA. Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus. 2009;18:767–776.
Sawsen JH, Uppal SS, Narayanan Nampoory MR, Johny KV, Gupta R, Al-Oun M. Safety and efficacy of infliximab in a patient with active WHO class IV lupus nephritis [Case report]. Clinical Rheumatology. 2007;26(6):973–975.
Shannon E, Daffy J, Jones H, Paulson A, Vicik SM. Etanercept (Enbrel®) alternative storage at ambient temperature. Clin Pharmacol. 2017 Jul 21;9:87-99. doi: 10.2147/CPAA.S131832. PMID: 28790869; PMCID: PMC5531722.
Smolen JS. Slide presentation and abstract. Blocking proinflammatory cytokines in lupus. Poster session at the 7th International Congress on SLE and Related Conditions, May 9–13, 2004, New York, NY.
Solomon DH, Mercer E, Kavanaugh A. Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: a review of their methodologies and results. Arthritis & Rheumatism. 2012;64(1):21–32.
Thompson AE, Rieder SW, Pope JE. Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis & Rheumatism. June 2011;63(6):1479–1485. Tumor necrosis factor-alpha.
Wang X, Yan J, Wang L, Pan D, Xu Y, Wang F, Sheng J, Li X, Yang M. Oral delivery of anti-TNF antibody shielded by natural polyphenol-mediated supramolecular assembly for inflammatory bowel disease therapy. Theranostics. 2020 Aug 29;10(23):10808-10822. doi: 10.7150/thno.47601. PMID: 32929381; PMCID: PMC7482796.​
Ward MM, Dasgupta A. Pre-operative withholding of infliximab and the risk of infections after major surgery in patients with rheumatoid arthritis. Rheumatology (Oxford). 2020 Dec 1;59(12):3917-3926. doi: 10.1093/rheumatology/keaa291. PMID: 32710102; PMCID: PMC7733718.
< span style=”color:rgb(129, 129, 129)”>Weckerle CE, Mangale D, Franek BS, Kelly JA, Kumabe M, et al. Large-scale analysis of tumor necrosis factor α levels in systemic lupus erythematosus. Arthritis & Rheumatism. September 2012;64(9):2947–2952.
Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis & Rheumatism.
2007;56(9):2886–2895.
Yang BB, Xiao H, Li XJ, Zheng M. Safety and efficacy of etanercept-methotrexate combination therapy in patients with rhupus: an observational study of non-glucocorticoid treatment for rheumatic diseases. Discov Med. 2018 Jan;25(135):14-20. PMID: 29466690.
Zhu L-J, Yang X, Yu X-Q. Anti-TNF-α therapies in systemic lupus erythematosus [Review article]. Journal of Biomedicine and Biotechnology. Vol. 2010, Article ID 465898, 8 pages, 2010. doi:10.1155/2010/465898. Retrieved September 4, 2011, from www.hindawi.com/journals/jbb/2010/465898/cta/.

Chapter 34

Allen A. New lupus drug gets only mixed reactions from patients, experts. Washington Post. June 13, 2011. Retrieved September 4, 2011, from https:///www.washingtonpost.com/national/health/new-lupus-drug-gets-only-mixed-reactions-from-patients-experts/2011/05/31/AGRffcTH_story.html
ACR, COVID-19 Vaccine Clinical Guidance Summary for Patients with Rheumatic and Musculoskeletal Diseases. Developed by the ACR COVID-19 Vaccine Clinical Guidance Task Force. 2/8/21. Retrieved on 2/13/21 at https:///www.rheumatology.org/Portals/0/Files/COVID-19-Vaccine-Clinical-Guidance-Rheumatic-Diseases-Summary.pdf​
Baker KP, Edwards BM, Main SH, Choi GH, Wager RE, Halpern WG, Lappin PB, Riccobene T, Abramian D, Sekut L, Sturm B, Poortman C, Minter RR, Dobson CL, Williams E, Carmen S, Smith R, Roschke V, Hilbert DM, Vaughan TJ, Albert VR. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 2003 Nov;48(11):3253-65. doi: 10.1002/art.11299. PMID: 14613291
Braunstein JB, Sherber NS, Schulman SP, Ding EL, Powe NR. Race, medical researcher distrust, perceived harm, and willingness to participate in cardiovascular prevention trials. Medicine. January 2008;87(1):1–9.
Chatham W, Chadha A, Fettiplace J, Kleoudis C, Bass D, Roth D, Gordon D. A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus. Lupus. 2017 Dec;26(14):1483-1490. doi: 10.1177/0961203317703495. Epub 2017 May 3. PMID: 28467293; PMCID: PMC5673008.​
Collins CE, Cortes-Hernández J, Garcia MA, et al. Real-World Effectiveness of Belimumab in the Treatment of Systemic Lupus Erythematosus: Pooled Analysis of Multi-Country Data from the OBSErve Studies. Rheumatol Ther. 2020;7(4):949-965. doi:10.1007/s40744-020-00243-2
Danve A, Perry L, Deodhar A. Use of belimumab throughout pregnancy to treat active systemic lupus erythematosus: a case report. Semin Arthritis Rheum. 2014 Oct;44(2):195-7. doi: 10.1016/j.semarthrit.2014.05.006. Epub 2014 Jun 6. PMID: 25005336.
D’Cruz D, Maksimowicz-McKinnon K, Oates J, et al. Efficacy and safety of belimumab in patients of black race with systemic lupus erythematosus: results from the EMBRACE studyLupus Science & Medicine 2019;6:doi: 10.1136/lupus-2019-lsm.200
Dooley MA, Houssiau F, Aranow C, D’Cruz DP, Askanase A, et al. Effect of belimumab treatment on renal outcomes: results from phase 3 belimumab clinical trials in patients with systemic lupus erythematosus. Lupus. January 2013;22:63–72.
Elixir Sulfanilamide. Retrieved September 4, 2011, from www.en.wikipedia.org/wiki/Elixir_ sulfanilamide.
Felten R, Scher F, Sagez F, Chasset F, Arnaud L. Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date. Drug Des Devel Ther. 2019 May 8;13:1535-1543. doi: 10.2147/DDDT.S170969. PMID: 31190735; PMCID: PMC6514126.​
FDA (4/1/2020). <Aspirin> comprehensive prescribing information under CFR – Code of Federal Regulations Title 21. Retrieved 2/19/21 from https:///www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=343.80
FDA (February 2021). Highlights of prescribing information Lupkynis. Retrieved on 2/20/21 https:///www.accessdata.fda.gov/drugsatfda_docs/label/2021/213716s000lbl.pdf
Freimuth VS, Quinn SC, Thomas SB, Cole G, Zook E, Duncan T. African Americans’ views on research and the Tuskegee Syphilis Study. Social Science and Medicine. 2001;52:797–808.
Fernandez-Ruiz Ruth, Niewold T. The role of interferons in systemic lupus erythematosus (Tsokos G. Editor) Systemic Lupus Erythematosus: Basic, applied, and clinical aspects. 2nd ed. San Diego, CA: Academic Press; 2020.
Furie R, Khamashta M, Merrill JT, Werth VP, Kalunian K, Brohawn P, Illei GG, Drappa J, Wang L, Yoo S; CD1013 Study Investigators. Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus. Arthritis Rheumatol. 2017 Feb;69(2):376-386. doi: 10.1002/art.39962. PMID: 28130918; PMCID: PMC5299497.
Furie RA, Morand EF Bruce IN, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol. 2019; 1 : e208-e219
Gatto M, Saccon F, Zen M, Regola F, Fredi M, Andreoli L, Tincani A, Urban ML, Emmi G, Ceccarelli F, Conti F, Bortoluzzi A, Govoni M, Tani C, Mosca M, Ubiali T, Gerosa M, Bozzolo E, Canti V, Cardinaletti P, Gabrielli A, Tanti G, Gremese E, De Marchi G, De Vita S, Fasano S, Ciccia F, Pazzola G, Salvarani C, Negrini S, Puppo F, Di Matteo A, De Angelis R, Orsolini G, Rossini M, Faggioli P, Laria A, Piga M, Mathieu A, Scarpato S, Rossi FW, de Paulis A, Brunetta E, Ceribelli A, Selmi C, Prete M, Racanelli V, Vacca A, Bartoloni E, Gerli R, Larosa M, Iaccarino L, Doria A. Early
Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting. Arthritis Rheumatol. 2020 Aug;72(8):1314-1324. doi: 10.1002/art.41253. Epub 2020 Jun 12. PMID: 32275125.
GlaxoSmithKline. Response rates of black/African-Americans systemic lupus erythematosus (SLE) patients in the clinical trials with Benlysta. Research Triangle Park, NC; June 28, 2011.
Góralczyk A, Kolossa K, Waszczak-Jeka M, Adamczak R, Jeka S. The exposure to biologic and targeted synthetic disease-modifying antirheumatic drugs in pregnancy and lactation. Postepy Dermatol Alergol. 2020 Jun;37(3):306-312. doi: 10.5114/ada.2020.96294. Epub 2020 Jul 14. PMID: 32774212; PMCID: PMC7394167.
Janssen WF. Cancer quackery: past and present. Cancer Treatment Watch. Retrieved September 11, 2011, from www.cancertreatmentwatch.org/q/janssen.shtml.
Lipsky PE, Dörner T. The red wolf remains a wily foe [Editorial]. Nature Reviews Rheumatology. June 2010;6:307–308.
Mahoney D. Expert outlines drug-development obstacles in lupus. Rheumatology News. Retrieved September 11, 2011
Manzi S, Sanchez-Guerrero J, Merrill JT, Furie R, Gladman D, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Annals of the Rheumatic Diseases. 2012;71:1833–1838.
Mechcatie E. BLISS-76 yields data on belimumab in SLE. Rheumatology News. July 2010. Retrieved September 22, 2011
Mechcatie E. FDA panel backs belimumab for lupus. Rheumatology News. December
2010;9(12):1,7.
Merrill JT, Furie RA, Wallace DJ, Stohl W, Chatham W, et al. Sustained disease improvement and safety profile over the 1500 patient-year experience (6 years) with belimumab in patients with systemic lupus erythematosus: phase 2 long-term extension. ACR/ARHP Annual Scientific Meeting, November 4–9, 2011.
Merrill JT, Ginzler EM, Wallace DJ, McKay JD, Lisse JR, et al. Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. Arthritis & Rheumatism. October 2012;64(10):3364–3373.
Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, Bae SC, Brohawn PZ, Pineda L, Berglind A, Tummala R; TULIP-2 Trial Investigators. Trial of Anifrolumab in Active Systemic Lupus Erythematosus. N Engl J Med. 2020 Jan 16;382(3):211-221. doi: 10.1056/NEJMoa1912196. Epub 2019 Dec 18. PMID: 31851795.
Niewold, T. Targeting type I interferon in systemic lupus erythematosus. Nat Rev Rheumatol 12, 377–378 (2016). https://doi.org/10.1038/nrrheum.2016.83
Oke, V.,  Iva Gunnarsson, Jessica Dorschner, Susanna Eketjäll, Agneta Zickert, Timothy B. Niewold & Elisabet Svenungsson. High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus. Arthritis Res Ther 21, 107 (2019). https://doi.org/10.1186/s13075-019-1878-y
Oon S, Huq M, Golder V, Ong PX, Morand EF, Nikpour M. Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus. Ann Rheum Dis. 2019 May;78(5):629-633. doi: 10.1136/annrheumdis-2018-214427. Epub 2019 Jan 24. PMID: 30679152.
Paredes JL, & Timothy B. Niewold (2020) Type I interferon antagonists in clinical development for lupus, Expert Opinion on Investigational Drugs, 29:9, 1025-1041, DOI: 10.1080/13543784.2020.1797677
Patent medicine. Retrieved September 4, 2011, from https://en.wikipedia.org/wiki/Patent_medicine
Peirce A, Lipsky, Schwartz BD. Mitigate risk and increase success of lupus clinical trials: design strategies from a Lupus Research Institute conference. The Rheumatologist. August 2010.
Pollack A. F.D.A. Approves Drug for Lupus, an Innovation After 50 Years. New York Times. March 9, 2011. Retrieved September 4, 2011, from www.nytimes.com/2011/03/10/health/10drug.html.
Postal M, Vivaldo JF, Fernandez-Ruiz R, Paredes JL, Appenzeller S, Niewold TB. Type I interferon in the pathogenesis of systemic lupus erythematosus. Curr Opin Immunol. 2020 Dec;67:87-94. doi: 10.1016/j.coi.2020.10.014. Epub 2020 Nov 24. PMID: 33246136; PMCID: PMC8054829.
Rehnberg M, Amu S, Tarkowski A, Bokarewa MI, Brisslert M. Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis. Arthritis Res Ther. 2009;11(4):R123. doi: 10.1186/ar2789. Epub 2009 Aug 17. PMID: 19686595; PMCID: PMC2745807.
Saito J, Yakuwa N, Ishizuka T, Goto M, Yamatani A, Murashima A. Belimumab Concentrations in Maternal Serum and Breast Milk During Breastfeeding and the Safety Assessment of the Infant: A Case Study. Breastfeed Med. 2020 Jul;15(7):475-477. doi: 10.1089/bfm.2020.0068. Epub 2020 Apr 23. PMID: 32326740; PMCID: PMC7374635.
Soh MC, Moretto M. The use of biologics for autoimmune rheumatic diseases in fertility and pregnancy. Obstet Med. 2020 Mar;13(1):5-13. doi: 10.1177/1753495X19841799. Epub 2019 May 30. PMID: 32284726; PMCID: PMC7133102.
Stohl W, Hiepe F, Latinis KM, Thomas M, Scheinberg MA, et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythema
tosus. Arthritis & Rheumatism. July 2012;64(7):2328–2337.
Stork A. The long, winding road to a new drug. National Psoriasis Foundation Psoriasis Advance. Summer 2010. Retrieved September 22, 2011, from www.psoriasis.org/publications/psoriasis-advance/2010/summer/drug-development.
Strand V, Berry P, Lin X, Asukai Y, Punwaney R, Ramachandran S. Long-Term Impact of Belimumab on Health-Related Quality of Life and Fatigue in Patients With Systemic Lupus Erythematosus: Six Years of Treatment. Arthritis Care Res (Hoboken). 2019 Jun;71(6):829-838. doi: 10.1002/acr.23788. Epub 2019 Apr 29. PMID: 30320964; PMCID: PMC6593666.
Swann JP. About FDA: FDA’s origin. Retrieved September 11, 2011, from U.S. Food and Drug Administration website: www.fda.gov
Tanaka Y, Tummala R. Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials. Mod Rheumatol. 2021 Jan;31(1):1-12. doi: 10.1080/14397595.2020.1812201. Epub 2020 Sep 17. PMID: 32814461.
Thalidomide. Retrieved September 11, 2011, https://en.wikipedia.org/wiki/Thalidomide
Tuskegee Syphilis Experiment. Retrieved September 4, 2011, from https://en.wikipedia.org/wiki/Tuskegee_Syphilis_Study
Urowitz MB, Ohsfeldt RL, Wielage RC, Kelton KA, Asukai Y, Ramachandran S. Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis. Ann Rheum Dis. 2019 Mar;78(3):372-379. doi: 10.1136/annrheumdis-2018-214043. Epub 2019 Jan 4. PMID: 30610066; PMCID: PMC6390027.
U.S. Food and Drug Administration. About FDA: milestones of drug regulation in the United States. Retrieved September 11, 2011, from www.fda.gov
ucm114463.htm.
U.S. Food and Drug Administration. About FDA: sulfanilamide disaster. June 1981. Retrieved September 11, 2011, from www.FDA.gov
U.S. Food and Drug Administration. Aspirin comprehensive prescribing information. Retrieved September 11, 2011
van Vollenhoven RF, Petri MA, Cervera R, Roth DA, Ji BN, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Annals of the Rheumatic Diseases. 2012;71:1343–1349.
Wallace DJ. The use of quinacrine (Atabrine) in rheumatic disease: a reexamination. Seminars in Arthritis and Rheumatism. 1989;18(4):282–297.
Wallace DJ, Ginzler EM, Merrill JT, Furie RA, Stohl W, Chatham WW, Weinstein A, McKay JD, McCune WJ, Petri M, Fettiplace J, Roth DA, Ji B, Heath A. Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019 Jul;71(7):1125-1134. doi: 10.1002/art.40861. Epub 2019 Jun 5. PMID: 30771238; PMCID: PMC6617785.
Wallace DJ, Navarra S, Petri MA, Gallacher A, Thomas M, et al. Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus. Lupus. January 2013;22(1):144–154.
Walsh N. New lupus drugs remain elusive after 50 years. Internal Medicine News. March 15, 2009. Retrieved September 11, 2011, from https://cdn.mdedge.com/files/s3fs-public/issues/articles/70206_main_2.pdf
Zoler ML. Belimumab reduced SLE activity in phase III study. Rheumatology News. November 2009;8(11):28.

Chapter 35

American Journal of Managed Care. Immunoglobulin Potency and Purity Considerations for Patients With Primary Immunodeficiency. Retrieved on 2/17/21 from https:///www.ajmc.com/view/immunoglobulin-potency-and-purity-considerations-for-patients-with-primary-immunodeficiency
Aviña-Zubieta JA, Galindo-Rodrìguez G, Robledo I, Vela-Ojeda J, Vadillo-Buenfil M, Rosas-Cabral A, Salazar-Exaire D. Long-term effectiveness of danazol corticosteroids and cytotoxic drugs in the treatment of hematologic manifestations of systemic lupus erythematosus. Lupus. 2003;12(1):52-7. doi: 10.1191/0961203303lu337oa. PMID: 12587827.

Cox N.H., Vitamin E for dapsone‐induced headache, British Journal of Dermatology, Volume 146, Issue 1, 1 January 2002, Page 175, https://doi.org/10.1046/j.1365-2133.2002.04486.x
Cutillas-Marco E, Marquina-Vila A, Grant WB, Vilata-Corell JJ, Morales-Suárez-Varela MM. Vitamin D and cutaneous lupus erythematosus: effect of vitamin D replacement on disease severity. Lupus. 2014 Jun;23(7):615-23. doi: 10.1177/0961203314522338. Epub 2014 Feb 6. PMID: 24503020.
Dau K, Cush JJ. A vaccination primer for rheumatologists. Drug Safety Quarterly (JAN 2012);4(1):1.
Domingo S, Solé C, Moliné T, Ferrer B, Ordi-Ros J, Cortés-Hernández J. Efficacy of Thalidomide in Discoid Lupus Erythematosus: Insights into the Molecular Mechanisms. Dermatology. 2020;236(5):467-476. doi: 10.1159/000508672. Epub 2020 Jul 13. PMID: 32659758.

Duan L, Chen L, Zhong S, Wang Y, Huang Y, He Y, Chen J, Shi G. Treatment of Bullous Systemic Lupus Erythematosus. J Immunol Res. 2015;2015:167064. doi: 10.1155/2015/167064. Epub 2015 May 18. PMID: 26090480; PMCID: PMC4451988.
García-Carrasco M, Jiménez-Herrera EA, Gálvez-Romero JL, Mendoza-Pinto C, Méndez-Martínez S, Etchegaray-Morales I, Munguía-Realpozo P, Vázquez de Lara-Cisneros L, Santa Cruz FJ, Cervera R. The anti-thrombotic effects of vitamin D and their possible relationship with antiphospholipid syndrome. Lupus. 2018 Dec;27(14):2181-2189. doi: 10.1177/0961203318801520. Epub 2018 Oct 3. PMID: 30282560.
Karim MY, Ruiz-Irastorza G, Khamashta MA, Hughes GRV. Update on therapy—thalidomide in
the treatment of lupus. Lupus. 2001;10:188–192.
Medscape (2018). How is intravenous immunoglobulin (IVIG) prepared? Retrieved 2/21/21 from https:///www.medscape.com/answers/210367-32892/how-is-intravenous-immunoglobulin-ivig-prepared
Nieto-Aristizábal I, Martínez T, Urbano MA, Posso-Osorio I, Plata IF, Garcia-Robledo JE, Aragón CC, Santos VA, Tobón GJ. Treatment with intravenous immunoglobulins in systemic lupus erythematosus: a single-center experience with 63 patients. Lupus. 2019 Nov;28(13):1566-1570. doi: 10.1177/0961203319883680. Epub 2019 Oct 25. PMID: 31653191.
Perri AJ, Hsu S. A review of thalidomide’s history and current dermatological applications. Dermatology Online Journal 9(3):5. Retrieved September 21, 2011.
Sergent SR, Ashurst JV. Plasmapheresis. [Updated 2020 Jul 15]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from https:///www.ncbi.nlm.nih.gov/books/NBK560566/
Xing ZX, Yu K, Yang H, Liu GY, Chen N, Wang Y, Chen M. Successful use of plasma exchange in fulminant lupus myocarditis coexisting with pneumonia: A case report. World J Clin Cases. 2020 May 26;8(10):2056-2065. doi: 10.12998/wjcc.v8.i10.2056. PMID: 32518801; PMCID: PMC7262706.
Zandman-Goddard G, Levy Y, Shoenfeld Y. Intravenous immunoglobulin therapy and systemic lupus erythematosus. Clin Rev Allergy Immunol. 2005 Dec;29(3):219-28. doi: 10.1385/CRIAI:29:3:219. PMID: 16391397.

Chapter 36

Abebe W. Herbal medication: potential for adverse interactions with analgesic drugs. Journal of Clinical Pharmacy and Therapeutics. December 2002;27(6):391–401.
American Academy of Pediatrics. Maternal medication usually compatible with breastfeeding. Retrieved September 25, 2011, from www.aappolicy.aappublications.org/cgi/content-nw/full/pediatrics;108/3/776/T6.
Bouck Z, Ivers NM, Bhatia RS. Association of NSAID Use and Renal Complications-Reply. JAMA Intern Med. 2019 Apr 1;179(4):587. doi: 10.1001/jamainternmed.2018.8681. PMID: 30933230.
Daniel S, Matok I, Gorodischer R, Koren G, Uziel E, et al. Major malformations following exposure to nonsteroidal anti-inflammatory drugs during the first trimester of pregnancy. Journal of Rheumatology. 2012;39:2163–2169.
Krenzelok EP, Royal MA. Confusion: acetaminophen dosing changes based on NO evidence in adults. Drugs R D. 2012 Jun 1;12(2):45-8. doi: 10.2165/11633010-000000000-00000. PMID: 22530736; PMCID: PMC3585765.
Möller B, Pruijm M, Adler S on behalf of the Swiss Clinical Quality Management in Rheumatic Diseases (SCQM) Foundation, CH-8048 Zurich, Switzerland, et alChronic NSAID use and long-term decline of renal function in a prospective rheumatoid arthritis cohort studyAnnals of the Rheumatic Diseases 2015;74:718-723.
Nakhai-Pour HR, Broy P, Sheehy O, Bérard A. Use of nonaspirin nonsteroidal anti-inflammatory drugs during pregnancy and the risk of spontaneous abortion. Canadian Medical Association Journal. 2011;183:1713.
U.S. Department of Justice, Drug Enforcement Administration, Office of Diversion Control. Code of regulations, section 1308, schedules of controlled substances. Retrieved September 25, 2011, from www.deadiversion.usdoj.gov/21cfr/cfr/2108cfrt.htm.

Chapter 37

An J, Woodward JJ, Lai W, Minie M, Sun X, Tanaka L, Snyder JM, Sasaki T, Elkon KB. Inhibition of Cyclic GMP-AMP Synthase Using a Novel Antimalarial Drug Derivative in Trex1-Deficient Mice. Arthritis Rheumatol. 2018 Nov;70(11):1807-1819. doi: 10.1002/art.40559. Epub 2018 Sep 14. PMID: 29781188.
Breuckmann F, Gambichler T, Altmeyer P, Kreuter A. UVA/UVA1 phototherapy and PUVA photochemotherapy in connective tissue diseases and related disorders: a research based review. BMC Dermatology. 2004;(1):11.
Comte C, Bessis D, Picot E, Peyron JL, Guillot B, Dereure O. [Treatment of connective tissue disorder-related acral syndromes using UVA-1 phototherapy: an open study of 11 cases]. Annales de Dermatologie et de Venereologie. April 2009;136(4):323–329.
Dall’Era M, Chakravarty E, Wallace D, et al. Reduced B lymphocyte and immunoglobulin levels after Atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalation trial. Arthritis & Rheumatism. 2007;56:4142–4150.
D’Andrea Denise (senior director, clinical research, for Cephalon, Inc.). Lupuzor(tm) being studied for treatment of systemic lupus erythematosus [Youtube video]. October 31, 2010. Lupus Foundation of America. Retrieved October 1, 2011, from www.youtube.com/ watch?v=Tg1BwAB86Jg.
DeBartolo A. Lupus Underground: A Patient’s Case for a Long-ignored, Drug-free, Non-patentable, Counter-intuitive Therapy That Actually Works. Chicago: Hyde Park Media; 2004. DrugLib.com. Drug information portal. Retrieved October 1, 2011, from www.druglib.com/.
Fanouriakis A, Boumpas DT, Bertsias GK. Balancing efficacy and toxicity of novel therapies in systemic lupus erythematosus. Expert Review of Clinical Pharmacology. 2011;4(4):437–451.
Gallagher L, Cregan S, Biniecka M, Cunningham C, Veale DJ, Kane DJ, Fearon U, Mullan RH. Insulin-Resistant Pathways Are Associated With Disease Activity in Rheumatoid Arthritis and Are Subject to Disease Modification Through Metabolic Reprogramming: A Potential Novel Therapeutic Approach. Arthritis Rheumatol. 2020 Jun;72(6):896-902. doi: 10.1002/art.41190. Epub 2020 May 10. PMID: 31840936.
Haarhaus ML, Elisabet Svenungsson, Iva Gunnarsson, Ofatumumab treatment in lupus nephritis patients, Clinical Kidney Journal, Volume 9, Issue 4, 1 August 2016, Pages 552–555, https://doi.org/10.1093/ckj/sfw022
Hasni S, Gupta S, Davis MA, et al. A phase 1B/2A trial of tofacitinib, an oral janus kinase inhibitor,
in systemic lupus erythematosus. Lupus Science & Medicine 2019;6:doi: 10.1136/lupus-2019-lsm.183
Hasni S, Gupta S, Davis M, Poncio E, Temesgen-Oyelakin Y, Joyal E, Fike A, Manna Z, Auh S, Shi Y, Chan D, Carlucci P, Biehl A, Dema B, Charles N, Balow JE, Waldman M, Siegel RM, Kaplan MJ, Rivera J. Safety and Tolerability of Omalizumab: A Randomized Clinical Trial of Humanized Anti-IgE Monoclonal Antibody in Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019 Jul;71(7):1135-1140. doi: 10.1002/art.40828. Epub 2019 May 8. PMID: 30597768; PMCID: PMC6594871.
Hawk D. Cancer drug shows promise in treating lupus. Value-Based Care in Rheumatology. August2012;1(3):1,15.
Heijke R, Björk M, Frodlund M, McDonald L, Alemao E, Sjöwall C. Relationship between remission, disease activity and patient-reported outcome measures in patients with recent-onset systemic lupus erythematosus. Lupus. 2020 May;29(6):625-630. doi: 10.1177/0961203320912338. Epub 2020 Mar 18. PMID: 32188304; PMCID: PMC7184926.
Helio Rheumatology. FDA grants fast track status to telitacicept for SLE. May 2020:58.
Humrich JY, Riemekasten G. Low-dose interleukin-2 therapy for the treatment of systemic lupus erythematosus. Curr Opin Rheumatol. 2019 Mar;31(2):208-212. doi: 10.1097/BOR.0000000000000575. PMID: 30562181.
Humrich JY, Spee-Mayer CV, Siegert E, et al. Low-dose il-2 therapy in refractory sle: results from a single centre phase i/iia clinical trial. Annals of the Rheumatic Diseases 2017;76:A62-A63.
Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis & Rheumatism. February 2010;62(2):542–552.
Kaufman MB. Drug updates: information on new approvals and medication safety. The Rheumatologist. March 2010. Retrieved October 1, 2011, from www.therheumatologist.org/details/article/865867/Drug_Updates.html.
Kaufman MB. Drug updates: information on new approvals and medication safety. The Rheumatologist. September 2011. Retrieved October 1, 2011, from www.the-rheumatologist.org/details/article/1332713/Drug_Updates.html.
Kaufman MB. FDA considers tanezumab application. The Rheumatologist May 2020:67. 
Khamashta M, Merrill JT, Werth VP, Furie R, Kalunian K, Illei GG, Drappa J, Wang L, Greth W; CD1067 study investigators. Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016 Nov;75(11):1909-1916. doi: 10.1136/annrheumdis-2015-208562. Epub 2016 Mar 23. PMID: 27009916; PMCID: PMC5099191.
McBride JM, Jiang J, Abbas AR, Morimoto A, Li J, et al. Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. Arthritis & Rheumatism. November
2012;64(11):3666–3676.
McGrath H, Bell JM, Hayne MR, Martinez-Osuna P. Ultraviolet-a irradiation therapy for patients with systemic lupus erythematosus: a pilot study. Current Therapeutic Research. April 1994;55(4):373–381.
Merrill JT, Burgos-Vargas R, Westhovens R, Chalmers A, D’Cruz D, Wallace DJ, et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestation of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis & Rheumatism. October 2010;62(10):3077–3087.
Merrill JT, Wallace DJ, Wax S, Kao A, Fraser PA, Chang P, Isenberg D; ADDRESS II Investigators. Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase IIb Study. Arthritis Rheumatol. 2018 Feb;70(2):266-276. doi: 10.1002/art.40360. Erratum in: Arthritis Rheumatol. 2018 Mar;70(3):467. PMID: 29073347; PMCID: PMC6099253.
Mikita N, Kanazawa, Yoshimasu T, Ikeda T, Li H-J, Yamamoto Y, et al. The protective effects of ultraviolet A1 irradiation on spontaneous lupus erythematosus-like skin lesions in MRL/lpr mice [Research article]. Clinical and Developmental Immunology. 2009. Retrieved October 1, 2011, from www.hindawi.com/journals/cdi/2009/673952/.
Narain S, Furie R. Update on clinical trials in systemic lupus erythematosus. Curr Opin Rheumatol. 2016 Sep;28(5):477-87. doi: 10.1097/BOR.0000000000000311. PMID: 27314466.
NIH U.S. National Library of Medicine. ClinicalTrials.gov. Retrieved 4/11/21 at clinicaltrials.gov.
Nikpour M. Metformin in SLE: metabolism as a therapeutic target in autoimmune disease. The Lancet Rheumatology APR 2020. 2(4):E196-E197.
Pavel S. Light therapy (with UVA-1) for SLE patients: is it a good or bad idea? [Editorial]. Rheumatology. 2006;45:653–655.
Polderman MCA, le Cessie S, Huizinga TWJ, Pavel S. Efficacy of UVA-1 cold light as an adjuvant therapy for systemic lupus erythematosus. Rheumatology. 2004;43:1402–1404. Research. Lupus Foundation of America: DC/MD/VA Chapter. Retrieved October 1, 2011, from www.lupus.org/webmodules/webarticlesnet/templates/gwashington_research.aspx?articleid=908&zone=144.
Rovin BH, Dooley MA, Radhakrishnan J, Ginzler EM, Forrester TD, Anderson PW. The impact of tabalumab on the kidney in systemic lupus erythematosus: results from two phase 3 randomized, clinical trials. Lupus. 2016;25(14):1597-1601. doi:10.1177/0961203316650734
Schwartzman JS, Gross R, Putterman C. Management of lupus in 2010: how close are the biologics? Journal of Musculoskeletal Medicine. November 2010;27(11):427–440. U.S. National Institutes of Health. Search for clinical trials. Retrieved October 1, 2011, from www.clinicaltrials.gov/ct2/search.
Segarra A, Arredondo KV, Jaramillo J, Jatem E, Salcedo MT, Agraz I, Ramos N, Carnicer C, Valtierra N, Ostos E. Efficacy and safety of bortezomib in refractory lupus nephritis: a single-center experience. Lupus. 2020 Feb;29(2):118-125. doi: 10.1177/0961203319896018. Epub 2019 Dec 22. PMID: 31865857.
Sjöwall C, Hjorth M, Eriksson P. Successful treatment of refractory systemic lupus erythematosus using proteas
ome inhibitor bortezomib followed by belimumab: description of two cases. Lupus. 2017;26(12):1333-1338. doi:10.1177/0961203317691371
Sun F, Geng S, Wang H, et alEffects of metformin on disease flares in patients with systemic lupus erythematosus: post hoc analyses from two randomised trialsLupus Science & Medicine 2020;7:e000429. doi: 10.1136/lupus-2020-000429
Trotter K, Clark MR, Liarski VM. Overview of pathophysiology and treatment of human lupus nephritis. Curr Opin Rheumatol. 2016 Sep;28(5):460-7. doi: 10.1097/BOR.0000000000000319. PMID: 27341623; PMCID: PMC4965286.
Vasudevan AR, Ginzler EM. Established and novel treatments for lupus: agents in clinical trithomasals are targeting various immunological processes. Journal of Musculoskeletal Medicine. August 2009;26(8):291–300.
Wallace D, Petri M, Strand V, Killgallen B, Barry A, et al. Epratuzumab demonstrates clinically meaningful improvements in patients with moderate to severe systemic lupus erythematosus (SLE): results from EMBLEM, a phase IIB study. Annals of Rheumatic Diseases. 2010;69:558.
Werth V., et al. EFFECT OF IBERDOMIDE ON CUTANEOUS MANIFESTATIONS IN SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS OF A 24-WEEK, PLACEBO-CONTROLLED, PHASE 2 STUDY. EULAR 2021 abstract OP0132. Retrieved 6/4/21 from http:/scientific.sparx-ip.net/archiveeular/index.cfm?c=a&item=2021OP0132
Wofsy D. Trials and tribulations in systemic lupus erythematosus. Bulletin of the NYU Hospital for Joint Diseases. 2010;68(3):175–178.
York NR, Jacobe HT. UVA1 phototherapy: a review of mechanism and therapeutic application [Review]. International Society of Dermatology. 2010;49:623–630.
Zhang H, Liu Z, Huang L, et al. The short-term efficacy of bortezomib combined with glucocorticoids for the treatment of refractory lupus nephritis. Lupus. 2017;26(9):952-958. doi:10.1177/0961203316686703

Chapter 38

Abbasi J. FDA trials find sunscreen ingredients in blood, but risk is uncertain. JAMA APR 2020:1431.
Abdel Galil SM, El-Shafey AM, Abdul-Maksoud RS, El-Boshy M. Interferon alpha gene expression and serum level association with low vitamin D levels in Egyptian female patients with systemic lupus erythematosus. Lupus. 2018 Feb;27(2):199-209. doi: 10.1177/0961203317716321. Epub 2017 Jun 28. PMID: 28659049.
Adamson AS, Shinkai K. Systemic Absorption of Sunscreen: Balancing Benefits With Unknown Harms. JAMA. 2020 Jan 21;323(3):223-224. doi: 10.1001/jama.2019.20143. PMID: 31961400.
Ahluwalia J, Marsch A. Photosensitivity and photoprotection in patients with lupus erythematosus. Lupus. 2019 May;28(6):697-702. doi: 10.1177/0961203319839486. Epub 2019 Apr 25. PMID: 31023132.
Ali, R.A., et al., Antineutrophil properties of natural gingerols in models of lupus. JCI Insight, 2021. 6(3).
Alzate MA et al. Coffee consumption and clinical outcomes in colombian patients wiht systemic lupus erythematosus.  Lupus and Science BMJ;4(1)
Amalraj, A., et al., A Novel Highly Bioavailable Curcumin Formulation Improves Symptoms and Diagnostic Indicators in Rheumatoid Arthritis Patients: A Randomized, Double-Blind, Placebo-Controlled, Two-Dose, Three-Arm, and Parallel-Group Study. J Med Food, 2017. 20(10): p. 1022-1030.
Arvonen M, Virta LJ, Pokka T, Kröger L, Vähäsalo P. Repeated exposure to antibiotics in infancy: a predisposing factor for juvenile idiopathic arthritis or a sign of this group’s greater susceptibility to infections? J Rheumatol. 2015 Mar;42(3):521-6. doi: 10.3899/jrheum.140348. Epub 2014 Oct 15. PMID: 25320218.
Ayán C, Martín V. Systemic lupus erythematosus and exercise. Lupus. 2007;16:5–9.
Azzouz D, Omarbekova A, Heguy A, Schwudke D, Gisch N, Rovin BH, Caricchio R, Buyon JP, Alekseyenko AV, Silverman GJ. Lupus nephritis is linked to disease-activity associated expansions and immunity to a gut commensal. Ann Rheum Dis. 2019 Jul;78(7):947-956. doi: 10.1136/annrheumdis-2018-214856. Epub 2019 Feb 19. PMID: 30782585; PMCID: PMC6585303.
Bao Y, Han J, Hu FB, Giovannucci EL, Stampfer MJ, Willett WC, Fuchs CS. Association of nut consumption with total and cause-specific mortality. N Engl J Med. 2013 Nov 21;369(21):2001-11. doi: 10.1056/NEJMoa1307352. PMID: 24256379; PMCID: PMC3931001.
Bax CE, Chakka S, Concha JSS, Zeidi M, Werth VP. The effects of immunostimulatory herbal supplements on autoimmune skin diseases. J Am Acad Dermatol. 2021 Apr;84(4):1051-1058. doi: 10.1016/j.jaad.2020.06.037. Epub 2020 Jun 15. PMID: 32553683; PMCID: PMC7736300.
Bello, K.J., et al., Omega-3 in SLE: a double-blind, placebo-controlled randomized clinical trial of endothelial dysfunction and disease activity in systemic lupus erythematosus. Rheumatol Int, 2013. 33(11): p. 2789-96.
Birmingham DJ, Nagaraja HN, Rovin BH, Spetie L, Zhao Y, Li X, et al. Fluctuations in self-perceived stress and increased risk of flare in patients with lupus nephritis carrying the serotonin receptor 1A-1019 G allele. Arthritis & Rheumatism. October 2006;54(10):3291–3299.
Bourré-Tessier J, et al. Association of smoking with cutaneous manifestations of systemic lupus erythematosus. Arthr Care Res 2013;65:1275-1280.
Bustamante, M.F., et al., Design of an anti-inflammatory diet (ITIS diet) for patients with rheumatoid arthritis. Contemp Clin Trials Commun, 2020. 17: p. 100524.
Califf RM, Shinkai K. Filling in the Evidence About Sunscreen. JAMA. 2019 Jun 4;321(21):2077-2079. doi: 10.1001/jama.2019.5528. PMID: 31058950.
Canadian Centre for Occupational Health and Safety. Ultraviolet radiation. Retrieved October 1, 2011, from www.ccohs.ca/oshanswers/phys_agents/ultravioletradiation.html.
Chandrasekhara S, Jayachandran NV, Rajasekhar L, Thomas J, Narsimulu G. The prevalence and associations of sleep disturbances in patients with systemic lupus erythematosus [Original article]. Modern Rheumatology. 2009; 19(4):407–415. de Boer IH, Levin G, Robinson-Cohen C, Biggs ML, Hoofnagle AN, et al. Serum 25-hydroxyvitamin D concentration and risk for major clinical disease events in a community- based population of older adults: a cohort study. Annals of Internal Medicine. May 2012;156(9):627–634.
Charoenwoodhipong P, Harlow SD, Marder W, Hassett AL, McCune WJ, Gordon C, Helmick CG, Barbour KE, Wang L, Mancuso P, Somers EC, Zick SM. Dietary Omega Polyunsaturated Fatty Acid Intake and Patient-Reported Outcomes in Systemic Lupus Erythematosus: The Michigan Lupus Epidemiology and Surveillance Program. Arthritis Care Res (Hoboken). 2020 Jul;72(7):874-881. doi: 10.1002/acr.23925. PMID: 31074595; PMCID: P
MC6842394.
Cutillas-Marco E, Marquina-Vila A, Grant WB, Vilata-Corell JJ, Morales-Suárez-Varela MM. Vitamin D and cutaneous lupus erythematosus: effect of vitamin D replacement on disease severity. Lupus. 2014 Jun;23(7):615-23. doi: 10.1177/0961203314522338. Epub 2014 Feb 6. PMID: 24503020.
Dehner C, Fine R, Kriegel MA. The microbiome in systemic autoimmune disease: mechanistic insights from recent studies. Curr Opin Rheumatol. 2019 Mar;31(2):201-207. doi: 10.1097/BOR.0000000000000574. PMID: 30624285; PMCID: PMC6408954.
Dennis J, Krewski D, Côté F-S, Fafard E, Little J, Ghadirian P. Breast cancer risk in relation to alcohol consumption and BRCA gene mutations—a case-only study of gene-environment interaction. The Breast Journal. 2011;17(5):477–484.
Drenkard C, Lim SS. Update on lupus epidemiology: advancing health disparities research through the study of minority populations. Curr Opin Rheumatol. 2019 Nov;31(6):689-696. doi: 10.1097/BOR.0000000000000646. PMID: 31436582; PMCID: PMC6791519.
Duffy, E.M., et al., The clinical effect of dietary supplementation with omega-3 fish oils and/or copper in systemic lupus erythematosus. J Rheumatol, 2004. 31(8): p. 1551-6.
Elkan A-C, Anania C, Gustafsson T, Jogestrand T, Hafström I, Frostegård J. Diet and fatty acid pattern among patients with SLE: associations with disease activity, blood lipids and atherosclerosis. Lupus. 2012;21:1405–1411.
Fabbri C, Fuller R, Bonfá E, Guedes LK, D’Alleva PS, Borba EF. Periodontitis treatment improves systemic lupus erythematosus response to immunosuppressive therapy. Clin Rheumatol. 2014 Apr;33(4):505-9. doi: 10.1007/s10067-013-2473-2. Epub 2014 Jan 11. PMID: 24415114.
Fangtham M, Kasturi S, Bannuru RR, Nash JL, Wang C. Non-pharmacologic therapies for systemic lupus erythematosus. Lupus. 2019 May;28(6):703-712. doi: 10.1177/0961203319841435. Epub 2019 Apr 8. PMID: 30961418; PMCID: PMC6585401.
Ford ES, Zhao G, Tsai J, Li C. Low-risk lifestyle behaviors and all-cause mortality: findings from the National Health and Nutrition Examination Survey III Mortality Study. American Journal of Public Health. October 2011;101(10):1922–1929.
Formica MK, Palmer JR, Rosenberg L, McAlindon TE. Smoking alcohol consumption, and risk of systemic lupus erythematosus in the Black Women’s Health Study. Journal of Rheumatology. June 2003;30(6):1222–1226.
García-Carrasco M, Jiménez-Herrera EA, Gálvez-Romero JL, Mendoza-Pinto C, Méndez-Martínez S, Etchegaray-Morales I, Munguía-Realpozo P, Vázquez de Lara-Cisneros L, Santa Cruz FJ, Cervera R. The anti-thrombotic effects of vitamin D and their possible relationship with antiphospholipid syndrome. Lupus. 2018 Dec;27(14):2181-2189. doi: 10.1177/0961203318801520. Epub 2018 Oct 3. PMID: 30282560.
Ghaussy NO, Sibbitt Jr WL, Qualls CR. Cigarette smoking, alcohol consumption, and the risk of systemic lupus erythematosus: a case-control study. Journal of Rheumatology. November 2001;28(11):2449–2453.
Giroir BP, Wright D. Physical Activity Guidelines for Health and Prosperity in the United States. JAMA. 2018 Nov 20;320(19):1971-1972. doi: 10.1001/jama.2018.16998. PMID: 30418473.
Grzanna, R., L. Lindmark, and C.G. Frondoza, Ginger–an herbal medicinal product with broad anti-inflammatory actions. J Med Food, 2005. 8(2): p. 125-32.
Gulati G, Brunner HI. Environmental triggers in systemic lupus erythematosus. Semin Arthritis Rheum. 2018 Apr;47(5):710-717. doi: 10.1016/j.semarthrit.2017.10.001. Epub 2017 Oct 5. PMID: 29169635.

Guo X, Yang X, Li Q, Shen X, Zhong H, Yang Y. The Microbiota in Systemic Lupus Erythematosus: An Update on the Potential Function of Probiotics. Front Pharmacol. 2021 Nov 23;12:759095. doi: 10.3389/fphar.2021.759095. PMID: 34887760; PMCID: PMC8650621.

Hafstrom, I., et al., A vegan diet free of gluten improves the signs and symptoms of rheumatoid arthritis: the effects on arthritis correlate with a reduction in antibodies to food antigens. Rheumatology (Oxford), 2001. 40(10): p. 1175-9.
Hagen, K.B., et al., Dietary interventions for rheumatoid arthritis. Cochrane Database Syst Rev, 2009(1): p. CD006400
Hahn J, Leatherwood C, Malspeis S, Liu X, Lu B, Roberts AL, Sparks JA, Karlson EW, Feldman CH, Munroe ME, James JA, Kubzansky LD, Costenbader KH. Associations between daily alcohol consumption and systemic lupus erythematosus-related cytokines and chemokines among US female nurses without SLE. Lupus. 2020 Jul;29(8):976-982. doi: 10.1177/0961203320929427. Epub 2020 Jun 6. PMID: 32507075; PMCID: PMC7497791.
Hardy CJ, Palmer BP, Muir KR, Sutton AJ, Powell RJ. Smoking history, alcohol consumption, and systemic lupus erythematosus: a case-control study. Annals of the Rheumatic Diseases. 1998;57:451–455.
Hassan N, Clarke AE, Da Costa D, Pineau CA, Bernatsky S. Sleep disturbance in lupus patients. International Journal of Clinical Rheumatology. 2009;4(6):641–643.
Khajehdehi P, Zanjaninejad B, Aflaki E, Nazarinia M, Azad F, Malekmakan L, Dehghanzadeh GR. Oral supplementation of turmeric decreases proteinuria, hematuria, and systolic blood pressure in patients suffering from relapsing or refractory lupus nephritis: a randomized and placebo-controlled study. J Ren Nutr. 2012 Jan;22(1):50-7. doi: 10.1053/j.jrn.2011.03.002. Epub 2011 Jul 13. PMID: 21742514.
Kiyohara C, Washio M, Horiuchi T, Asami Y, Saburo I, et al. Cigarette smoking, alcohol consumption, and risk of systemic lupus erythematosus: a case-control study in a Japanese population. Journal of Rheumatology. 2012;39:1363–1370.
Kjeldsen-Kragh, J., et al., Controlled trial of fasting and one-year vegetarian diet in rheumatoid arthritis. Lancet, 1991. 338(8772): p. 899-902.
Klein LR, Elmets CA, Callen JP. Photoexacerbation of cutaneous lupus erythematosus due to ultraviolet A emissions from a photocopier. Arthritis & Rheumatism. August 1995;38(8):1152–1156.
Klein RS, Sayre RM, Dowdy JC, Werth VP. The risk of ultraviolet radiation exposure from indoor lamps in lupus erythematosus. Autoimmunity Reviews. February 2009;8(4):320–324.
Kozora E, Ellison MC, West S. Life stress and coping styles related to cognition in systemic lupus erythematosus [Research article]. Stress and Health. December 2009;25(5):413–422.
LeBlanc ES, Perrin N, Johnson JD, Ballatore A, Hillier T. Over-the-counter and compounded vitamin D: is potency what we expect? Journal of the American Medical Association Internal Medicine (Online First). February 2013. Retrieved February 24, 2013, from archinte.jamanetwork.com/article.aspxarticleID=1570096&utm_source=Silverchair+Information+Systems&utm_medium=email&utm_ campaign=ArchivesofInternalMedicine%3AOnlineFirst02%2F11%2F2013.
Leiba A, Amital H, Gershwin MD, Shoenfeld Y. Diet and lupus. Lupus. 2001;10:246–248. National Institutes of Health. Sun safety: Save your skin! The Lupus Newslink [Brochure].
Lorente-Cebrian, S., et al., An update on the role of omega-3 fatty acids on inflammatory and degenerative diseases. J Physiol Biochem, 2015. 71(2): p. 341-9.
Luders E, Thompson PM, Kurth F. Larger hippocampal dimensions in meditation practitioners: differential effects in women and men. Front Psychol. 2015;6:186. Published 2015 Mar 6. doi:10.3389/fpsyg.2015.00186
Luu HN, Blot WJ, Xiang YB, Cai H, Hargreaves MK, Li H, Yang G, Signorello L, Gao YT, Zheng W, Shu XO. Prospective evaluation of the association of nut/peanut consumption with total and cause-specific mortality. JAMA Intern Med. 2015 May;175(5):755-66. doi: 10.1001/jamainternmed.2014.8347. Erratum in: JAMA Intern Med. 2016 Aug 1;176(8):1236. PMID: 25730101; PMCID: PMC4474488.
Malinow MR, Bardana EJ Jr, Goodnight SH Jr. Pancytopenia during ingestion of alfalfa seeds. Lancet. 1981 Mar 14;1(8220 Pt 1):615. doi: 10.1016/s0140-6736(81)92063-8. PMID: 6110847.
Malinow MR, Bardana EJ Jr, Pirofsky B, Craig S, McLaughlin P. Systemic lupus erythematosus-like syndrome in monkeys fed alfalfa sprouts: role of a nonprotein amino acid. Science. 1982 Apr 23;216(4544):415-7. doi: 10.1126/science.7071589. PMID: 7071589.
Marques CP, Maor Y, de Andrade MS, Rodrigues VP, Benatti BB. Possible evidence of systemic lupus erythematosus and periodontal disease association mediated by Toll-like receptors 2 and 4. Clin Exp Immunol. 2016;183(2):187-192. doi:10.1111/cei.12708
Mashhadi, N.S., et al., Anti-oxidative and anti-inflammatory effects of ginger in health and physical activity: review of current evidence. Int J Prev Med, 2013. 4(Suppl 1): p. S36-42.
Matta MK, Zusterzeel R, Pilli NR, Patel V, Volpe DA, Florian J, Oh L, Bashaw E, Zineh I, Sanabria C, Kemp S, Godfrey A, Adah S, Coelho S, Wang J, Furlong LA, Ganley C, Michele T, Strauss DG. Effect of Sunscreen Application Under Maximal Use Conditions on Plasma Concentration of Sunscreen Active Ingredients: A Randomized Clinical Trial. JAMA. 2019 Jun 4;321(21):2082-2091. doi: 10.1001/jama.2019.5586. PMID: 31058986; PMCID: PMC6549296.
McGhie T, DeCeulaer K, Walters C, Soyibo A, Lee M. Vitamin D levels in Jamaican patients with systemic lupus erythematosus. Lupus. 2014;23(10):1092-1096. doi:10.1177/0961203314528556
McKellar, G., et al., A pilot study of a Mediterranean-type diet intervention in female patients with rheumatoid arthritis living in areas of social deprivation in Glasgow. Ann Rheum Dis, 2007. 66(9): p. 1239-43.
Nenonen, M.T., et al., Uncooked, lactobacilli-rich, vegan food and rheumatoid arthritis. Br J Rheumatol, 1998. 37(3): p. 274-81.
Nguyen M, Bryant K, O’Neill S. Vitamin D in SLE: a role in pathogenesis and fatigue? A review of the literature. Lupus. 2018;27(13):2003-2011. doi:10.1177/0961203318796293
Peralta-Ramírez MI, Coín-Mejías MÁ, Jiménez-Alonso J, Ortego-Ceneno N, Callejas-Rubio JL, Caracuel-Romero A, et al. Stress as a predictor of cognitive functioning in lupus [Paper]. Lupus. 2006;15:858–864.
Petri M. Diet and systemic lupus erythematosus: from mouse and monkey to woman? Lupus. 2001;10(11):775-777. doi:10.1177/096120330101001102
Petri M, Bello KJ, Fang H, Magder LS. Vitamin D in systemic lupus erythematosus: modest association with disease activity and the urine protein-to-creatinine ratio. Arthritis Rheum. 2013 Jul;65(7):1865-71. doi: 10.1002/art.37953. PMID: 23553077; PMCID: PMC3701725.
Pires JR, Nogueira MRS, Nunes AJF, Degand DRF, Pessoa LC, Damante CA, Zangrando MSR, Greghi SLA, de Rezende MLR, Sant’Ana ACP. Deposition of Immune Complexes in Gingival Tissues in the Presence of Periodontitis and Systemic Lupus Erythematosus. Front Immunol. 2021 Mar 25;12:591236. doi: 10.3389/fimmu.2021.591236. PMID: 33841392; PMCID: PMC8027066.
Pocovi-Gerardino G, Correa-Rodríguez M, Callejas-Rubio JL, et al. Beneficial effect of Mediterranean diet on disease activity and cardiovascular risk in systemic lupus erythematosus patients: a cross-sectional study. Rheumatology. 2021;60(1):160-169. doi:10.1093/rheumatology/keaa210
Okereke OI, Rosner BA, Kim DH, Kang JH, Cook NR, et al. Dietary fat types and 4-year cognitive change in community-dwelling older women. Annals of Neurology. July 2012;72(1):124–134.
Orefice V, Ceccarelli F, Barbati C, Perricone C, Alessandri C, Conti F. The Impact of Caffeine Intake on Patients with Systemic Lupus Erythematosus: Protect Yourself, Drink More Coffee!. Mediterr J Rheumatol. 2020;31(4):374-375. Published 2020 Dec 28. doi:10.31138/mjr.31.4.374
Pessoa L, Aleti G, Choudhury S, Nguyen D, Yaskell T, Zhang Y, Li W, Nelson KE, Neto LLS, Sant’Ana ACP, Freire M. Host-Microbial Interactions in Systemic Lupus Erythematosus and Periodontitis. Front Immunol. 2019 Nov 12;10:2602. doi: 10.3389/fimmu.2019.02602. PMID: 31781106; PMCID: PMC6861327.
Petri M. Diet and systemic lupus erythematosus: from mouse and monkey to woman? [Editorial]. Lupus. 2001;10:775–777.
Petri M, Bello KJ, Fang H, Magder LS. Vitamin D in systemic lupus erythematosus: modest association with disease activity and the urine protein-to-creatinine ratio. Arthritis Rheum. 2013 Jul;65(7):1865-71. doi: 10.1002/art.37953. PMID: 23553077; PMCID: PMC3701725.
Proudman, S.M., et al., Fish oil in recent onset rheumatoid arthritis: a randomised, double-blind controlled trial within algorithm-based drug use. Ann Rheum Dis, 2015. 74(1): p. 89-95.
Rodriguez D. Healthy Living: 7 ways to zap stress before it strikes. Everyday Health. Retrieved on October 1, 2011, from www.everydayhealth.com/healthy-living/ways-to-avoid-stress.aspx?xid=nl_EverydayHealthEmotionalHealth_20101103.
Sanders CJ, Van Weelden H, Kazzaz GA, Sigurdsson V, Toonstra J, Bruijnzeel-Koomen CA. Photosensitivity in patients with lupus erythematosus: a clinical and photobiological study of 100 patients using a prolonged phototest protocol. Br J Dermatol. 2003 Jul;149(1):131-7. doi: 10.1046/j.1365-2133.2003.05379.x. PMID: 12890206.
Skoldstam, L., L. Hagfors, and G. Johansson, An experimental study of a Mediterranean diet intervention for patients with rheumatoid arthritis. Ann Rheum Dis, 2003. 62(3): p. 208-14.
Somers EC, Richardson BC. Environmental exposures, epigenetic changes and the risk of lupus. Lupus 2014;23:568-576.

Sonia S, Witjaksono F, Ridwan R. Effect of cooling of cooked white rice on resistant starch content and glycemic response. Asia Pac J Clin Nutr. 2015;24(4):620-5. doi: 10.6133/apjcn.2015.24.4.13. PMID: 26693746.
Tasneem, S., et al., Molecular pharmacology of inflammation: Medicinal plants as anti-inflammatory agents. Pharmacol Res, 2019. 139: p. 126-140.
Tedeschi, S.K. and K.H. Costenbader, Is There a Role for Diet in the Therapy of Rheumatoid Arthritis? Curr Rheumatol Rep, 2016. 18(5): p. 23.</stro ng>
Vadell, A.K.E., et al., Anti-inflammatory Diet In Rheumatoid Arthritis (ADIRA)-a randomized, controlled crossover trial indicating effects on disease activity. Am J Clin Nutr, 2020. 111(6): p. 1203-1213.
Vieira S, Pagovich O, Kriegel M. Diet, microbiota and autoimmune diseases. Lupus. 2014;23(6):518-526. doi:10.1177/0961203313501401
Virta L, Auvinen A, Helenius H, Huovinen P, Kolho KL. Association of repeated exposure to antibiotics with the development of pediatric Crohn’s disease–a nationwide, register-based finnish case-control study. Am J Epidemiol. 2012 Apr 15;175(8):775-84. doi: 10.1093/aje/kwr400. Epub 2012 Feb 24. PMID: 22366379.
Vordenbäumen S, Sokolowski A, Kutzner L, Rund KM, Düsing C, Chehab G, Richter JG, Brinks R, Schneider M, Schebb NH. Erythrocyte membrane polyunsaturated fatty acid profiles are associated with systemic inflammation and fish consumption in systemic lupus erythematosus: a cross-sectional study. Lupus. 2020 May;29(6):554-559. doi: 10.1177/0961203320912326. Epub 2020 Mar 18. PMID: 32188303.
Walton AJ, Snaith ML, Locniskar M, Cumberland AG, Morrow WJ, Isenberg DA. Dietary fish oil and the severity of symptoms in patients with systemic lupus erythematosus. Ann Rheum Dis. 1991 Jul;50(7):463-6. doi: 10.1136/ard.50.7.463. PMID: 1877851; PMCID: PMC1004457.
Wang J, Pan H-F, Ye D-Q, Su H, Li X-P. Moderate alcohol drinking might be protective for systemic lupus erythematosus: a systematic review and meta-analysis. Clinical Rheumatology 2008;27(12):1557–1563.
Wojcik E. Sun rules: 5 facts to know about summer sun safety. Lupus Now. Summer 2011;6–7.
Wright, S.A., et al., A randomised interventional trial of omega-3-polyunsaturated fatty acids on endothelial function and disease activity in systemic lupus erythematosus. Ann Rheum Dis, 2008. 67(6): p. 841-8.
Zegarra-Ruiz DF, El Beidaq A, Iñiguez AJ, Lubrano Di Ricco M, Manfredo Vieira S, Ruff WE, Mubiru D, Fine RL, Sterpka J, Greiling TM, Dehner C, Kriegel MA. A Diet-Sensitive Commensal Lactobacillus Strain Mediates TLR7-Dependent Systemic Autoimmunity. Cell Host Microbe. 2019 Jan 9;25(1):113-127.e6. doi: 10.1016/j.chom.2018.11.009. Epub 2018 Dec 20. PMID: 30581114; PMCID: PMC6377154.

Chapter 39

Ali, R.A., et al., Antineutrophil properties of natural gingerols in models of lupus. JCI Insight, 2021. 6(3).
Andreae MH, Carter GM, Shaparin N, et al. Inhaled Cannabis for Chronic Neuropathic Pain: A Meta-analysis of Individual Patient Data. J Pain 2015; 16:1221.
Aron-Maor A, Shoenfeld Y. Alternative therapies in rheumatic diseases—pros and cons. Lupus. 2001;10:453–456.
Astin JA, Harkness E, Ernst E. The efficacy of “distant healing”: a systematic review of randomized trials. Annals of Internal Medicine. 2000;132(11):903–910.
Bhatt BD, Zuckerman MJ, Foland JA, Polly SM, Marwah RK. Disseminated Salmonella arizonae infection associated with rattlesnake meat ingestion. American Journal of Gastroenterology. 1989;84:433–435.
Birocco N, Guillame C, Storto S, Ritorto G, Catino C, Gir N, et al. The effects of Reiki therapy on pain and anxiety in patients attending a day oncology and infusion services unit. American Journal of Hospice and Palliative Medicine. October 2011. Retrieved October 26, 2011, from www.ajh.sagepub.com/content/early/2011/09/08/1049909111420859.abstract.
Blanco C, Hasin DS, Wall MM, et al. Cannabis Use and Risk of Psychiatric Disorders: Prospective Evidence From a US National Longitudinal Study. JAMA Psychiatry 2016; 73:388.
Bonakdar ZS, Jahanshahifar L, Jahanshahifar F, Gholamrezaei A. Vitamin D deficiency and its association with disease activity in new cases of systemic lupus erythematosus. Lupus. 2011;20:1155–1160.
Bonn-Miller MO, Loflin MJE, Thomas BF, Marcu JP, Hyke T, Vandrey R. Labeling Accuracy of Cannabidiol Extracts Sold Online. JAMA. 2017;318(17):1708–1709. doi:10.1001/jama.2017.11909
Borgelt LM, Franson KL, Nussbaum AM, Wang GS. The pharmacologic and clinical effects of medical cannabis. Pharmacotherapy 2013; 33:195.
Casner PR, Zuckerman MJ. Salmonella arizonae in patients with AIDS along the U.S.-Mexican Border. New England Journal of Medicine. 323(3):198–199.
Chen YS, Hu XE. Auriculo-acupuncture in 15 cases of discoid lupus erythematosus. Journal of Traditional Chinese Medicine. 1985;5(4):261–262.
Chou C-T. Alternative therapies: what role do they have in the management of lupus? Lupus. 2010;19:1425–1429.
del Pino-Sedeño T, Trujillo-Martín MM, Ruiz-Irastorza G, Cuellar-Pompa L, de Pascual-Medina AM, Serrano-Aguilar P; Spanish Systemic Lupus Erythematosus CPG Development Group. Effectiveness of Nonpharmacologic Interventions for Decreasing Fatigue in Adults With Systemic Lupus Erythematosus: A Systematic Review. Arthritis Care Res (Hoboken). 2016 Jan;68(1):141-8. doi: 10.1002/acr.22675. PMID: 26238554.
DiRenzo, D., Crespo-Bosque, M., Gould, N. et al. Systematic Review and Meta-analysis: Mindfulness-Based Interventions for Rheumatoid Arthritis. Curr Rheumatol Rep 20, 75 (2018). https://doi.org/10.1007/s11926-018-0787-4

DiRenzo DD, Hunt C, Sibinga EM, Gould NF, Shah AA, Bartlett SJ, Bingham CO 3rd. Feasibility and acceptability of using a meditation app in adults with rheumatic disease. Explore (NY). 2022 Sep-Oct;18(5):523-525. doi: 10.1016/j.explore.2021.11.003. Epub 2021 Nov 9. PMID: 34801408; PMCID: PMC9081288.
Dongping L. Clinical observation of integrated traditional Chinese medicine and western medicine therapy on the treatment of lupus nephritis. In [ Journal of Shanxi College of Traditional Chinese Medicine]. 2008. Retrieved on October 26, 2011, from www.en.cnki.com.cn/Article_en/CJFDTOTAL-SHAN200801016.htm.
Ernst E. Chiropractic treatment for fibromyalgia: a systematic review. Clinical Rheumatology. 2009;28(10):1175–1178.
Goyal M, Singh S, Sibinga EM, Gould NF, Rowland-Seymour A, Sharma R, Berger Z, Sleicher D, Maron DD, Shihab HM, Ranasinghe PD, Linn S, Saha S, Bass EB, Haythornthwaite JA. Meditation programs for psychological stress and well-being: a systematic review and meta-analysis. JAMA Intern Med. 2014 Mar;174(3):357-68. doi: 10.1001/jamainternmed.2013.13018. PMID: 24395196; PMCID: PMC4142584.
Greco CM, Kao AH, Maksimowicz-McKinnon K, Glick RM, Houze M, Sereika SM, et al. Acupuncture for systemic lupus erythematosus: a pilot RCT feasibility and safety study. Lupus. 2008;17:1108–1116.
Grewal JK, Loh LC. Health considerations of the legalization of cannabis edibles. CMAJ. 2020 Jan 6;192(1):E1-E2. doi: 10.1503/cmaj.191217. PMID: 31907227; PMCID: PMC6944297.
Grzanna, R., L
. Lindmark, and C.G. Frondoza, Ginger–an herbal medicinal product with broad anti-inflammatory actions. J Med Food, 2005. 8(2): p. 125-32.
Gunathunga MW, Wijeratne LS, Dissanayake AS, Ruwanchinthani A, Perera KD. Effect of an insight meditation programme on the disease outcome of patients with rheumatoid and related arthritis. Ceylon Medical Journal. 2010;55(suppl 1):46.
Hill K. Medical Use of Cannabis in 2019. JAMA AUG 2019;322(10):974.
Hostiuc S, Moldoveanu A, Negoi I, Drima E. The Association of Unfavorable Traffic Events and Cannabis Usage: A Meta-Analysis. Front Pharmacol 2018; 9:99.
Jimenez-Caliani A, Jimenez-Jorge S, Molinero P, Rubio A, Guerrero JM, Osuna C. Treatment with testosterone or estradiol in melatonin treated females and males MRL/MpJ-Faslpr mice induces negative effects in developing systemic lupus erythematosus. Journal of Pineal Research. September 2008; 45(2):204–211.
Khajehdehi P, Zanjaninejad B, Aflaki E, Nazarinia M, Azad F, Malekmakan L, Dehghanzadeh GR. Oral supplementation of turmeric decreases proteinuria, hematuria, and systolic blood pressure in patients suffering from relapsing or refractory lupus nephritis: a randomized and placebo-controlled study. J Ren Nutr. 2012 Jan;22(1):50-7. doi: 10.1053/j.jrn.2011.03.002. Epub 2011 Jul 13. PMID: 21742514.
Kirkpatric RA. Witchcraft and lupus erythematosus. Journal of the American Medical Association. 1981;245(19):1937.
Kirkpatric RA. Witchcraft and lupus erythematosus [Letters]. Journal of the American Medical Association. 1982;247(2):176.
Kraus A, Guerra-Bautista G, Alarcon-Segovia D. Salmonella arizonae arthritis and septicemia associated with rattlesnake ingestion by patients with connective tissue disease: a dangerous complication of folk medicine. Journal of Rheumatology. 1991;18:1328–1331.
Kuehn B. Synthetic Cannabidiol Poisoning. JAMA 2018; 319:2264.
Lautenschlager J. [Acupuncture in treatment of inflammatory rheumatic diseases.] Zeitschrift für Rheumatologie. 1997;56(1):8–20.
Lee MS, Shin BC, Ernst E. Acupuncture for rheumatoid arthritis: a systematic review. Rheumatology (Oxford). 2008;47(12):1747–1753.
Lv QW, Zhang W, Shi Q, Zheng WJ, Li X, Chen H, Wu QJ, Jiang WL, Li HB, Gong L, Wei W, Liu H, Liu AJ, Jin HT, Wang JX, Liu XM, Li ZB, Liu B, Shen M, Wang Q, Wu XN, Liang D, Yin YF, Fei YY, Su JM, Zhao LD, Jiang Y, Li J, Tang FL, Zhang FC, Lipsky PE, Zhang X. Comparison of Tripterygium wilfordii Hook F with methotrexate in the treatment of active rheumatoid arthritis (TRIFRA): a randomised, controlled clinical trial. Ann Rheum Dis. 2015 Jun;74(6):1078-86. doi: 10.1136/annrheumdis-2013-204807. Epub 2014 Apr 14. PMID: 24733191.
Maestroni GJ, Otsa K, Cutolo M. Melatonin treatment does not improve rheumatoid arthritis. British Journal of Clinical Pharmacology. May 2008;65(5):797–798.
Mashhadi, N.S., et al., Anti-oxidative and anti-inflammatory effects of ginger in health and physical activity: review of current evidence. Int J Prev Med, 2013. 4(Suppl 1): p. S36-42.
Matthews DA. Prayer and spirituality. Rheumatic Disease Clinics of North America. 2000;26(1):177–187.
Meier MH, Caspi A, Cerdá M, et al. Associations Between Cannabis Use and Physical Health Problems in Early Midlife: A Longitudinal Comparison of Persistent Cannabis vs Tobacco Users. JAMA Psychiatry 2016; 73:731.
Mysliwiec V, Martin JL, Ulmer CS, Chowdhuri S, Brock MS, Spevak C, Sall J. The Management of Chronic Insomnia Disorder and Obstructive Sleep Apnea: Synopsis of the 2019 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guidelines. Ann Intern Med. 2020 Mar 3;172(5):325-336. doi: 10.7326/M19-3575. Epub 2020 Feb 18. PMID: 32066145.
Nader DA, Sanchez ZM. Effects of regular cannabis use on neurocognition, brain structure, and function: a systematic review of findings in adults. Am J Drug Alcohol Abuse 2018; 44:4.
Nainis N, Paice JA, Ratner J, Wirth JH, Lai J, Shott S. Relieving symptoms in cancer: innovative use of art therapy. Journal of Pain and Symptom Management. 2006;31(2):162–169.
National Academies of Sciences, Engineering, and Medicine, et al. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. In: The National Academies Collection: Reports funded by National Institutes of Health, National Academies Press, Washington (DC) 2017.
Nevarrete-Navarrete N, Peralta- Ramírez MI, Sabio-Sánchez JM, Coín MÁ, Robles-Ortega H, Hidalgo-Tenorio C, et al. Efficacy of cognitive behavioural therapy for the treatment of chronic stress in patients with lupus erythematosus: a randomized controlled trial. Psychotherapy and Psychosomatics. 2010;79:107–115.
Nugent SM, Morasco BJ, O’Neil ME, et al. The Effects of Cannabis Among Adults With Chronic Pain and an Overview of General Harms: A Systematic Review. Ann Intern Med 2017; 167:319.
Petri M. Diet and systemic lupus erythematosus: from mouse and monkey to woman? Lupus. 2001;10:775–777.
Posadzki P, Alotaibi A, Ernst E. Adverse effects of homeopathy: a systematic review of published case reports and case series. International Journal of Clinical Practice. December 2012;66(12):1178–1188.
Richmond SJ, Brown S, Campion PD, Porter AJL, Moffett JAK, Jackson DA, et al. Therapeutic effects of magnetic and copper bracelets in osteoarthritis: a randomized placebo-controlled crossover trial. Complementary Therapies in Medicine. 2009;17(5–6):249–256.
Rosenzweig S. Complementary and alternative medicine (CAM). 2009. In: The Merck Manual: Home Health Handbook. Retrieved October 26, 2011, from www.merckmanuals.com/ home/special_subjects/complementary_and_alternative_medicine_cam/overview_of_
complementary_and_alternative_medicine.html.
Schnitzer TJ, Truitt K, Fleischmann R, Dalgin P, Block J, Zeng Q, et al. The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Clinical Therapeutics. October 1999;21(10):1688–1702.
Scott JC, Slomiak ST, Jones JD, et al. Association of Cannabis With Cognitive Functioning in Adolescents and Young Adults: A Systematic Review and Meta-analys
is. JAMA Psychiatry 2018; 75:585.
Shamekhi Z, Amani R, Habibagahi Z, Namjoyan F, Ghadiri A, Saki Malehi A. A Randomized, Double-blind, Placebo-controlled Clinical Trial Examining the Effects of Green Tea Extract on Systemic Lupus Erythematosus Disease Activity and Quality of Life. Phytother Res. 2017 Jul;31(7):1063-1071. doi: 10.1002/ptr.5827. Epub 2017 Jun 6. PMID: 28585735.
Smetana GW, Tetrault JM, Hill KP, Burns RB. Should You Recommend Cannabinoids for This Patient With Painful Neuropathy? : Grand Rounds Discussion From Beth Israel Deaconess Medical Center. Ann Intern Med. 2021 Feb;174(2):237-246. doi: 10.7326/M20-7945. Epub 2021 Feb 9. PMID: 33556279.
Stanton C. Cannabis in rheumatology care. The Rheumatologist March 2019:32-34.
Stefanescu M, Matache C, Onu A, Tanaseanu S, Dragomir C, Constantinescu I, et al. Pycnogenol efficacy in the treatment of systemic lupus erythematosus patients. Phytotherapy Research. December 2001;15(8):698–704.
Stockings E, Campbell G, Hall WD, et al. Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. Pain 2018; 159:1932.
Sun K, Szymonifka J, Tian H, Chang Y, Leng JC, Mandl LA. Association of Traditional Chinese Medicine Use With Adherence to Prescribed Western Rheumatic Medications Among Chinese American Patients: A Cross-Sectional Survey. Arthritis Care Res (Hoboken). 2020 Oct;72(10):1474-1480. doi: 10.1002/acr.24031. PMID: 31325227; PMCID: PMC6980159.
Sun K, Szymonifka J, Tian H, Chang Y, Leng JC, Mandl LA. Is Traditional Chinese Medicine Use Associated with Worse Patient-reported Outcomes among Chinese American Rheumatology Patients? J Rheumatol. 2019 Dec;46(12):1634-1639. doi: 10.3899/jrheum.181148. Epub 2019 May 1. PMID: 31043540; PMCID: PMC7256873.
Sun S-F, Su J-H, Ye R-G. Integrated traditional Chinese medicine and western medicine therapy for lupus nephritis: a meta-analyses of randomized and controlled trials. [China Journal of Modern Medicine]. 2004. Retrieved October 26, 2011, from www.en.cnki.com.cn/Article_en/CJFDTOTAL-ZXDY200417005.htm.
Tasneem, S., et al., Molecular pharmacology of inflammation: Medicinal plants as anti-inflammatory agents. Pharmacol Res, 2019. 139: p. 126-140.
Tao X, Lipsky PE. The Chinese anti-inflammatory and immunosuppressive herbal remedy
Tripterygium wilfordii Hook F. Rheumatic Disease Clinics of North America. 2000; 26(1):29–50.
Vickers AJ, Cronin AM, Maschino AC, Lewith G, MacPherson H, et al. Acupuncture for chronic pain: individual patient data meta-analysis. Archives of Internal Medicine. October 2012;172(19):1444–1453.
Wallace DJ, ed. The Sjögren’s Book. New York: Oxford University Press; 2012.
Wang C, Schmid CH, Fielding RA, et al. Effect of tai chi versus aerobic exercise for fibromyalgia: comparative effectiveness randomized controlled trial. BMJ 2018; 360:k851.
Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: A systematic review and meta-analysis. JAMA 2015; 313:2456.
Wolfe DP. CBD (cannabidiol) role in treatment. Rheumors Winter 2020. 
Yang X, Liu X. Effect of Chinese herbal medicine combined with western medicine on active systemic lupus erythematosus: an observation of 72 cases. [ Journal of New Chinese Medicine]. 2008. Retrieved on October 26, 2011, from www.en.cnki.com.cn/Article_en/CJFDTOTAL-REND200803032.htm.
Zautra AJ, Davis MC, Reich JW, Nicassario P, Tennen H, Finnan P, et al. Comparison of cognitive behavioral and mindfulness meditation interventions on adaptation to rheumatoid arthritis for patients with and without history of recurrent depression. Journal of Consulting
and Clinical Psychology. June 2008;76(3):408–421.
Zhao CN, Wang P, Mao YM, Dan YL, Wu Q, Li XM, Wang DG, Davis C, Hu W, Pan HF. Potential role of melatonin in autoimmune diseases. Cytokine Growth Factor Rev. 2019 Aug;48:1-10. doi: 10.1016/j.cytogfr.2019.07.002. Epub 2019 Jul 16. PMID: 31345729.
Zhou L-l, Wei W, Si J-F, Yuan D-P. Regulatory effect of melatonin on cytokine disturbances in the pristine-induced lupus mice: mediators of Inflammation. Vol. 2010, Article ID 951210, 7 pages, 2010. doi:10.1155/2010/951210. Retrieved July 4, 2011, from www.hindawi.com/ journals/mi/2010/951210/cta/.

Chapter 40

American College of Rheumatology Committee on Rheumatology Training and Workforce Issues, FitzGerald JD, Battistone M, Brown CR Jr, Cannella AC, Chakravarty E, Gelber AC, Lozada CJ, Punaro M, Slusher B, Abelson A, Elashoff DA, Benford L. Regional distribution of adult rheumatologists. Arthritis Rheum. 2013 Dec;65(12):3017-25. doi: 10.1002/art.38167. PMID: 24284967. Battafarano DF, Ditmyer M, Bolster MB, Fitzgerald JD, Deal C, Bass AR, Molina R, Erickson AR, Hausmann JS, Klein-Gitelman M, Imundo LF, Smith BJ, Jones K, Greene K, Monrad SU. 2015 American College of Rheumatology Workforce Study: Supply and Demand Projections of Adult Rheumatology Workforce, 2015-2030. Arthritis Care Res (Hoboken). 2018 Apr;70(4):617-626. doi: 10.1002/acr.23518. PMID: 29400009. ​Borenstein D. Hug your rheumatologist: the shortage is coming. The Arthritis Connection Summer 2020. Retrieved on 4/11/21 at https:///www.thearthritisconnection.com/rheumatoid-arthritis/hug-your-rheumatologist-the-shortage-is-coming Golder V, Ooi JJY, Antony AS, et al. Discordance of patient and physician health status concerns in systemic lupus erythematosus. Lupus. 2018;27(3):501-506. doi:10.1177/0961203317722412 Thomas DE. The Patient in (Tsokos G. Editor) Systemic Lupus Erythematosus: Basic, applied, and clinical aspects. 2nd ed. San Diego, CA: Academic Press; 2020.

Chapter 41

Abrams SA, Daniels SR. Protecting Vulnerable Infants by Ensuring Safe Infant Formula Use. J Pediatr. 2019;211:201. Epub 2019 May 10. 
Alijotas-Reig J. Treatment of refractory obstetric antiphospholipid syndrome: the state of the art and new trends in the therapeutic management. Lupus. January 2013;22(1):6–17.
American Academy of Pediatrics. Maternal medication usually compatible with breastfeeding. Retrieved September 25, 2011, from www.aappolicy.aappublications.org/cgi/content-nw/full/pediatrics;108/3/776/T6.
Andreoli L, Bertsias GK, Agmon-Levin N, Brown S, Cervera R, Costedoat-Chalumeau N, Doria A, Fischer-Betz R, Forger F, Moraes-Fontes MF, Khamashta M, King J, Lojacono A, Marchiori F, Meroni PL, Mosca M, Motta M, Ostensen M, Pamfil C, Raio L, Schneider M, Svenungsson E, Tektonidou M, Yavuz S, Boumpas D, Tincani A. EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis. 2017 Mar;76(3):476-485. doi: 10.1136/annrheumdis-2016-209770. Epub 2016 Jul 25. PMID: 27457513; PMCID: PMC5446003.​
Askanase AD, Miranda-Carus ME, Tang X, Katholi M, Buyon JP. The presence of IgG antibodies reactive with components of the SSA/Ro-SSB/La complex in human breast milk: implications in neonatal lupus. Arthritis Rheum. 2002 Jan;46(1):269-71. doi: 10.1002/1529-0131(200201)46:1<269::AID-ART10043>3.0.CO;2-6. PMID: 11817601.
Ateka-Barrutia O, Khamashta MA. The challenge of pregnancy for patients with SLE. Lupus. 2013 Oct;22(12):1295-308. doi: 10.1177/0961203313504637. PMID: 24098002
Bellver J, Pellicer A. Ovarian stimulation for ovulation induction and in vitro fertilization in patients with systemic lupus erythematosus and antiphospholipid syndrome. Fertility and Sterility. December 2009;92(6):1803–1810.
Bermas BL, Chambers C. Hydroxychloroquine early in pregnancy and risk of birth defects: don’t throw out the baby with the bathwater. Am J Obstet Gynecol. 2021 May;224(5):548-549. doi: 10.1016/j.ajog.2020.12.1218. Epub 2021 Jan 9. PMID: 33434555.
Birru Talabi M, Clowse MEB, Schwarz EB, Callegari LS, Moreland L, Borrero S. Family Planning Counseling for Women With Rheumatic Diseases. Arthritis Care Res (Hoboken). 2018 Feb;70(2):169-174. doi: 10.1002/acr.23267. PMID: 28437837.​
Buyon JP, Kim MY, Guerra MM, et al. Predictors of Pregnancy Outcomes in Patients With Lupus: A Cohort Study. Ann Intern Med 2015; 163:153
Cappola AR, Casey BM. Thyroid Function Test Abnormalities During Pregnancy. JAMA. 2019 Aug 20;322(7):617-619. doi: 10.1001/jama.2019.10159. PMID: 31429879.
Centers for Disease Control and Prevention. Vaccination Considerations for People who are Pregnant or Breastfeeding https:///www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/pregnancy.html (Accessed on December 21, 2020).
Chehab G, Krüssel J, Fehm T, Fischer-Betz R, Schneider M, Germeyer A, Suerdieck MB, Kreuzer V, Liebenthron J. Successful conception in a 34-year-old lupus patient following spontaneous pregnancy after autotransplantation of cryopreserved ovarian tissue. Lupus. 2019 Apr;28(5):675-680. doi: 10.1177/0961203319839482. Epub 2019 Mar 24. PMID: 30907296; PMCID: PMC6515711.
Clowse ME, Magder LS, Witter F, Petri M. The impact of increased lupus activity on obstetric outcomes. Arthritis Rheum 2005; 52:514.
Costedoat-Chalumeau N., Nathalie Morel, Rebecca Fischer-Betz, Kateri Levesque, Alice Maltret, et al.. Routine repeated echocardiographic monitoring of fetuses exposed to maternal anti-SSA antibodies: time to question the dogma. The Lancet Rheumatology, Elsevier, 2019, 1 (3), pp.e187-e193. ⟨10.1016/S2665-9913(19)30069-4⟩. ⟨hal-02981891⟩
Davis-Porada J, Kim MY, Guerra MM, et al. Low frequency of flares during pregnancy and post-partum in stable lupus patients. Arthritis Res Ther. 2020;22(1):52. Published 2020 Mar 19. doi:10.1186/s13075-020-2139-9
de Jesús GR, Benson AE, Chighizola CB, Sciascia S, Branch DW. 16th International Congress on Antiphospholipid Antibodies Task Force Report on Obstetric Antiphospholipid Syndrome. Lupus. 2020 Oct;29(12):1601-1615. doi: 10.1177/0961203320954520. Epub 2020 Sep 3. PMID: 32883160.
Eslick R, McLintock C. Managing ITP and thrombocytopenia in pregnancy. Platelets. 2020;31(3):300-306. doi: 10.1080/09537104.2019.1640870. Epub 2019 Jul 11. PMID: 31296105.
Eudy AM, Siega-Riz AM, Engel SM, Franceschini N, Howard AG, Clowse MEB, Petri M. Preconceptional Cardiovascular Health and Pregnancy Outcomes in Women with Systemic Lupus Erythematosus. J Rheumatol. 2019 Jan;46(1):70-77. doi: 10.3899/jrheum.171066. Epub 2018 Jul 15. PMID: 30008449; PMCID: PMC6314889.
Götestam Skorpen C, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C, da Silva J, Nelson-Piercy C, Cetin I, Costedoat-Chalumeau N, Dolhain R, Förger F, Khamashta M, Ruiz-Irastorza G, Zink A, Vencovsky J, Cutolo M, Caeyers N, Zumbühl C, Østensen M. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016 May;75(5):795-810. doi: 10.1136/annrheumdis-2015-208840. Epub 2016 Feb 17. PMID: 26888948.
Gubatan J, et al. Biologics During Pregnancy in Women With Inflammatory Bowel Disease and Risk of Infantile Infections: A Systematic Review and Meta-Analysis. Am J Gastroent OCT 2020;doi: 10.14309/ajg.0000000000000910. Online ahead of print.
Halder R, Malik R, Kashyap R. Warm antibody hemolytic anemia-a rare presentation of neonatal lupus. Lupus. 2017 May;26(6):661-663. doi: 10.1177/0961203316664594. Epub 2016 Aug 11. PMID: 27516434.
Henderson JT, Whitlock EP, O’Conner E, et al. Low-Dose Aspirin for the Prevention of Morbidity and Mortality From Preeclampsia: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2014 Apr. (Evidence Syntheses, No. 112.) Available from: https:///www.ncbi.nlm.nih.gov/books/NBK196392/
Huguelet PS, Sheehan C, Spitzer RF, Scott S. Use of the levonorgestrel 52-mg intrauterine system in adolescent and young adult solid organ transplant recipients: a case series. Contraception 2017; 95:378.
Izmirly P, Kim M, Friedman DM, Costedoat-Chalumeau N, Clancy R, Copel JA, Phoon CKL, Cuneo BF, Cohen RE, Robins K, Masson M, Wainwright BJ, Zahr N, Saxena A, Buyon JP. Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers. J Am Coll Cardiol. 2020 Jul 21;76(3):292-302. doi: 10.1016/j.jacc.2020.05.045. PMID: 32674792; PMCID: PMC7394202.
Kavanaugh A, Cush J. 11 Pearls for Pregnancy Management in Rheumatoid Arthritis. RheumNow AUG 2015. Retrieved on 12/31/20 from https://rheumnow.com/blog/11-pearls-pregnancy-management-rheumatoid-arthritis
Kwok LW, Tam LS, Zhu T, et al. Predictors of maternal and fetal outcomes in pregnancies of patients with sys
temic lupus erythematosus. Lupus 2011; 20:829.
Jancin B. Managing rheumatologic diseases in pregnancy. Rheumatology News. April 2010;9(4), 28.
Lockshin MD, Kim M, Laskin CA, Guerra M, Branch DW, et al. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis & Rheumatism. July 2012;64(7):3211–2318.
Jones, R. K., Lindberg, L. D., & Higgins, J. A. (2014). Pull and pray or extra protection? Contraceptive strategies involving withdrawal among US adult women. Contraception, 90(4), 416–421. https://doi.org/10.1016/j.contraception.2014.04.016​
LeFevre ML; U.S. Preventive Services Task Force. Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014 Dec 2;161(11):819-26. doi: 10.7326/M14-1884. PMID: 25200125.
Lefkou E, Mamopoulos A, Dagklis T, Vosnakis C, Rousso D, Girardi G. Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy. J Clin Invest. 2016;126(8):2933‐2940. doi:10.1172/JCI86957
Lockshin MD, Guerra M, Salmon JE. Elective Termination of Pregnancy in Autoimmune Rheumatic Diseases: Experience From Two Databases. Arthritis Rheumatol. 2020 Aug;72(8):1325-1329. doi: 10.1002/art.41249. Epub 2020 Jun 17. PMID: 32162838; PMCID: PMC7486237.
Normand G, Sens F, Puthet J, Jourde-Chiche N, Lemoine S, Chauveau D, Moranne O, Rémy P, Doret M, Daugas E, Juillard L; French Collaborative Group on Lupus Nephritis. Not only disease activity but also chronic hypertension and overweight are determinants of pregnancy outcomes in patients with systemic lupus erythematosus. Lupus. 2019 Apr;28(4):529-537. doi: 10.1177/0961203319832097. Epub 2019 Feb 24. PMID: 30799679.
Noviani M, Wasserman S, Clowse ME. Breastfeeding in mothers with systemic lupus erythematosus. Lupus. 2016 Aug;25(9):973-9. doi: 10.1177/0961203316629555. Epub 2016 Feb 16. PMID: 26888577.
Office of the Surgeon General. Breastfeeding: Surgeon General’s Call to Action Fact Sheet. 2011. Available at: https:///www.hhs.gov/surgeongeneral/reports-and-publications/breastfeeding/factsheet/index.html (Accessed on December 27, 2020).​
Orquevaux P, Masseau A, Le Guern V, Gayet V, Vauthier D, Guettrot-Imbert G, Huong DLT, Wechsler B, Morel N, Cacoub P, Pennaforte JL, Piette JC, Costedoat-Chalumeau N. In Vitro Fertilization in 37 Women with Systemic Lupus Erythematosus or Antiphospholipid Syndrome: A Series of 97 Procedures. J Rheumatol. 2017 May;44(5):613-618. doi: 10.3899/jrheum.160462. Epub 2017 Jan 15. PMID: 28089975.
Østensen M, Khamashta M, Lockshin M, Parke A, Brucato A, Carp H, et al. Anti-inflammatory and immunosuppressive drugs and reproduction [Review]. Arthritis Research & Therapy. May 2006;8:209–227.
Petri M. The Hopkins Lupus Pregnancy Center: ten key issues in management. Rheumatic Disease Clinics of North America. May 2007;33(2):227–235.
Petri M. Lupus and Pregnancy. Retrieved October 9, 2011, from The Johns Hopkins Lupus Center website, www.hopkinslupus.org/lupus-info/lifestyle-additional-information/lupus-pregnancy/.

Pfaller B, Pupco A, Leibson T, Aletaha D, Ito S. A critical review of the reproductive safety of Leflunomide. Clin Rheumatol. 2020 Feb;39(2):607-612. doi: 10.1007/s10067-019-04819-4. Epub 2019 Nov 22. PMID: 31758422.

Pullen LC. The state-of-the-art of rheumatology: lupus and pregnancy. The Rheumatologist. June 2012:43.
Salmon J. Can We Predict & Prevent Pregnancy Complications in Patients with Lupus & APS? Presentation at the American College of Rheumatology Convergence scientific meeting November 2020. 
Sammaritano LR, Bermas BL, Chakravarty EE, Chambers C, Clowse MEB, Lockshin MD, Marder W, Guyatt G, Branch DW, Buyon J, Christopher-Stine L, Crow-Hercher R, Cush J, Druzin M, Kavanaugh A, Laskin CA, Plante L, Salmon J, Simard J, Somers EC, Steen V, Tedeschi SK, Vinet E, White CW, Yazdany J, Barbhaiya M, Bettendorf B, Eudy A, Jayatilleke A, Shah AA, Sullivan N, Tarter LL, Birru Talabi M, Turgunbaev M, Turner A, D’Anci KE. 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis Rheumatol. 2020 Apr;72(4):529-556. doi: 10.1002/art.41191. Epub 2020 Feb 23. PMID: 32090480.​
Somers EC, Richardson BC. Environmental exposures, epigenetic changes and the risk of lupus. Lupus 2014;23:568-576.

US Preventive Services Task Force; Davidson KW, Barry MJ, Mangione CM, Cabana M, Caughey AB, Davis EM, Donahue KE, Doubeni CA, Kubik M, Li L, Ogedegbe G, Pbert L, Silverstein M, Simon MA, Stevermer J, Tseng CW, Wong JB. Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: US Preventive Services Task Force Recommendation Statement. JAMA. 2021 Sep 28;326(12):1186-1191. doi: 10.1001/jama.2021.14781. PMID: 34581729.
Wechsler B, Huong du LT, Vautheir-Broues D, et al. Hormone stimulation and replacement therapy in women with rheumatic disease. Scandinavian Journal of Rheumatology 1998;27(S107):53–59.
Wincup C, McDonnell TCR, Rahman A. Menorrhagia: an underappreciated problem in pre-menopausal women with systemic lupus erythematosus. Lupus. 2019;28(7):916-917. doi:10.1177/0961203319851868​
Yang H, Liu H, Xu D, et al. Pregnancy-related systemic lupus erythematosus: clinical features, outcome and risk factors of disease flares–a case control study. PLoS One 2014; 9:e104375.
Yelnik CM, Lambert M, Drumez E, Le Guern V, Bacri JL, Guerra MM, Laskin CA, Branch DW, Sammaritano LR, Morel N, Guettrot-Imbert G, Launay D, Hachulla E, Hatron PY, Salmon JE, Costedoat-Chalumeau N. Bleeding complications and antithrombotic treatment in 264 pregnancies in antiphospholipid syndrome. Lupus. 2018 Sep;27(10):1679-1686. doi: 10.1177/0961203318787032. Epub 2018 Jul 17. PMID: 30016929.

Chapter 42

Ang-Lee MK, Moss J, Yuan CS. Herbal medicines and perioperative care. Journal of the American Medical Association. July 2001;286(2):208–216.
Boumpas DT, Bertsias G. Immunosuppressive treatment for lupus in the next decade: it’s time for a new strategy. The Rheumatologist. April 2011;5(4):1+.
Chibber R, Al-Sibai MH, Qahtani N. Adverse outcome of pregnancy following air travel: a myth or a concern? Aust N Z J Obstet Gynaecol 2006; 46:24.
Clay M, Mazouyes A, Gilson M, et al. Risk of postoperative infections and the discontinuation of TNF inhibitors in patients with rheumatoid arthritis: A meta-analysis. Joint Bone Spine 2016; 83:701.
Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999; 281:2189.
De Carolis S, Botta A, Santucci S, Salvi S, Moresi S, et al. Complementemia and obstetric outcome in pregnancy with antiphospholipid syndrome. Lupus. June 2012;21(7):776–778.
Freedman DO, Chen LH, Kozarsky PE. Medical Considerations before International Travel. N Engl J Med 2016; 375:247.</f ont>
George MD, Baker JF, Hsu JY, et al. Perioperative Timing of Infliximab and the Risk of Serious Infection After Elective Hip and Knee Arthroplasty. Arthritis Care Res (Hoboken) 2017; 69:1845.
George MD, Baker JF, Winthrop K, Curtis JR. Risk of Biologics and Glucocorticoids in Patients With Rheumatoid Arthritis Undergoing Arthroplasty. Ann Intern Med. 2019 Nov 5;171(9):680. doi: 10.7326/L19-0528. PMID: 31683280.
Goodman SM, Springer BD, Chen AF, Davis M, Fernandez DR, Figgie M, Finlayson H, George MD, Giles JT, Gilliland J, Klatt B, MacKenzie R, Michaud K, Miller A, Russell L, Sah A, Abdel MP, Johnson B, Mandl LA, Sculco P, Turgunbaev M, Turner AS, Yates A Jr, Singh JA. 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. Arthritis Care Res (Hoboken). 2022 Sep;74(9):1399-1408. doi: 10.1002/acr.24893. Epub 2022 Jun 19. PMID: 35718887.

Gualtierotti R, Parisi M, Ingegnoli F. Perioperative Management of Patients with Inflammatory Rheumatic Diseases Undergoing Major Orthopaedic Surgery: A Practical Overview. Adv Ther. 2018 Apr;35(4):439-456. doi: 10.1007/s12325-018-0686-0. Epub 2018 Mar 20. PMID: 29556907; PMCID: PMC5910481.

Kozato A, Fox GWC, Yong PC, et al. No Venous Thromboembolism Increase Among Transgender Female Patients Remaining on Estrogen for Gender-Affirming Surgery. J Clin Endocrinol Metab 2021; 106:e1586.
Li Z, Du Y, Xiang S, Feng B, Bian Y, Qian W, Jin J, Lin J, Weng X. Risk factors of perioperative complications and transfusion following total hip arthroplasty in systemic lupus erythematosus patients. Lupus. 2019 Aug;28(9):1134-1140. doi: 10.1177/0961203319862609. Epub 2019 Jul 11. PMID: 31296142.
Lin JA, Liao CC, Lee YJ, Wu CH, Huang WQ, Chen TL. Adverse outcomes after major surgery in patients with systemic lupus erythematosus: a nationwide population-based study. Ann Rheum Dis. 2014 Sep;73(9):1646-51. doi: 10.1136/annrheumdis-2012-202758. Epub 2013 Jun 5. PMID: 23740232.
Mukherjee S, Culliford D, Arden N, Edwards C. What is the risk of having a total hip or knee replacement for patients with lupus? Lupus. 2015;24(2):198-202. doi:10.1177/0961203314547894
Oliveira DS, Hillal JPD, Cordova DDP, de Araujo DB. The lupus patient traveller: a guide to the rheumatologist. Lupus. 2019;28(14):1690-1698. doi:10.1177/0961203319888688
Pope J, Jerome D, Fenlon D, Krizova A, Ouimet J. Frequency of adverse drug reactions in patients with systemic lupus erythematosus. Journal of Rheumatology. 2003;30:480–484.
Quintanilla-González L, Torres-Villalobos G, Hinojosa-Azaola A. Risk factors for development of early infectious and noninfectious complications in systemic lupus erythematosus patients undergoing major surgery. Lupus. 2018;27(12):1960-1972. doi:10.1177/0961203318799188
Renoux C, Dell’Aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. J Thromb Haemost 2010; 8:979.
Salt E, Wiggins AT, Rayens MK, et al. Moderating effects of immunosuppressive medications and risk factors for post-operative joint infection following total joint arthroplasty in patients with rheumatoid arthritis or osteoarthritis. Semin Arthritis Rheum 2017; 46:423.
Shalev Ram H, Ram S, Miller N, et al. Air travel during pregnancy and the risk of adverse pregnancy outcomes as gestational age and weight at birth: A retrospective study among 284,069 women in Israel between the years 2000 to 2016. PLoS One 2020; 15:e0228639.
Singh JA, Cleveland JD. Lupus is associated with poorer outcomes after primary total hip arthroplasty. Lupus. 2019;28(7):834-842. doi:10.1177/0961203319851573
Strand V, Ahadieh S, French J, et al. Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials. Arthritis Res Ther 2015; 17:362.

Chapter 43

Bihari M. Pre existing conditions—understanding exclusions and creditable coverage. About. com Guide. April 15, 2010.
Birken EG. The ten best part-time jobs with benefits. In: PT Money Personal Finance. Retrieved October 23, 2011, from www.ptmoney.com/the-ten-best-part-time-jobs-with-benefits/.
Celeste R. Top 10 part-time jobs with benefits. November 9, 2010. Retrieved October 23, 2011, from www.jobs.aol.com/articles/2010/11/09/top-10-part-time-jobs-with-benefits/.
Cohen E. No health insurance? Get help here: health insurance in CNN Health. February 12, 2009. Retrieved October 23, 2011, from www.articles.cnn.com/2009-02-12/health/ep .health.insurance.help_1_health-insurance-entire-premium-insurance-policy?_s=
PM:HEALTH.
Davis M. How to Get SSI and Social Security Disability. Lincoln, Ne: Writers Club Press; 2000.
HIPAA Pre-Existing Condition Protections. About.com Health Insurance. Retrieved October 23, 2011, from www.healthinsurance.about.com/od/healthinsurancebasics/a/preexisting _conditions_overview.htm.
Insure.com. Health insurance basics. May 14, 2011. Retrieved on October 23, 2011, from www.insure.com/articles/healthinsurance/basics.html.
Koelker, Cynthia J. 101 Ways to Save Money on Health Care: Tips to Help You Spend Smart and Stay Healthy (Kindle Location 610). September 1, 2010. Plume. Kindle Edition.
Li T, Carls GS, Panopalis P, Wang S, Gibson TB, Goetzel RZ. Long-term medical costs and resource utilization in systemic lupus erythematosus and lupus nephritis: a five-year analysis of a large Medicaid population. Arthritis & Rheumatism. June 2009;61(6):755–763.
Matthews J, Berman DM. Social Security, Medicare and Government Pensions: Get the Most out of Your Retirement and Medical Benefits. 16th ed. Berkeley, Ca: NOLO; 2011.
Mercadante K. 11 best part-time jobs with health insurance benefits. Retrieved October 23, 2011, from www.moneycrashers.com/part-time-jobs-health-insurance-benefits/.
Miller GE. 5 Part-time jobs with health insurance & benefits. June 21, 2011. Retrieved October 23, 2011, from http:/20somethingfinance.com/art-time-jobs-with-health-insurance-benefits/.
Panopalis P, Yazdany J, Gillis JZ, Julian L, Trupin L, Hersh AO, et al. Health care costs and costs associated with changes in work productivity among persons with systemic lupus erythematosus. Arthritis Care & Research. December 2008;59(12):1788–1795.
Q1Medicare.com. 2012 Medicare Part D Outlook. Retrieved October 23, 2011, from www.q1medicare.com/PartD-About-Us-About-Us-About-Us-About.php?utm_source=partd&utm_medium=textlink&utm_campaign=footer.
U.S. Department of Health and Human Services. Find a health center. Retrieved October 23, 2011, from www.findahealthcenter.hrsa.gov/Search_HCC.aspx.
U.S. Department of Labor Bureau of Labor Statistics. American time use survey: charts from the American time use survey. June 22, 2011. Retrieved October 23, 2011, from https:///www.bls.gov/tus/charts/.Bihari M. Pre existing conditions—understanding exclusions and creditable coverage. About. com Guide. April 15, 2010.
Birken EG. The ten best part-time jobs with benefits. In: PT Money Personal Finance. Retrieved October 23, 2011, from www.ptmoney.com/the-ten-best-part-time-jobs-with-benefits/.
Celeste R. Top 10 part-time jobs with benefits. November 9, 2010. Retrieved October 23, 2011, from www.jobs.aol.com/articles/2010/11/09/top-10-part-time-jobs-with-benefits/.
Cohen E. No health insurance? Get help here: health insurance in CNN Health. February 12, 2009. Retrieved October 23, 2011, from www.articles.cnn.com/2009-02-12/health/ep.health.insurance.help_1_health-insurance-entire-premium-insurance-policy?_s=PM:HEALTH.
Davis M. How to Get SSI and Social Security Disability. Lincoln, Ne: Writers Club Press; 2000.
HIPAA Pre-Existing Condition Protections. About.com Health Insurance. Retrieved October 23, 2011, from www.healthinsurance.about.com/od/healthinsurancebasics/a/preexisting_conditions_overview.htm.
Insure.com. Health insurance basics. May 14, 2011. Retrieved on October 23, 2011, from www.insure.com/articles/healthinsurance/basics.html.
Koelker, Cynthia J. 101 Ways to Save Money on Health Care: Tips to Help You Spend Smart and Stay Healthy (Kindle Location 610). September 1, 2010. Plume. Kindle Edition.
Li T, Carls GS, Panopalis P, Wang S, Gibson TB, Goetzel RZ. Long-term medical costs and resource utilization in systemic lupus erythematosus and lupus nephritis: a five-year analysis of a large Medicaid population. Arthritis & Rheumatism. June 2009;61(6):755–763.
Matthews J, Berman DM. Social Security, Medicare and Government Pensions: Get the Most out of Your Retirement and Medical Benefits. 16th ed. Berkeley, Ca: NOLO; 2011.
Mercadante K. 11 best part-time jobs with health insurance benefits. Retrieved October 23, 2011, from www.moneycrashers.com/part-time-jobs-health-insurance-benefits/.
Miller GE. 5 Part-time jobs with health insurance & benefits. June 21, 2011. Retrieved October 23, 2011, from http:/20somethingfinance.com/art-time-jobs-with-health-insurance-benefits/.
Panopalis P, Yazdany J, Gillis JZ, Julian L, Trupin L, Hersh AO, et al. Health care costs and costs associated with changes in work productivity among persons with systemic lupus erythematosus. Arthritis Care & Research. December 2008;59(12):1788–1795.
Q1Medicare.com. 2012 Medicare Part D Outlook. Retrieved October 23, 2011, from www.q1medicare.com/PartD-About-Us-About-Us-About-Us-About.phputm_source=partd&utm_medium=textlink&utm_campaign=footer.
U.S. Department of Health and Human Services. Find a health center. Retrieved October 23, 2011, from www.findahealthcenter.hrsa.gov/Search_HCC.aspx.
U.S. Department of Labor Bureau of Labor Statistics. American time use survey: charts from the American time use survey. June 22, 2011. Retrieved October 23, 2011, from https:///www.bls.gov/tus/charts/.

Yelin E, Trupin L, Katz P, Criswell LA, Yazdany J, Gillis J, Panopalis P. Impact of health maintenance organizations and fee-for-service on health care utilization among people with systemic lupus erythematosus. Arthritis Rheum. 2007 Apr 15;57(3):508-15. doi: 10.1002/art.22625. PMID: 17394180; PMCID: PMC2875127.

Chapter 44

Abrams S. Work disability/SSDI/health insurance [Chat transcript for Ms. Sheri Abrams in Lupus Foundation of America]. Retrieved October 23, 2011, from www.lupus.org/ webmodules/webarticlesnet/templates/new_community.aspx?articleid=2779&zoneid=91. Batiste LC. Accommodation and compliance series: employees with lupus in Job Accommodation Network. Retrieved October 23, 2011, from www.askjan.org/media/Lupus.html. Davis M. How to Get SSI and Social Security Disability. Lincoln, Ne: Writers Club Press; 2000. DisabilitySecrets.com. Social Security Disability (SSDI & SSI): advice from a disability examiner. Retrieved October 23, 2011, from www.disabilitysecrets.com/advice.html. Kazmierczak & Kazmierczak, LLP. Ultimate Social Security Disability Guide: SSDI, SSI, How to Win, Information. 2009. Retrieved October 23, 2011, from https:///www .ultimatedisabilityguide.com/. Law Office of John L. Roberts. The 5 step Social Security disability claims process. Retrieved October 23, 2011, from www.disabilitydecision.com/html/disability-claims-process.html. Matthews J, Berman DM. Social Security, Medicare and Government Pensions: Get the Most out of Your Retirement and Medical Benefits. 16th ed. Berkeley, Ca: NOLO; 2011. McGrath E. Self-esteem at work. Psychology Today. October 1, 2001. Retrieved October 23, 2011, from www.psychologytoday.com/articles/200310/self-esteem-work. Morton III DA. Social Security Disability: eight reasons you may be denied benefits. Will your claim for SSDI or SSI disability benefits be denied? Retrieved October 23, 2011, from www .nolo.com/legal-encyclopedia/social-security-disability-reasons-denial-32396.html. Social Security Administration (September 2008). Disability Evaluation Under Social Security (Blue Book). Retrieved on 1/21/20 from https:///www.ssa.gov/disability/professionals/bluebook/14.00-Immune-Adult.htm#14_02